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Abstract
The synthesis and characterisation of RuII complexes of the form [(η6-
arene)Ru(N,N')X]+ (where N,N' is a bidentate chelating ligand and X is a halogen) are
described; including the X-ray crystal structures of four of these complexes. The hydrolysis
rates at 310 K of the complexes vary over many orders of magnitude and in some cases are
followed by partial arene loss. Density Functional Theory (DFT) calculations suggest that the
aquation mechanism occurs via a more associative pathway. The significant cytotoxic activity
towards A2780 human ovarian cancer cells of some of the complexes is found to be
dependent on the chelating ligand. Selective binding to 9-ethylguanine (9-EtG) but not to 9-
ethyladenine (9-EtA) is observed in aqueous solution at 310 K in all cases. The X-ray crystal
structure of a RuII arene 9-EtG adduct is also described. DFT calculations show that the 9-
EtG nucleobase adducts of all complexes are thermodynamically preferred compared to those
of 9-EtA. Preliminary CT-DNA studies in cell-free media suggest that some of these
complexes can interact with DNA.
A family of piano-stool RuII arene complexes of the form [(η6-arene)Ru(N,N')(L)]2+
(where N,N' is a chelating ligand and L is a pyridine or a pyridine-derivative), that can
selectively photodissociate the monodentate ligand (L) when excited with UVA or visible
light is described. The X-ray crystal structures of five of these complexes are also discussed.
Their photoactivation allows the formation of a reactive aqua species that otherwise would
not form in the dark. Results from TD-DFT calculations suggest that all the RuII pyridine
complexes follow a relatively similar L-ligand photodissociation mechanism, likely to occur
from a series of 3MC triplet states. It is shown how light activation can be used to
phototrigger binding of these complexes to nucleobases with specific preference towards 9-
EtG over 9-EtA. CT-DNA studies suggest that photoirradiated complexes interact with DNA
via a combined coordinative, intercalative, and monofunctional binding mode. Some of the
complexes are also cytotoxic against A2780 human ovarian cancer cell line in the absence of
irradiation.
The possibility of photo(triggering) hydride-transfer reactions using RuII arene
complexes, NAD+, and formate as the hydride source under biologically relevant conditions
is shown. The reactions occur either upon the spontaneous hydrolysis of a Ru–Cl bond in
complexes of the form [(η6-arene)Ru(N,N')Cl]+ (where N,N' is a bidentate chelating ligand)
or upon the photolysis of a Ru–N(Py) bond in [(η6-arene)Ru(N,N')Py]2+ (Py is pyridine). A
mechanism involving the formation of a stable formate adduct followed by a hydrogen β-
elimination is proposed. It is also demonstrated how a hydride-transfer from 1,4-NADH to
some RuII arene chlorido complexes can occur in aqueous solution.
Neutral RuII arene complexes of the form [(η6-arene)Ru(NH3)Cl2] which are
constitutional analogues of cisplatin were synthesised by a novel synthetic method. These
analogues display extensive H-bond interactions in the solid state as shown by X-ray crystal
structures determination and their biexponential hydrolysis rates at 310 K vary over many
orders of magnitude. The complexes are found to readily form mono- and di-guanine adducts
upon hydrolysis but are not cytotoxic against the A2780 human ovarian cancer cell line up to
the maximum concentration tested (100 μM).  
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Chapter 1
Introduction
The aim of this Chapter is to introduce briefly the field of metallodrugs with particular
emphasis on metal complexes as anticancer agents; a more detailed description of the
cytotoxic properties of RuII arene complexes is included. The subsequent sections
focus on the advantageous photochemical properties of RuII (poly)pyridyl complexes
for their potential use in biological applications. Finally, the involvement of RuII
complexes in biologically relevant hydride-transfer reactions is described.
1.1 Metal-Based Therapeutics
Metal ions are required for many critical functions in living organisms. In humans,
scarcity of some of them can lead to disease states; well-known examples include
pernicious anaemia resulting from iron deficiency,1 growth retardation arising from
insufficient dietary zinc,2 and heart disease in infants owing to copper deficiency.3
Less well-known than the fact that metal ions are required in biology, is their role as
pharmaceuticals. The use of metals in medicine traces back to antiquity with various
elements such as arsenic, gold, and iron being used to treat different ailments.4 The
first metal-based drug in modern times used in medicine, an arsenical formulation
(arsphenamine) commercially known as Salvarsan or Ehrlich 606, was used for the
treatment of syphilis.5,6 However, with the later discovery of the better antibiotic
activity of penicillin, the use of the arsenic drug was discontinued. More recent
examples of metals in medicine include the use of lithium salts for neurological
disorders,7 gold drugs for treating rheumatoid and psoriatic arthiritis,8 and vanadium
compounds being studied as insulin-metabolism mimetic agents in the treatment of
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diabetes.9 It is known that the efficacy of the various organic therapeutic agents can
often be enhanced upon coordination with a suitable metal ion;10 a key concept in the
design of metal complexes is the tuning and optimisation of the chemical reactivity to
promote possible interactions with the target site yet avoiding side-reactions.11 By
rational ligand design it has been possible for example, to control the toxicity of GdIII
complexes so that they can be safely injected as Magnetic Resonance Imaging (MRI)
contrast agents or to enable the targeting of radiodiagnostic and radiotherapeutic
isotopes such as 99mTc and 186Re, respectively to the desired organs.12
1.1.1 Metal Complexes in Cancer Chemotherapy
Each year, approximately 12.7 million people worldwide are diagnosed with cancer
and 7.5 million people die from it; the five most common types of diagnosed cancers
are breast, colorectum, stomach, prostate, and lung.13 The main widely used drugs for
treatment of various types of cancers are platinum-based complexes. More than 3000
of these compounds have been synthesised and tested for biological activity;14 four of
them are nowadays registered globally as marketed drugs: cisplatin, carboplatin,
oxaliplatin, and nedaplatin, Figure 1.1.
Figure 1.1. Structures of marketed platinum anticancer drugs.
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Oxaliplatin is the only of these drugs that has been yet approved by the Food and
Drug Administration (FDA) for colorectal cancer.15,29 Cisplatin, discovered in the
1960s,16,17,18 is extensively used and effects cures in >80% of cases of testicular
cancer.19 It is also highly efficient against ovarian cancer and contributes to the
treatment of head, neck, and bladder cancer, as well as lymphomas,20 melanomas, and
breast cancer.21 Investigations into the activity of cisplatin at the biomolecular level
indicate that genomic DNA is the primary target.75c Its anticancer activity comes from
its capability to form bifunctional DNA cross-links (after activation by hydrolysis)
through binding to adjacent purine bases,22 predominantly with N7 of guanine (G).
This site is known to be the most electron-rich on DNA and it is believed to be easily
accessible for cisplatin in the major groove of B-DNA. Other binding sites include N7
of adenine (A) and N3 of cytosine (C).23 Figure 1.2 shows the structures and
numbering scheme for the four DNA nucleobases.
Figure 1.2. Structures and numbering schemes for the four DNA nucleobases. R
represents the deoxyribose phosphate backbone.
1,2-Intrastrand cross-links that involve guanine and sometimes adenine, are known to
be the most common platinated adducts of DNA in cancer cells treated with
cisplatin.23 In this GG intrastrand cross-linking pathway, activation by hydrolysis is
followed by monofunctional binding (causing ring closure) to give the bifunctional
GG macrochelate. It is also known that hydrogen-bonding formation between NH
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protons of cisplatin and the phosphate backbone or C6O of G nucleobase can play a
role in stabilising such cross-links.24 GG coordination results in distortion of the B-
DNA helix towards the major groove25 (by about 35–40°) followed by unwinding of
the DNA. This bend is recognised by the so called High-Mobility Group (HMG)
proteins which are believed to strongly bind to bent platinated DNA,26 Figure 1.3.
Finally, the cells undergo apoptosis due to unsuccessful DNA repair.27
Figure 1.3. A DNA-cisplatin adduct bound to the nonsequence-specific domain A of
the High-Mobility Group protein B1 (HMGB1). Pt(NH3)2 shown as red and white
spheres, DNA blue, HMBG1 grey cartoon with intercalated phenylalanine as yellow
spheres.28
A search for related complexes with similar or better activity than cisplatin is being
currently carried out. It has become fundamental not only to circumvent the resistance
(both natural or acquired) of many tumours to cisplatin, but also to find compounds
that would have less toxic side effects, such as nephrotoxicity, neurotoxicity and
emetogenesis, as well as a broader spectrum of activity.29 The TiIV complex
Budotitane, Figure 1.4 was the first non-platinum complex to be approved for clinical
trials as a potential anticancer drug. Its poor solubility and instability in aqueous
solution hampered its formulation even when used in combination with micelles.30
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Figure 1.4. Structure of the TiIV anticancer complex, Budotitane.
AuI and AuIII complexes have also been tested for anticancer activity in different cell
lines, displaying good activity but cardiovascular toxicity.8 More recently, the
anticancer properties of a family of [Au(por)]+ (por = porphyrinato ligand) have been
reported. Their cytotoxic IC50 values (0.033–100 μM) correlate well with their 
lipophilicity and cellular uptake. Some of them induce apoptosis and display
preferential cytotoxicity towards cancer cells than to normal noncancerous cells.31
The RuIII complexes Na[trans-RuCl4(DMSO)(imid)] (NAMI), its imidazolium
analogue [imidH][trans-RuCl4(DMSO)(imid)] (NAMI-A), and the indazole
compound [indzH][trans-RuCl4(indz)2] (KP1019), Figure 1.5 are the most prominent
examples of ruthenium-based anticancer drugs. Complex NAMI was not sufficiently
stable in solution for clinical applications32 whereas compound NAMI-A showed high
selectivity for solid tumour metastases33 along with low toxicity at pharmacologically
active doses34 and successfully completed phase I clinical trials.35 Compound KP1019
successfully completed phase I clinical trials in 2005.36
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Figure 1.5. Structures of the RuIII anticancer complexes NAMI, NAMI-A and
KP1019.
It has been suggested that RuIII complexes are activated by reduction in vivo to RuII,52
form in which they are more reactive due to the increased lability of RuII–Cl bonds.37
The reduction of RuIII to RuII is believed to occur in vivo by single-electron transfer
reactions from proteins belonging to the mitochondrial electron-transfer chain or from
proteins within microsomal electron-transfer systems; the latter ones are believed to
be more efficient.38
1.1.2 Organometallic Complexes as Anticancer Agents
Organometallic compounds exhibit different ligand exchange kinetics in solution to
those observed for other coordination complexes;39 this feature has shown to be useful
in drug design. For example, the organometallic complex titanocene dichloride,
Cp2TiCl2 was found to exhibit significant activity against lung, breast, and
gastrointestinal cancers in mice. It was originally believed to react with DNA to form
bifunctional cross-links through the cis-TiCl2 motif, in a similar fashion as cisplatin,
but surprisingly, it was found to bind more strongly to the DNA phosphate
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backbone.40 Due to hydrolysis of the Ti–Cl and Ti–Cp bonds and formation of
hydroxido- and oxido-bridged species, it was finally ruled out from clinical trials.41,42
In the search for an improved hydrolytic stability, recent studies report on the
synthesis of titanocene derivatives43,44,45 with bridged-cyclopentadienyls (ansa-
titanocenes) and non-bridged organotitanium titanocenes46 which have shown in vivo
activity against A431 and PC-3 xenografts, models for epidermoid and human
prostate cancer, respectively, similar to cisplatin. Although a change on the metal
centre in the sandwich complexes for V, Nb, or Mo did not alter the cytotoxic activity
exhibited in vitro,47 none of these metallocenes have reached clinical trials. Further
attempts with the corresponding metallocenes of Zr and Hf have proved to be
unfruitful too.48,49 More recently, a series of ferrrocenyl derivatives of the breast
cancer drug tamoxifen, commonly named ferrocifens, have proved to be active
against both estrogen-dependent and estrogen-independent breast cancer cells.50
Ferrocifens are believed to act against estrogen-independent breast cancer cells by
causing oxidative damage to DNA via oxidation of the ferrocenyl group in the cells.
Furthermore, several studies on the cytotoxicity, hydrophobicity (Log P), cellular
uptake, aqueous solution reactivity, and/or extent of DNA adduct formation in several
human cancer cell lines have been reported for organometallic OsII arene complexes.51
1.1.3 Cytotoxic RuII Arene Complexes
The use of RuII arene complexes as potential anticancer agents has been explored
given that they often possess good aqueous solubility and the arene ligand is relatively
inert towards displacement under physiological conditions.52 RuII arene complexes
were first shown to form adducts with nucleosides and nucleotides, forming
mononuclear53 or di-, tri-, and tetranuclear complexes.54 In particular, the discovery of
Chapter 1: Introduction
9
the biological activity of organoruthenium complexes of the type [(η6-
arene)Ru(X)(Y)(Z)]n+ (where X and Y are either monodentate ligands or if they are
linked, XY represents a chelating ligand; and Z is a leaving group) has opened up a
new route towards the design and synthesis of novel anticancer agents.55,56 Although
their mode of action is not yet completely understood, recent results suggest that DNA
might be an important target.55 It is believed that the aquation, particularly if chloride
is the leaving group, is largely suppressed in extracellular fluids where high chloride
concentrations are found (100 mM), whereas in the cell cytoplasm and nucleus where
the chloride concentrations are lower (25 and 4 mM, respectively), the complex is
predominantly in the reactive aqua form.56 Within the cell nucleus it is believed that
these complexes bind to DNA forming monofunctional adducts with a high affinity
for N7 of guanine bases (G), as opposed to the bifunctional adducts formed by
cisplatin.
1.1.3.1 Structural Features of RuII Arene Complexes for Anticancer Activity
A particularly attractive feature of RuII arene anticancer complexes is the possibility
of modifying their basic structural framework, Figure 1.6.
Figure 1.6. Typical structure of a half-sandwich RuII arene complex [(η6-
arene)Ru(X)(Y)(Z)]n+ where X and Y can be either monodentate ligands or if linked,
XY represents a chelating ligand; Z is a leaving group.
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This provides considerable scope for the optimisation of their design in terms of
mechanisms of action, selection of target sites, and modulation of possible side-
effects.40,55,56,57,58,60
1.1.3.1.1 The Arene
It has been found that the arene in organometallic complexes of the general formula
[(η6-arene)Ru(X)(Y)(Z)]n+ can stabilise Ru in its 2+ oxidation state. The nature of the
arene can also help to influence cell uptake and interactions with potential targets.57
For example, it is believed that the more extended coordinated arenes such as
biphenyl (bip) or tetrahydroanthracene (tha), could provide a hydrophobic face that
might assist the passage of the RuII drug across cell membranes.58 It has also been
observed that the cytotoxic activity of RuII arene complexes appears to increase with
the size of the coordinated arene.55 When tested against the human ovarian cancer cell
line (A2780), the 50% inhibitory concentrations (IC50 values) of a series of RuII arene
ethylenediamine (en) complexes were found to decrease in the order: benzene (bz, 17
μM) > para-cymene (p-cym, 10 μM) > biphenyl (bip, 5 μM) > dihydroanthracene 
(dha, 2 μM) > tetrahydroanthracene (tha, 0.5 μM).68 The increased cytotoxic potency
in these (and other related RuII extended arene complexes) is assumed to arise from
the ability of such arenes to intercalate into DNA, thus generating medium-to-strong
π-stacking interactions that cause a significant distortion of the structure of DNA, 
Figure 1.7.58,59 Intramolecular π-π arene-nucleobase stacking has also been observed 
in the crystal structure of [(η6-bip)Ru(en)(9-EtG-N7)][PF6]2.70 Recently, the effect on
cytotoxicity and DNA binding of RuII arene en complexes of structural isomers of the
terphenyl ligand (para-, meta-, and ortho-terphenyl)60 have been explored, Figure 1.8.
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Figure 1.7. Schematic representation of a RuII extended arene complex intercalating
between DNA bases.58 RuII atom shown as a purple sphere, bip arene shown as grey
and white spheres, en chelating ligand shown as blue and white spheres, and guanine
bases in red.
Figure 1.8. Structures of [(η6-arene)Ru(en)Cl]+ complexes where arene is para-,
meta-, or ortho-terphenyl.60
The complex containing para-terphenyl as the arene ligand, exhibits increased
cytotoxicity in several human tumour cell lines, including those resistant to cisplatin.
In contrast, complexes containing meta- or ortho-terphenyl are comparatively less
cytotoxic. The results also revealed that in agreement with the relatively high
cytotoxicity of the RuII para-terphenyl complex, its DNA-binding mode involves
combined non-coordinative intercalative and monofunctional coordination binding
modes. In contrast, the ortho-terphenyl complex was found to bind to DNA only
through monofunctional coordination to DNA bases.
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1.1.3.1.2 The X and Y Monodentate Ligands
Introducing bifunctional reactivity into RuII arene complexes can be achieved by
synthesising derivatives of the form [(η6-arene)Ru(X)(Y)(Z)]n+ where X, Y, and Z are
all monodentate ligands. The use of this approach should in theory increase
interactions with potential targets such as DNA, in a comparable way to cisplatin. The
synthesis and properties of the novel RuII arene complex [(η6-p-cym)Ru(NH3)2Cl]+
have been recently described.61 Despite its constitutional similarity to cisplatin, the
complex displays an IC50 value ca. 500 times larger than that of the platinum drug
under the same conditions. It is probable that the lack of activity arises from its
instability in aqueous (and organic) solutions. The substitution of at least one of the
NH3 groups for a sterically more demanding ligand, usually a heterocyclic amine, a
pyridine62 or phosphine,63 has also been tried. For example, the complex [(η6-p-
cym)Ru(P-pta)Cl2] where pta is 1,3,5-triaza-7-phospha-tricyclo-[3.3.1.1]decane
(RAPTA-C),64 exhibits only a low activity in vitro but it is active in vivo, where it
inhibits lung metastases in Cytometric Bead Array (CBA) mice, analogously to
NAMI-A.65 Aquation seems to be the activating step in its cytotoxic mechanism,66
Figure 1.9 upon which is believed to induce a local kink in double-stranded DNA
(dsDNA) via intrastrand cross-linking of adjacent guanine bases (1,2-GG ).67
Figure 1.9. Hydrolysis of RAPTA-C in water.
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1.1.3.1.3 The XY Chelating Ligand
It seems to be highly advantageous for anticancer activity and aqueous solution
stability of [(η6-arene)Ru(X)(Y)(Z)]n+ complexes, that the monodentate X and Y
ligands are replaced by a bidentate chelating group, usually represented as XY.
Generally, complexes containing chelating ligands tend to be more active than those
containing only monodentate ligands.68 Several studies on structure activity
relationships (SARs) with regard to changes in the nature of the donor atoms in the
XY chelating ligand have been done. When XY is changed from ethylenediamine (en)
to the anionic acetylacetonate (acac), the rate and extent of the hydrolysis of the
leaving group (Z) are considerably increased.69 The chelate ligand is also known to
determine the rate of binding to DNA nucleobases and more dramatically, to change
the selectivity for them. This feature is believed to be directly related to the ability to
inhibit cancer cell growth in vitro. For example, when the chelating ligand is the
hydrogen bond acceptor acac, the overall affinity for adenine bases (A) appears to be
greater than that for guanine (G) bases,70 as opposed to the affinity for G when the
chelating ligand is en. The evidence points towards the crucial role that N–H groups
play in the stabilisation of adducts with G bases via H-bonding,71 just as the oxygen
atoms (in acac) can form favourable H-bonds (Figure 1.10) with the C6NH2 group of
A bases. Such H-bonding is also thought to play a role in the recognition of DNA by
cisplatin.72 Moreover, SARs reported for RuII arene complexes containing N,N'
chelating ligands have shown that whereas the species containing en showed an
increased cytotoxic potency, complexes containing tetramethylethylenediamine
(TMEDA) were inactive.69 Steric effects of the methyl groups as well as lack of H-
bonding capability may contribute to the loss of activity of the TMEDA derivative.
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Figure 1.10. Molecular model of [(η6-p-cym)Ru(acac)(9-EtA-N7)]+.63 The hydrogen
bond between acac O and A N6H is represented by a dashed line.73
In general, good cytotoxic activity is observed when en is replaced by aromatic
amines such as 1,2-diaminobenzene (dab); the IC50 values determined for a series of
RuII complexes were in the range between 7 and 32 μM.69 Furthermore, other non-
amine N,N'-chelating ligands have also been investigated and the results show that
2,2'-bipyridine (bpy) complexes tend to be non-cytotoxic towards A2780 cells.69 A
similar behaviour was observed for some 1,10-phenanthroline (phen) complexes (with
either neutral or negatively charged substitutents), which showed either poor or no
activity. This evidence points to the important roles that N–H groups on the bound N
atoms of the chelated ligand can play.
1.1.3.1.4 The Z Leaving Group
The leaving group (Z), which is typically a halogen, plays a crucial role in the control
of the activation of RuII arene complexes given that with its release from the metal
centre, a vacant site for coordinating potential biomolecules is readily made available.
Initial studies showed that the substitution of the chloride leaving group by other
halides, such as iodide, seemed to have only a small effect on the cytotoxicity.68
However, recent reports have discussed the correlation between the rate (and extent)
of hydrolysis and the cytotoxicity of RuII arene complexes with various chelating
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ligands.74 The evidence suggests that a combination of fast hydrolysis rates and high
reactivity usually leads to non-cytotoxic complexes, similarly very slow hydrolysis
rates and chemical inertness leads to low in vitro cytotoxicity.75 An exception to this
observation was found when the leaving group is not a halide but a thiophenolate.74
This compound was found active, displaying an IC50 value of 23 μM against A2780 
human ovarian cancer cells, despite its inertness towards hydrolysis. It was then
suggested that the mechanism of action could probably involve the oxidation of the
thiolate group, followed by the hydrolysis of the sulfenato thus formed.
1.2 Photochemistry in Medicine
Modern phototherapy involves the use of specific wavelengths of light, both for the
treatment of diseases and/or as diagnostic tools.76 If light therapy is combined with the
effect of a drug for the treatment of a disease, it is then commonly known as
photochemotherapy. Historically, the concept of combining radiation with a chemical
agent dates back to 3000 years ago when the therapeutic effect of sunlight activation
of chromophore-containing plants was used for repigmentation of vitiligo in both
ancient Egypt and India.77 Nowadays, the most commonly known form of
photochemotherapy is photodynamic therapy (PDT). It involves a tumour-localised
photosensitiser (PS) which when appropriately irradiated by visible light, converts
triplet oxygen (3O2) into cytotoxic reactive singlet oxygen species (1O2). This latter
are known to attack key structural entities within the targeted cells and ultimately
resulting in necrosis or apoptosis.78 Typically employed photosensitisers are
porphyrins or porphyrin-like molecules.79 Photofrin, the first approved
photosensitiser, is a mixture of haematoporphyrin derivatives of varying linkages,
lengths, and stereochemistries with an absorption maximum around 630 nm. Foscan,
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a photofrin derivative, requires a lower light dose to achieve similar responses and has
a shorter retention time in the body,80 Figure 1.11. The lanthanide complex lutetium
texaphryn, Lutrin, has also been approved for use in cervical, prostate, and brain
tumours along with other several potential new photosensitisers now in clinical
trials.76
Figure 1.11. Two porphyrin-based drugs in clinical use for photodynamic therapy
(PDT).
While using photochemistry in medicine, there are practical considerations to take
into account. Whilst irradiation of the skin is easily achievable, internal organs are
less accessible. Recent advances in laser technology have helped to overcome this
limitation;81 and it is now possible to irradiate various organs such as lungs, cervix,
colon and oesophagus. The rapid development in sophisticated fibre optic
technologies82 could soon allow difficult areas of the body to be reached.
Additionally, a large difference between the therapeutic effect of the drug in the
presence and in absence of irradiation is desirable, mainly (but not only) to limit
unwanted side-effects. The energy of activation should ideally lie within a
phototherapeutic window of 620–850 nm83 and preferably would also be in the range
needed to achieve the optimal quantum yield or efficiency of the photochemical
process. Short wavelength irradiation such as UVA (λ = 320–400 nm) and UVB (λ = 
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290–320 nm) are not recommended for therapeutic uses, not only because of their
poor penetration through mammalian tissues,84 Figure 1.12 but mainly because they
induce extensive damage to tissues, DNA, and proteins.85,86 Higher wavelengths are
less damaging but penetration through tissues is poor below 600 nm (as a result of
absorption by biomolecules such as haemoglobin, cytochromes, and melanin as well
as scattering from organelles).84
Figure 1.12. The skin penetration depths of UVA (λ = 320–400 nm) and UVB (λ = 
290–320 nm) irradiation.87
1.2.1 Photoactive Metal Complexes for Biological Applications
In the development of metal complexes as anticancer agents, one design concept
receiving increasing interest in recent years is that of photoactivation. For example,
titanium dioxide (TiO2) has been studied extensively for its photochemical
properties88 and it has been reported that it can kill cancer cells when irradiated by
UVA.89 It was recently shown how a mononuclear citrate TiIV complex is able to
undergo photoreduction (with UVA irradiation) to TiIII; this species is a strong
reductant which can initiate free radical reactions in cells.90 Vandium complexes are
also being investigated for their potential use as PDT agents.91 For example, oxo-
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vanadium(IV) complexes containing the heterocyclic bases dpq where dpq is
dipyrido[3,2-d:2',3'-f]quinoxaline and dppz is dipyrido[3,2-d:2',3'-c]phenazine, Figure
1.13 have been shown to exhibit DNA cleavage mechanisms involving both singlet
oxygen and hydroxyl radicals when activated at 365 nm, with only the OH· radical
mechanism operating when irradiated with near-infrared (NIR) light.92
Figure 1.13. Structures of oxovanadium(IV) complexes containing the heterocyclic
bases dpq (dipyrido[3,2-d:2',3'-f]quinoxaline) and dppz (dipyrido[3,2-d:2',3'-
c]phenazine) which can photocleave DNA.92
The photochemistry of complexes of the type [M(CO)4(α-diimine)] where M = Cr, 
Mo, and W has also been investigated.93 They undergo photochemical substitution of
an axial CO ligand when irradiated with UV or visible light. Although such studies
have not yet targeted medical applications, controlled CO release can be an efficient
and advantageous way of promoting cell death.94 Furthermore, it has also been shown
how UVA and blue light can be successfully employed to activate Pt azide
complexes95 and produce highly cytotoxic compounds which, in contrast, are inactive
in the dark. More recently, a novel trans-diimine diazido platinum(IV) complex,
trans,trans,trans-[Pt(N3)2(OH)2(Py)2] where Py is pyridine, which is potently
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cytotoxic towards cancer cells using low doses of visible light, has been reported.96
The results also suggest that the presence of planar σ-donor/π-acceptor pyridine 
ligands in the system can have a critical effect not only on the photoactivation
pathways, but also on the biological activity.
1.2.2 Photoactivatable RuII (poly)Pyridyl Complexes
The fact that photochemical activation is a very attractive way to achieve precise
spatial and temporal control of the biological action of transition metal complexes that
behave as inactive drugs in the dark97 has been recently coupled to the tremendous
potential of RuII (poly)pyridyl complexes as diagnostic and therapeutic agents.98,99,100
The basic approach involves the modification of the RuII molecules by introducing a
group that can be selectively cleaved by the absorption of light, thus releasing it. The
strategy requires breaking of a bond by the use of either high energy UVA (λ ≈ 300 
nm) or visible (λ ≈ 400 nm) photons. RuII (poly)pyridyl complexes present a strong
metal-to-ligand charge transfer (MLCT) band in the visible region.101 It has been
shown that light absorption can populate the triplet state that is thermally activated to
a dissociative d−d state, which usually leads to photoproducts with very fast 
kinetics.102,103 The photochemistry of the bis-arene species such as [(η6-C6H6)Ru(η5-
C5H5)]+ has been investigated.104 It was found that photosubstitution of the arene is
the dominant reaction pathway where benzene is released. Irradiation in aqueous
solution of the RuII complexes of the form [(η6-arene)Ru(L)3]2+ where arene =
benzene, toluene, or isopropyltoluene; and L = NH3 or H2O, was found to lead in each
case to the aquation of the arene as the only observable photoreaction to produce
[Ru(OH2)3L3]2+ plus the corresponding free arene.105 Other investigations have
reported that [(η6-arene)Ru(P(n-Bu)3)Cl2] dissolved in another arene undergoes
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exchange of coordinated and solvent arenes when irradiated with UVA.106 A few
dinuclear complexes based on the typical half-sandwich motif have been also studied.
Amongst them, the complex [{(η6-ind)Ru(Cl)}2(μ-2,3-dpp)2]2+ where dpp is 2,3-
bis(2-pyridyl)pyrazine, Figure 1.14 was found to bind to DNA in the dark, via a
hydrolysis pathway that generates a reactive aqua intermediate (as observed in
analogous mononuclear RuII arene complexes).107
Figure 1.14. Structure of the cation in the photoactivatable dinuclear RuII arene
complex [{(η6-ind)Ru(Cl)}2(μ-2,3-dpp)2][PF6]2.107
In vitro DNA transcription experiments on [{(η6-ind)Ru(Cl)}2(μ-2,3-dpp)2]2+ suggest
that the adduct formed in the dark inhibits RNA synthesis by a RNA polymerase only
to a small extent. In contrast, the adduct formed between DNA and the pre-irradiated
complex inhibits the DNA transcription more efficiently, attributed to interstrand
crosslinkings. Interestingly, enhanced interstrand crosslinkings were also observed
with subsequent irradiation of DNA modified by the dinuclear complex in the dark.
The increased reactivity has been attributed to the indane (ind) arene loss upon
irradiation. Moreover, a number of biologically relevant biomolecules have also been
coupled to non-arene RuII metal complexes to produce species that can be
phototriggered and exert their effect when free. This general principle has been
applied in the development of RuII (poly)pyridyl complexes as inorganic photolabile
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caging groups for several amine-containing neurotransmitters.108,109,110 In one of these
systems, two molecules of γ-aminobutyric acid (GABA) are coordinated to a RuII
centre supported by two 2,2'-bipyridine (bpy) ligands to form the caged complex
[Ru(bpy)2L2]2+ where L is GABA, Figure 1.15, or also one of several amine
compounds including serotonin, tryptamine, butylamine, and tyramine.
Figure 1.15. Selective photorealese of a γ-aminobutiric acid (GABA) molecule from 
a RuII (poly)pyridyl complex with visible light.108,109,110
Other examples also include the photoactivation of RuII complexes with highly π-
deficient (poly)azaaromatic ligands like 1,4,5,8-tetraazaphenanthrene (tap) or
1,4,5,8,9,12-hexaazatriphenylene (hat). These complexes led to covalent adducts with
functional groups on DNA model nucleobases.111 Similar photoactivatable RuII
(poly)pyridyl complexes are also able to form covalent adducts with nucleobases
upon irradiation.111
Chapter 1: Introduction
22
1.3 RuII Arene Complexes as Catalytic Agents
Aqueous-phase organometallic catalysis has attracted much recent interest due to the
relatively easy recycling of water-soluble catalysts in aqueous-organic biphasic
reaction mixtures.112 Some initial studies have focussed on the catalytic properties of
the various cluster species obtained from organometallic RuII species such as [(η6-
arene)RuCl2]2 under elevated H2 pressure.113 More recently, RuII arene complexes are
finding increasing application in organic synthesis114 either as catalysts, or as catalyst
precursors.115 Some RuII arene complexes with bidentate N,N' donor ligands are
known to catalyse transfer hydrogenation reactions of ketones and imines;116,117 they
are active in Lewis acid-catalysed Diels–Alder reactions,118 and some are even active
catalysts for the isomerisation of allylic alcohols.119 The chemistry of transition metal
compounds containing the formato ligand bonded in a monodentate fashion is of
considerable interest. They offer the potential of participating in the catalysis of both
the water-gas shift reaction and the conversion of CO2 into formic acid.120 These
formato species also participate in the decomposition of formic acid to hydrogen and
carbon dioxide121 and can be usually prepared by reaction of CO2 into a transition
metal-hydrogen bond (a type of reaction showing some similarity to olefin insertion,
Eq. 1). Some transition metal-formato complexes have also been obtained previously
by metathesis involving formate ion, Eq. 2.122,123,124
MH + CO2 MOCOH (Eq. 1)
MX + OCHO– MOCHO + X– (Eq. 2)
The reverse reaction in Eq. 1, MOCOH MH + CO2, is of interest because hydrido
species can be obtained by CO2 elimination from RuII arene formato complexes.125,126
One of the critical steps in such mechanisms is believed to involve progressive
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coordination mode of the arene ligand from η6 to η4 to η2, and complete loss of the
arene ligand in some cases127 (which may be an unwanted process). Of currently
prime importance in the field of biocatalysis, is the increasing demand for enantiopure
biologically active compounds and their precursors.128,129 One example is the
(re)generation of the coenzyme 1,4-NADH, which is the reduced form of
nicotinamide adenine dinucleotide (NAD+), Figure 1.16.
Figure 1.16. Nicotinamide adenine dinucleotide (NAD+) and the reduced form of the
coenzyme 1,4-NADH.
Current interest is also generated by the observation that NAD+ content in cancer cells
is equal or higher than in normal cells.130 An interference with this distribution could
lead to either cell death or a stimulated cell growth. In living cells, NAD+ and its
phosphorylated and reduced forms (NADP, NADP+, NADH and NADPH) have
central roles in cellular metabolism and energy production as hydride-accepting and
hydride-donating coenzymes.131 In glucose fermentation for instance, NAD+ functions
as the hydride acceptor in a step catalysed by glyceraldehyde 3-phosphate
dehydrogenase, producing NADH and diphosphoglycerate. Similarly, NADH
functions as the hydride donor for alcohol dehydrogenase,132,133 which is required for
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the reduction of acetaldehyde to ethanol, regenerating NAD+.134 Conversion of NAD+
to NADH by enzymatic,135 photo- or electrochemical136 methods has been extensively
studied. Various transition metal hydrides have been studied as catalysts for the
regioselective reduction of NAD+ and NAD+-models to the corresponding 1,4-NADH
derivatives.137 Some RhIII pentamethylcyclopentadienyl complexes138 and RuII arene
complexes have shown to catalyse the reduction of NAD+ in the presence of formate
as the hydride source.139 This reduction is regioselective, giving the biologically
relevant 1,4-NADH isomer.140
1.4 Aims
The general aim of this Thesis is concerned with the rational design, synthesis and
characterisation of three new families of half-sandwich RuII arene anticancer
complexes which can be activated by different modes. The individual aims can be
rationalised as follows.
a) To gain an understanding of the aqueous solution chemistry and ability to kill
cancer cells of a series of RuII arene halido complexes in relation to their chemical
structures.
b) To investigate the wavelength-dependent (photo)chemical reactivity of a series
of RuII arene pyridine or pyridine-derivative complexes as novel types of
photoactivatable anticancer drugs.
c) To explore the possibility of (photo)triggering hydride-transfer reactions using
biologically-relevant substrates and RuII arene halido complexes or
photoactivatable RuII arene pyridine or pyridine-derivative complexes.
d) To investigate the potential of bifunctional RuII arene complexes with
constitutional similarity to cisplatin as cytotoxic agents.
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Chapter 2
Materials and Methods
In this Chapter the general techniques and instrumentation used are described. More
specific methods related to individual experiments are described in the appropriate
Chapters. The synthesis and characterisation of the RuII dimers used for the synthesis
of the mononuclear RuII arene complexes in subsequent sections is also covered here.
2.1 NMR Spectroscopy
1H and 13C NMR spectra were acquired in 5 mm NMR tubes at 298 K (unless
otherwise stated) on either a Bruker AV-400, Bruker DRX-500, Bruker AV III 600 or
Bruker AV II 700 NMR spectrometers. All data processing was carried out using
XWIN-NMR version 3.6 (Bruker U.K. Ltd.). 1H NMR chemical shifts were internally
referenced to TMS via 1,4-dioxane (δ = 3.71) or residual CHCl3 (δ = 7.27), MeOH (δ 
= 3.31) or DMSO (δ = 2.50). 1D spectra were recorded using standard pulse 
sequences. Typically, data were acquired with 128 transients into 16 k data points
over a spectral width of 14 ppm (unless otherwise stated). 2D spectra were recorded
using standard pulse-pulse sequences. COSY (COrrelation SpectroscopY) or TOCSY
(TOtal Correlation SpectroscopY) were used to identify pairs of nuclei which are J-
coupled to one another. Typically, data were acquired with 72 transients into 1024 k
data points over a spectral width of 14 ppm (unless otherwise stated) using a
relaxation delay of 1.5 s and a mixing time of 0.06 s. 2D NOESY (Nuclear
Overhauser Effect SpectroscopY) was used to establish structural information
resulting from through-space interactions between protons that are close in spatial
proximity. Typically, the data were acquired with 72 transients into 2048 k data points
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over a spectral width of 14 ppm using a relaxation delay of 1.5 s and a mixing time of
0.4–0.6 s.
2.2 Water Suppression Methods
Many experiments in this work were performed on samples in aqueous solutions
(99.9% D2O, 5% methanol-d4/95% D2O or 90% H2O/10% D2O) so as to be of
biological relevance. The use of such aqueous solutions results in a large HOD signal
that can obscure the others in the 1H NMR spectrum. To minimise this, two main
techniques were used: presaturation used a weak, continuous wave at the water
resonance whereas SHAKA excitation sculpting with gradients1 saturated the HOD
peak by irradiating the frequency of water in between pulse sequences.
2.3 pH* Measurements
pH values were measured at ambient temperature using a Corning 240 pH meter
equipped with a micro combination KNO3 (chloride free) electrode calibrated with
Aldrich buffer solutions of pH 4, 7, and 10. The pH* values (pH meter reading
without correction for effects of deuterium (D) on glass electrode) of NMR samples in
D2O were measured at about 298 K directly in the NMR tube, before and after
recording NMR spectra, using the same method. The pH* values were adjusted with
dilute NaOH or HNO3 solutions in D2O.
2.4 Calculation of pKa* Values
For determinations of pKa* values (determined from solutions in D2O), the pH* values
of the aqua complexes in D2O were varied from ca. pH* 1 to 12 by the addition of
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dilute NaOH or HNO3 solutions in D2O, and 1H NMR spectra were recorded. The
chemical shifts of the arene ring protons were plotted against pH* values. The pH*
titration curves were fitted to the Henderson-Hasselbalch equation using ORIGIN
version 8.0, with the assumption that the observed chemical shifts are weighted
averages according to the populations of the protonated and deprotonated species.
These pKa* values can be converted to pKa values by use of the equation pKa = 0.929
pKa*+ 0.42 as suggested by Krezel and Bal2 for comparison with related values in the
literature.
2.5 X-ray Crystallography
Diffraction data were collected either on an Oxford Diffraction Gemini four-circle
system with a Ruby CCD area detector or on a Siemens SMART three-circle system
with CCD area detector equipped with an Oxford Cryosystem Cryostream Cooler.
Data collection and solution of the structures were carried out by Dr Guy Clarkson
from the Department of Chemistry at the University of Warwick. All structures were
refined by full-matrix least squares against F2 using SHELXL 97.3 Details of the
acquisition and solving of the individual crystal structures are explained in the
corresponding chapters.
2.6 Elemental Analysis
Elemental analyses were performed by the Warwick Analytical Service which is the
analytical division of Exeter Analytical (U.K. Ltd.) using an Exeter Analytical
Elemental Analyser (CE440).
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2.7 High Resolution Electrospray Ionisation Mass Spectrometry
(HR-MS)
The HR-MS data acquisition was carried out by Dr Lijiang Song or Mr Philip Aston
from the Department of Chemistry at the University of Warwick. HR-MS data were
obtained on a Bruker MaXis UHR-TOF. All the samples were analysed by positive-
ion ESI(+) mass spectra. Samples were prepared either in 100% H2O or 95%
MeOH/5% H2O mixture and typically injected at 2 μL min–1, nebuliser gas (N2) 0.4
bar, dry gas (N2) 4 L min–1 and dry temp 180 ºC, Funnel RF 200V, Multiple RF 200,
quadrupole ion energy 4 eV, collision cell 5 eV, ion cooler RF settings, ramp from 50
to 250 V, unless otherwise stated.
2.8 Low Resolution Electrospray Ionisation Mass Spectrometry
(ESI-MS)
Positive-ion ESI(+) mass spectra were obtained either on a Bruker Esquire2000 Ion
Trap Spectrometer or a Bruker MicroTOF Spectrometer. Samples were prepared in
either 100% H2O or 95% MeOH/5% H2O mixture and typically injected at 2 μL   
min–1, nebuliser gas (N2) 25 psi, dry gas (N2) 9 L min–1, dry temp 300 ºC, capillary –
4000 V (+ mode), end plate offset –500 V, capillary exit 70–170 V, and Oct RF 50–
400 V pp, unless otherwise stated. Data were processed using DataAnalysis version
3.3 (Bruker Daltonics).
2.9 UV-vis Absorption Spectroscopy
UV-vis absorption spectra were recorded on a Cary 50-Bio spectrophotometer using
1-cm pathlength quartz cuvettes (600 μL) and a PTP1 Peltier temperature controller. 
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Spectra were recorded at 310 K in deionised water from 200 to 800 nm and were
processed using UV-Winlab software for Windows 95.
2.10 Computational Methods
All Density Functional Theory (DFT) calculations for Chapter 3 were carried out in
collaboration with Prof Robert J. Deeth from the Department of Chemistry at the
University of Warwick. DFT calculations used the Amsterdam Density Functional
(ADF)4 program (version 2009.01). The coordinates of complexes used for the
calculations were directly obtained from the X-ray crystal structures. Modifications to
the structures were performed in Chemcraft (version 1.6). Further details of the
individual calculations are described within Chapter 3.
Calculations in Chapter 4 were performed in collaboration with Dr Luca Salassa from
the Department of Chemistry at the University of Warwick. Gaussian 03 (G03)
program5 employing the DFT method, Becke three parameter hybrid functional, and
Lee-Yang-Parr’s gradient corrected correlation functional (B3LYP)6 were used. The
LanL2DZ basis set7 and effective core potential were used for the Ru atom and the 6-
31G** basis set8 was used for all other atoms. Geometry optimisations in the ground
state (S0) and lowest-lying triplet state (T0) were performed in the gas phase and the
nature of all stationary points was confirmed by normal mode analysis. The
conductor-like polarisable continuum model method (CPCM)9 with water as solvent
was used to calculate the electronic structure and the excited states in solution. Fifty
singlet excited states and the corresponding oscillator strengths were determined with
a Time-Dependent Density Functional Theory (TD-DFT)10 calculation. Eight triplet
excited states were calculated by TD-DFT starting both from the ground-state
geometry and the lowest-lying triplet state geometry. The electronic distribution and
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the localisation of the singlet and triplet excited states were visualized using the
electron density difference maps (EDDMs).11 GaussSum1.0512 was used for EDDMs
calculations and for the electronic spectrum simulation.
2.11 CT-DNA Interactions in Cell-Free Media
These experiments were performed by the author (as a Visiting Researcher) in
collaboration with Dr Olga Nováková in the laboratory of Prof Viktor Brabec at the
Academy of Sciences of the Czech Republic, Brno as part of COST Action D39
(November−December 2009). Cisplatin was obtained from Sigma-Aldrich (Prague, 
Czech Republic). Chloridodiethylenetriamineplatinum(II) chloride ([PtCl(dien)]Cl)
was a generous gift of Professor Giovanni Natile from the University of Bari.
Restriction endonucleases NdeI and HpaI were purchased from New England Biolabs.
Acrylamide, bis(acrylamide), and ethidium bromide (EtBr) were obtained from Merck
KgaA (Darmstadt, Germany). Agarose was purchased from FMC BioProducts
(Rockland, ME). Radioactive reagents were obtained from Amersham (Arlington
Heights, IL, U.S.A.).
2.11.1 DNA Binding Kinetics
Calf thymus DNA (CT-DNA) and plasmid DNAs were incubated with the RuII arene
complexes or platinum complexes in 10 mM NaClO4 (pH ≈ 6) at 310 K for 24 h in the 
dark, unless otherwise stated. For each individual assay the values of rb (rb values are
defined as the number of atoms of the metal bound per nucleotide residue) were
determined by Flameless Atomic Absorption Spectrometry (FAAS). CT-DNA (42%
G + C, mean molecular mass ca. 20 000 kD) was prepared and characterised as
described previously.13
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2.11.2 DNA Transcription by RNA Polymerase In Vitro
Transcription of the (NdeI/HpaI) restriction fragment of pSP73KB DNA with T7
RNA polymerase and electrophoretic analysis of the transcripts were performed
according to the protocols recommended by Promega (Promega Protocols and
Applications, 43−46 (1989/90)) as previously described.14 The DNA concentration
used was 7.8 × 10−5 M (0.5 g/20 L) (related to the monomeric nucleotide content).
2.11.3 Unwinding of Negatively Supercoiled DNA
Unwinding of closed circular supercoiled pUC19 plasmid DNA was assayed by an
agarose gel mobility shift assay.15 The mean unwinding angle can be calculated from
the equation Φ = −18σ/rb(c), where σ is the superhelical density (representing the 
number of turns added or removed relative to the total number of turns in the relaxed
plasmid, indicating the level of supercoiling), and rb(c) is the rb value at which the
supercoiled and nick forms comigrate.16 Samples of plasmid DNA at the
concentration of 1.0 × 10−4 M (0.5 g/15 L) (related to the monomeric nucleotide
content) were incubated with the RuII arene halido complexes (Chapter 3) at 310 K for
24 h. The pre-irradiated forms (irradiation for 24 h) of the RuII arene pyridine
complexes were used in Chapter 4. All samples were precipitated by ethanol and
redissolved in the TAE (Tris-acetate/EDTA, pH ≈ 8.0) buffer to remove free, 
unbound RuII arene complexes. One aliquot of the precipitated sample was subjected
to electrophoresis on 1% agarose gels running at 298 K with TAE buffer and the
voltage was set at 25 V. The gels were then stained with ethidium bromide (EtBr),
followed by photography with a transilluminator. Electron Absorption Spectrometry
(EAS) and/or Flameless Atomic Absorption Spectroscopy (FAAS) were used for the
determination of rb values.
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2.11.4 DNA Melting Temperature
CT-DNA at the concentration of 32 μg/mL was modified by RuII arene complexes at
various rb values in 10 mM NaClO4 with 1 mM Tris-HCl/0.1 mM EDTA and pH =
7.4 at 310 K for 24 h. The samples were then dialysed and the rb was determined by
EAS and FAAS. The salt concentration was then further adjusted by the addition of
NaClO4 to values in the range of 0.01−0.22 M. The melting curves of CT-DNA were 
recorded by measuring the absorbance at 260 nm. The value of the melting
temperature (tm) was determined as the temperature corresponding to a maximum on
the first-derivative profile of the melting curves. The tm values could be thus
determined with an accuracy of ± 0.5 °C.
2.11.5 Circular Dichroism (CD)
Isothermal CD spectra of CT-DNA modified by the RuII arene complexes were
recorded at 298 K in 10 mM NaClO4 by using a Jasco J-720 spectropolarimeter
equipped with a thermoelectrically controlled cell holder. The cell pathlength was 1
cm. Spectra were recorded in the range of 230−600 nm in 0.5 nm increments with an 
averaging time of 0.5 s.
2.11.6 Flow Linear Dichroism (LD)
Flow LD spectra were collected by using a flow Couette cell in a Jasco J-720
spectropolarimeter adapted for LD measurements. Long molecules, such as DNA
(minimum length of ca. 250 bp) can be orientated in a flow Couette cell. The flow cell
consists of a fixed outer cylinder and a rotating solid quartz inner cylinder, separated
by a gap of 0.5 mm, giving a total pathlength of 1 mm. LD spectra of DNA at the
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concentration 2.3 × 10−4 M modified by the RuII arene complexes were recorded at
298 K in 10 mM NaClO4.
2.11.7 Ethidium Bromide (EtBr) Fluorescence
Measurements were performed on a Varian Cary Eclipse spectrofluorophotometer
using a 1-cm pathlength quartz cell. Fluorescence measurements of CT-DNA
modified by RuII arene complexes in the presence of EtBr were performed at an
excitation wavelength of 546 nm, and the emitted fluorescence was analysed at 590
nm. The fluorescence intensity was measured at 298 K in 0.4 M NaCl to avoid
secondary binding of EtBr to DNA.17 The concentrations were 0.01 mg/mL for DNA
and 0.04 mg/mL for EtBr, which corresponded to the saturation of all intercalation
sites for EtBr in DNA.18
2.11.8 Other Physical Methods
Absorption spectra were measured with a Beckman DU 7 4000 UV-Vis
spectrophotometer equipped with a thermoelectrically controlled cell holder and 1-cm
pathlength quartz cells. The FAAS measurements were carried out on a Varian
AA240Z Zeeman atomic absorption spectrometer equipped with a GTA 120 graphite
tube atomiser. The PAA gels were visualized by using a BAS 2500 FUJIFILM
bioimaging analyser, with the AIDA image analyzer software (Raytest, Germany).
2.12 Cancer Cell Growth Inhibition
The following assays were carried out under normal ambient light conditions (i.e. no
irradiation provided).
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2.12.1 Materials and Maintenance
The A549 human lung, HCT116 human colon, A2780 human ovarian, and A2780cis
human ovarian cisplatin resistant cancer cell lines were obtained from the European
Collection of Animal Cell Cultures (ECACC). The A549 lung cell line was grown in
DMEM (Dulbecco's Modified Eagle's Medium) and A2780 human ovarian and
A2780cis human ovarian cisplatin resistant cell lines were grown in RPMI (Roswell
Park Memorial Institute) medium. The HCT116 colon cancer cell line was grown in
McCoys 5A medium. All media were supplemented with 10% fetal calf serum (FCS),
1% L-glutamine and 1% penicillin/streptomycin. Experiments were performed with
cells within 15 passages from each other. All cells were split when around 80–95%
confluence was reached using 0.25% trypsin/EDTA.
2.12.2 In Vitro Growth Inhibition Assay
IC50 values (concentration at which 50% of the cell growth is inhibited) against A549
human lung, HCT116 human colon, A2780 human ovarian, and A2780cis human
ovarian cisplatin resistant cancer cell lines were determined. Plates containing 96
wells with 300 μL capacity were used. A2780 and A2780cis cells were plated out at a 
density of 5000 cells/well whereas A549 and HCT116 cancer cells were plated out at
a density of 2000 and 2500 cells/well, respectively. Plated A2780 and A2780cis cells
were grown for 48 h, and A549 and HCT116 cells for 24 h at 310 K before addition
of the RuII arene complexes. The RuII arene test compound (plus a cisplatin control
added to the plates to act as a positive and comparative control) was made up in 5%
DMSO and saline to give a 1 mM stock solution by initial dissolution in DMSO
followed by dilution with saline. Two rows free of drug solution acted as the 100%
cell survival control. Sonication was sometimes used to facilitate complete
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dissolution. Serial dilutions were carried out to give final screening concentrations of
drug of 400, 200 and 20 μM (final concentration of DMSO of 0.5% (v/v)). Aliquots of 
50 μL of these solutions were added to the wells (in triplicate) already containing 150 
μL of media, so that the final concentrations were 100, 50, and 5 μM (final 
concentration of DMSO of 0.125% (v/v)). The cells were exposed to the complex for
24 h, which then was removed and the cells washed with 100 μL phosphate buffered 
saline (PBS) followed by the addition of 200 μL of fresh media. Then the cells were 
incubated for 72 h of recovery time. The remaining biomass was then estimated by
the sulforhodamine B assay (SRB assay, vide infra). The three screening
concentrations were used in an initial test of activity. The selected complexes were
then tested for half maximal inhibitory concentration (IC50) values determination. The
previously described assay was then repeated but using six different concentrations of
complex instead, ranging from 0.1 to 100 μM. Each assay was done in triplicate. IC50
values were obtained from plots of % cell survival against Log of the drug
concentration.
2.12.3 Sulforhodamine B (SRB) Assay19
SRB is a pink aminoxanthene dye with two sulfonic acid groups, Figure 2.1. Under
mildly acidic conditions it binds to basic amino acid residues in proteins and under
more basic conditions the dye is liberated and can be quantitatively extracted for
measurement of optical density (λ = 568 nm). 
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Figure 2.1. Structure of sulforhodamine B sodium salt.
To each well, 50 μL 50% (w/v) of trichloro acetic acid (TCA) was added and the 
wells were incubated at 277 K for one hour to fix the remaining biomass before
washing 10 times with running tap water. Plates were dried with the assistance of a
heat-gun until no standing moisture was visible. The TCA-fixed cells were stained
with 50 μL 0.4% (w/v) SRB in 1% acetic acid and left to stand for 30 min at ambient 
temperature. The excess dye was removed with 5 quick rinses of 1% acetic acid and
again dried with the assistance of a heat-gun. The cell-bound dye was solubilised by
addition of 150 μL of a 10 mM Tris base (tris(hydroxymethyl)aminomethane, pH ≈ 
10.5) solution and plates were gently shaken for 15 min and left standing at ambient
temperature for 1 h to allow the solutions to become homogeneous. The absorbance
was read using a Labsystems Multiscan Ascent354 microplate reader at 590 nm. The
absorbance value taken as 100% cell survival was the averaged duplicate absorbance
for the control wells. The percentage cell survival relative to this control could then be
determined.
2.13 Photocytotoxicity: Cancer Cell Growth Inhibition with UVA
Irradiation
These experiments were performed by Mr Aron F. Westendorf in the laboratory of
Prof Patrick Bednarski at the Institut für Pharmazie der Ernst-Moritz-Arndt der
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Greisfwald Universität in Germany. All stock solutions were prepared in DMSO and
were stored at 243 K. Prior to testing, the stock solutions were removed from the
freezer and serially diluted in DMSO 2-fold to the desired concentrations, giving
series of five dilutions. To investigate the cytotoxic potency of the compounds, six
different human cancer cell lines were used: SISO cervical cancer, 5637 and RT-4
bladder cancer, A-427 and LCLC-103H lung cancer, and DAN-nG pancreas
carcinoma cell lines. All human cancer cell lines were obtained from the German
Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig), Table 2.1.
Table 2.1 Human cancer cell lines used in the photocytotoxicity test.
Cell line Patient
(sex, age)
Origin Doubling time
(h)
5637 M, 68 Urinary bladder carcinoma 30
A-427 M, 52 Lung carcinoma 38
SISO F, 67 Cervix adenocarcinoma 48
DAN-G – Pancreas carcinoma 42
LCLC-103H M, 61 Large cell lung cancer 40
RT-4 M, 63 Urinary bladder carcinoma 44
Cells were grown in medium containing 90% RPMI 1640 medium (Sigma,
Taufenkirchen, Germany) and 10% Fetal Calf Serum (FCS) (Sigma), supplemented
with penicillin G/streptomycin. Cells were kept at 310 K in a water-saturated
atmosphere of 5% CO2 air. Shortly before the cells reached confluence, the cells were
passaged.
2.13.1 Screening Method
The cells were seeded out in 96-well microtiter plates in 100 μL medium at a density 
of 1000 cells/well. The plates were returned to the incubator for 24 h. For the primary
screening the stock solutions of the compounds were used. The next day the stock
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solutions were directly diluted in medium 500-fold. Medium (100 μL) containing the
compounds was added to each well with a maximum DMSO concentration of 0.1 %
(v/v). After a preincubation period of 1 h the plates were either irradiated for 30 min
with UVA light λ = 366 nm or kept in the dark. Luzchem Expo panels (Luzchem 
Reasearch Inc., Ontario, Canada) were used for irradiation. The two Expo panels were
accommodated with 5 fluorescent lamps each. Lower UV light was cut off by a filter.
The light source was positioned 25 cm away from the samples giving an intensity of
0.12 W/cm2. Medium removal occurred after 6 h. After the complete incubation
period of 96 h the medium was discarded and replaced for 25 min with a 1%
glutaraldehyde buffer (PBS) solution to fix the cells. The fixing buffer was discarded
and the cells were stored under PBS at 269 K until staining. Staining was done with a
0.02% solution of Crystal Violet in water. The dye was added to each well and
discarded after 30 min of staining, followed by 15 min washing in water. The cell-
bound dye was redissolved in 70% ethanol/water. Optical density was measured at λ =
570 nm with an Anthos 2010 plate reader (Anthos, Salzburg, Austria). The corrected
T/C values for the dose-response curves were calculated.
T is the mean optical density of the treated cells and C is the optical density of
controls. ODtest is the mean optical density of the treated cells after staining, ODcon is
the mean optical density of the controls and ODt=0 is the mean optical density at the
time the compounds were added. The IC50 values can be calculated by a linear least-
squares regression of the T/Ccorr values versus the logarithm of the added compound
concentration and extrapolating to the T/Ccorr values of 50%.20
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2.14 Synthesis of Starting Materials
The RuII arene precursor dimers of the form [(6-arene)RuX2]2 where arene is p-cym
= para-cymene, or bip = biphenyl, and X is Cl, Br, or I were synthesised according to
a previously reported method21; [(6-etb)RuCl2]2 where etb = ethylbenzoate was
synthesised following published literature.22 The RuII arene precursor dimers [(6-
arene)RuCl2]2 where arene is hmb = hexamethylbenzene, ind = indane, or thn =
tetrahydronaphtalene were kindly provided by Dr Abraha Habtemariam and
synthesised according to a reported method.21
2.14.1 Materials
RuCl3·3H2O was acquired from Precious Metals Online (PMO Pty Ltd) and used as
received. The arenes (p-cym and bip) were purchased from Sigma-Aldrich. 1,4-
dihydrobiphenyl was prepared by a previously reported procedure.23
2.14.2 Preparation of RuII Arene Dimers
[(η6-p-cym)RuCl2]2. To a solution of RuCl3·3H2O (0.15 g, 0.57 mmol) in dry EtOH
(reagent grade) (15 mL), a three-fold excess of α-phellandrene (which upon oxidation
is to be named para-cymene (p-cym)) (0.23 g, 1.7 mmol) was added with constant
stirring and allowed to react during 18 h. The solvent was then completely removed
under vacuum and the remaining solid was washed with portions of EtOH and Et2O (3
× 20 mL) to obtain the corresponding dimer [(η6-p-cym)RuCl2]2 as a red brown solid;
yield 85% (3.50 g, 5.71 mmol). Elemental Analysis calc. for C21H28Cl4Ru2 %C:
39.23, %H: 4.61; found %C: 39.27, %H: 4.51. 1H NMR ((CD3)2SO, 400 MHz) δH:
1.28 (12H, d), 2.15 (3H, s), 2.50 (2H, sep), 5.35 (4H, m), 5.52 (4H, m).
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[(η6-bip)RuCl2]2. To a solution of RuCl3·3H2O (5.0 g, 19.1 mmol) in dry EtOH (15
mL) a three-fold excess of 1,4-dihydrobiphenyl (4.3 g, 27.5 mmol) was added with
constant stirring and allowed to react during 18 h. The solvent was then completely
removed under vacuum and the remaining solid was washed with portions of EtOH
and Et2O (3 × 20 mL) to obtain the corresponding dimer [(η6-bip)RuCl2]2 as a red
brown solid; yield 43% (5.06 g, 7.76 mmol). Elemental analysis calc. for
C24H20Cl4Ru2 C: 44.19%; H: 3.09%; found: C: 44.18%, H: 3.07%. 1H NMR
((CD3)2SO, 400 MHz) δH: 6.08 (6H, m), 6.44 (4H, m), 7.50 (6H, m), 7.82 (4H, m).
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Chapter 3
Ruthenium(II) Arene Halido Complexes
3.1 Introduction
The well-established mechanism of action of the cytotoxic drug cisplatin is the
alteration of the secondary structure of DNA via coordination to the N7 atom of a
guanine (G) or an adenine (A) base, which requires its prior aquation in the cell to
generate the more reactive aqua complexes [Pt(NH3)2(OH2)Cl]+ and
[Pt(NH3)2(OH2)2]2+.1,2 It is believed that one important potential activation mechanism
of anticancer metal complexes prior to their interactions with biomolecules could be
hydrolysis. It has been shown that certain organometallic RuII complexes of the type
[(η6-arene)Ru(XY)Z]n+ where XY is a bidentate chelating ligand and Z is a leaving
group, can exhibit promising cytotoxic activity against a variety of cancer cell lines,
including cisplatin-resistant cells.3,4 These studies have shown that the nature of the
arene, the chelating ligand, and the leaving group can have a major influence on the
rates of activation (towards hydrolysis and/or binding to biomolecules) as well as on
the cytotoxic activity.5 It appears that a more hydrophobic arene ligand along with a
single ligand exchange site might be associated with significant anticancer activity.
Blockage from further ligand exchange reactions in the remaining two coordination
sites can be usually achieved by coordination of a stable bidentate ligand; in this
regard, particularly effective are those containing N,N'-heterocyclic groups.6 For
example, RuII arene complexes with chelating 1,10-phenanthroline (phen), 2,2'-
bipyridine (bpy), or arylazopyridine (azpy) ligands have been extensively studied and
have been reported to show promising cytotoxicity.7,8 In the present work, the
possibility to tune the chemical reactivity of organometallic RuII complexes of the
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type [(η6-arene)Ru(N,N')X][PF6] by systematically varying the ligands around the
metal centre is explored. RuII arene complexes containing various N,N'-chelating
ligands, which all form six-membered chelate rings upon binding, as well as various
arenes, and different halides were synthesised and characterised. The aqueous solution
chemistry as well as nucleobases binding (to 9-EtG and 9-EtA) were investigated.
Their potential as cytotoxic agents was explored not only by determining IC50 values
against A2780 (human ovarian), A2780cis (human ovarian cisplatin resistant), A549
(human lung) or HCT116 (human colon) cancer cell lines but also by studying
preliminary DNA interactions in cell-free media.
3.2 Experimental Section
3.2.1 Materials
RuCl3·3H2O was acquired from Precious Metals Online (PMO Pty Ltd) and used as
received. 2,2'-bipyrimidine (bpm), 1,10-phenanthroline (phen), 1,10-phenanthroline-
5,6-dione (phendio), 4,7-diphenyl-1,10-phenanthroline (bathophen), 6-
mercaptopurine (MP), 9-ethylguanine (9-EtG), 9-ethyladenine (9-EtA), and KPF6
were obtained from Sigma-Aldrich. KBr and KI (reagent grade) were obtained from
Fisher. The RuII arene precursor dimers [(6-arene)RuX2]2 where arene is para-
cymene (p-cym), or biphenyl (bip), and X is Cl, Br, or I were synthesised according to
a previously reported method9 as described in Chapter 2. The dimer [(6-etb)RuCl2]2
where etb is ethylbenzoate was synthesised following published literature.10 [(6-
arene)RuCl2]2 precursor dimers where arene is hexamethylbenzene (hmb), indane
(ind), or tetrahydronaphthalene (thn) were kindly provided by Dr Abraha
Habtemariam from the Department of Chemistry at the University of Warwick and
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synthesised according to a published method.9 The solvents used for UV-vis
absorption spectroscopy were dry methanol (reagent grade) and deionised water. For
NMR spectroscopy the solvents used were (CD3)2CO-d6, DMSO-d6, MeOD-d4 and
D2O obtained from Aldrich unless otherwise stated. All chemicals were used without
further puriﬁcation. 
3.2.2 Preparation of RuII Arene Halido Complexes
Complexes of the form [(η6-arene)Ru(N,N')X][PF6] where arene is p-cym, bip, etb,
ind, hmb, or thn; N,N' is bpm, phen, phendio, or bathophen; and X is Cl, Br, or I were
synthesised as previously described5b using a similar procedure. Typically, two mol
equiv of the N,N' chelating ligand and two mol equiv of KPF6 were added to a
solution of one mol equiv of the appropriate RuII arene dimer in 20 mL of dry
methanol (reagent grade) with constant stirring, and reacted for 48 h upon which the
precipitate formed was collected by filtration. The remaining solution was
concentrated and portions of Et2O were added to further precipitate the product which
was again collected by filtration. Both solids were combined and washed with
portions of Et2O and MeOH and dried overnight under vacuum resulting in
microcrystalline products. Details of the amounts of reactants, volumes of solvents,
colour changes, and nature of the products are described below for the individual
reactions, as well as any variations in the synthetic procedure. 13C{1H} NMR
spectroscopy data are also provided for samples where a satisfactory elemental
analysis was not obtained.
[(6-p-cym)Ru(bpm)Cl][PF6] (1). [(6-p-cym)RuCl2]2 (0.15 g, 0.24 mmol), 2,2'-
bipyrimidine (bpm) (0.08 g, 0.49 mmol) and KPF6 (0.09 g, 0.49 mmol) in dry
methanol; the solution turned from red to yellow; a bright yellow solid was obtained;
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yield 83% (0.12 g, 0.20 mmol). Elemental analysis calc. for C19H23ClF6N4PRu %C:
37.67, %H: 3.51, %N: 9.76; found %C: 36.98, %H: 3.40, %N: 9.44. HR-MS: calc for
C18H20ClN4Ru [M]+ m/z 429.0420, found m/z 429.0416. 1H NMR (D2O, 700 MHz)
δH: 1.06 (6H, d, J = 7.0), 2.16 (3H, s), 2.68 (1H, sep, J = 7.0), 5.97 (2H, d, J = 6.4),
6.16 (2H, d, J = 6.4), 7.94–7.96 (2H, m), 9.20 (2H, dd, J = 1.9, J = 4.8), 9.70 (2H, dd,
J = 2.0, J = 5.8).
[(6-p-cym)Ru(bpm)Br][PF6] (2). [(6-p-cym)RuBr2]2 (0.15 g, 0.19 mmol), 2,2'-
bipyrimidine (bpm) (0.08 g, 0.49 mmol) and KPF6 (0.09 g, 0.49 mmol) in dry
methanol; the solution turned from red to yellow; a dark yellow solid was obtained;
yield 83% (0.04 g, 0.13 mmol). HR-MS: calc for C18H20BrN4Ru [M]+ m/z 474.9892,
found m/z 474.9915. 1H NMR (D2O, 700 MHz) δH: 1.07 (6H, d, J = 7.2), 2.22 (3H, s),
2.74 (1H, sep, J = 7.2), 5.94 (2H, d, J = 6.4), 6.12 (2H, d, J = 6.4), 7.92–7.94 (2H, m),
9.18 (2H, dd, J = 1.9, J = 4.9), 9.66 (2H, dd, J = 1.9, J = 5.9). 13C{1H} NMR
((CD3)2CO, 175 MHz) δC: 19.1, 22.3, 32.2, 86.6, 86.9, 103.5, 108.6, 125.4, 161.1,
161.3, 164.2.
[(6-p-cym)Ru(bpm)I][PF6] (3). [(6-p-cym)RuI2]2 (0.15 g, 0.15 mmol), 2,2'-
bipyrimidine (bpm) (0.049 g, 0.30 mmol) and KPF6 (0.06 g, 0.30 mmol) in dry
methanol; the solution turned from red to yellow; a bright orange solid was obtained;
yield 80% (0.08 g, 0.12 mmol). Suitable crystals for X-ray crystallography were
obtained from a saturated acetone-d6 solution at room temperature. Elemental analysis
calc. for C18H20IF6N4PRu %C: 32.49, %H: 3.03, %N: 8.42; found %C: 31.81, %H:
2.85, %N: 8.25. HR-MS: calc for C18H20IN4Ru [M]+ m/z 520.9775, found m/z
520.9782. 1H NMR (D2O, 700 MHz) δH: 1.08 (6H, d, J = 7.1), 2.32 (3H, s), 2.84 (1H,
sep, J = 7.1), 5.92 (2H, d, J = 6.4), 6.07 (2H, d, J = 6.4), 7.88–7.90 (2H, m), 9.15 (2H,
dd, J = 1.8, J = 4.8), 9.60 (2H, dd, J = 2.0, J = 5.9).
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[(6-bip)Ru(bpm)Cl][PF6] (4). [(6-bip)RuCl2]2 (0.10 g, 0.15 mmol), 2,2'-
bipyrimidine (bpm) (0.05 g, 0.30 mmol) and KPF6 (0.06 g, 0.30 mmol) in dry
methanol; the solution turned from brown to dark green; a dark yellow solid was
obtained; yield 77% (0.07 g, 0.11 mmol). Suitable crystals for X-ray crystallography
were obtained from slow diffusion of Et2O into an acetone saturated solution at 278
K. Elemental analysis calc. for C20H16ClF6N4PRu·H2O %C: 39.26, %H: 2.97, %N:
9.16; found %C: 38.90, %H: 2.58, %N: 8.64. HR-MS: calc for C20H16ClN4Ru [M]+
m/z 449.0103, found m/z 449.0116. 1H NMR ((CD3)2SO, 500 MHz) δH: 6.22–6.24
(1H, m,) 6.63–6.64 (2H, m), 6.69–6.70 (2H, m), 7.46–7.48 (2H, m), 7.52–7.53 (1H,
m), 7.76–7.77 (2H, m), 7.93–7.95 (2H, m), 9.28–9.29 (2H, m), 9.72–9.73 (m, 2H).
[(6-bip)Ru(bpm)Br][PF6] (5). [(6-biph)RuBr2]2 (0.13 g, 0.16 mmol), 2,2'-
bipyrimidine (bpm) (0.05 g, 0.32 mmol) and KPF6 (0.06 g, 0.32 mmol) in dry
methanol; the solution turned from dark red to dark yellow; a green solid was
obtained; yield 71% (0.07 g, 0.11 mmol). Elemental analysis calc. for
C20H16BrF6N4PRu·H2O %C: 36.60, %H: 2.76, %N: 8.54; found C: %36.60, %H: 2.46,
%N: 8.55. HR-MS: calc for C20H16BrN4Ru [M]+ m/z 492.9596, found m/z 492.9637.
1H NMR ((CD3)2SO, 500 MHz) δH: 6.25–6.27 (1H, m), 6.62–6.63 (2H, m), 6.69–6.70
(2H, m), 7.45–7.46 (2H, m), 7.51–7.52 (1H, m), 7.72–7.74 (2H, m), 7.90–7.92 (2H,
m), 9.26–9.27 (2H, m), 9.68–9.69 (2H, m).
[(6-bip)Ru(bpm)I][PF6] (6). [(6-biph)RuI2]2 (0.10 g, 0.10 mmol), 2,2'-
bipyrimidine (bpm) (0.03 g, 0.20 mmol) and KPF6 (0.04 g, 0.20 mmol) in dry
methanol; the solution turned from dark red to dark yellow; a yellow-greenish solid
was obtained; yield 73% (0.05 g, 0.07 mmol). Suitable crystals for X-ray
crystallography were obtained from a saturated acetone-d6 solution at room
temperature. Elemental analysis calc. for C20H16F6IN4PRu·2H2O %C: 33.30, %H:
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2.79, %N: 7.77; found %C: 33.27, %H: 2.23, %N: 6.37. HR-MS: calc for
C20H16IN4Ru [M]+ m/z 540.9463, found m/z 540.9481. 1H NMR ((CD3)2SO, 500
MHz) δH: 6.11–6.13 (1H, m), 6.65–6.66 (2H, m), 6.72–6.73 (2H, m), 7.40–7.41 (2H,
m), 7.48–7.49 (1H, m), 7.66–7.67 (2H, m), 7.85–7.87 (m, 2H), 9.23–9.24 (2H, m),
9.57–9.58 (2H, m).
[(6-etb)Ru(bpm)Cl][PF6] (7). [(6-etb)RuCl2]2 (0.10 g, 0.16 mmol), 2,2'-
bipyrimidine (bpm) (0.06 g, 0.32 mmol) and KPF6 (0.06 g, 0.32 mmol) in dry
methanol; the solution turned from red to orange; a bright orange solid was obtained;
yield 93% (0.20 g, 0.36 mmol). Suitable crystals for X-ray crystallography were
obtained from slow diffusion of Et2O into an acetone saturated solution at 278 K.
Elemental analysis calc. for C17H16ClF6N4O2PRu %C: 34.62, %H: 2.73, %N: 9.50;
found %C: 34.54, %H: 2.65, %N: 9.40. HR-MS: calc for C17H16ClN4O2Ru [M]+ m/z
445.0001, found m/z 445.0018. 1H NMR ((CD3)2CO, 600 MHz) δH: 1.42 (3H, t, J =
7.1), 4.52 (2H, q, J = 7.1), 6.44–6.47 (2H, m), 6.77–6.80 (1H, m), 7.22 (2H, d, J =
6.1), 8.08–8.11 (2H, m), 9.37 (2H, dd, J = 2.4, J = 4.9), 9.90 (2H, dd, J = 1.8, J = 5.5).
[(6-hmb)Ru(bpm)Cl][PF6] (8). [(6-hmb)RuCl2]2 (0.10 g, 0.15 mmol), 2,2'-
bipyrimidine (bpm) (0.05 g, 0.29 mmol) and KPF6 (0.02 g, 0.15 mmol) in dry
methanol; the solution turned from red to dark yellow; a bright yellow solid was
obtained; yield 82% ( 0.04 g, 0.06 mmol). Elemental analysis calc. for
C20H24ClF6N4PRu·H2O %C: 38.75, %H: 4.23, %N: 9.04; found %C: 38.17, %H: 3.92,
%N: 8.76. HR-MS: calc for C20H24ClN4Ru [M]+ m/z 457.0729, found m/z 457.0732.
1H NMR ((CD3)2CO, 600 MHz) δH: 2.31 (18H, s), 8.06–8.09 (2H, m), 9.31 (2H, dd, J
= 1.8, J = 4.7), 9.47 (2H, dd, J = 1.8, J = 5.7).
[(6-ind)Ru(bpm)Cl][PF6] (9). [(6-ind)RuCl2]2 (0.10 g, 0.17 mmol), 2,2'-
bipyrimidine (bpm) (0.06 g, 0.34 mmol) and KPF6 (0.03 g, 0.17 mmol) in dry
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methanol; the solution turned from red to dark brown; a dark green solid was
obtained; yield 79% (0.06 g, 0.11 mmol). Elemental analysis calc. for
C17H16ClF6N4PRu·H2O %C: 35.46, %H: 3.15, %N: 9.73; found %C: 35.41, %H: 2.67,
%N: 9.67. HR-MS: calc for C17H16ClN4Ru [M]+ m/z 413.0103, found m/z 413.0100.
1H NMR (CD3OD, 600 MHz) δH: 2.05–2.22 (4H, m), 2.92–3.00 (2H, m), 6.00–6.02
(2H, m), 6.28–6.30 (2H, m), 7.95–7.98 (2H, m), 9.28–9.30 (2H, m), 9.71–9.73 (2H,
m).
[(6-thn)Ru(bpm)Cl][PF6] (10). [(6-thn)RuCl2]2 (0.10 g, 0.17 mmol), 2,2'-
bipyrimidine (bpm) (0.06 g, 0.34 mmol) and KPF6 (0.03 g, 0.17 mmol) in dry
methanol; the solution turned from red to dark green; a bright yellow solid was
obtained; yield 87% (0.08 g, 0.15 mmol). Elemental analysis calc. for
C18H18ClF6N4PRu·2H2O %C: 35.57, %H: 3.65, %N: 9.22; found %C: 35.32, %H:
2.90, %N: 9.23. HR-MS: calc for C17H16ClN4Ru [M]+ m/z 426.8885, found m/z
426.0235. 1H NMR (CD3OD, 600 MHz) δH: 1.56–1.64 (2H, m), 1.69–1.77 (2H, m),
2.66–2.69 (2H, m), 2.74–2.77 (2H, m), 5.92–5.96 (2H, m), 6.03–6.05 (2H, m), 7.82–
7.85 (2H, m), 9.12 (2H, dd, J = 2.0, J = 4.7), 9.66 (2H, dd, J = 2.0, J = 5.7)
[(6-p-cym)Ru(phen)Cl][PF6] (11). [(6-p-cym)RuCl2]2 (0.10 g, 0.16 mmol), 1,10-
phenanthroline (phen) (0.06 g, 0.32 mmol) and KPF6 (0.06 g, 0.32 mmol) in dry
methanol; the solution turned from red to bright yellow; a bright yellow solid was
obtained; yield 92% (0.17 g, 0.30 mmol). Elemental analysis calc. for
C22H22ClF6N2PRu %C: 44.34, %H: 3.72, %N: 4.40; found %C: 43.66, %H: 3.63, %N:
4.75. HR-MS: calc for C22H22ClN2Ru [M]+ m/z 451.0512, found m/z 451.0530. 1H
NMR (D2O, 600 MHz) δH: 0.88 (6H, d, J = 6.9), 2.19 (3H, s), 2.54 (1H, sep, J = 6.9),
5.96 (2H, d, J = 6.4), 6.19 (2H, d, J = 6.4), 8.7 (2H, dd, J = 5.3, J = 8.3), 8.16 (2H, s),
8.78 (2H, dd, J = 1.0, J = 8.3), 9.75 (2H, dd, J = 1.0, J = 5.3).
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[(6-p-cym)Ru(phendio)Cl][PF6] (12). [(6-p-cym)RuCl2]2 (0.10 g, 0.16 mmol),
1,10-phenanthroline-5,6-dione (phendio) (0.06 g, 0.32 mmol) and KPF6 (0.06 g, 0.32
mmol) in dry methanol; the solution turned from red to dark green; a bright dark
green solid was obtained; yield 93% (0.17 g, 0.30 mmol). HR-MS: calc for
C22H20ClF6N2O2Ru [M]+ m/z 481.0254, found m/z 481.0261. 1H NMR ((CD3)2CO,
600 MHz) δH: 1.14 (6H, d, J = 6.9), 2.36 (3H, s), 2.84 (1H, sep, J = 6.9), 6.11 (2H, d,
J = 5.9), 6.37 (2H, d, J = 5.9), 8.07–8.10 (2H, m), 8.77–8.79 (2H, m), 9.82–9.83 (2H,
m). 13C{1H} NMR ((CH3)2CO, 125 MHz) δC: 18.1, 21.4, 31.0, 65.2, 84.5, 86.3, 104.2,
106.1, 128.8, 137.8, 154.1, 159.3, 174.2.
[(6-p-cym)Ru(bathophen)Cl][PF6] (13). [(6-p-cym)RuCl2]2 (0.10 g, 0.16 mmol),
4,7-diphenyl-1,10-phenanthroline (bathophen) (0.11 g, 0.32 mmol) and KPF6 (0.06 g,
0.32 mmol) in dry methanol; the solution turned from red to dark green; a bright dark
green solid was obtained; yield 88% (0.21 g, 0.29 mmol). Elemental analysis calc. for
C34H30ClF6N2PRu %C: 54.59, %H: 4.04, %N: 3.74; found %C: 54.10, %H: 3.88, %N:
3.71. HR-MS: calc for C34H30ClN2Ru [M]+ m/z 603.1141, found m/z 603.1154. 1H
NMR ((CD3)2CO, 600 MHz) δH: 1.16 (6H, d, J = 7.0), 2.36 (3H, s), 2.92 (1H, sep, J =
7.0), 6.22 (2H, d, J = 6.5), 6.42 (2H, d, J = 6.5), 7.69–7.77 (10H, m), 8.15 (2H, d, J =
5.5), 8.23 (2H, s), 10.07 (2H, d, J = 5.5).
[(6-p-cym)Ru(MP)Cl][PF6] (14). [(6-p-cym)RuCl2]2 (0.10 g, 0.16 mmol), 6-
mercaptopurine (MP) (0.11 g, 0.32 mmol) and KPF6 (0.06 g, 0.32 mmol) in dry
methanol; the solution turned from red to dark yellow; a bright yellow solid was
obtained; yield 22% (0.04 g, 0.07 mmol). Elemental analysis calc. for
C15H18ClF6N4PRuS %C: 31.72, %H: 3.19, %N: 9.87; found %C: 31.52, %H: 3.18,
%N: 9.41. HR-MS: calc for C15H17N4RuS [M]+ m/z 387.0215, found m/z 387.0207. 1H
NMR (CD3OD, 600 MHz) δH: 1.23 (3H, d, J = 6.9), 1.26 (3H, d, J = 6.9), 2.25 (3H,
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s), 2.84 (1H, sep, J = 6.9), 5.73 (1H, d, J = 5.9), 5.87 (1H, d, J = 6.0), 5.95 (1H, d, J =
6.1), 6.05 (1H, d, J = 5.9), 8.56 (1H, s), 9.21 (1H, s).
[(6-p-cym)Ru(bpm)(9-EtG-N7)][PF6]2 (15). [(6-p-cym)Ru(bpm)Cl][PF6] (0.10 g,
0.17 mmol), AgNO3 (0.03 g, 0.17 mmol), 9-ethylguanine (9-EtG) (0.10 g, 5.22 mmol)
and KPF6 (0.16 g, 0.85 mmol) in 10 mL of a 1:1 mixture of MeOH/H2O; the solution
turned from bright to dark yellow; a dark yellow solid was obtained; yield 68% (0.10
g, 0.12 mmol). Suitable crystals for X-ray crystallography were obtained from a
saturated water/acetone solution at room temperature. Elemental analysis calc. for
C25H29F12N9OP2Ru·2H2O %C: 33.42, %H: 3.70, %N: 14.03; found %C: 33.13, %H:
3.42, %N: 13.67. HR-MS: calc. for C25H29N9ORu [M]2+ m/z 286.5767, found m/z
286.5774. 1H NMR (D2O, 500 MHz) δH: 0.95 (6H, d, J = 7.0), 1.15 (3H, d, J = 7.0),
1.89 (3H, s), 2.46 (1H, sep, J = 7.0), 3.85 (2H, q, J = 7.0), 6.12 (2H, d, J = 7.0), 6.35
(2H, d, J = 6.5), 7.29 (1H, s), 7.99 (2H, t, J = 5.0), 9.19 (2H, dd, J = 2.0, J = 5.0),
10.08 (2H, dd, J = 2.0, J = 6.0).
3.2.3 X-ray Crystallography
The details of the diffraction instrumentation are described in Chapter 2. The X-ray
crystal structures discussed in this chapter were determined by Dr Guy Clarkson from
the Department of Chemistry at the University of Warwick. The structures of
complexes 3, 4, 6, 7 and 15 were solved by direct methods using SHELXS11 (TREF)
with additional light atoms found by Fourier methods. Hydrogen atoms were added at
calculated positions and refined using a riding model with freely rotating methyl
groups. Anisotropic displacement parameters were used for all non-H atoms; H-atoms
were given isotropic displacement parameters equal to 1.2 (or 1.5 for methyl
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hydrogen atoms) times the equivalent isotropic displacement parameter of the atom to
which the H-atom is attached. Refinement used SHELXL 97.12
3.2.4 Aqueous Solution Chemistry
3.2.4.1 Determination of the Ru−X Bond Hydrolysis  
Hydrolysis of the RuII arene halido complexes was monitored by UV-vis
spectroscopy. The nature of the hydrolysis products as well as the extent of the
reactions were verified by 1H NMR spectroscopy or HR-MS. For UV-vis
spectroscopy the complexes were dissolved in methanol and diluted with H2O to give
100 μM solutions (5% MeOH/95% H2O). The absorbance was recorded at several
time intervals at the selected wavelength (at which the maximum changes in
absorbance were registered) over ca. 8–16 h at 310 K. Plots of the change in
absorbance with time were computer-fitted to the pseudo first-order rate equation, A =
C0 + C1e–kt (where C0 and C1 are computer-fitted constants and A is the absorbance
corresponding to time) using Origin version 8.0 (Microcal Software Ltd.) to give the
half-lives (t1/2, min) and rate constant values (k, min–1). For 1H NMR spectroscopy,
the complexes were dissolved in MeOD-d4 and diluted with D2O to give 100 μM 
solutions (5% MeOD-d4/95% D2O). The spectra were acquired at various time
intervals on a Bruker DMX 700 spectrometer (1H = 700 MHz) using 5 mm diameter
tubes. All data processing was carried out using XWIN NMR version 2.0 (Bruker
U.K. Ltd.). 1H NMR signals were referenced to dioxane as an internal reference (δ =
3.71). The relative amounts of RuII arene halido species or aqua adducts (determined
by integration of peaks in 1H NMR spectra) were quantified.
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3.2.4.2 Determination of the Rate of Arene Loss
The complexes were dissolved in MeOD-d4 and diluted with D2O to give 100 μM 
solutions (5% MeOD-d4/95% D2O). Arene loss over time was followed by 1H NMR
spectroscopy at 310 K for 24 h.
3.2.5 Interactions with Nucleobases
The reaction of the RuII arene halido complexes with 9-ethylguanine (9-EtG) or 9-
ethyladenine (9-EtA) was monitored over time. D2O solutions (100 μM) of the RuII
arene complexes were mixed with equimolar amounts of the corresponding
nucleobases and the 1H NMR spectra of the resulting solution was recorded at 310 K
at various time intervals for 48 h.
3.2.6 DFT Calculations
Density functional theory (DFT) calculations were performed using the Amsterdam
Density Functional (ADF) program suite (version 2009.01).13 The conductor-like
screening model (COSMO), as implemented in the ADF program, was used to
simulate aqueous environments.
3.2.6.1 Mechanism of Hydrolysis
Geometries and energies were obtained by using the non-relativistic Perdew/Wang
gradient-corrected functional (PW91). The conductor-like screening model (COSMO)
as implemented in ADF was used to simulate the aqueous environment with ε = 78.4, 
probe radius = 1.9 Å, and the ND parameter which controls integration accuracy set to
4 (default 3). The frozen-core approximation14 was applied with the orbitals up to and
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including that labelled in brackets as follows: Ru[3d], O[1s], C[1s], N[1s], Cl[2p],
Br[4p], and I[4d]. Basis sets and other details are described in A.3.1.
3.2.6.2 DFT-Geometry Optimisation of RuII Arene Nucleobase Adducts
Geometry optimisations were carried out for the 9-EtG and 9-EtA adducts of [(6-p-
cym)Ru(bpm)(9-EtG-N7)]2+ (1-9EtG), [(6-p-cym)Ru(bpm)(9-EtA-N7)]2+ (1-9EtA),
[(6-hmb)Ru(bpm)(9-EtG-N7)]2+ (8-EtG), [(6-hmb)Ru(bpm)(9-EtA-N7)]2+ (8-EtA)
[(6-ind)Ru(bpm)(9-EtG-N7)]2+ (9-EtG), [(6-ind)Ru(bpm)(9-EtA-N7)]2+ (9-EtA),
[(6-thn)Ru(bpm)(9-EtG-N7)]2+ (10-EtG-N7), [(6-thn)Ru(bpm)(9-EtG-N3)]2+ (10-
EtG-N3), [(6-thn)Ru(bpm)(9-EtA-N7)]2+ (10-EtA), [(6-p-cym)Ru(phen)(9-EtG-
N7)]2+ (11-EtG), [(6-p-cym)Ru(phen)(9-EtA-N7)]2+ (11-EtA), [(6-p-
cym)Ru(bathophen)(9-EtG-N7)]2+ (13-EtG), and [(6-p-cym)Ru(bathophen)(9-EtA-
N7)]2+ (13-EtA); for the free 9-ethylguanine and 9-ethyladenine molecules, as well as
for the RuII arene cations without the bound 9-EtG or 9-EtA. The energies of the
separate fragments were subtracted from the energy of the entire RuII arene
nucleobase adducts in the optimised geometry calculation to obtain the total binding
energy of 9-EtG and 9-EtA in each complex.
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3.3 Results
3.3.1 Synthesis and Characterisation
The [(6-arene)Ru(N,N')X]n+ complexes studied in this work are listed in Table 3.1
and their general structures are shown in Figure 3.1. The monocationic RuII arene
halido complexes 1−14 were synthesised as PF6 salts in good yields (>50% in almost
all cases) by the reaction of the corresponding [(6-arene)RuX2]2 dimer and an excess
of the N,N'/N,S chelating ligand in methanol. The 9-EtG-N7 complex 15 was
synthesised as a PF6 salt in good yield (~68%) by the reaction of [(6-p-
cym)Ru(bpm)Cl][PF6] (1) with AgNO3 in a 1:1 mixture of MeOH/H2O to afford the
corresponding aqua species [(6-p-cym)Ru(bpm)(OH2)]2+ to which excesses of 9-EtG
and KPF6 were added. All the synthesised complexes were fully characterised by 1D
and 2D 1H NMR methods as well as 1D 13C{1H} NMR. The 1H NMR resonances of
the 6-coordinated arenes and N,N'/N,S ligands in all the RuII arene halido complexes
are low-field-shifted ca. 0.6 ppm compared to the free ligands. In the case of the
mercaptopurine complex [(6-p-cym)Ru(MP)Cl][PF6] (14), the four aromatic protons
within the p-cym ring were observed as a set of four doublets (one doublet per
proton), Figure 3.2.
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Figure 3.1. General structures of the complexes studied in this work synthesised as
PF6 salts.
Table 3.1. [(6-arene)Ru(N,N'/N,S)X]+ complexes studied in this work.
Compound Arene N,N'/N,S X
(1) p-cym bpm Cl
(2) p-cym bpm Br
(3) p-cym bpm I
(4) bip bpm Cl
(5) bip bpm Br
(6) bip bpm I
(7) etb bpm Cl
(8) hmb bpm Cl
(9) ind bpm Cl
(10) thn bpm Cl
(11) p-cym phen Cl
(12) p-cym phendio Cl
(13) p-cym bathophen Cl
(14) p-cym MP Cl
(15) p-cym bpm 9-EtG
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Figure 3.2. 1H NMR spectra of complex [(6-p-cym)Ru(MP)Cl][PF6] (14) in MeOD-
d4 solution. ■ = MP, ● = p-cym.
3.3.2 X-ray Crystal Structures
The molecular structures of complexes 3, 4, 6, 7 and 15 were determined by single
crystal X-ray diffraction. The molecular structure of complex 1 has been previously
published.9b Selected bond lengths and angles are given in Table 3.2, the structures
with numbering schemes are shown in Figure 3.3 and the crystallographic data are
listed in Table A.3.1. Selected H-bond lengths and angles not described herein are
shown in Table A.3.2. In all cases, the complexes adopt the familiar pseudo-
octahedral three-legged piano stool geometry common to all other RuII arene
structures15 with the RuII atom π-bonded to the corresponding arene ligand (p-cym in
3 and 15; bip in 4 and 6; or etb in 7), coordinated to a chloride (4 and 7), to an iodide
(3 and 6), or to N7 of 9-EtG (15), and to two nitrogen atoms of the chelating ligand
2,2'-bipyrimidine (bpm) which constitute the three legs of the piano stool.
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Table 3.2. Selected bond lengths (Å) and angles (o) for [(6-p-cym)Ru(bpm)I][PF6]
(3), [(6-bip)Ru(bpm)Cl][PF6] (4), [(6-bip)Ru(bpm)I][PF6] (6), [(6-
etb)Ru(bpm)Cl][PF6] (7), and [(6-p-cym)Ru(bpm)(9-EtG-N7)][PF6]2 (15).
Bond length/angle (3) (4) (6) (7) (15)
Ru−arene
(centroid)
1.704 1.691 1.693 1.684 1.693
Ru(1)−I(1) 2.706(3) – 2.70476(16) – –
Ru(1)−Cl(1) – 2.402(8) – 2.3743(9) –
Ru(1)−N(13) 
Ru(1)−N(1) 
–
2.091(2)
–
2.092(2)
–
2.0901(12)
–
2.073(3)
2.1125(19)
2.0972(18)
Ru(1)−N(8) 2.0833(19) 2.093(2) 2.0833(12) 2.081(3) 2.0941(18)
C(6)−C(7) 1.472(4) 1.476(4) 1.477(2) 1.472(5) 1.477(3) 
N(8)−Ru(1)−N(1) 76.78(8) 76.72(9) 76.90(5) 77.06(12) 77.05(7)
I(1)−Ru(1)−N(8) 86.38(6) – 82.60(3) – – 
Cl(1)−Ru(1)−N(8) – 83.64(6) – 83.36(8) – 
I(1)−Ru(1)−N(1) 85.79(6) – 88.00(3) – – 
Cl(1)−Ru(1)−N(1) – 83.00(7) – 84.67(8) – 
N(13)−Ru(1)−N(8) – – – – 86.59(7)
N(13)−Ru(1)−N(1) – – – – 88.64(7)
The RuII to p-cym(centroid) distances (as measured from Mercury version 2.2) do not
vary significantly between all the derivatives. Similarly, the Ru−Cl bond lengths in 
the RuII arene chlorido complexes are almost the same (~2.4 Å). The Ru(1)−I(1) bond 
lengths in 3 and 6 are also within the same range (~2.7 Å). The Ru(1)−N(1)(bpm) and
Ru(1)−N(8)(bpm) bond lengths in these arene complexes are ~2.09 Å. The
N(1)−Ru(1)−N(8) bond angles in complexes 3, 4, 6, 7, and 15 do not differ
significantly from each other. In the case of complex [(6-bip)Ru(bpm)Cl][PF6] (4),
Figure 3.4 the RuII molecules lay back-to-back with an adjacent complex in an
intermolecular π-π stacking interaction. The mean planes, defined by both the bound 
and the unbound phenyl rings (ph) in the bip arene, are perfectly parallel. The shortest
atomic contact C(16)∙∙∙C(22) is 3.298 Å and the centroid-centroid distance is 4.182 Å. 
The uncoordinated ph ring is tilted 36.2º relative to the main plane defined by the Ru–
coordinated ph ring.
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Figure 3.3. X-ray structure of the cations [(6-p-cym)Ru(bpm)I]+ (3), [(6-
bip)Ru(bpm)Cl]+ (4), [(6-bip)Ru(bpm)I]+ (6), [(6-etb)Ru(bpm)Cl]+ (7), and [(6-p-
cym)Ru(9-EtG-N7)]2+ (15). Thermal ellipsoids show 50% probability. The PF6 anions
and hydrogens have been omitted for clarity.
An intramolecular π-π interaction was found in the crystal structure of [(6-
bip)Ru(bpm)I][PF6] (6). The angle between mean planes of the interacting π systems 
(the uncoordinated ph ring in bip and a pyrazine ring from bpm) is 30.9°, the shortest
atomic contact C(19)∙∙∙C(2) is 3.130 Å, and the centroid-centroid distance is 4.183 Å, 
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Figure 3.5. The uncoordinated ph ring is tilted 31.48º towards the bpm chelating
ligand.
Figure 3.4. X-ray crystal structure of the cation [(6-bip)Ru(bpm)Cl]+ (4) showing -
 stacking through the interacting π systems (bip ligand). Inset: Spacefilling model 
showing the - interaction. The PF6 anions and hydrogens have been omitted for
clarity.
Figure 3.5. X-ray crystal structure of the cation [(6-bip)Ru(bpm)I]+ (6) showing -
stacking through the π systems in the bip (uncoordinated benzene ring) and the bpm 
(pyrazine ring). Inset: Spacefilling model showing the - stacking. The PF6 anions
and hydrogens have been omitted for clarity.
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Molecules in the unit cell of complex [(6-etb)Ru(bpm)Cl][PF6] (7) lie in
perpendicularly arranged pairs establishing a CH-π interaction between the C−H 
protons of one of the pyrazine rings in the bpm ligand and the centroid of one of the
pyrazine rings in the bpm (belonging to the neighbouring molecule) with a
C(4)−H(4A)∙∙∙bpm(centroid) distance of 2.927 Å, Figure 3.6.
Figure 3.6. X-ray crystal structure of the cation [(6-etb)Ru(bpm)Cl]+ (7) showing a
CH-π interaction. The PF6 anions and other hydrogens have been omitted for clarity.
In the crystal structure of [(6-p-cym)Ru(bpm)(9-EtG-N7)][PF6]2 (15), two cationic
molecules are interconnected by means of a H-bond interaction in which two water
molecules act as bridges (N26−H26∙∙∙O100(water)∙∙∙H25−N25), Figure 3.7. 
Additionally, the 9-EtG adduct was also characterised by 1H NMR spectroscopy and
Figure 3.8 shows its 2D 1H-1H NOESY spectra. An NOE cross-peak between H8 of
bound 9-EtG and the 2,2'-CH in bpm was observed, suggesting that these two atoms
are in close proximity (as previously observed in analogous RuII arene complexes).16
The twist angles between the aromatic pyrazine rings of the bpm chelating ligand in
complexes 3, 4, 6, 7, and 15 are 4.5°, 4.6°, 9.4°, 10.0° and 4.6°, respectively.
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Figure 3.7. Bis-water bridged interaction found in the X-ray crystal structure of the
cation [(6-p-cym)Ru(bpm)(9-EtG-N7)]2+ (15). The PF6 anions and other hydrogens
have been omitted for clarity.
Figure 3.8. 1H-1H NOESY NMR spectrum of [(η6-p-cym)Ru(bpm)(9-EtG-N7)]2+ (15)
in D2O (aromatic region only). Magenta = [(6-p-cym)Ru(bpm)(9-EtG-N7)]2+; ■ = 
bpm protons, ♦ = H8 of coordinated 9-EtG. 
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3.3.3 Aqueous Solution Chemistry
The aqueous solution chemistry (with respect to hydrolysis) of the RuII arene
complexes 1−14 was studied at 310 K over ca. 8 h–16 h.
3.3.3.1 Hydrolysis Equilibria
In order to characterise the products of hydrolysis and determine the extent of the
reactions, freshly-made 100 μM (5% MeOD-d4/95% D2O) solutions of complexes
1−13 were allowed to equilibrate for 24−48 h at 310 K and were then studied at the 
same temperature using 1H NMR spectroscopy. Complex 14 was synthesised in low
yields and its hydrolysis products were only verified by HR-MS. The 1H NMR spectra
of complexes 1−13 initially contained one major set of peaks (halido species) and then
a second set of peaks increased in intensity with time. The new set of peaks had the
same chemical shifts as those of the aqua adducts under the same conditions (~100
μM solutions, 5% MeOD-d4/95% D2O) at 310 K; the aqua adducts were separately
prepared by treatment of the chlorido complexes with AgNO3 in water at 298 K
overnight and removal of AgCl by filtration. The mass-to-charge ratios and isotopic
models obtained from HR-MS spectra were consistent with the formation of the aqua
adducts as the corresponding products, Table 3.3.
Table 3.4 summarises the percentage of species detected at equilibrium by 1H NMR
after 24 h of reaction for complexes 1−11 and 13 followed by 1H NMR. For
complexes [(6-bip)Ru(bpm)Cl][PF6] (4), [(6-bip)Ru(bpm)Br][PF6] (5), [(6-
etb)Ru(bpm)Cl][PF6] (7), and [(6-p-cym)Ru(phendio)Cl][PF6] (12) a separate set of
peaks was also observed for the products which had undergone arene loss during the
aquation. In the case of complex 12, it was observed that it displayed a complicated
1H NMR spectrum upon dissolution in 5% MeOD-d4/95% D2O at 310 K, suggesting
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that besides hydrolysis of the chlorido bond, another reaction(s) (probably on the N,N'
chelating ligand, 1,10-phenanthroline-5,6-dione (phendio)) had occurred over time.
No further attempts to characterise the reaction products were made.
Table 3.3. Mass-to-charge ratios obtained from HR-MS spectra for the products of
hydrolysis of RuII arene complexes 1−14.
Observed peak
[M]2+
Chemical formula
Calc m/z
Found m/z
(1) [(6-p-cym)Ru(bpm)(OH2)]2+ C18H22N4O
206.0418
206.0408
(2) [(6-bip)Ru(bpm)(OH2)]2+ C20H18N4ORu
216.0262
216.0255
(7) [(6-etbz)Ru(bpm)(OH2)]2+ C17H18N4O3Ru
214.0208
214.0203
(8) [(6-hmb)Ru(bpm)(OH2)]2+ C20H26N4ORu
220.0572
220.0567
(9) [(6-ind)Ru(bpm)(OH2)]2+ C17H18N4ORu
198.0259
198.0254
(10) [(6-thn)Ru(bpm)(OH2)]2+ C17H18N4ORu
204.7250
204.9615
(11) [(6-p-cym)Ru(phen)(OH2)]2+ C22H24N2ORu
217.0466
217.0458
(12) [(6-p-cym)Ru(phendio)(OH2)]2+ C22H22N2O3Ru
232.0337
232.0325
(13) [(6-p-cym)Ru(bathophen)(OH2)]2+ C34H32N2ORu
293.0779
293.0665
(14) [(6-p-cym)Ru(MP)(OH2)]2+ C15H20N4OSRu
202.7415
202.0207
It can be seen that within the series of complexes having p-cym as arene and bpm as
chelating ligand, the Cl (1) and Br (2) complexes hydrolysed to more than ca. 75% at
equilibrium, but the I (3) complex afforded only ca. 31% of the aqua adduct.
Similarly, in the bip/bpm series it was found that the Cl (4) and Br (5) complexes
hydrolysed to a larger extent than the analogous I (6) complex. For complexes 1, 11,
and 12−14 where p-cym (arene) and Cl (leaving group) are constant but the chelating
ligand is varied, the amount of aqua adduct determined by 1H NMR at equilibrium
increases in the order bathophen (13) < phen (11) < bpm (1). When the chelating
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ligand is maintained as bpm and the leaving group as Cl, changing the arene modifies
the extent of hydrolysis in the decreasing order p-cym (1) > thn (10) > ind (9) > hmb
(8) > etb (7) > bip (4).
Table 3.4. Percentage of species present at equilibrium after 24 h of the hydrolysis
reaction in a 100 μM (5% MeOD-d4/95% D2O solution) at 310 K of complexes 1−11
and 13 followed by 1H NMR.
 Compound % Ru−X % Ru−OH2 % Arene loss
(1) [(6-p-cym)Ru(bpm)Cl][PF6] 21.8 78.2 0.0
(2) [(6-p-cym)Ru(bpm)Br][PF6] 10.2 89.8 0.0
(3) [(6-p-cym)Ru(bpm)I][PF6] 68.9 31.1 0.0
(4) [(6-bip)Ru(bpm)Cl][PF6] 34.3 17.6 48.1
(5) [(6-bip)Ru(bpm)Br][PF6] 18.0 13.7 68.3
(6) [(6-bip)Ru(bpm)I][PF6] 95.5 4.5 0.0
(7) [(6-etb)Ru(bpm)Cl][PF6] 78.4 18.7 2.9
(8) [(6-hmb)Ru(bpm)Cl][PF6] 56.2 43.8 0.0
(9) [(6-ind)Ru(bpm)Cl][PF6] 42.1 57.9 0.0
(10) [(6-thn)Ru(bpm)Cl][PF6] 24.6 75.4 0.0
(11) [(6-p-cym)Ru(phen)Cl][PF6] 46.5 53.5 0.0
(13) [(6-p-cym)Ru(bathophen)Cl][PF6] 49.3 50.7 0.0
3.3.3.2 Kinetics of Hydrolysis
Dissolution of compounds 1–14 in 5% MeOH/95% H2O at 310 K gave rise to ligand
exchange reactions as indicated by the concomitant changes in UV-Vis absorption
bands. The time evolution spectra for all the RuII arene complexes at 310 K are shown
in Figure 3.9. The time dependence of the absorbance of all the complexes at the
selected wavelength followed pseudo first-order kinetics in each case. The
corresponding rate constants and half-life values are listed in Table 3.5. The
dependence of the absorbance at 332 nm over ca. 16 h during aquation of [(6-p-
cym)Ru(bpm)Cl][PF6] (1) at 310 K is shown in Figure 3.10.
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Figure 3.9. Time evolution of the hydrolysis reaction of complexes 1–14 in a 100 μM 
(5% MeOH/95% H2O) solution at 310 K followed by UV-vis spectroscopy.
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Table 3.5. Hydrolysis data for complexes 1−14 determined by UV-vis spectroscopy
as 100 μM (5% MeOH/95% H2O) solutions at 310 K.
Compound t1/2 (min) k × 10−3 (min−1)a
(1) [(6-p-cym)Ru(bpm)Cl][PF6] 92.3 7.51 ± 0.07
(2) [(6-p-cym)Ru(bpm)Br][PF6] 22.4 31.0 ± 0.91
(3) [(6-p-cym)Ru(bpm)I][PF6] 234.8 2.95 ± 0.08
(4) [(6-bip)Ru(bpm)Cl][PF6]b 175.9 3.94 ± 0.04
(5) [(6-bip)Ru(bpm)Br][PF6]b 39.7 17.0 ± 0.31
(6) [(6-bip)Ru(bpm)I][PF6]b 714.6 0.97 ± 0.04
(7) [(6-etb)Ru(bpm)Cl][PF6]b 14.5 50.0 ± 0.05
(8) [(6-hmb)Ru(bpm)Cl][PF6] 40.2 17.2 ± 1.32
(9) [(6-ind)Ru(bpm)Cl][PF6] 43.3 16.0 ± 0.15
(10) [(6-thn)Ru(bpm)Cl][PF6] 89.9 7.71 ± 0.44
(11) [(6-p-cym)Ru(phen)Cl][PF6] 22.8 30.5 ± 0.43
(12) [(6-p-cym)Ru(phendio)Cl][PF6]b 59.6 11.6 ± 0.10
(13) [(6-p-cym)Ru(bathophen)Cl][PF6] 16.9 40.8 ± 0.86
(14) [(6-p-cym)Ru(MP)Cl][PF6] 23.9 29.0 ± 0.81
a The errors quoted are fitting errors
b The rate constants for complexes that underwent arene loss detected by 1H NMR (4, 5, 7, and 12)
were determined over the period of time before the onset of arene loss
Figure 3.10. Dependence of the absorbance at 332 nm over ca. 16 h during aquation
of [(6-p-cym)Ru(bpm)Cl][PF6] (1) at 310 K. The red solid line is the best fit to
pseudo-first order kinetics.
From Table 3.5 can be seen that within the series of complexes having p-cym as arene
and bpm as chelating ligand, the hydrolysis rates decrease in the order Br (2) > Cl (1)
> I (3). The same observation is found for the bip/bpm series where the corresponding
rates decrease in the order Br (5) > Cl (4) > I (6). In the case where p-cym (arene) and
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Cl (leaving group) are kept constant but the bpm chelating ligand is replaced, the half-
life values increase in the order bathophen (13) < phen (11) < MP (14) < phendio (12)
< bpm (1). In the case when the chelating ligand is maintained as bpm and the leaving
group as Cl, changing the arene modifies the rate of hydrolysis in the increasing order
p-cym (1) < thn (10) < ind (9) < hmb (8) < etb (7).
3.3.3.3 pKa* Determination.
The changes in the 1H NMR chemical shifts of the aromatic protons in either the
corresponding arene rings or the corresponding N,N' chelating ligands of the aqua
adducts of complexes 1 (p-cym/bpm), 8 (hmb/bpm), 9 (ind/bpm), 10 (thn/bpm), 11 (p-
cym/phen), and 13 (p-cym/bathophen) present in an equilibrated 100 μM (D2O)
solution at 310 K were followed with change in pH* over the range ca. 1 to 12. Figure
3.11 shows how the peaks shift to higher field due to deprotonation of the bound
water molecule in the aqua adduct of complex 1, [(η6-p-cym)Ru(bpm)(OH2)]2+, but do
not change in intensity as an indication that no other species are being formed.
Figure 3.11. 1H NMR spectra recorded during a pH* titration of a solution of the
aqua adduct of complex 1, [(η6-p-cym)Ru(bpm)(D2O)]2+. Blue indicates the
ortho(methyl) protons and Green indicates the metha(methyl) protons on the coordinated p-
cym ring shifting with a change of pH*.
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The data for complexes 1, 8−11, and 13 were fitted to the Henderson-Hasselbalch
equation which yielded the corresponding pKa* values listed in Table 3.6. It can be
seen that close to physiological pH values (~7.0) complexes 1, 8, 9 and 11 exist as a
mixture of their aqua and hydroxido forms. However complexes 10 and 13, which
have higher pKa* values (10.12 and 10.84, respectively), exist predominantly as the
aqua adducts.
Table 3.6. pKa* values for the aqua species of complexes 1, 8−11, and 13 at 310 K.
Compound pKa*
(1) [(6-p-cym)Ru(bpm)(OH2)]2+ 6.96
(8) [(6-hmb)Ru(bpm)(OH2)]2+ 7.04
(9) [(6-ind)Ru(bpm)(OH2)]2+ 6.91
(10) [(6-thn)Ru(bpm)(OH2)]2+ 10.12
(11) [(6-p-cym)Ru(phen)(OH2)]2+ 7.32
(13) [(6-p-cym)Ru(bathophen)(OH2)]2+ 10.84
3.3.4 Mechanism of Hydrolysis: Density Functional Theory (DFT) Approach
Density Functional Theory (DFT) computational methods were employed to obtain
information about the influence of the leaving group on the mechanism of hydrolysis
for the p-cym/bpm series of RuII arene complexes 1−6. A test of the structural
accuracy of the functional PW91 with COSMO solvation was performed by
comparing the fully optimised structures of the cations in complexes 1–6 with the
corresponding X-ray crystal structures of 1,9b 3, 4 and 6. The functional PW91 was
found to overestimate the RuII bond lengths by ca. 0.01−0.04 Å, particularly for the 
computed Ru−X distances (~2.44 Å) which were ~0.05 Å longer than those found in 
the solid state. However, the overall agreement with the experimental data was
satisfactory. A scheme for the reaction modelled is shown in Figure 3.12.
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Figure 3.12. Hydrolysis reaction modelled for the cationic RuII arene complexes [(6-
arene)Ru(bpm)X]+ (1–6). [TS] is transition state.
For each of the resting states ([RS] = {[(6-arene)Ru(bpm)X]+·H2O]}) and the
corresponding products ([P] = {[(6-arene)Ru(bpm)(OH2)]2+·X–]}), the results from
the calculations indicated that the systems retained both the entering (H2O) and the
leaving groups (X–) within the second coordination sphere of the RuII centre.
Complex 1 was chosen as a model system; based on previously reported work5b on
analogous RuII arene complexes, a full geometry optimisation of its transition state
([TS]) was performed starting from Ru–Cl and Ru–OH2 distances of 3.200 Å and
2.899 Å, respectively, in the initial geometry. The optimised structure for the [TS] for
the RuII arene cation [(6-p-cym)Ru(bpm)Cl]+ is shown in Figure 3.13. The geometry-
optimised structure in the [TS] of the RuII arene cation in complex 1, gave Ru–Cl and
Ru–OH2 distances of 3.11 Å and 2.68 Å, respectively. The corresponding energy
value determined for the [TS] (–6657.51 kcal mol–1) was found to be 20.09 kcal mol–1
larger than that for the reagent in [RS]. Since the hydrolysis reaction could be a priori
assumed to be either an associative, a dissociative, or a concerted process, a set of
frequencies calculation was performed for the [TS] of the RuII arene cation in
complex 1. Two negative values of frequencies were retrieved from the computation,
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–152 and –20 cm–1. The first (and more negative) frequency value (–152 cm–1) was
related to the vibrational mode of the system where the entry of the water molecule
(H2O) and loss of the halido ligand (Cl–) are a concerted process. The corresponding
scaled displacement vectors are shown in Figure 3.14.
Figure 3.13. DFT-optimised geometry in the transition state [TS] during the
hydrolysis reaction of the RuII arene cation [(6-p-cym)Ru(bpm)Cl]+ (1).
Figure 3.14. DFT-optimised geometry in the transition state [TS] during the
hydrolysis reaction of the RuII arene cation [(6-p-cym)Ru(bpm)Cl]+ (1) showing the
scaled displacement vectors.
Under the assumption that the same associative hydrolysis mechanism applies, the
effect of varying X and the arene was explored. The results are listed in Table 3.7,
from where it can be seen that the corresponding barrier heights do not vary
significantly when the arene p-cym (in complexes 1, 2, and 3) is substituted by bip (in
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complexes 4, 5, and 6). The forward reaction barriers and overall reaction energies for
the aquation of the corresponding halido ligand (Cl, Br, or I) follow the increasing
order Cl < Br < I and p-cym < bip.
Table 3.7. Selected bond lengths, forward reaction barriers, and overall reaction
energies from Density Functional Theory (DFT) calculations for {[(6-p-
cym)Ru(bpm)X]+·H2O]}→[TS]→{[(6-p-cym)Ru(bpm)(OH2)]2+·Cl–]}.
Ru–X/Ru–OH2
[RS] (Å)
Ru–X/Ru–OH2
[TS] (Å)
Ru–X/Ru–OH2
[P] (Å)
ΔE‡
(kcal mol–1)
ΔEreacc
(kcal mol–1)
p-cym/bpm
(1) Cl 2.45/3.87 3.11/2.68 4.01/2.17 20.1 5.5
(2) Br 2.58/3.93 3.29/2.68 4.14/2.18 21.0 7.3
(3) I 2.77/4.09 3.58/2.68 4.43/2.19 22.8 9.6
bip/bpm
(4) Cl 2.47/3.82 3.02/2.72 4.01/2.16 20.0 6.2
(5) Br 2.57/3.88 3.19/2.73 4.15/2.17 20.9 7.5
(6) I 2.76/4.01 3.45/2.74 4.41/2.17 22.3 10.3
[RS] = Resting state
[TS] = Transition state
[P] = Product
ΔEreacc values relative to reactant species at zero
3.3.5 Interactions with Nucleobases
The possibility that some of the RuII arene halido complexes studied herein could
react directly with nucleobases was investigated. Interactions between 9-ethylguanine
(9-EtG), 9-ethyladenine (9-EtA), and complexes 1, 8–11, and 13 were studied by
means of multidimensional 1H NMR spectroscopy and the nature of the products was
verified by HR-MS. All the reactions were carried out in an NMR tube in D2O and
followed for 48 h at 310 K. Figure 3.15 shows the reaction of complex 11 with 9-EtG
as a generic example.
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Figure 3.15. Time dependence of the 1H NMR spectra of a 100 μM solution of [(6-
p-cym)Ru(phen)Cl][PF6] (11) in D2O at 310 K in the presence of an equimolar
amount of 9-EtG. Blue = [(6-p-cym)Ru(phen)Cl]+, Green =[(6-p-
cym)Ru(phen)(OH2)]2+, Magenta = [(6-p-cym)Ru(phen)(9-EtG-N7)]2+; = phen, ● 
= p-cym; ♦ = bound 9-EtG-N7.
The interactions occur via the in situ formation of the corresponding reactive aqua
adduct for each complex upon hydrolysis, followed by coordination (mainly) to the
N7 position as has been previously observed for similar RuII arene guanine and
adenine adducts.5a,17 Figure 3.16 shows the numbering scheme for the nucleobases 9-
EtG and 9-EtA.
Figure 3.16. Numbering scheme for the nucleobases 9-EtG and 9-EtA.
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Peaks assigned to the bound 9-EtG-N7 in all complexes are shifted to high field in
comparison to those of free 9-EtG. The H8 peak in all the RuII arene guanine adducts
has a chemical shift in the range of 7.15–7.60 ppm (free 9-EtG is found at 7.79 ppm
under the same conditions). Table 3.8 lists the percentage of species present in
solution for the reaction of complexes 1, 8–11, and 13 with 9-EtG at selected sets of
time. The most quantitative reactions with 9-EtG were found for complexes 8, 9, and
10. Interestingly, for complex 10 around 12% of a second guanine-bound species was
also detected at equilibrium (ca. 510 min), Figure 3.17. A similar experiment was
carried out to investigate the possibility of forming 9-ethyladenine (9-EtA) adducts
with the RuII arene complexes 1, 8–11, and 13. The addition of an equimolar amount
of 9-EtA to freshly prepared 100 μM D2O solutions of the complexes at 310 K
resulted in no new species formed even after 48 h of reaction.
Table 3.8. Time dependence and extent of formation of nucleobase adducts for 100
μM aqueous solutions of RuII arene complexes 1, 8–11, and 13 determined by 1H
NMR spectroscopy at 310 K.
Compound Time
(min)
% 9-EtG-N7
adduct
% 9-EtA-N7
adduct
(1) [(6-p-cym)Ru(bpm)Cl][PF6] 104a 34.1 –
2880 34.1 0.0
(8) [(6-hmb)Ru(bpm)Cl][PF6] 56a 80.6 –
2880 80.6 0.0
(9) [(6-ind)Ru(bpm)Cl][PF6] 52a 94.3 –
2880 94.3 0.0
(10) [(6-thn)Ru(bpm)Cl][PF6] 510a 88.9/11.1b –
2880 88.9/11.1b 0.0
(11) [(6-p-cym)Ru(phen)Cl][PF6] 589a 72.0 –
2880 72.0 0.0
(13) [(6-p-cym)Ru(bathophen)Cl][PF6] 1419a 40.2 –
2880 40.2 0.0
a Time needed to reach equilibrium
b Coordination to form the second 9-EtG adduct occurs presumably via N3
Chapter 3: RuII Arene Halido Complexes
91
Figure 3.17. 1H NMR spectra of the reaction of a 100 μM solution of [(6-
thn)Ru(bpm)Cl][PF6] (10) with equimolar amounts of 9-EtG in D2O at 310 K after
510 min. Magenta = [(6-thn)Ru(bpm)(9-EtG-N7)]2+; Yellow = [(6-thn)Ru(bpm)(9-
EtG-N3)]2+; = bpm, ● = p-cym; ♦ = bound 9-EtG. 
The second H8 peak observed by 1H NMR from the reaction of 9-EtG and complex
10 has a chemical shift of 7.11 ppm and is assumed to arise from the N3 coordination
to the RuII centre to form [(6-thn)Ru(bpm)(9-EtG-N3)]2+ (as it has also been
suggested for other metal complexes).17 The mass-to-charge ratios and isotopic
models obtained from HR-MS spectra were consistent with the formation of the
guanine adducts as the corresponding products of the individual reactions, Table 3.9.
Table 3.9. Mass-to-charge ratios obtained from HR-MS spectra for the products of
interactions of RuII arene complexes 1, 8–11, and 13 with 9-EtG
Observed peak
[M]2+
Chemical formula
Calc m/z
Found
m/z
(1) [(6-p-cym)Ru(bpm)(9-EtG-N7)]2+ C25H29N9ORu
286.5767
286.5755
(8) [(6-hmb)Ru(bpm)(9-EtG-N7)]2+ C27H33N9ORu
300.5924
300.5916
(9) [(6-ind)Ru(bpm)(9-EtG-N7)]2+ C24H25N9ORu
278.5610
278.5601
(10) [(6-thn)Ru(bpm)(9-EtG-N7)]2+ C25H27N9ORu
570.6165
570.6155
(11) [(6-p-cym)Ru(phen)(9-EtG-N7)]2+ C29H31N7ORu
297.5815
297.5820
(13) [(6-p-cym)Ru(bathophen)(9-EtG-N7)]2+ C41H39N7ORu
373.6130
373.6127.
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3.3.6 DFT-Geometry Optimisation of RuII Arene Nucleobase Adducts
In order to gain further knowledge on the nature and relative stabilities of the guanine
and adenine adducts of the RuII arene complexes 1, 8−11, and 13, their optimised
geometries were obtained using DFT calculations. Their minimum energy structures
are shown in Figures 3.18 and 3.19 (for the 9-EtG-N7 and the 9-EtA-N7 adducts,
respectively). The total binding energies for both nucleobases are shown in Table
3.10.
Figure 3.18. Optimised geometries for the guanine adducts (A) [(6-p-
cym)Ru(bpm)(9-EtG-N7)]2+ (1-EtG), (B) [(6-hmb)Ru(bpm)(9-EtG-N7)]2+ (8-EtG),
(C) [(6-ind)Ru(bpm)(9-EtG-N7)]2+ (9-EtG), (D) [(6-thn)Ru(bpm)(9-EtG-N7)]2+
(10-EtG), (E) [(6-p-cym)Ru(phen)(9-EtG-N7)]2+ (11-EtG), and (F) [(6-p-
cym)Ru(bathophen)(9-EtG-N7)]2+ (13-EtG).
The binding energies include a COSMO contribution which simulates an aqueous
environment. Under these conditions, the binding of 9-ethylguanine was found to be
more favorable than that of 9-ethyladenine by ~10.0 kcal mol–1. Furthermore, the
nucleobase 9-ethylguanine shows significant binding energies towards all compounds
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(≥38.5 kcal mol–1), the largest value being for the adduct [(6-thn)Ru(bpm)(9-EtG-
N7]2+ (10-9EtG) with a binding energy of 41.0 kcal mol–1. In the case of 9-
ethyladenine, it was found that it has a smaller binding energy value towards all
compounds (≤34.4 kcal mol–1); the largest energy was calculated for the adduct [(6-
thn)Ru(bpm)(9-EtA-N7]2+ (10-9EtA).
Figure 3.19. Optimised geometries for the adenine adducts (A') [(6-p-
cym)Ru(bpm)(9-EtA-N7)]2+ (1-EtA), (B') [(6-hmb)Ru(bpm)(9-EtA-N7)]2+ (8-EtA),
(C') [(6-ind)Ru(bpm)(9-EtA-N7)]2+ (9-EtA), (D') [(6-thn)Ru(bpm)(9-EtA-N7)]2+
(10-EtA), (E') [(6-p-cym)Ru(phen)(9-EtA-N7)]2+ (11-EtA), and (F') [(6-p-
cym)Ru(bathophen)(9-EtA-N7)]2+ (13-EtA).
Table 3.10. Solution (COSMO) 9-EtG and 9-EtA binding energies for adducts of RuII
arene complexes 1, 8–11, and 13.
Compound 9-EtG (kcal mol–1) 9-EtA (kcal mol–1)
(1) 38.5 30.8
(8) 39.3 30.3
(9) 39.3 32.4
(10) 41.0 34.4
(11) 39.8 33.7
(13) 38.7 32.3
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The binding of 9-EtG to the N3 position in complex 10 was also investigated. The
minimum energy structures are shown in Figure 3.20 for both the 9-EtG-N7 and 9-
EtG-N3 adducts. The calculated total binding energies are 41.0 and 18.5 kcal mol–1
for the 9-EtG-N7 and the 9-EtG-N3 adduct, respectively.
Figure 3.20. DFT-optimised geometries for the guanine adducts [(6-thn)Ru(bpm)(9-
EtG-N7)]2+ (10-EtG-N7) and [(6-thn)Ru(bpm)(9-EtG-N3)]2+ (10-EtG-N3).
3.3.7 DNA Interactions in Cell-Free Media
In order to explore the possibility of having DNA as the potential target for this new
family of compounds, the complexes [(6-p-cym)Ru(bpm)Cl]+ (1) and [(6-p-
cym)Ru(phen)Cl]+ (11) were selected for preliminary studies of CT-DNA interactions
in cell-free media.
3.3.7.1 DNA Binding Kinetics
The results of binding experiments are summarised in Table 3.11. The results show
that both complexes reacted with CT-DNA to a moderate extent and the reactions
were complete after ca. 20 h. Complex 11 was found to bind much faster and to a
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larger extent than complex 1. Complex 11 reaches equilibrium within the first 1.5
hours of reaction. After 24 h of reaction both complexes were found to reach the same
extent of binding of ~60%, Figure 3.21. The dialysis experiments against two
different sodium salts indicate that the coordination of the RuII arene complexes to
CT-DNA is reversible and dependent on the nature of the salt. In the case of [(6-p-
cym)Ru(phen)(Cl)][PF6] (11), dialysis either against 10 mM NaClO4 or 0.1 M of
NaCl resulted in a decrease on the percentage of complex bound to DNA (down to
~20.0%). For complex 1, dialysis against 10 mM NaClO4 did not change the
percentage of complex reacted with DNA whereas dialysis against 0.1 M of NaCl
reduced the amount to the same extent as found for complex 11 (~20.0%).
Figure 3.21. Percentage of binding to CT-DNA obtained from the experiment of
DNA precipitation by EtOH of complexes [(6-p-cym)Ru(bpm)(Cl)][PF6] (1) and
[(6-p-cym)Ru(phen)(Cl)][PF6] (11) as a function of time.
Table 3.11. Percentage of binding of complexes 1 and 11 to CT-DNA (1.0 × 10−4 M)
in 10 mM NaClO4 at 310 K as determined by FAAS after 24 h.
% RuII bound
Method (1)a (11)a
DNA precipitation by EtOH 61.0 62.0
Dialysis against 10 mM NaClO4 77.0 19.6
Dialysis against 0.1 M NaCl 21.6 17.3
a Data are the average of two independent experiments
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3.3.7.2 DNA Transcription by RNA Polymerase In Vitro
Further investigations were aimed at finding the Ru binding sites in natural DNA for
the reactions of [(6-p-cym)Ru(bpm)(Cl)][PF6] (1) and [(6-p-
cym)Ru(phen)(Cl)][PF6] (11). The autoradiogram of the inhibition of RNA synthesis
by T7 RNA polymerase on pSP73KB DNA containing adducts of the RuII arene
complexes or cisplatin is shown in Figure 3.22. The bands corresponding to the
transcription of DNA modified by complexes 1 and 11 yielded fragments of newly
synthesised RNA of defined sizes, which indicates that RNA synthesis on these
templates was prematurely terminated. The major stop sites produced occurred at
similar positions in the gel and were solely at guanine residues, Figure 3.23 for both
RuII arene complexes. Both the profiles are similar to that obtained for DNA treated
with the anticancer drug cisplatin and also to those reported previously for the RuII
arene compounds, such as [(η6-arene)Ru(en)Cl]+.18
Figure 3.22. Autoradiogram of 6% polyacrylamide/8 M urea sequencing gel showing
inhibition of RNA synthesis by T7 RNA polymerase on pSP73KB DNA containing
adducts of RuII arene complexes or cisplatin. Lanes: chain terminated marker RNAs,
cisplatin, at rb = 0.02; A, U, G and C, the template modified by RuII arene compounds
1 and 11.
Chapter 3: RuII Arene Halido Complexes
97
Figure 3.23. Left: Schematic diagram showing the portion of the sequence used to
monitor inhibition of RNA synthesis by the RuII arene complexes 1 and 11. The
arrows indicate the start of the T7 RNA polymerase, which used as template the upper
strand of pSP73KB DNA, respectively. The numbers correspond to the nucleotide
numbering in the sequence map of pSP73KB plasmid. (●) Indicates major stop sites 
for DNA modified by ruthenation.
3.3.7.3 Unwinding of Supercoiled pUC19 Plasmid DNA
The native agarose gel resulting from DNA modified by complexes [(6-p-
cym)Ru(bpm)(Cl)][PF6] (1) and [(6-p-cym)Ru(phen)(Cl)][PF6] (11) are shown in
Figure 3.24. The DNA unwinding angle produced by the adducts of 1 and 11 was
determined to be 7.7° and 6.6°, respectively. The comigration point of the modified
supercoiled and nicked DNA (rb(c)) was reached at rb = 0.13 and 0.15 (for 1 and 11,
respectively) as shown in Table 3.12.
Figure 3.24. The unwinding of supercoiled pUC19 plasmid DNA (1.0 × 10−4 M) by
complexes [(6-p-cym)Ru(bpm)(Cl)][PF6] (1) and [(6-p-cym)Ru(phen)(Cl)][PF6]
(11). Left and right lanes are controls (unmodified DNA); top bands correspond to the
form of nicked plasmid (OC) and the bottom bands to the closed and negatively
supercoiled plasmid (SC). ri is the molar ratio of free Ru complex to nucleotide
phosphates at the onset of incubation with DNA.
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Table 3.12. Unwinding of supercoiled pUC19 DNA by RuII arene complexes [(6-p-
cym)Ru(bpm)(Cl)][PF6] (1) and [(6-p-cym)Ru(phen)(Cl)][PF6] (11).
Compound rb(c) Unwinding Angle (°)
(1) [(6-p-cym)Ru(bpm)(Cl)][PF6] 0.14 7.7±1.7
(11) [(6-p-cym)Ru(phen) (Cl)][PF6] 0.15 6.6±1.7
Cisplatin 0.08 13.0±0.4
3.3.8 Cancer Cell Growth Inhibition (IC50 Values)
The concentrations of complexes at which 50% inhibition of growth of cancer cells is
achieved (IC50 values) were determined. The halido complexes 1−6 were tested
against the A2780 human ovarian, A2780 cisplatin resistant human ovarian, A459
human lung, and HCT116 human colon cancer cell lines whereas the remaining
halido complexes 8−11 and 13−14 were tested against the A2780 human ovarian
cancer cell line. Complexes 1−6, 8−10 and 14 displayed IC50 values larger than 100
μM against the corresponding cell lines tested (IC50 value for cisplatin was 1.0 μM 
under the same conditions). Complexes 11 and 13 were found to be cytotoxic to the
A2780 human ovarian cancer cell line, Table 3.13. Both complexes contain p-cym as
arene and Cl as leaving group. The most active complex is [(6-p-
cym)Ru(bathophen)Cl][PF6] (13) with an IC50 value of 0.5 μM, (cisplatin 1.1 μM 
under the same conditions). The activity of complex [(6-p-cym)Ru(phen)Cl][PF6]
(11) against this cancer cell line is IC50 23 μM. 
Table 3.13. IC50 values for RuII arene complexes 11 and 13 against the A2780 human
ovarian cancer cell line.
Compound IC50 μM (A2780)a
(11) [(6-p-cym)Ru(phen)Cl][PF6] 22.9
0.5
1.1
(13) [(6-p-cym)Ru(bathophen)Cl][PF6]
Cisplatin
a Complexes 1−6, 8−10 and 14 had IC50 values larger than 100 μM against the cell lines tested (vide
supra; cisplatin 1.0 μM under the same conditions) 
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3.4 Discussion
Thirteen new RuII arene complexes containing N,N' chelating ligands (1–13) and one
RuII arene complex with an N,S chelating ligand (14) (Figure 3.1) have been
synthesised and fully characterised. The 9-EtG-N7 adduct of [(6-p-cym)Ru(bpm)(9-
EtG-N7)][PF6]2 (15) was also synthesised and fully characterised. Their aquation,
acidity of their aqua adducts, nucleobase binding, cell-free media DNA interactions
and IC50 values in relation to the nature of the substituents on the RuII centre were
investigated.
3.4.1 Synthesis and Characterisation
The 1H NMR resonances of the coordinated 6-arene and N,N'/N,S in all the new RuII
arene halido complexes 1–14 are low-field-shifted ca. 0.6 ppm (compared to the free
ligands) due to coordination to the RuII centre. Although work on CoIII, PtII, RhIII, and
IrIII complexes with 6-mercaptopurine (MP) has been reported before,19,20,21 examples
of RuII−MP complexes are not so widespread and in most cases, they are not half-
sandwich complexes.22,23 Therefore, the RuII arene complex [(6-p-cym)Ru(MP)Cl]+
(14) might be one of the few examples of piano-stool complexes which incorporate
MP as a chelating ligand. Given that MP has multiple potential binding sites, its
coordination to the RuII centre was elucidated using 1H NMR spectroscopy. It is
assumed that the MP ligand coordinates in a bidentate manner via the S and N7 atoms,
to form a five-membered chelate ring as previously observed in analogous
complexes.24 A magnetic inequivalency of the aromatic p-cym ring protons on going
from the [(η6-p-cym)RuCl2]2 dimer to the [(6-p-cym)Ru(MP)Cl][PF6] (14) monomer
was observed in the 1H NMR spectrum of complex 14 in methanol-d4 solution. This
evidence is in agreement with the generation of a Ru chiral centre.
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3.4.2 X-ray Crystal Structures
The molecular structures of complexes 3, 4, 6, 7 and 15 were determined by single
crystal X-ray diffraction. The values for Ru–arene(centroid) bond lengths are comparable
to analogous RuII arene complexes containing N,N' chelated ligands.25,29,40,52 Neither
the nature of the corresponding N,N' chelating ligand nor the halogen greatly
influence the corresponding Ru–arene(centroid) distances (~1.70 Å). The Ru−X 
distances are not affected either by a change of arene or the N,N' chelating ligand. The
corresponding Ru–I bond lengths in 3 and 6 are slightly shorter compared to other
RuII arene complexes containing iodide as a leaving group.26,27,28 For the four halido
complexes, the Ru–N,N' bond lengths are significantly longer than those found in the
crystal structures of similar arene RuII arene bipyridine complexes.29 The X-ray
crystal structures of compounds 3, 4, 6 and 7 show an increased number of intra
and/or intermolecular π-π stacking interactions, particularly for complexes 4 and 6,
which contain bip as the arene. Their crystal packing also displays strong H-bonding
throughout the unit cell, which is a common feature observed in similar RuII arene
complexes containing extended aromatic rings.30 In the case of complex 7,
particularly interesting is the presence of CH-π interactions between the C−H protons 
of one of the pyrazine rings in the 2,2'-bipyrimidine (bpm) chelating ligand and the
centroid of one of the pyrazine rings in the bpm belonging to the neighbouring
molecule. The occurrence of CH-π interactions is now well established31,29 and the
interaction ranges from weak (CH∙∙∙π centre 2.6–3.0 Å) to very strong (CH∙∙∙π centre
< 2.6 Å).32 Such interactions can play an important role in protein stability and in
recognition processes. The CH∙∙∙π interactions observed for complex 7 (2.9 Å) are
well within the weak-interaction category. The nature of the arene ligand in these
complexes seems to exert an important influence on the planarity of the bpm ligand.
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The two pyrazine rings in the cation [(η6-etb)Ru(bpm)Cl]+ (7) are considerably more
twisted (~10.0º) compared to the chlorido analogue [(η6-bip)Ru(bpm)Cl]+ (4) (~4.6º).
This observation is in good agreement with the intramolecular π-π interactions found 
between the uncoordinated-bip ring and one of the pyrazine rings (assuming that a
more planar bpm is needed to enhance such interactions). In contrast, complex 7
displays a more distorted bpm ligand since one of the pyrazine rings is properly
spatially placed to promote the CH-π interactions with the neighbouring molecule. 
The crystal structure of the 9-EtG adduct 15 shows multiple H-bonding interactions
throughout the crystal packing. The main fragments involved are bpm, 9-EtG, and the
solvent molecules (water). Such aggregations have been observed in a number of RuII
and PtII crystal structures containing purine derivatives.33 Water is an important
participant in intercalation modes and specific binding of water to DNA complexes
can make a significant contribution to the free energy of drug binding.34 The presence
of numerous water molecules together with PF6 anions contribute to the overall
stabilisation of the crystal packing. The average H-bonding distances and angles (~3.0
Å and 160º, respectively) are indicative of their strong nature.
3.4.3 Mechanism of Hydrolysis
The transition state obtained from density functional theory (DFT) calculations,
suggested that aquation of the [(6-arene)Ru(bpm)X]+ complexes where arene is p-
cym (1−3) or bip (4−6) and X is Cl, Br, or I proceeds via a concerted interchange
associative (Ia) mechanism rather than a stepwise dissociation/coordination process
(dissociative, Id). For the p-cym/bpm series of complexes (1−3) the reaction does not
appear to be strongly associatively nor dissociatively activated, because the
corresponding Ru–X bonds at the transition state extend by ~0.66, 0.71, and 0.81 Å
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for Cl, Br, and I, respectively relative to the reactant species. In the case of the
corresponding Ru–O bonds in the transition state, it was found that they are ~0.50 Å
longer than in the aqua products in the three cases. The results for the bip/bpm series
of complexes (4−6) showed that the hydrolysis might not be strongly associatively
nor dissociatively activated either. The corresponding Ru–X bonds at the transition
state extend by ~0.58, 0.61, and 0.69 Å for Cl, Br, and I, respectively relative to the
reactants, whereas the Ru–O bonds in the transition state were found to be ~0.55 Å
longer than in the aqua products. Given that Ru–X bond-breaking alone is not the rate
controlling step in the associative pathway (Ia), a heavier (and larger) halide will
impede the access of the H2O molecule to the central RuII atom in associative states.
This hypothesis is in good agreement with the experimental observation that
complexes 3 and 6 (bearing I as the leaving group) display the slowest rates of
hydrolysis within the corresponding series. This assumption has been also suggested
for Ru complexes displaying higher coordination numbers (i.e. seven).35 The
calculated reaction barriers and overall reaction energies for the aquation of the halido
complexes 1–6 follow the increasing order Cl ≈ Br < I. However, the effect of 
different halides on the experimental hydrolysis rates of these RuII arene complexes
differs from the calculation and follows the increasing order Br < Cl < I. This trend
has been experimentally observed before for platinum compounds of the type
[PtXn(OH2)4−n](2−n)+, for which Br analogues of Cl complexes hydrolyse faster in all
three hydrolysis steps.28 The calculated higher activation energies might be
responsible for the observed slower hydrolysis of the iodido complexes during the
associative ligand interchange in each series. The accuracy of the calculation was not
able to account for the differences found experimentally in the hydrolysis rates
between the Cl and Br complexes.
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3.4.4 Aqueous Solution Chemistry
Complexes 2, 5, 7−9 and 11−14 undergo relatively fast hydrolysis with half-lives
inthe order of minutes (less than 60 min). The reported half-lives of aquation of the
previously reported chlorido ethylenediamine (en) RuII arene complexes, [(6-
dha)Ru(en)Cl][PF6], [(6-tha)Ru(en)Cl][PF6] and [(6-bip)Ru(en)Cl][PF6]36 are 10–80
times smaller than those of these complexes under comparable conditions. Within the
p-cym/Cl series containing various chelating ligands, the presence of a better π-
acceptor chelating ligand appears to increase the overall half-lives. By withdrawing
electron-density from the RuII centre, the positive charge on the metal centre might
increase making it less favourable for the chlorido ligand to leave thus slowing down
the hydrolysis reaction. This argument explains why the rates increase in the order 1
(bpm) < 12 (phendio) < 11 (phen) ≈ 14 (MP) < 13 (bathophen). The fact that the
substituent heteroatoms on the chelating ligands (such as the extra pair of nitrogens in
2,2'-bipyrimidine (bpm) or two oxygens in 1,10-phenanthroline-5,6-dione (phendio))
are electron donors37 and may contribute to stabilise the Ru−Cl bonds by π-back 
donation. In this respect, previous work36,38 has shown that an N,N' chelating group
such as 2,2'-bipyridine (bpy) slows down substitution of the aqua ligand in [(η6-
C6H6)Ru(bpy)(OH2)]2+ just as the replacement of en by acetylacetonate (acac) to give
[(η6-arene)Ru(acac)(OH2)]+ complexes accelerates hydrolysis. Within the RuII arene
bpm/Cl series, it was observed that the incorporation of arenes with either an
increased aromatic character or electron withdrawing substituents in the coordinated
ring, significantly decreases the rate of the hydrolysis reaction in the order 7 (etb) > 8
(hmb) > 9 (ind) > 10 (thn) > 1 (p-cym) > 4 (bip). Bip has a high aromaticity and
competes as a π-acceptor39 with the chelating ligand (bpm) for electron density. This
leads to a weakening of the corresponding Ru−arene bonds and consequently to the 
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complete loss of the bip and etb in the case of complexes 4 and 7, respectively. No
arene loss is observed in the case of the other arenes, all of which have electron
donating aliphatic substituents on the ring. The same arene loss was previously
observed for other RuII bip complexes containing phenylazopyridines as π-acceptor 
ligands.40 Within this same series of complexes 1−6, it can also be noticed that a
combination of a large leaving group (such as I) and a large arene (such as bip) in
complexes 3 and 6, together make the RuII centre less accessible to an incoming
ligand. This effect corresponds to the experimental observation of a very slow
hydrolysis rate. The inclusion of a more electronegative halide (like Cl or Br in 1 and
2 or 4 and 5) leads to an increase in the hydrolysis rate, which is enhanced when the
bulky arene is replaced by a less sterically-demanding ligand such as p-cym in
complexes 1−3. Arene ligands such as benzene (bz) are reported to exhibit a strong
trans-labilising effect for the aqua ligand in [(η6-bz)Ru(OH2)3]2+.41 This class of
strong π-acid ligands are able to accept electron density from the central RuII atom
giving rise to a higher charge on the metal. Acidic hydrolysis of RuIII complexes such
as [Ru(NH3)4(X)2]+ and [Ru(NH3)5X] 2+ (X is Cl, Br, and I) occurs via an associative
pathway in which bond-making is more important than bond-breaking. Therefore, the
electron-accepting effect of strong π-acid arene ligands might be responsible for the 
shift toward a more associative pathway in the Id ↔ Ia mechanistic continuum for the
[(η6-p-cym)Ru(N,N')Cl]+ complexes studied herein.
For complexes 1 (p-cym/bpm), 8 (hmb/bpm), 9 (ind/bpm), and 11 (p-cym/phen) the
pKa* values were found to be in the range from 6.91 to 7.32 and are all significantly
lower (ca. 1.5 units) than those of analogous [(η6-arene)Ru(OH2)]2+ complexes.5b,42 In
the case of complexes 10 (thn/bpm) and 13 (p-cym/bathophen), the values are
considerably higher (10.12 and 10.84, respectively). Such a decrease in acidity has
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been attributed before46 to an increased electron density on the metal centre (as might
be the case for 10 and 13) favoured by a proper combination of electron donating/π-
acceptor−arene/chelating ligands. Therefore, the coordinated aqua ligands of 
complexes 1, 8, 9, and 11 will therefore undergo a slightly less basic dissociation
(than that of complexes 10 and 13) to give equal amounts of the corresponding aqua
and hydroxido adducts at physiological pH (7.2–7.4). However, only the aqua adducts
of complexes 10 and 13 will be present at biologically relevant pH. This behaviour
could account for the observed extents of reactions with nucleobases (vide infra)
given that hydroxido species are recognised to be relatively inert to substitution
reactions than the corresponding aqua complexes.43
3.4.5 Interactions with Nucleobases
Since DNA is known to be a potential target for transition metal anticancer agents,44
the reaction of complexes 1, 8–11, and 13 with 9-EtG and 9-EtA were investigated in
aqueous solution at 310 K. The 1H NMR peaks corresponding to H8 in all the 9-EtG-
N7 adducts are shifted to high field (~0.5 ppm) relative to free 9-EtG under the same
conditions. Usually, metallation at the N7 site of purine bases produces a low field
shift of the H8 resonance by about 0.3–1 ppm.45,46 This effect has also been observed
before for analogous RuII arene complexes containing bpy29 or acac5a as the chelating
ligands. The observation could be attributed to the shielding effect exerted on H8 by a
donation of electron density from the RuII−N7(9-EtG) bond by the corresponding N,N'-
chelating ligands in complexes 1, 8–11, and 13. The compounds studied in this work
showed significant and rapid binding to 9-EtG-N7 (detectable after ca. 10 min and to
ca. 34–94% extent). The interactions for complexes [(η6-p-cym)Ru(bpm)Cl)]+ (1),
[(η6-thn)Ru(bpm)Cl)]+ (10) and [(η6-p-cym)Ru(bathophen)Cl)]+ (13) require ca. 8 h
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to reach equilibrium in each case. However, a different behaviour was observed for
complexes [(η6-hmb)Ru(bpm)Cl)]+ (8) and [(η6-ind)Ru(bpm)Cl)]+ (9), whose
interactions with 9-EtG showed to be much faster, reaching equilibrium after 56 and
52 min, respectively. The corresponding amounts of 9-EtG-N7 adducts detected at
equilibrium for all complexes did not change over the course of 48 h. The reactions
were found to proceed to a wide range of extents and appear to be sensitive to both
the nature of the arene and the N,N' chelating ligand. The reactions of complexes 1,
11 and 13 having p-cym as arene but different chelating ligands seem to produce the
lesser amounts of 9-EtG-N7 adducts, increasing in the order 13 (bathophen) < 1 (bpm)
< 11 (phen). A change of the arene significantly increases the extent of the reactions;
the percentage of guanine adduct detected increases in the order 8 (hmb) < 9 (ind) <
10 (thn). Since nucleobase binding is likely to require initial hydrolysis of the chlorido
bonds, the slow aquation rates and reduced extent of hydrolysis reactions determined
for these complexes at equilibrium may be in turn one of the factors accounting for
the observed extents of nucleobase binding. A second factor which might have an
important role in the extent of the nucleobase reactions with the RuII arene complexes,
is the stability of the guanine adduct formed. The calculated binding energies for 9-
EtG in the corresponding nucleobase adducts appear to be related to the trend
determined for the extent of nucleobase binding (vide infra); the more stable adducts
are formed from the more quantitative reactions. None of the RuII arene complexes 1,
8–11, and 13 showed evidence of binding towards 9-ethyladenine. These complexes
display a more discriminating behaviour towards binding to guanine bases when
compared to cisplatin, for which binding to adenine is also observed.47 It has been
found that H-bonding from C6O in guanine to N–H protons in the bidentate chelating
ligand ethylenediamine (en), is an important factor contributing to the high preference
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for binding of {(η6-arene)Ru(en)}2+ to guanine versus adenine. Replacement of en
(NH as H-bond donor) by bpm in these series of complexes did not change the
selectivity for guanine bases.
3.4.6 DFT-Optimised Geometries for Nucleobase Adducts
Computational methods were used to gain insight into the guanine-specific binding
observed for 1, 8–11, and 13. Surprisingly, compounds 1, 8, 9, and 10, which were
found to be non cytotoxic, showed a significant binding energy for 9-EtG-N7 (~38.8
kcal mol–1). The 9-EtG-N7 adduct of compound 10 [(η6-thn)Ru(bpm)(9-EtG-N7)]2+
(10-9EtG-N7) was found to be the most thermodynamically preferred with 41.0 kcal
mol–1. The binding of 9-ethyladenine was found to be less favourable than that of 9-
ethylaguanine by ~10.0 kcal mol–1 in all cases and again, the highest binding energy
value was determined for the 9-EtA-N7 in [(η6-thn)Ru(bpm)(9-EtA-N7)]2+ (10-9EtA-
N7). This significant thermodynamic difference may account for the guanine-specific
binding observed for the RuII arene complexes 1, 8–11, and 13 in solution. As would
be expected, the binding energy of 9-EtG to complex 10 through N7 is ~20 kcal mol-1
more stable than the binding through N3 (the 9-EtG-N3 adduct was also detected by
1H NMR). The calculations were also able to reproduce the H-bond distance (CH(N,N'-
chelating)···O(9-EtG)) found in the crystal structure of the 9-EtG adduct, complex 15 within
sufficient accuracy. Therefore, it is assumed that the analogous values from the DFT-
optimised geometries for the rest of the 9-EtG adducts of complexes 1, 8–11 and 13
will also be within the expected ranges. The calculations predict CH(N,N'-chelating)···O(9-
EtG) distances within the range of 2.20–3.11 Å and C–H(N,N'-chelating)···O(9-EtG) angles
within 114.93–134.97º. Surprisingly, the shortest H-bond distance was found for the
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9-EtG adduct of complex 10, which might explain the high binding energy calculated
for this adduct.
3.4.7 DNA Interactions in Cell-Free Media
Two complexes of the form [(η6-p-cym)Ru(N,N')Cl]+ where N,N' is bpm (1) or phen
(11) were selected for preliminary studies with CT-DNA in cell-free media. Upon
hydrolysis the two complexes form the corresponding monofunctional reactive aqua
species [(η6-p-cym)Ru(N,N')(OH2)]2+ to different extents (~22% and 47% for 1 and
11, respectively). Their effects on DNA differ from each other as revealed by the
preliminary DNA binding experiments. The nature of the N,N' chelating ligands was
found to play a key role in the mode of interaction of these complexes. The aqua
adduct of complex 11 binds faster (within the initial 1.5 h) but to the same extent as
the adduct of complex 1. These results are in good agreement with the hydrolysis
rates and half-lifes determined for both complexes by UV-vis absorption spectroscopy
in such a way that the time needed to generate the corresponding aqua adducts might
be limiting the initial binding of the RuII arene complexes to DNA. As soon as the
maximum conversion is achieved, the final overall extent does not vary significantly.
The rate of binding to DNA for complex 1 is slower than that determined for the
anticancer drug cisplatin (t1/2 ca. 2 h under similar conditions),48 for which DNA
binding is thought to be responsible for its cytotoxic properties. Interestingly, the
corresponding binding rate for complex 11 was found to be in the same range as that
of cisplatin. In contrast, other RuII arene analogues i.e. [(η6-bip)Ru(en)Cl]+, which has
also been shown to be cytotoxic to cancer cells,15a,49 react much more rapidly with
DNA under similar conditions (t1/2 ca. 10 min). The results of the transcription
mapping experiments suggest that complexes 1 and 11 preferentially form DNA
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adducts that represent a rather strong block for RNA polymerase. Binding to DNA,
inhibits RNA synthesis in a similar fashion and with similar stopsites to cisplatin and
to the RuII arene complex [(η6-bip)Ru(en)Cl]+. For both complexes these stopsites
were only guanine residues, which agrees well with the nucleobase binding studies
(followed by multidimensional 1H NMR spectroscopy) which showed that they bind
to 9-EtG but do not bind to 9-EtA. The strong preference for guanine bases may allow
these RuII arene complexes to target selectively G-rich regions of DNA, such as
telomeres which play key role in cell division.50 The binding upon hydrolysis of the
RuII arene complexes 1 and 11 to DNA results in a mild degree of unwinding (7–8°)
which is very similar for the two complexes but smaller than that observed for the
RuII arene complex [(η6-arene)Ru(en)Cl]+ (7–14°).30 The unwinding angles produced
by the adducts of RuII arene compounds 1 and 11 resemble more those produced by
monofunctional cisplatin adducts (6° and 13° for mono or bifunctional adducts,
respectively).51
3.4.8 Cancer Cell Growth Inhibition (IC50 Values)
Complexes containing either 2,2'-bipyrimidine (bpm), 10-phenanthroline-5,6-dione
(phendio) or 6-mercaptopurine (MP) as the N,N' or N,S chelating ligand, respectively
(1–10, 12 and 14) were non cytotoxic against neither A2780, A2780cis, A549 or
HCT116 up to the maximum concentration tested (100 μM). A loss of cytotoxicity 
towards cancer cells has been previously observed for complexes of the type [(6-
arene)Ru(en)Cl]+ when en, a σ-donor, is replaced by 2,2'-bipyridine,52 a strong π-
acceptors. Two extra pairs of nitrogens in bpm could contribute to make the ligand
comparatively an even weaker π-acceptor. Changing the electronic features of the 
chelating ligands by incorporating electron donating heteroatoms on the 4,4' position
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of bpm (such as in the phendio complex 12) or changing the N,N' for N,S chelation
(as in the single MP complex 14), did not restore the cytotoxic activity. From a
structural point of view, loss of activity in these derivatives could arise from the
absence of N(sp3)H groups, which are known to stabilise nucleobase adducts through
strong H-bonding between an NH of en and C6O from the guanine (G) nucleobase.53
The electronic properties of the complexes might also account for the observed loss of
activity. The increased back-donation of electron density from RuII onto bpm, phendio
or MP, would in turn make the metal centre more acidic compared to en analogues
promoting side-interactions with other biomolecules before reaching the DNA target
in cell-containing media, accounting for the preliminary DNA interactions found for
complex 1 in cell-free media despite of its low cytotoxicity. The acidic nature of these
derivatives is in good agreement with the experimental hydrolysis rates determined
for these series of bpm-bearing complexes, where the rate values determined by UV-
vis spectroscopy follow the increasing order of 1 (bpm) < 12 (phendio) < 14 (MP). By
increasing the aromatic character of the ligand and the incorporation of electron
withdrawing substituents on the 4,4' position of bpm in phen complex 11 or
bathophen complex 13, respectively showed a dramatic increase in anticancer activity
towards the A2780 human ovarian cancer cell line compared to the other analogues
(IC50 22.9 and 0.5 μM, respectively; cisplatin 1.1 μM under the same conditions). 
Complex 13, [(6-p-cym)Ru(bathophen)Cl][PF6] shows higher activity than cisplatin
under these conditions. The different cytotoxicity profiles of these two active
compounds indicate that the nature of the N,N' chelating ligand is important in the
mechanism of action. The activity of 13 (compared to 11) is probably enhanced by the
presence of a more extended N,N' chelating ligand such as bathophen, which could
act as a better DNA intercalator than 11, contributing to its high cytotoxicity.
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3.5 Summary
It is shown herein that incorporation of different motifs surrounding the RuII centre
can lead not only to significant changes in the chemical reactivity of the complexes
towards hydrolysis but also in the interaction with biologically relevant molecules
such as DNA. The hydrolysis rates of [(η6-arene)Ru(N,N')X]+ complexes vary over
many orders of magnitude, from half-lives of minutes (14.5 min for complex [(η6-
etb)Ru(bpm)Cl]+ (7)) to hours (12 h for complex [(η6-bip)Ru(bpm)I]+ (6)) at 310 K.
Density functional theory calculations on complexes 1–6 suggest that aquation occurs
via a more associative pathway in an Ia ↔ Id mechanistic continuum for which bond-
making is of greater importance than bond-breaking. For both p-cym and bip
complexes 1–6, the calculated reaction barriers and overall reaction energies follow
the order I > Br ≈ Cl which may be the basis of the explanation for the slow 
hydrolysis rate determined by UV-vis spectroscopy for I complexes 3 and 6. The
calculation was not able to reproduce the subtle reverse trend between Cl and Br
complexes. In general, we were not able to establish an obvious correlation between
hydrolysis rates and anticancer activity which implies that the mechanism of action
for these series of complexes does not depend solely on this process. It has also been
shown that the half-sandwich RuII arene complexes containing phenanthroline (11) or
bathophenanthroline (13) as N,N'-chelating ligands exhibit increased cytotoxic
activity towards A2780 human ovarian cancer cells, in contrast to analogous
complexes containing bipyridine previously reported. X-ray crystal structures have
shown that bip complexes (4 and 6) can form strong inter- and intraligand π-π 
interactions which enforces planarity on the bpm ligand, particularly in the case of
complex 4. An interesting feature of the structure of complex 7 is the presence of
Chapter 3: RuII Arene Halido Complexes
112
aromatic CH-π (bpm) interactions. Strong binding to 9-EtG but not to 9-EtA was
observed for complexes containing N,N' chelating ligands such as bpm, phen and
bathophen as well as different arenes such as p-cym, hmb, ind and thn. By the use of
DFT calculations, the binding energies for model DNA nucleobases were assessed.
DFT calculations show that the 9-EtG nucleobase adducts of all complexes are
thermodynamically preferred compared to their 9-EtA adducts by ~10 kcal mol–1,
explaining the guanine-specific binding observed experimentally for complexes 1, 8–
11 and 13. Preliminary DNA binding studies show that complexes 1 and 11 bind to
DNA, suggesting that it might be an important target for these complexes. Therefore,
the reduced cytotoxic potency determined for complexes (1, 8, 9, and 10) might not
be due to lack of reactivity towards DNA but perhaps due to the occurrence of side
reactions with other biomolecules or to a reduced cell uptake. Further studies are
needed to identify the mechanism that inactivates some of the complexes suppressing
the cytotoxic activity up to the maximum concentration tested (100 μM). 
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Chapter 4
Photoactivatable Ruthenium(II) Arene Complexes
Containing Pyridine and Pyridine–Derivative Ligands
4.1 Introduction
Metal coordination compounds as therapeutics for malaria, arthiritis, Human
Immunodeficiency Virus (HIV), cancer, and other medicinal applications have been
investigated in the last twenty years.1,2 Apart from cisplatin and some of its
derivatives, there are few examples of successful metallopharmaceuticals in
(pre)clinical trials for antitumour therapy. In light of this, new metal complexes with
novel promising activation properties are starting to evolve and photochemical
activation is one of the most important concepts currently exploited;3 it uses the
notion of metal-pro-drug activation specifically triggered by photoirradiation with
light. The strategy offers the possibility of controlling the location, timing, and dosage
of the therapeutic metal complex. Moreover, RuII arene complexes of general formula
[(η6-arene)Ru(XY)Z]n+ where XY is a bidentate chelating ligand and Z is a leaving
group (typically an halogen), have been extensively investigated for their promising
cytotoxic properties towards various cancer cell lines.4,5 A crucial step in one mode of
activation of these anticancer agents is usually the initial aquation of the Ru–Z bond
to form a more reactive aqua species.6 It has been shown that a combination of fast
hydrolysis rates and high reactivity can lead to inactive complexes, similarly very
slow hydrolysis rates and chemical inertness often leads to low in vitro cytotoxicity.5,7
One key strategy to increase the potential of this class of complexes is to activate the
release of the monodentate ligand Z with visible light or UVA photoirradiation to
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promote the formation of the aqua adduct, which otherwise would not form in the
dark. The work reported here is concerned with the synthesis and characterisation of a
series of organometallic RuII complexes of the form [(η6-arene)Ru(N,N')(L)][PF6]2
where N,N' is a bidentate chelating ligand and L is a pyridine or pyridine-derivative
ligand that can be selectively dissociated upon photoirradiation. Their behaviour in
the dark (ambient light conditions) and under photoirradiation in aqueous solution, as
well as in the presence of nucleobases such as 9-ethylguanine (9-EtG) and 9-
ethyladenine (9-EtA) was investigated. A description of the excited states for all the
RuII arene complexes was made with the aid of Time-Dependent Density Functional
Theory (TD-DFT) calculations. Finally, their potential as cytotoxic agents was also
investigated by performing cell growth inhibition assays (IC50 values) in various
human cancer cell lines and by studying DNA interactions in cell-free media, both in
the dark and upon photoirradiation.
4.2 Experimental Section
4.2.1 Materials
RuCl3·3H2O was acquired from Precious Metals Online (PMO Pty Ltd) and used as
received. 2,2'-bipyrimidine (bpm), 1,10-phenanthroline (phen), 1,10-phenanthroline-
5,6-dione (phendio), 4,7-diphenyl-1,10-phenanthroline (bathophen), pyridine (Py), 4-
methylpyridine (4-MePy), 4-methoxypyridine (4-MeOPy), 4,4'-bipyridine (4,4'-bpy),
4-phenylpyridine (4-PhPy), 4-benzylpyridine (4-BzPy), 1,2,4-triazole (trz), 3-
acetylpyridine (3-AcPy), nicotinamide (NA), 3-acetatepyridine (3-AcOPy), 9-
ethylguanine (9-EtG), 9-ethyladenine (9-EtA) and KPF6 were obtained from Sigma-
Aldrich. The RuII halido mononuclear precursors [(6-arene)Ru(N,N')Cl][PF6], where
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arene is para-cymene (p-cym); N,N' is bpm, phen, phendio, bathophen, or bpy were
synthesised according to a previously reported method8 while [(6-
arene)Ru(bpy)Cl][PF6] where arene is hexamethylbenzene (hmb) or indane (ind) were
kindly provided by Dr Abraha Habtemariam and synthesised according to a reported
method.8 The solvents used for photochemistry and UV-vis absorption spectroscopy
were dry methanol (reagent grade) and deionised water. For NMR spectroscopy the
solvents used were acetone-d6, DMSO-d6, methanol-d4 and D2O obtained from
Aldrich unless otherwise stated. All chemicals were used without further purification.
4.2.2 Preparation of RuII Arene Complexes Containing Pyridine or Pyridine-
Derivative Ligands
Complexes of the form [(η6-arene)Ru(N,N')(L)][PF6]2 where arene is p-cym, hmb, or
ind; N,N' is bpm, phen, phendio, bathophen, or bpy; and L is Py, 4-MePy, 4-MeOPy,
4,4'-bpy, 4-PhPy, 4-BzPy, trz, 3-AcPy, NA, or 3-AcOPy were synthesised using a
similar procedure as previously described.4 Using an aluminium-foil-covered flask at
room temperature the corresponding chlorido complex [(6-arene)Ru(N,N')Cl][PF6]
and AgNO3 in 10 mL of a 1:1 mixture of MeOH/H2O were refluxed overnight.
Precipitated AgCl was then removed by filtration. A large excess of the appropriate
ligand L was added, and the mixture was left stirring for 24−48 h. The volume was 
reduced by rotary evaporation and a two to five mol equiv excess of KPF6 was added.
The precipitate that formed was collected by filtration and washed with portions of
Et2O/MeOH and dried overnight in vacuum resulting in a microcrystalline product.
Details of the amounts of reactants, colour changes, and nature of the products for the
individual reactions are described below, as well as any variations in the synthetic
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procedure. 13C{1H} NMR spectroscopy data is also provided for samples where a
satisfactory elemental analysis was not returned.
[(6-p-cym)Ru(bpm)(Py)][PF6]2 (1). [(6-p-cym)Ru(bpm)Cl][PF6] (0.10 g, 0.17
mmol), AgNO3 (0.03 g, 0.17 mmol), pyridine (Py) (0.34 g, 4.35 mmol) and KPF6
(0.16 g, 0.85 mmol) in the solvent mixture; the solution turned from bright to dark
yellow; a dark yellow solid was obtained; yield 72% (0.09 g, 0.12 mmol). HR-MS:
calc for C23H25N5Ru [M]2+ m/z 236.5574, found m/z 236.5580. 1H NMR (D2O, 500
MHz) δH: 0.94 (6H, d, J = 7.0), 1.85 (3H, s), 2.48 (1H, sep, J = 7.0), 6.18 (2H, d, J =
6.5), 6.49 (2H, d, J = 6.5), 7.42–7.45 (2H, m), 7.93–7.95 (1H, m), 8.14–8.16 (2H, m),
8.41 (2H, dd, J = 1.3, J = 6.4), 9.29 (dd, 2H, J = 1.9, J = 4.9), 10.05 (dd, 2H, J = 1.9, J
= 5.9). 13C{1H} NMR ((CH3)2CO, 125 MHz) δC: 17.1, 21.5, 30.7, 85.9, 90.6, 107.2,
108.0, 126.1, 127.4, 140.1, 153.8, 154.8, 161.0, 161.4, 163.7.
[(6-p-cym)Ru(bpm)(4-MePy)][PF6]2 (2). [(6-p-cym)Ru(bpm)Cl][PF6] (0.10 g,
0.17 mmol), AgNO3 (0.03 g, 0.17 mmol), 4-methylpyridine (4-MePy) (0.40 g, 4.35
mmol) and KPF6 (0.16 g, 0.85 mmol) in the solvent mixture; the solution turned from
bright to dark yellow; a dark green solid was obtained; yield 75% (0.10 g, 0.13
mmol). Suitable crystals for X-ray crystallography were obtained from slow diffusion
of Et2O into an acetone saturated solution at 278 K. Elemental analysis calc. for
C24H27F12N5P2Ru %C: 37.12, %H: 3.50, %N: 9.02; found %C: 36.89, %H: 3.32, %N:
8.95. HR-MS: calc for C24H27N5Ru [M]2+ m/z 243.5653, found m/z 243.5649. 1H
NMR (D2O, 500 MHz) δH: 0.91 (6H, d, J = 7.0), 1.81 (3H, s), 2.29 (3H, s), 2.44 (1H,
sep, J = 7.0), 6.13 (2H, d, J = 6.5), 6.44 (2H, d, J = 6.5), 7.21–7.23 (2H, m), 8.09–
8.11 (2H, m), 8.14–8.16 (2H, m), 9.25 (2H, dd, J = 2.0, J = 5.0), 10.00 (dd, 2H, J =
2.0, J = 6.0).
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[(6-p-cym)Ru(bpm)(4-MeOPy)][PF6]2 (3). [(6-p-cym)Ru(bpm)Cl][PF6] (0.10 g,
0.17 mmol), AgNO3 (0.03 g, 0.17 mmol), 4-methoxypyridine (4-MeOPy) (0.38 g,
3.48 mmol) and KPF6 (0.16 g, 0.85 mmol) in the solvent mixture; the solution turned
from bright to dark yellow; a dark green solid was obtained; yield 76% (0.10 g, 0.13
mmol). HR-MS: calc for C24H27N5ORu [M]2+ m/z 251.5627, found m/z 251.5623. 1H
NMR (D2O, 500 MHz) δH: 0.91 (6H, d, J = 6.9), 1.83 (3H, s), 2.44 (1H, sep, J = 6.9),
3.79 (3H, s), 6.13 (2H, d, J = 6.2), 6.43 (2H, d, J = 6.4), 6.92 (2H, d, J = 6.7), 8.10–
8.11 (4H, m), 9.25 (dd, 2H, J = 1.9, J = 5.0), 10.00 (dd, 2H, J = 1.9, J = 6.0). 13C{1H}
NMR ((CH3)2CO, 125 MHz) δC: 17.2, 21.5, 30.7, 56.1, 85.8, 90.4, 107.3, 108.0,
113.6, 126.0, 154.3, 160.9, 161.3, 163.7, 168.4.
[(6-p-cym)Ru(bpm)(4,4'-bpy)][PF6]2 (4). [(6-p-cym)Ru(bpm)Cl][PF6] (0.10 g,
0.17 mmol), AgNO3 (0.03 g, 0.17 mmol), 4,4'-bipyridine (4,4'-bpy) (0.37 g, 2.38
mmol) and KPF6 (0.16g, 0.85 mmol) in the solvent mixture; the solution turned from
bright to dark yellow; a bright yellow solid was obtained; yield 76% (0.10 g, 0.13
mmol). HR-MS: calc for C28H28N6Ru [M]2+ m/z 275.0708, found m/z 275.0709. 1H
NMR (D2O, 500 MHz) δH: 0.92 (6H, d, J = 7.0), 1.86 (3H, s), 2.48 (1H, sep, J = 7.0),
6.19 (2H, d, J = 6.6), 6.50 (2H, d, J = 6.4), 7.63 (2H, dd, J = 1.8, J = 6.3), 7.77 (2H,
m), 8.16 (t, 2H, J = 5.3), 8.49–8.51 (2H, m), 8.59–8.61 (2H, m), 9.27 (2H, dd, J = 2.0,
J = 4.9), 10.06 (2H, dd, J = 1.9, J = 5.8). 13C{1H} NMR ((CH3)2CO, 125 MHz) δC:
18.1, 22.4, 31.6, 87.0, 91.5, 108.4, 109.0, 122.1, 125.5, 127.0, 143.0, 150.0, 151.6,
155.2, 161.9, 162.3, 164.6.
[(6-p-cym)Ru(bpm)(4-PhPy)][PF6]2 (5). [(6-p-cym)Ru(bpm)Cl][PF6] (0.10 g, 0.17
mmol), AgNO3 (0.03 g, 0.17 mmol), 4-phenylpyridine (4-PhPy) (0.28 g, 3.48 mmol)
and KPF6 (0.16g, 0.85 mmol) in the solvent mixture; the solution turned from bright
to dark yellow; a bright yellow solid was obtained; yield 76% (0.11 g, 0.13 mmol).
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Elemental analysis calc. for C29H31F12N5OP2Ru %C: 40.66, %H: 3.65, %N: 8.18;
found %C: 40.01, %H: 3.32, %N: 7.92. HR-MS: calc for C29H29N5Ru [M]2+ m/z
274.5731, found m/z 274.5735. 1H NMR (D2O, 500 MHz) δH: 0.94 (6H, d, J = 6.9),
1.88 (3H, s), 2.49 (1H, sep, J = 6.9), 6.20 (2H, d, J = 6.4), 7.49–7.50 (3H, m), 7.67
(2H, dd), 7.70–7.71 (3H, m), 8.15 (t, 2H, J = 5.3), 8.36–8.37 (2H, m), 8.59–8.60 (2H,
m), 9.28 (2H, dd, J = 1.9, J = 4.9), 10.07 (2H, dd, J = 1.9, J = 5.8).
[(6-p-cym)Ru(bpm)(4-BzPy)][PF6]2 (6). [(6-p-cym)Ru(bpm)Cl][PF6] (0.10 g, 0.17
mmol), AgNO3 (0.03 g, 0.17 mmol), 4-benzylpyridine (4-BzPy) (0.28 g, 3.48 mmol)
and KPF6 (0.16g, 0.85 mmol) in the solvent mixture; the solution turned from bright
to dark yellow; a bright yellow solid was obtained; yield 73% (0.11 g, 0.12 mmol).
Suitable crystals for X-ray crystallography were obtained from slow diffusion of Et2O
into an acetone saturated solution at 278 K. Elemental analysis calc. for
C30H31F12N5P2Ru·H2O %C: 41.39, %H: 3.82, %N: 8.04; found %C: 41.28, %H: 3.36,
%N: 8.21. HR-MS: calc for C30H31N5Ru [M]2+ m/z 281.5810, found m/z 231.5802. 1H
NMR (D2O, 500 MHz) δH: 0.90 (6H, d, J = 6.9), 1.81 (3H, s), 2.43 (1H, sep, J = 6.9),
4.00 (2H, s), 6.16 (2H, d, J = 6.5), 6.46, (2H, d, J = 6.5), 7.25–7.27 (3H, m), 7.39 (2H,
d, J = 6.2), 8.12 (2H, t, J = 5.3), 8.22 (2H, d, J = 6.6), 8.65 (2H, d, J = 6.4), 9.27 (2H,
dd, J = 1.9, J = 4.9), 10.02 (2H, dd, J = 1.9, J = 5.8).
[(6-p-cym)Ru(bpm)(trz)][PF6]2 (7). [(6-p-cym)Ru(bpm)Cl][PF6] (0.10 g, 0.17
mmol), AgNO3 (0.03 g, 0.17 mmol), 1,2,4-triazole (trz) (0.24 g, 3.48 mmol) and KPF6
(0.16 g, 0.85 mmol) in the solvent mixture; the solution turned from bright to dark
yellow; a pale yellow solid was obtained; yield 23% (0.03 g, 0.04 mmol). Suitable
crystals for X-ray crystallography were obtained from a saturated acetone-d6 at room
temperature. HR-MS: calc for C20H23N7Ru [M]2+ m/z 231.5526, found m/z 231.5518.
1H NMR ((CD3)2CO, 500 MHz) δH: 1.14 (6H, d, J = 6.9), 2.15 (3H, s), 2.77 (1H, sep,
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J = 6.9), 6.48 (2H, d, J = 6.4), 6.71 (2H, d, J = 6.4), 8.12–8.14 (3H, m), 8.57 (1H, s),
9.22 (1H, s), 9.38 (2H, dd, J = 1.9, J = 4.7), 10.16 (2H, dd, J = 1.9, J = 5.8). 13C{1H}
NMR ((CH3)2CO, 125 MHz) δC: 17.2, 21.4, 30.8, 87.0, 88.9, 105.8, 108.6, 125.2,
143.1, 146.4, 160.9, 163.9.
[(6-hmb)Ru(bpm)(Py)][PF6]2 (8). [(6-hmb)Ru(bpm)Cl][PF6] (0.10 g, 0.17 mmol),
AgNO3 (0.03 g, 0.17 mmol), pyridine (Py) (0.34 g, 4.35 mmol) and KPF6 (0.16 g,
0.85 mmol) in the solvents mixture; the solution turned from bright to dark yellow; a
bright yellow solid was obtained; yield 86 % (0.06 g, 0.11 mmol). Elemental analysis
calc. for C25H29F12N5P2Ru·2H2O %C: 36.33, %H: 4.02, %N: 8.47; found %C: 36.40,
%H: 3.47, %N: 8.49. HR-MS: calc for C25H29N5Ru [M]2+ m/z 250.5731, found m/z
250.5719. 1H NMR ((CD3)2CO, 500 MHz) δH: 2.32 (18H, s), 7.56–7.58 (2H, m),
8.05–8.06 (1H, m), 8.29–8.30 (2H, m), 8.68 (2H, dd, J = 1.3, J = 6.4), 9.41 (2H, dd, J
= 1.9, J = 4.8), 9.94 (2H, dd, J = 1.9, J = 5.7).
[(6-ind)Ru(bpm)(Py)][PF6]2 (9). [(6-ind)Ru(bpm)Cl][PF6] (0.10 g, 0.17 mmol),
AgNO3 (0.03 g, 0.17 mmol), pyridine (Py) (0.34 g, 4.35 mmol) and KPF6 (0.16 g,
0.85 mmol) in the solvent mixture; the solution turned from bright to dark yellow; a
bright yellow solid was obtained; yield 71 % (0.09 g, 0.13 mmol). Elemental analysis
calc. for C22H21F12N5P2Ru·3H2O %C: 33.01, %H: 3.40, %N: 8.75; found %C: 32.41,
%H: 3.63, %N: 8.87. HR-MS: calc for C22H21N5Ru [M]2+ m/z 228.5415, found m/z
228.5418. 1H NMR ((CD3)2CO, 500 MHz) δH: 2.80–2.87 (4H, m), 3.00–3.07 (2H, m),
6.46 (2H, dd, J = 2.3, J = 4.5), 7.00 (2H, dd, J = 2.3, J = 4.3), 7.56 (2H, t, J = 7.0),
8.06–8.08 (1H, m), 8.27–8.28 (2H, m), 8.86–8.87 (2H, m), 9.45 (2H, dd, J = 1.8, J =
4.7), 10.44 (2H, dd, J = 1.8, J = 5.8).
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[(6-p-cym)Ru(phen)(Py)][PF6]2 (10). [(6-p-cym)Ru(phen)Cl][PF6] (0.10 g, 0.17
mmol), AgNO3 (0.03 g, 0.17 mmol), pyridine (Py) (0.34 g, 4.35 mmol) and KPF6
(0.16 g, 0.85 mmol) in the solvents mixture; the solution turned from bright to dark
yellow; a bright yellow solid was obtained; yield 83% (0.11 g, 0.14 mmol). Suitable
crystals for X-ray crystallography were obtained from a saturated acetone solution at
room temperature. Elemental analysis calc. for C27H27F12N3P2Ru·2H2O %C: 39.52,
%H: 3.81, %N: 5.12; found %C: 38.96, %H: 3.17, %N: 5.46. HR-MS: calc for
C27H27N3Ru [M]2+ m/z 247.5622, found m/z 247.5616. 1H NMR (D2O, 500 MHz) δH:
0.75 (6H, d, J = 6.9), 1.83 (3H, s), 2.39 (1H, sep, J = 6.9), 6.18 (2H, d, J = 6.5), 6.55
(2H, d, J = 6.5), 7.31 (2H, t, J = 7.1), 7.80–7.82 (1H, m), 8.17 (2H, s), 8.26–8.27 (2H,
m), 8.40–8.42 (2H, m), 8.90 (2H, dd, J = 1.0, J = 8.3), 10.09 (2H, dd, J = 1.0, J = 5.3).
[(6-p-cym)Ru(phendio)(Py)][PF6]2 (11). [(6-p-cym)Ru(phendio)Cl][PF6] (0.10 g,
0.16 mmol), AgNO3 (0.03 g, 0.16 mmol), pyridine (Py) (0.25 g, 3.2 mmol) and KPF6
(0.16 g, 0.85 mmol) in the solvents mixture; the solution turned from dark green to
yellow; a bright yellow solid was obtained; yield 70% (0.09 g, 0.11 mmol). HR-MS:
calc for C27H25N3O2Ru [M]2+ m/z 262.5493, found m/z 262.5498. 1H NMR
((CD3)2CO, 500 MHz) δH: 1.06 (6H, d, J = 6.9), 2.00 (3H, s), 2.80 (1H, sep, J = 6.9),
6.46 (2H, d, J = 6.5), 6.92 (2H, d, J = 6.6), 7.55–7.56 (2H, m), 8.07–8.08 (1H, m),
8.28–8.29 (2H, m), 8.73 (2H, dd, J = 1.4, J = 6.5), 8.88 (2H, dd, J = 1.2, J = 8.0),
10.26 (2H, dd, J = 1.3, J = 5.6). 13C{1H} NMR ((CH3)2CO, 125 MHz) δC: 17.2, 21.6,
30.7, 84.8, 91.7, 127.5, 130.6, 131.2, 139.0, 140.6, 153.4, 159.8, 173.7.
[(6-p-cym)Ru(bathophen)(Py)][PF6]2 (12). [(6-p-cym)Ru(bathophen)Cl][PF6]
(0.10 g, 0.13 mmol), AgNO3 (0.02 g, 0.13 mmol), pyridine (Py) (0.21 g, 2.7 mmol)
and KPF6 (0.05 g, 0.26 mmol) in the solvents mixture; the solution turned from dark
green to yellow; a bright yellow solid was obtained; yield 89% (0.11 g, 1.2 mmol).
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Elemental analysis calc. for C39H35F12N3P2Ru·H2O %C: 49.06, %H: 3.91, %N: 4.40;
found %C:48.96, %H: 3.35, %N: 4.28. HR-MS: calc for C39H35N3Ru [M]2+ m/z
323.5937, found m/z 323.5931. 1H NMR ((CD3)2CO, 500 MHz) δH: 0.98 (6H, d, J =
7.0), 2.06 (3H, s), 2.72 (1H, sep, J = 7.0), 6.61 (2H, d, J = 6.5), 6.96 (2H, d, J = 6.0),
7.50 (2H, t, J = 6.5), 7.70–7.73 (10H, m), 7.99–8.01 (1H, m), 8.24 (2H, s), 8.38 (2H,
dd, J = 1.0, J = 5.5). 8.88 (2H, d, J = 6.5), 10.55 (2H, dd, J = 1.0, J = 5.5).
[(6-ind)Ru(bpy)(Py)][PF6]2 (13). [(6-ind)Ru(bpy)Cl][PF6] (0.10 g, 0.17 mmol),
AgNO3 (0.02 g, 0.17 mmol), pyridine (Py) (0.36 g, 4.5 mmol) and KPF6 (0.06 g, 0.26
mmol) in the solvents mixture; the solution remained bright yellow; a bright yellow
solid was obtained; yield 92% (0.11 g, 1.5 mmol). Suitable crystals for X-ray
crystallography were obtained from slow diffusion of Et2O into an acetone saturated
solution at 278 K. Elemental analysis calc. for C24H23F12N3P2Ru %C: 38.72, %H:
3.11, %N: 5.64; found %C: 38.42, %H: 2.99, %N: 5.60. HR-MS: calc for
C24H23N3Ru2+ [M]2+ m/z 227.5465, found m/z 227.5461. 1H NMR ((CD3)2CO, 500
MHz) δH: 2.60–2.64 (4H, m), 2.91–2.95 (2H, m), 6.39–6.42 (2H, m), 6.91–6.93 (2H,
m), 7.51 (2H, t, J = 6.6), 8.02–8.04 (1H, m), 8.11–8.13 (2H, m), 8.48–8.50 (2H, m),
8.68 (2H, d, J = 8.1), 8.73–8.75 (2H, m), 10.10 (2H, d, J = 5.7).
[(6-p-cym)Ru(bpm)(3-AcPy)][PF6]2 (14). [(6-p-cym)Ru(bpm)Cl][PF6] (0.10 g,
0.17 mmol), AgNO3 (0.03 g, 0.17 mmol), 3-acetylpyridine (3-AcPy) (0.21 g, 1.74
mmol) and KPF6 (0.16 g, 0.85 mmol) in the solvents mixture; the solution turned
from bright to dark yellow; a pale yellow solid was obtained; yield 91% (0.13 g, 0.16
mmol). Elemental analysis calc. for C25H27F12N5OP2Ru·3H2O %C: 34.97, %H: 3.87,
%N: 8.16; found %C: 34.31, %H: 3.04, %N: 8.04. HR-MS: calc for C25H27N5ORu
[M]2+ m/z 257.5627, found m/z 257.5630. 1H NMR ((CD3)2CO, 500 MHz) δH: 1.05
(6H, d, J = 7.0), 2.11, (3H, s), 2.56 (3H, s), 2.76 (1H, sep, J = 7.0), 6.56 (2H, d, J =
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6.5), 6.85 (2H, d, J = 6.5), 7.69–7.71 (1H, m), 8.28–8.30 (2H, m), 8.49–8.51 (1H, m),
8.98–8.99 (1H, m), 9.04 (1H, s), 9.44 (2H, dd, J = 1.9, J = 4.8), 10.48 (2H, dd, J =
1.92, J = 7.75).
[(6-p-cym)Ru(bpm)(NA)][PF6]2 (15). [(6-p-cym)Ru(bpm)Cl][PF6] (0.10 g, 0.17
mmol), AgNO3 (0.03 g, 0.17 mmol), nicotinamide (0.21 g, 1.74 mmol) and KPF6
(0.16 g, 0.85 mmol) in the solvents mixture; the solution turned from bright to dark
yellow; a pale yellow solid was obtained; yield 84% (0.11 g, 0.15 mmol). HR-MS:
calc for C24H26N6ORu [M]2+ m/z 258.0603, found m/z 258.0598. 1H NMR ((CD3)2CO,
500 MHz) δH: 1.05 (6H, d, J = 6.9), 2.11, (3H, s), 2.76 (1H, sep, J = 6.9), 2.86 (2H,
br), 6.57 (2H, d, J = 6.1), 6.85 (2H, d, J = 6.1), 7.64–7.67 (2H, m), 8.25–8.26 (2H, m),
8.43–8.45 (1H, m), 8.72–8.73 (1H, m), 9.12 (1H, s), 9.43–9.44 (2H, m), 10.45–10.46
(2H, m). 13C{1H} NMR ((CH3)2CO, 125 MHz) δC: 17.2, 21.5, 30.7, 86.2, 90.5, 107.4,
108.0, 126.2, 127.0, 128.8, 138.7, 153.0, 155.6, 161.0, 161.5, 163.7, 164.0
[(6-p-cym)Ru(bpm)(3-AcOPy)][PF6]2 (16). [(6-p-cym)Ru(bpm)Cl][PF6] (0.10 g,
0.17 mmol), AgNO3 (0.03 g, 0.17 mmol), 3-acetatepyridine (3-AcOPy) (0.21 g, 1.74
mmol) and KPF6 (0.16 g, 0.85 mmol) in the solvents mixture; the solution turned
from bright to dark yellow; a pale yellow solid was obtained; yield 69 % (0.10 g, 0.12
mmol). HR-MS: calc for C25H27N5ORu [M]2+ m/z 265.5602, found m/z 265.5600. 1H
NMR ((CD3)2CO, 500 MHz) δH: 0.92 (6H, d, J = 7.0), 2.62 (1H, sep, J = 7.0), 2.66
(3H, s), 3.76 (3H, s), 6.46 (2H, d, J = 6.2), 6.72 (2H, d, J = 6.1), 7.57–7.59 (1H, m),
8.18–8.20 (2H, m), 8.34–8.35 (1H, m), 8.90–8.92 (1H, m), 8.98 (1H, s), 9.31–9.33
(2H, m), 10.39–10.40 (2H, m). 13C{1H} NMR ((CH3)2CO, 125 MHz) δC: 17.2, 21.5,
30.6, 53.0, 86.6, 90.2, 107.8, 108.2, 126.8, 127.5, 129.6, 140.7, 154.0, 156.9, 160.2,
161.6, 162.9, 164.2.
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4.2.3 X-ray Crystallography
The details of the diffraction instrumentation used are described in Chapter 2. X-ray
crystal structures discussed in this Chapter were determined by Dr Guy Clarkson from
the Department of Chemistry at the University of Warwick. The structures of 2, 6, 7,
10, and 13 were solved by direct methods using SHELXS9 (TREF) with additional
light atoms found by Fourier methods. Hydrogen atoms were added at calculated
positions and refined using a riding model with freely rotating methyl groups.
Anisotropic displacement parameters were used for all non-H atoms; H-atoms were
given isotropic displacement parameters equal to 1.2 (or 1.5 for methyl hydrogen
atoms) times the equivalent isotropic displacement parameter of the atom to which the
H-atom is attached. Refinement used SHELXL 97.10
4.2.4 Photoirradiation of RuII Arene Complexes
Aqueous solutions of the RuII arene complexes were photoirradiated at 310 K using
the phtoreactor LZC 4V Illuminator (Luzchem, Canada) with temperature controller
and UVA (λirr = 300−400 nm with a maximum intensity at ~360 nm, 5 mW cm
−2) or
visible light lamps (λirr = 400−660 nm providing average light power of 100 mW). 
Outside the photoreactor, solutions were stored in the dark to minimise unwanted
photoreactions between measurements.
4.2.5 Photoirradiation of RuII Arene Complexes followed by UV-vis Absorption
Spectroscopy
UV-vis absorption spectra of 100 μM solutions of the RuII arene complexes were
recorded on a Cary 50-Bio spectrophotometer using a 1-cm pathlength quartz cuvette
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(600 μL) and a PTP1 Peltier temperature controller. Spectra were recorded at 310 K in 
deionised water from 200 to 800 nm at different stages of photoirradiation, and were
processed using UV-Winlab software for Windows 95. Solutions were stored in the
dark to minimise unwanted photoreactions between measurements.
4.2.6 Photoirradiation of RuII Arene Complexes followed by 1H NMR
Spectroscopy
1H NMR spectra of 300 mM solutions (D2O) of the RuII arene complexes were
acquired at different stages of photoirradiation on a Bruker DMX 500 spectrometer
(1H = 500 MHz) using 5 mm diameter NMR tubes. All data processing was carried
out using XWIN NMR version 2.0 (Bruker U.K. Ltd.). 1H NMR signals were
referenced to dioxane as an internal reference (δ = 3.71).
4.3 Results
4.3.1 Synthesis and Characterisation
The complexes [(6-arene)Ru(N,N')(L)]2+ studied in this work are listed in Table 4.1
and their general structures are shown in Figure 4.1. The dicationic RuII arene
pyridine or pyridine-derivative ligands complexes 1−16 were synthesised as PF6 salts
in good yields (>50% in almost all cases) by the reaction of the corresponding [(6-
arene)Ru(N,N')Cl][PF6] complex with AgNO3 in a 1:1 mixture of MeOH/H2O to
afford the corresponding aqua species [(6-arene)Ru(N,N')(OH2)]2+, to which
excesses of the appropriate ligand L and KPF6 were added. All the synthesised
complexes were fully characterised by 1D and 2D 1H NMR methods as well as 1D
13C{1H} NMR.
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Table 4.1. [(6-arene)Ru(N,N')(L)]2+ complexes studied in this work.
Compound Arene N,N' L
(1) p-cym bpm Py
(2) p-cym bpm 4-MePy
(3) p-cym bpm 4-MeOPy
(4) p-cym bpm 4,4'-bpy
(5) p-cym bpm 4-PhPy
(6) p-cym bpm 4-BzPy
(7) p-cym bpm trz
(8) hmb bpm Py
(9) ind bpm Py
(10) p-cym phen Py
(11) p-cym phendio Py
(12) p-cym bathophen Py
(13) ind bpy Py
(14) p-cym bpm 3-AcPy
(15) p-cym bpm NA
(16) p-cym bpm 3-AcOPy
Compared to the chlorido analogues, the 1H NMR resonances for all the new RuII
arene complexes are low frequency shifted by ca. 0.6 ppm. The binding of the
monodentate ligand to the RuII centre was confirmed by the appearance of a set of
new peaks corresponding to the bound form (which appears low shifted compared to
the free L ligand). Figure 4.2 shows the 1H NMR spectra in the aromatic region for
complex [(6-p-cym)Ru(phendio)(Py)][PF6]2 (11) in acetone-d6 solution as a generic
example.
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Figure 4.1. Structures of the dicationic complexes studied in this work synthesised as
PF6 salts.
Figure 4.2. 1H NMR spectra in the aromatic region of complex [(6-p-
cym)Ru(phendio)(Py)][PF6]2 (11) in acetone-d6 solution. ■ = phendio, ▲ = Py, ● = p-
cym.
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4.3.2 X-ray Crystal Structures
The molecular structure of complexes 2, 6, 7, 10, and 13 were determined by single
crystal X-ray diffraction. Selected bond lengths and angles are given in Table 4.2, the
structures with numbering schemes are shown in Figure 4.3, and the crystallographic
data are listed in Table A.4.1. The complexes are found to adopt the familiar pseudo-
octahedral three-legged piano stool geometry common to all RuII arene structures5
with the Ru atom π-bonded to the arene ligand (p-cym in 2, 6, 7, and 10; ind in 13),
coordinated to a pyridine nitrogen (2, 6, 7, 10, and 13), and to two nitrogen atoms of
the chelating ligand (bpm for 2, 6, and 7; phen for 10; bpy for 13) which constitute the
three legs of the piano stool.
Table 4.2. Selected bond lengths (Å) and angles (o) for [(6-p-
cym)Ru(bpm)(4MePy)][PF6]2 (2), [(6-p-cym)Ru(bpm)(4-BzPy)][PF6]2 (6), [(6-p-
cym)Ru(bpm)(trz)][PF6]2 (7), [(6-p-cym)Ru(phen)(Py)][PF6]2 (10), and [(6-
ind)Ru(bpy)(Py)][PF6]2 (13).
The RuII to p-cym(centroid) distances (as measured from Mercury version 2.2) do not
vary significantly between the derivatives. The molecules in complex [(6-p-
cym)Ru(bpm)(4-MePy)][PF6]2 (2) lie in a mirror-image fashion opposite to an
adjacent complex, giving rise to a π-π stacking interaction. The angle between mean 
planes in the interacting π systems (within the bpm ligand) is 7.09°, the shortest 
Bond length/Angle 2 6 7 10 13
Ru−arene
(centroid)
1.691 1.703 1.699 1.698 1.703
Ru(1)−N(13) 2.110(2) 2.121(2) 2.1041(19) 2.1169(14) 2.1250(14) 
Ru(1)−N(1) 2.099(2) 2.090(2) 2.0866(18) 2.0853(13) 2.0877(13) 
Ru(1)−N(8) 2.094(2) 2.094(2) 2.0808(18) 2.0970(14) 2.0727(13) 
C(6)−C(7) 1.478(4) 1.479(3) 1.493(3) 1.421(2) 1.466(2) 
N(8)−Ru(1)−N(1) 76.86(9) 76.93(8) 77.09(7) 78.07(5) 77.23(5) 
N(13)−Ru(1)−N(8) 87.40(9) 87.96(8) 85.94(7) 85.36(5) 86.22(5) 
N(13)−Ru(1)−N(1) 86.40(9) 87.43(8) 83.94(7) 87.03(5) 87.05(5) 
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atomic contact is C(11)−C(6) 3.492 Å, and the centroid-centroid distance is 4.067 Å, 
Figure 4.4. The internal cleft defined by the planes of the 4-MePy and the bpm ligand
is 88.09°.
Figure 4.3. X-ray structure of the cations in [(6-p-cym)Ru(bpm)(4-MePy)][PF6]2 (2),
[(6-p-cym)Ru(bpm)(4-BzPy)][PF6]2 (6), [(6-p-cym)Ru(bpm)(trz)][PF6]2 (7), [(6-p-
cym)Ru(phen)(Py)][PF6]2 (10), and [(6-ind)Ru(bpy)(Py)][PF6]2 (13). Thermal
ellipsoids show 50% probability. The PF6 anions and hydrogens have been omitted
for clarity.
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Figure 4.4. X-ray crystal structure of [(6-p-cym)Ru(bpm)(4-MePy)][PF6]2 (2)
showing a - stacking interaction. The PF6 anions and hydrogens have been omitted
for clarity.
In the unit cell of [(6-p-cym)Ru(bpm)(4-BzPy)][PF6]2 (6) there is a - stacking
interaction between the bpm and the benzyl (bz) ring of a neighbouring complex. The
closest atomic contact between mean planes is N(5)−C(21) 3.280 Å, and the angle 
between the bpm chelating ligand and the bz ring is 14.94°, Figure 4.5. The angle
between the Py and the bz rings is 71.62°; the internal cleft defined by the planes of
the 4-BzPy and the bpm ligand is 84.45°. Several hydrogen bonds and short contacts
were found in the unit cell of complex [(6-p-cym)Ru(bpm)(trz)]2+ (7), also involving
the methanol solvent molecules, and the PF6 anions, Figure 4.6. The internal cleft
defined by the planes of the trz and the bpm ligand is 83.92°. Selected contact
distances not discussed herein are shown in Table A.4.2.
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Figure 4.5. X-ray crystal structure of [(6-p-cym)Ru(bpm)(4-BzPh)][PF6]2 (6)
showing a - stacking interaction. The PF6 anions and hydrogens have been omitted
for clarity.
Figure 4.6. X-ray structure of the cation [(6-p-cym)Ru(bpm)(trz)]2+ (7) showing the
presence of intermolecular contacts between the RuII complex, a PF6 anion, and a
methanol solvent molecule. Inset: Spacefilling model of [(6-p-
cym)Ru(bpm)(trz)][PF6]2 (7) showing the intermolecular contacts. The PF6 anions and
other hydrogens have been omitted for clarity.
In the unit cell of [(6-p-cym)Ru(phen)(Py)][PF6]2 (10), two adjacent molecules lay in
an upside-down alternate fashion giving rise to a π-π stacking interaction. The mean 
planes are defined by the phen chelating ligands of individual molecules and display a
distance of 3.374 Å and an angle of 180°. The shortest atomic contact is C(6)−C(7) 
3.449 Å and the centroid-centroid distance is 4.850 Å, Figure 4.7.
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Figure 4.7. X-ray crystal structure of [(6-p-cym)Ru(phen)(Py)][PF6]2 (10) showing a
- stacking interaction.
An acetone molecule very close to complex 10 was modelled sitting in a cleft between
the pyridine and the phen chelating ligands showing close contacts, Figure 4.8. The
spacefilling model shows the presence of intermolecular contacts between C(16) in
the phen ligand and O(202a) in the acetone molecule with a C(16)−O(202a) distance 
of 2.914 Å. The cleft is defined by the planes of the Py and the phen ligand (angle
between mean planes 89.21°), a centroid-centroid distance of 4.575 Å, and the
shortest atomic contact N(15)−N(12) of 2.857 Å. Selected contact distances not 
discussed herein are shown in Table A.4.2. In the crystal structure of [(6-
ind)Ru(bpy)(Py)][PF6]2 (13) there is a weak -stacking interaction between the bpy
chelating ligands of neighbouring complexes. The molecules are related by an
inversion centre with the closest atomic contact of 3.539 Å between C(4) and C(8),
Figure 4.9. The mean planes through the interacting  systems are parallel. The
internal cleft defined by the planes of the Py and the bpy ligand is 89.54°.
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Figure 4.8. X-ray structure of the cation [(6-p-cym)Ru(phen)(Py)]2+ (10) showing a
disordered acetone lying in a cleft between the bound phen and the pyridine. Inset:
Spacefilling model of [(6-p-cym)Ru(phen)(Py)][PF6]2 (10) showing the presence of
intramolecular contacts. The PF6 anions and hydrogens have been omitted for clarity.
Figure 4.9. X-ray crystal structure of [(6-ind)Ru(bpy)(Py)][PF6]2 (13) showing a -
stacking interaction. The PF6 anions and hydrogens have been omitted for clarity.
The twist angles between the aromatic pyrazine rings of the bpm ligand are 7.09°,
6.80°, 2.21°, and 4.56° in complexes 2, 6, and 7, respectively. The twist angle
between the aromatic pyridine rings of the bpy is 3.91° in 13.
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4.3.3 DFT Optimised-Geometry Structures of RuII Arene Complexes
A geometry optimisation of complexes 1−6 and 8−16 with the general formula [(6-
arene)Ru(N,N')(L)]2+ was performed for both the ground state (S0) and the lowest-
lying triplet state (T0), employing the DFT method with the B3LYP functional, as
described in the Computation section in Chapter 2. The corresponding bond lengths
for each geometry are shown in Tables 4.3 and 4.4.
Table 4.3. Selected calculated bond distances (Å) for RuII arene complexes 1−6 and
8−16 in the ground state (S0) geometry.
Compound Ru−N(L) Ru−N,N' Ru−N,N' Ru−arene(centroid)
(1) 2.151 2.117 2.115 1.852
(2) 1.940 2.101 2.104 1.811
(3) 1.940 2.105 2.100 1.811
(4) 2.145 2.118 2.115 1.850
(5) 1.940 2.104 2.101 1.810
(6) 1.940 2.104 2.101 1.810
(8) 2.159 2.124 2.125 1.862
(9) 2.150 2.114 2.114 1.850
(10) 2.148 2.119 2.121 2.032
(11) 2.147 2.119 2.121 1.844
(12) 2.148 2.119 2.121 1.844
(13) 2.151 2.104 2.104 1.853
(14) 2.148 2.118 2.114 1.850
(15) 2.146 2.118 2.112 1.853
(16) 2.148 2.117 2.114 1.850
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Table 4.4. Selected calculated bond distances (Å) for RuII arene complexes 1−6 and
8−16 in the lowest-lying triplet state (T0) geometry.
4.3.3.1 Ground State (S0) Geometry
All the DFT geometry-optimised RuII arene complexes have a pseudo-octahedral
structure in the ground-state (S0). The calculated Ru−N,N'(bpm) distances in the bpm-
containing complexes 1−6, vary around the same value (~2.12 Å). The Ru−N(L) bond
lengths in 1−6 are ~1.94 Å, except for complexes 1 and 4 which are slightly larger
(2.15 and 2.14 Å, respectively). For complexes 2 and 6, the computed Ru−N(L)
distances are slightly shorter than the ones determined by X-ray diffraction
crystallography (2.11 and 2.12 Å, respectively). The experimental evidence that they
are almost identical was also reproduced by the computational results. The calculated
Ru−p-cym(centroid) distances for complexes 1 and 4 have similar values, which are
slightly larger (~1.85 Å) when compared to those of complexes 2, 3, 5 and 6.
Particularly in the case of complexes 2 and 6, the computed Ru−p-cym(centroid)
distances are larger than those found in their X-ray crystal structures (1.69 and 1.70
Å, respectively). The calculated Ru−N,N'(bpm) distances in the bpm−Py containing 
RuII arene complexes 1 (p-cym), 8 (hmb), and 9 (ind), resulted in almost identical
Compound Ru−N(L) Ru−N,N' Ru−N,N' Ru−arene(centroid)
(1) 2.108 2.158 2.452 2.089
(2) 2.139 2.404 2.131 2.058
(3) 2.140 2.081 2.345 2.625
(4) 2.133 2.414 2.129 2.067
(5) 2.119 2.132 2.410 2.069
(6) 2.133 2.396 2.132 2.058
(8) 2.159 2.151 2.466 2.014
(9) 2.132 2.134 2.389 2.110
(10) 2.479 2.120 2.119 1.844
(11) 2.148 2.119 2.119 1.846
(12) 2.478 2.100 2.102 2.035
(13) 2.137 2.355 2.125 2.108
(14) 2.149 2.117 2.114 1.851
(15) 2.146 2.116 2.113 1.849
(16) 2.146 2.122 2.439 2.078
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values, being slightly larger (~0.1 Å) in the case of complex 8 (2.13 Å). The same
trend was observed for its Ru−N(Py) and Ru−hmb(centroid) bond lengths in, which are
both ~0.1 Å longer. The Ru−N,N' and the Ru−N(Py) bond distances in complexes 10
and 12 (phen and bathophen, respectively) display the same value (~2.12 Å);
however, complex 10 was found to have a longer Ru−p-cym(centroid) distance in
comparison to complex 12. This same bond distance also differs significantly from
that determined by X-ray crystallography for complex 10 (vide supra), where the
value predicted is ca. 0.4 Å larger. Conversely, the calculated Ru−N(Py) distances in 10
were found to be in good agreement with those in the X-ray crystal structure.; its
Ru−N,N'(phen) distances are barely longer. The DFT calculations show that the
Ru−N,N'(bpm) distance in complex 9 is ca. 0.10 Å shorter than the analogue
Ru−N,N'(bpy) distance found in complex 13. The Ru−N(Py) and Ru−ind(centroid) distances
in 9 and 13 are practically within the same range. When compared to the X-ray crystal
structure, the calculated Ru−ind(centroid) as well as the Ru−N,N'(bpy) bond length
distances of complex 13 were found to be slightly larger, whereas the corresponding
Ru−N(Py) is in good agreement. Finally, for complexes 14−16, the calculations show
that the Ru−N,N'(bpm), the Ru−N(L), and the Ru−p-cym(centroid) distances are identical in
the three cases (~2.12, 2.15, and 1.85 Å, respectively).
4.3.3.2 Lowest-Lying Triplet State (T0) Geometry
The lowest-lying triplet states geometries were also optimised for complexes 1−6 and
8−16, due to the key role that this state can play in their photochemistry. It was found
that the Ru−N(Py) distances are practically within the same range for complexes 1−6
(~2.14 Å), except for complexes 1 and 4 which display slightly smaller values. All
complexes have similar Ru−N(L) distances, except complexes 1 and 5 which are
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slightly shorter, when compared to the ground state (S0). Within this series (1−6), one
of the Ru−N,N' bond distances in the T0 state is considerably longer than the other, 
typically 2.18 and 2.40 Å. The Ru−p-cym(centroid) distances are in general longer
compared to the ground state (~2.06 Å); complex 4 having the largest value (ca. 2.26
Å). For complexes 8 and 9, the corresponding Ru−N(Py) bond lengths are slightly
longer, and also remain unchanged compared to those in the ground state. Both of the
calculated Ru−N,N'(bpm) distances in each case have two different values, being one of
them significantly larger (~2.4 Å). Each of the computed Ru−arene(centroid) distances
(hmb for 8 and ind for 9) are longer than those calculated for the ground state.
Complex 11 was found to keep nearly the same geometry as in S0. In the case of
complexes 10 and 12, the estimated Ru−N(Py) distance are considerably elongated
(~2.5 Å) whereas the corresponding Ru−N,N' bond lengths are almost identical to the 
ones observed for S0 and also very similar between them (~2.11 Å). In the same way
as observed in the X-ray crystal structure, the computational results show that the
calculated Ru−p-cym(centroid) distance in complex 10 is shorter than that found in the
ground state, whereas the opposite trend is found in the calculation results of complex
12. Complexes 9 and 13 display similar Ru−N(Py) bond distances as those calculated
for their S0. Furthermore, these two complexes follow the common trend of having
one Ru−N,N'(bpm) bond length longer than the other, while the Ru−ind(centroid) lengths
are in general larger than those in the ground state. Finally, for complexes 14−16, the
calculated Ru−N(L) distances are found to be larger than those computed for complex
1 (and practically for any of all the bpm−p-cym containing derivatives). The value
resembles more to that obtained for the ground state. In the case of the Ru−N,N'(bpm)
distances, while complex 16 follows the common trend of having one Ru−N,N'(bpm)
bond length larger than the other, complexes 14 and 15 do not follow it. Both of the
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calculated Ru−N,N'(bpm) distances for complexes 14 and 15 are within the same range
(~2.11 Å).
4.3.4 Orbital Analysis
The shapes of selected frontier orbitals for the RuII arene complexes 1−6 and 8−16 in
the ground state (S0) were analysed, in particular the Highest Occupied Molecular
Orbitals (HOMOs) and the first four Lowest Unoccupied Molecular Orbitals
(LUMOs). The Single Occupied Molecular Orbitals (SOMOs) of the lowest-lying
triplet state are also described along with their Spin Density Surfaces (total electron
density of electrons of one spin (α), minus the total electron density of the electrons of 
the other spin (β)).11 Visualisation of the SOMOs and the spin density surface of a
metal complex is useful to understand where unpaired electrons of a triplet state are
localised.
4.3.4.1 Molecular Orbitals in the Ground State
Complexes [(6-p-cym)Ru(bpm)(Py)]2+ (1) and [(6-p-cym)Ru(bpm)(4-MePy)]2+ (2)
are found to have similar frontier orbitals. The HOMO is delocalised mainly on the
Ru−p-cym moiety, with some contribution from the bpm chelating ligand. The
LUMO is bpm-centred while the LUMO+1 is delocalised around the Ru−p-cym bond.
The LUMO+1 for complexes 1 (Figure 4.10) and 2 has an important σ*-antibonding 
character towards the pyridine-derivative ligand (Py and 4-MePy, respectively). The
LUMO+2 is mainly bpm-centred, whereas the LUMO+3 resembles the LUMO+1 in
character. In the case of [(6-p-cym)Ru(bpm)(4-MeOPy)]2+ (3), all the orbitals share
similar features to those found for complex 1 and its analogue complex 2, with the
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exception of the HOMO, where a significant delocalisation over the 4-MeOPy was
observed. The 4,4'-bpy ligand in complex 4 (Figure 4.10) contributes to the overall
character of the LUMO+2 and LUMO+3, evidence which, however, is not observed
for the corresponding complexes 1 and 3. The HOMOs of [(6-p-cym)Ru(bpm)(4-
PhPy)]2+ (5) and [(6-p-cym)Ru(bpm)(4-BzPy)]2+ (6) are fully centred on the
corresponding pyridine-derivative, while the empty orbitals are consistently similar to
those found in 1, as well as for the other derivatives complexes 2−4. A direct orbital
comparison between complex 1 and complexes 14, 15 (Figure 4.10) and 16 reveals
that while complexes 15 and 16 maintain the similar features found for complex 1,
complex 14 displays a different character. Its high-energy LUMOs (i.e. LUMO+1,
LUMO+2, and LUMO+3) display not only a significant σ*-antibonding character 
towards the 3-AcPy ligand, but also an important contribution coming from its π 
orbitals. Additionally, LUMO+3 in complex 14 has a reduced arene(p-cym) character, as
well as an increased bpm contribution. The character of both the low- and the high-
energy orbitals for complexes 8 and 9 resemble more to those observed for 1, with the
only exception of the LUMO+1 which is observed to have lost the σ*-antibonding 
character towards the Py ligand. Only small differences were found between
complexes 9 and 13 when compared to 1. The RuII complex 13 has HOMO, LUMO
and LUMO+1 very similar to complex 9. However, the LUMO+2 has a σ*-
antibonding character toward the Py ligand, while the LUMO+3 shares the bpm-
centred nature of LUMO+2 found in the other derivatives, along with a considerable
contribution from its π orbitals. Finally, complexes 10 and 12 have HOMOs with an
increased contribution from the corresponding N,N'-chelating ligand, particularly in
the case of 12 (bathophen). Compared to complex 1, the LUMO+1 and LUMO+2
have reversed characters, so that LUMO+2 and LUMO+3 are more σ*-antibonding in 
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character. Complex 11 is found to have orbital character similar to complex 1. A
complete representation of the frontier orbitals for complexes 1−6 and 8−16 are
reported in the Appendix section.
Figure 4.10. Selected frontier orbitals for complexes 1, 4, 14, and 15 in the ground
state (S0) geometry.
4.3.4.2 Molecular Orbitals in the Lowest-Lying Triplet State
In the case of complex 1, both the highest-SOMO and the lowest-SOMO (h-SOMO
and l-SOMO, respectively) are delocalised over the Ru−arene(p-cym) and Ru−N,N'(bpm)
bonds, Figure 4.11. In the case of complex 2, these two orbitals (h-SOMO and l-
SOMO) are in general, similar to those found in complex 1, only differing in the
contribution from the 4-MePy to the l-SOMO. For complexes 3 and 4 this same effect
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is also observed but rather increased, and the contribution of the 4,4'-bpy in the latter
complex comes mainly from the uncoordinated Py ring which contributes to the l-
SOMO also through the non-coordinated-N-centred σ orbital. 
Figure 4.11. Calculated lowest- and highest- Single Occupied Molecular Orbitals (h-
SOMO and l-SOMO, respectively), and spin density surface for [(6-p-
cym)Ru(bpm)(Py)]2+ (1).
Complex [(6-p-cym)Ru(bpm)(4-PhPy)]2+ (5) is very similar to 1, where both the h-
SOMO and the l-SOMO are delocalised over the Ru−arene(p-cym) and Ru−N,N'(bpm)
bonds. As observed for complex 4, the l-SOMO in 5 is also delocalised on the phenyl
ring of the 4-PhPy ligand. Similar features are found for complex [(6-p-
cym)Ru(bpm)(4-BzPy)]2+ (6), where both the h-SOMO and the l-SOMO are centred
in the benzyl ring of the 4-BzPy ligand. The spin density maps for complexes 1−6
show that the nature of these lowest-lying triplet states are mainly Ru−arene(p-cym)
centred. Comparison of complex 1 with complexes 14, 15 and 16, show that the l-
SOMO on the two first complexes has the same character as that in complex 1,
whereas the h-SOMO is N,N'(bpm) localised and similar to the LUMO in the ground
state (S0). In the case of 16, the l-SOMO and the h-SOMO lie at inverted energy
levels compared to those of complexes 14 and 15. The spin density maps for
complexes 14 and 15 show that the unpaired electrons are mainly localised on the
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pyridine-derivative ligand, while for 16 they are centred on the Ru−arene(p-cym)
moiety. The l-SOMO and the h-SOMO of complex 11 are centred on the p-cym and
the phendio N,N'-chelating ligand, respectively. In the case of complexes 10 (phen)
and 12 (bathophen), both the l-SOMO and the h-SOMO display a σ*-antibonding 
character towards the Py ligand (particularly the h-SOMO). The l-SOMO is also more
localised on the corresponding N,N' chelating ligand (phen in 10, and bathophen in
12), whereas the h-SOMO is centred on the Ru-arene(p-cym) fragment. The spin density
map of complex 11 is mainly N,N'(phendio) centred, while for 10 and 12 they are
delocalised over all the RuII complex. Complexes [(6-hmb)Ru(bpm)(Py)]2+ (8) and
[(6-ind)Ru(bpm)(Py)]2+ (9) display high similarity when compared to 1. However,
their h-SOMOs have some σ*-antibonding character towards the monodentate 
pyridine ligand. Their spin density maps are mainly Ru−arene centred (only the 
aromatic ring of the ind arene is involved in the case of 9). Complex 13 shows a
N,N'(bpy)-l-SOMO localisation as that observed for complex 1. The spin density maps
of complexes 9 and 13 are Ru−arene(ind) centred in both cases.
4.3.5 Electronic Absorption Spectra and Singlet Excited States
The behaviour under visible light and UVA photoirradiation in aqueous solution of
complexes 1−6, 8−10, and 12−16 was explored. Due to its instability in aqueous
solution, photoirradiation experiments of complex 11 were performed in an acetone
solution. Complex 7 was not obtained in sufficient yields and therefore was not
considered for photochemical studies. The UV-vis absorption spectra of complexes
1−6 and 8−16 were recorded at 310 K as 100 M solutions in H2O from 200 to 800
nm. In the dark (i.e. no irradiation provided), aqueous solutions of all the complexes
Chapter 4: Photoactivatable RuII Arene Complexes
148
were remarkably stable over a large range of pH* values (pH* = 2–12) and no
hydrolysis reaction was observed at room temperature over a period of ca. 2 months.
Figure 4.12 shows the experimental UV-vis absorption spectra and the calculated
electronic transitions for all the complexes. The corresponding maxima of absorption
(, nm) and extinction coefficients (, M−1 cm−1) are listed in Table 4.5. A complete
set of DFT and TD-DFT calculations was performed with Gaussian 0312 on
complexes 1−6 and 8−16 at the B3LYP/LanL2Dz/6-31G** level, to characterise the
singlet and triplet excited states and to obtain insights into the mechanism of ligand
photodissociation. The TD-DFT-calculated singlet transitions of all the derivatives
are, in general, in good agreement with the experimental data. For complex 1 and the
analogue complexes 2, 3, and 4, the absorbance tail in the 380–420 nm region is
assigned to mixed metal centred/metal-to-ligand charge transfer (1MC/1MLCT)
transitions. These transitions are partially dissociative; they have significant
contributions from Ru−N,N'(bpm) and the corresponding Ru−N(L) σ*-antibonding 
orbitals that could be populated by light excitation. In the case of complex [(6-p-
cym)Ru(bpm)(4-PhPy)][PF6]2 (5) this low-energy absorbance tail, however, displays
more 1MLCT character, with contributions from the phenyl ring (within the 4-PhPy).
Pure 1MLCT (Ru → bpm) states are found at higher energy (UVA region) for 1. In
the case of complex 2 these transitions are present as a broad shoulder ca. 300 nm,
along with a maximum at ca. 275 nm which can be associated with transitions of
mixed character.
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Table 4.5. Wavelength of absorption maxima (, nm) and extinction coefficients (ε, 
M−1 cm−1) for complexes 1−6 and 8−16.
Compound Wavelength(, nm)
Extinction Coefficient
× 103 (ε M1 cm1)
(1) [(6-p-cym)Ru(bpm)(Py)][PF6]2
383
254
2.31
23.1
(2) [(6-p-cym)Ru(bpm)(4-MePy)][PF6]2
374
251
1.30
45.6
(3) [(6-p-cym)Ru(bpm)(4-MeOPy)][PF6]2
384
247
1.34
4.85
(4) [(6-p-cym)Ru(bpm)(4,4'-bpy)][PF6]2
382
252
0.28
3.43
(5) [(6-p-cym)Ru(bpm)(4-PhPy)][PF6]2
373
286
265
0.75
8.30
9.10
(6) [(6-p-cym)Ru(bpm)(4-BzPy)][PF6]2
357
254
0.43
5.69
(8) [(6-hmb)Ru(bpm)(Py)][PF6]2
382
242
0.88
12.2
(9) [(6-ind)Ru(bpm)(Py)][PF6]2
392
293
249
0.51
4.93
12.0
(10) [(6-p-cym)Ru(phen)(Py)][PF6]2
362
275
1.47
11.5
(11) [(6-p-cym)Ru(phendio)(Py)][PF6]2
301
275
0.76
1.31
(12) [(6-p-cym)Ru(bathophen)(Py)][PF6]2
395
289
1.21
10.7
(13) [(6-ind)Ru(bpy)(Py)][PF6]2
348
313
300
255
0.01
0.45
0.54
1.18
(14) [(6-p-cym)Ru(bpm)(3-AcPy)][PF6]2
372
250
3.29
17.9
(15) [(6-p-cym)Ru(bpm)(3-NA)][PF6]2
366
253
2.86
15.6
(16) [(6-p-cym)Ru(bpm)(3-AcOPy)][PF6]2
365
248
2.13
12.5
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Figure 4.12. Experimental UV-Vis spectrum (black) of the RuII pyridine or pyridine-
derivative complexes 1−6 and 8−16 in aqueous solution at 310 K. The calculated
electronic transitions are shown as red vertical bars with heights equal to their
oscillator strength.
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Selected Electron Density Difference Maps (EDDMs) for complexes 1, 4, 14, and 15
are shown in Figure 4.13. For complex 3, several transitions around this same region
(ca. 300 nm) acquire a more pronounced interligand (1IL) character given that the
methoxy group (on 4-MeOPy) is involved as an electron-density donor. In the case of
complex 4, within the UV region, the higher energy transitions display a mixed
character, whereas the lower energy tend to be more intense (compared to 1, 2, or 3).
Figure 4.13. Selected electron difference density maps (EDDMs) of singlet excited
state transitions for complexes 1, 4, 14, and 15 in H2O. Light violet indicates a
decrease in electron density; dark purple indicates an increase.
Complex 5 displays a different contribution to the overall character of the transitions
(highest intensity) at ca. 300 nm when compared to the analogue complexes 1−4,
being mainly composed by metal-to-ligand charge transfer/ligand centred
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(1MLCT/1LC, Ru → bpm/Ph → Py) states. For complex 6, the maximum of
absorbance is around the 250 nm region (as also observed for complexes 1−4) though
in this case they are predominantly 1MLCT (Ru → bpm) in character. Its low energy 
transitions (λ < 370 nm) are similar to the analogue complexes 1−4, with some of
them being 1IL (Bz → bpm) based. The UV-vis spectrum of the RuII ind complexes 8
and 9 is found to keep all the spectroscopic features exhibited by 1, both in the low
and the high-energy regions. Overall, complex 8 displays transitions that are red-
shifted, whereas the corresponding for complex 9 are slightly blue-shifted. Complexes
10 and 11 have both lower-energy singlet transitions that are either 1MLCT or 1MC in
character, which could have a dissociative nature. The main absorption band in
complex 10 is mixed in character, composed by a 1LC transition centred on the phen
chelating ligand and a 1MLCT (Ru → p-cym, phen) transition, whereas the analogue
absorption band on complex 11 is a mixed 1LC on the phendio along with a 1MC. For
complex 10, the calculations predict singlet transitions that are in general slightly
blue-shifted, whereas the opposite effect is predicted for complex 11. Complex 13
shows similar electronic transitions as those found in the analogue complexes 9 and 1,
which are 1MC or 1MLCT in character, the first ones being dissociative (LUMO+2
contribution). An intense transition can be observed around 300 nm that accounts for
the pronounced shoulder seen in the experimental spectrum. Such transition is a
mixed 1MLCT (Ru → bpm)/1LC. The second maximum of absorption at higher
energy (λ = 255 nm) is again of mixed character, with both 1MC/1LC and 1MLCT
transitions contributing to it. In the case of complex 12, as could be expected for
molecules with extended and highly conjugated aromatic surfaces, the DFT
calculations overestimated its contribution to the transitions at about 370 nm. This is
probably due to an error on the computing of the corresponding HOMO−LUMO
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energy.13 However, in a similar fashion as found in the other related complexes, the
lower energy transitions are mainly 1MC and 1MLCT (Ru → bpm), while the higher 
energy tend to be mainly composed of 1MLCT (Ru → bathophen) states. The overall 
features of the UV-vis absorption spectra of complexes 14, 15, and 16, resemble
significantly to those observed for complex 1. Orbital composition of computed
singlet transitions and selected EDDMs for complexes 1−6 and 8−16 are reported in
the Appendix section.
4.3.6 Photoirradiation of RuII Arene Complexes with Visible Light Followed by
UV-vis Absorption Spectroscopy
As shown by UV-vis data, if aqueous solutions of complexes 1−6, 8−10, and 12−16
are photoirradiated with visible light (irr = 400−660 nm, 1 J cm−2 h−1) at 310 K, the
electronic absorption bands shift and change in intensity, the largest changes being
observed around the 200−300 nm region, Figure 4.14. The presence of an isosbestic 
point at ca. 310 nm indicates the formation of a single photoproduct in all cases.
Chapter 4: Photoactivatable RuII Arene Complexes
155
Chapter 4: Photoactivatable RuII Arene Complexes
156
Figure 4.14. Photolysis (irr = 400–660 nm) of the RuII arene pyridine or pyridine-
derivative complexex 1−6, 8−10, and 12−16 in aqueous solution during ca. 10−12 h 
followed by UV-Vis.
4.3.7 Triplet Excited States
In addition to the singlet excited state calculations described (vide supra), triplet
excited states were calculated by DFT and TD-DFT for complexes 1−6 and 8−16. The
full set of calculations performed is schematised in Figure 4.15 and described in the
computational methods in Chapter 2. Both the ground state (S0) and the lowest-lying
triplet state (T0) geometries were employed in the triplet calculations. Eight
transitions were calculated in each case. The triplets calculated from the S0 geometry
(shown in red in Figure 4.15) describe the triplet excited states formed right after
excitation (Franck-Condon) and intersystem crossing (ultrafast ~fs), but before
significant structural relaxation14 (i.e. vibrational relaxation and solvation dynamics);
these excited states are reported in the appropriate Appendix section and are not
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considered for discussion. In d6 metal complexes (as those of RuII studied in this
work) the lowest-lying triplet T0 (shown in black in Figure 4.15) is typically the state
to which the excited molecules relax after excitation and intersystem crossing, before
returning to the ground state. It plays a key role in their photophysical and
photochemical properties, and for this reason its characterisation was performed by
geometry optimisation (vide supra) and spin density surface calculations using TD-
DFT methods (T1 shown in green in Figure 4.15). The characterisation of higher
energy triplet states (shown in green in Figure 4.15) was obtained as well by TD-DFT.
The complete computational results are reported in the appropriate Appendix section.
Analysis of the T0 geometry of complexes 1−6 reveals that they have a distorted
geometry, highlighting both an elongated Ru−N,N'(bpm) bond (with respect to the
ground state), which is typically ca. 0.3 Å longer, as well as an elongated Ru−N(L)
bond in the case of complexes 2, 3, 5, and 6. In the case of complexes 1 and 4, no
Ru−N(L) bond elongation is observed. Spin density surfaces (Figure 4.11) show that
the nature of the T0 for complexes 1−6 is 3MC, which is consistent with the lack of
emission from this family of compounds (altogether with the low energy of this state).
A similar T0 is usually found to be in favour of non-emissive deactivation pathways.15
Significantly, such T0 states do not have a dissociative character towards the L-
monodentate ligand, since the SOMOs have no antibonding character with respect to
the Ru−N(L) bond (except in the case of complex 1). In fact, there is not a dramatic
increase in the Ru−N(L) bond length for the optimised lowest-lying triplet geometries.
Chapter 4: Photoactivatable RuII Arene Complexes
158
Figure 4.15. Schematic representation of the computational method applied to the
study of the singlet and triplet excited states for complexes 1−6 and 8−16.
The observed increase in the Ru−N,N'(bpm) distance can be ascribed to the population
of a Ru−N,N'(bpm) σ*-antibonding h-SOMO; this involves only one of the bound-N
within the bpm. Dissociation of bpm is prevented by the strong coordination of the
other pyrazine ring of the ligand. The 3MC nature of the lowest-lying triplet state for
complexes 1−6 was confirmed by the TD-DFT calculations, which provide T1 states
that are consistent with their analogue T0. At higher energies, a series of other 3MC
states have dissociative character towards L, (see EDDMs). They contain
contributions from Ru–N(L) σ*-antibonding orbitals and dissociation of L can occur 
from these states during the excited state evolution to the ground state. For complexes
1−6, the first low-energy triplets (T0/T1, T2, and T3) have generally a 3MC character
which is not dissociative, whereas only T4−T6 are dissociative towards the
corresponding L-monodentate ligand (they involve the LUMO+3, which has a
dissociative character), Figure 4.16.
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At even higher energy, i.e. T7 and T8 (see Appendix section), 3MLCT of Ru → 
N,N'(bpm) character are present. In the case of complexes 4−6, the 3MLCT character in
the T2−T8 triplet states is more pronounced. 
Figure 4.16. Selected electron difference density maps (EDDMs) of triplet excited
state transitions for complex 1 in H2O (shown in green in Figure 4.15). Pink indicates
a decrease in electron density, while red indicates an increase.
In the case of complexes 8 and 9, the T0 geometries show elongated Ru−N,N'(bpm)
bonds. The spin density surface suggests a lowest-lying triplet state with a 3MC
dissociative character towards one of the pyrazine rings in the bpm ligand, due to the
h-SOMO orbital having a σ*-antibonding nature. Similarly to 1−6, TD-DFT triplet
calculations highlight the presence of dissociative Ru−N(L)
3MC for both complexes 8
and 9 (T4 and T5), confirming as well that the lowest-lying triplet state is not
dissociative. The T0 geometries of complexes 10 and 12 have a distorted Ru → N(Py)
bond. Their spin density surfaces are 3MC and have a Ru−N(L) σ*-antibonding h-
SOMO. They both behave like their analogue complexes 1–6 and 9, where the
dissociative 3MC states are present above the lowest-lying triplet state. In the case of
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11, no distortions are observed when comparing S0 and T0. The TD-DFT calculations
show that there is a greater 3MLCT character, with no significant involvement of the
σ*-antibonding orbitals and the 3MC states. Complex 13 behaves more similarly to
complex 1. For complexes 14 and 15, a non-distorted T0 geometry was found,
whereas complex 16 displays an elongated Ru−N,N'(bpm) bond, just as observed for the
analogue complexes 1−6. The three complexes 14−16 display Ru−N(L) bond distances
similar to the ground state (S0). The spin density surfaces of complexes 14 and 15 are
L-centred (where L is 3-AcPy and NA, respectively), while for complex 16 (where L
is 3-AcOPy) is 3MC (Ru → arene(p-cym)). The SOMOs of complexes 14 and 15 are
consistent with a non-dissociative lowest-lying triplet state. Conversely, according to
TD-DFT calculations, the T1 state for complexes 14 and 15 has a marked dissociative
nature towards the Ru−N(L) bond (contribution from LUMO+1 and LUMO+3).
4.3.8 Photoirradiation of RuII Arene Complexes with Visible Light followed by
1H NMR Spectroscopy
1H NMR spectra recorded at different stages of photolysis with visible light (irr =
400−660 nm) confirm that all the photoirradiated complexes selectively release their 
pyridine or pyridine-derivative ligand (L) with the subsequent in situ formation of the
corresponding aqua adduct as the only photoproduct. The spectra for complexes 1 and
10 are shown in Figure 4.17; for the remaining derivatives the observed changes were
identical to the ones described as follows.
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Figure 4.17. Selected 1H NMR spectra of complexes 1 (top) and 10 (bottom) during
their aqueous photolysis (irr = 400660 nm). Blue = Py complex, green = aqua
adduct; ■ = bpm,  = phen,▲ = Py, ● = p-cym. Free Py is indicated with orange ▲.
The spectra of each of the complexes in D2O (or complex 11 in (CD3)2CO) at 310 K
initially contained a set of peaks assigned to the original Ru−L complex, [(6-
arene)Ru(N,N')(L)]2+. Further photoirradiation with visible light (irr = 400−660 nm) 
at 310 K produces a second set of peaks which increase in intensity as
photoirradiation is maintained. These peaks are assigned to the corresponding aqua
species [(6-arene)Ru(N,N')(OH2)]2+. A third set of peaks attributed to the free
pyridine or pyridine-derivative was also detected. Solutions of all the RuII arene
complexes kept in the dark at 310 K for longer than ca. 2 months did not show any
detectable formation of the aqua adducts. The pH* values of the solutions were
determined at the beginning and at the end of each photoirradiation experiment. In
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most cases a slight decrease on the values was registered, from an average of ~7.14 at
the starting point down to ~6.52 at the final stage. The mass-to-charge ratios and
isotopic models obtained from HR-MS spectra were consistent with the formation of
the aqua complexes as the corresponding photoproducts, Table 4.6.
Table 4.6. Mass-to-charge ratios obtained from HR-MS spectra for the photolysis
products of RuII arene complexes 1−6, 8−10, and 12−16.
Observed peak
[M]2+
Chemical formula
Calc m/z
Found
m/z
(1)−(6),
(14)−(16)
[(6-p-cym)Ru(bpm)(OH2)]2+ C18H22N4O
206.0418
206.0408
(8) [(6-hmb)Ru(bpm)(OH2)]2+ C20H26N4ORu
220.0572
220.0567
(9) [(6-ind)Ru(bpm)(OH2)]2+ C17H18N4ORu
198.0259
198.0254
(10) [(6-p-cym)Ru(phen)(OH2)]2+ C22H24N2ORu
217.0466
217.0458
(11) [(6-p-cym)Ru(phendio){(CH3)2CO}]2+ C25H26N2O3Ru
503.5608
503.5610
(12) [(6-p-cym)Ru(bathophen)(OH2)]2+ C34H32N2ORu
293.0779
293.0665
(13) [(6-ind)Ru(bpy)(OH2)]2+ C19H20N2ORu
197.0307
197.0304
4.3.9 Structure–Photoactivity Relationship
4.3.9.1 Dependence on the 4-(substituted)pyridine Derivative
Each of the [(6-arene)Ru(N,N')(L)]2+ complexes 1−6 and 8−16 was found to
photoconvert to their corresponding aqua adducts to various extents after a given
amount of photoirradiation time. Figure 4.18 shows and Table 4.7 lists the
percentage of species detected by 1H NMR after ca. 10−12 h of continuous visible 
light photoirradiation (irr = 400−660 nm) at 310 K for complexes 1−6 (all of
which incorporate bpm, p-cym and 4-(substitued)pyridines); complex 1 is also
included for comparison. Within this group, complex [(6-p-cym)Ru(bpm)(4,4'-
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bpy)]2+ (4) photoconverts at the slowest rate and to the lesser extent. Complexes 1
and 3 where L = Py and 4-MeOPy, respectively were found to convert to a higher
extent.
Figure 4.18. Comparison chart showing the percentage of species formed after the
photoirradiation of complexes 1−6 in aqueous solution at 310 K with visible light (irr
= 400660 nm) followed by 1H NMR. Blue = L complex, green = aqua adduct;
orange = free L.
Table 4.7. Percentage of species present after ca. 10−12 h of photoirradiation in 
aqueous solution with visible light (irr = 400660 nm) at 310 K of complexes 1−6
followed by 1H NMR.
Compound Time(min) Ru−L 
% Species
Ru−OH2 Free L
(1) [(6-p-cym)Ru(bpm)(Py)]2+ 605 52.1 47.9 47.9
(2) [(6-p-cym)Ru(bpm)(4-MePy)]2+ 641 57.9 42.1 42.1
(3) [(6-p-cym)Ru(bpm)(4-MeOPy)]2+ 645 52.0 48.0 48.0
(4) [(6-p-cym)Ru(bpm)(4,4'-bpy)]2+ 605 72.1 27.9 27.9
(5) [(6-p-cym)Ru(bpm)(4-PhPy)]2+ 687 58.3 41.7 41.7
(6) [(6-p-cym)Ru(bpm)(4-BzPy)] 2+ 610 69.0 31.0 31.0
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4.3.9.2 Dependence on the 3-(substituted)pyridine Derivative
When L is 3-acetylpyridine (14), nicotinamide (15) or 3-acetatepyridine (16), the
amount of aqua adduct produced is larger after a shorter time of photoirradiation
when compared to complex 1. A full conversion of compound 14 to the aqua adduct
before the offset of continuous 10 h of photoirradiation is achieved. Figure 4.19
shows and Table 4.8 lists the percentage of species detected by 1H NMR after ca.
10−12 h of continuous visible light photoirradiation at 310 K for complexes 14−16. It
can be seen complex 14 is the most effectively photoactivated complex of the series.
Figure 4.19. Comparison chart showing the percentage of species present after ca.
10–12 h of photophotoirradiation in aqueous solution with visible light (irr =
400660 nm) at 310 K for complexes 1416 followed by 1H NMR. Blue = L
complex, green = aqua adduct; orange = free L.
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Table 4.8. Percentage of species present after ca. 10−12 h of photoirradiation in 
aqueous solution with visible light (irr = 400660 nm) at 310 K for complexes 1, and
14−16 followed by 1H NMR
4.3.9.3 Dependence on the N,N'-chelating Ligand
Table 4.9 lists and Figure 4.20 shows the percentage of species detected by 1H NMR
after ca. 1012 h of continuous visible light photoirradiation at 310 K for complexes
10 and 12; complex 1 is also included for comparison. Complex 11 appeared to be
unstable in aqueous media and was only considered for photoirradiation in acetone-d6
solution. It can be seen that after ca. 628 and 610 min of photoirradiation, 75% and
60% of complexes 10 and 12, respectively are still present intact in the solution and
ca. 25% and 40% of their corresponding aqua adduct has been formed (accompanied
by the same percentage of released Py).
Table 4.9. Percentage of species present after ca. 1012 h of photoirradiation in
aqueous solution with visible light (irr = 400660 nm) at 310 K for complexes 1, 11,
and 13 followed by 1H NMR.
Compound Time
(min) Ru−L 
%Species
Ru−OH2 /
Ru−Acetone Free L
(1) [(6-p-cym)Ru(bpm)(Py)]2+ 605 52.1 47.9 47.9
(10) [(6-p-cym)Ru(phen)(Py)]2+ 628 74.6 25.4 25.4
(11) [(6-p-cym)Ru(phendio)(Py)]2+ 402 62.4 37.6a 53.9
(12) [(6-p-cym)Ru(bathophen)(Py)]2+ 610 60.3 39.7 39.7
a The photoirradiation for complex 11 was carried out in acetone-d6 solution
Compound Time(min) Ru−L
% Species
Ru−OH2 Free L
(1) [(6-p-cym)Ru(bpm)(Py)]2+ 605 52.1 47.9 47.9
(14) [(6-p-cym)Ru(bpm)(3-AcPy)]2+ 560 0 100.0 100.0
(15) [(6-p-cym)Ru(bpm)(NA)]2+ 649 22.0 78.0 78.0
(16) [(6-p-cym)Ru(bpm)(3-AcOPy)]2+ 668 27.3 72.7 72.7
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Figure 4.20. Comparison chart showing the percentage of species present after ca.
10−12 h of photoirradiation in aqueous solution with visible light (irr = 400660 nm)
at 310 K for complexes 1, 10, 11 and 12 followed by 1H NMR. Blue = L complex,
green = aqua adduct/bright green = acetone adduct; orange = free L.
4.3.9.4 Dependence on the Arene
Table 4.10 lists and Figure 4.21 shows and the percentage of species detected by 1H
NMR after ca. 10−12 h of continuous visible light photoirradiation at 310 K for 
complexes 8 and 9; complex 1 is also included for comparison. It can be seen that
after ca. 305 and 425 min of photoirradiation, 100% of complexes 8 and 9 have been
photo-converted to their corresponding aqua adduct (accompanied by the same
percentage of released Py).
Table 4.10. Percentage of species present after ca. 1012 h of photoirradiation in
aqueous solution with visible light (irr = 400660 nm) at 310 K for complexes 1, 8,
9, and 10 followed by 1H NMR.
Compound Time(min) Ru−L 
% Species
Ru−OH2 Free L
(1) [(6-p-cym)Ru(bpm)(Py)]2+ 605 52.1 47.9 47.9
(8) [(6-hmb)Ru(bpm)(Py)]2+ 305 0 100.0 100.0
(9) [(6-ind)Ru(bpm)(Py)]2+ 396 0 100.0 100.0
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Figure 4.21. Comparison chart showing the percentage of species present after ca.
1012 h of photoirradiation in aqueous solution with visible light (irr = 400660 nm)
at 310 K for complexes 1, 8, and 9 followed by 1H NMR. Blue = L complex, green =
aqua adduct; orange = free L.
Table 4.11 lists and Figure 4.22 shows the percentage of species detected by 1H NMR
after ca. 10–12 h of continuous visible light photoirradiation at 310 K for complex 13;
complexes 1 and 9 are also included for comparison. It can be seen that after ca. 643
min of photoirradiation, 78% of complex 13 is still present intact in the solution.
Table 4.11. Percentage of species present after ca. 10−12 h of photoirradiation in 
aqueous solution with visible light (irr = 400660 nm) at 310 K for complexes 1, 9,
and 13 by 1H NMR.
Compound Time(min) Ru−L 
% Species
Ru−OH2 Free L
(1) [(6-p-cym)Ru(bpm)(Py)]2+ 605 52.1 47.9 47.9
(9) [(6-ind)Ru(bpm)(Py)]2+ 425 0 100.0 100.0
(13) [(6-ind)Ru(bpy)(Py)]2+ 643 77.4 22.6 22.6
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Figure 4.22. Comparison chart showing the percentage of species present after ca.
10−12 h of photoirradiation in aqueous solution with visible light (irr = 400660 nm)
at 310 K for complexes 1, 9, and 13 followed by 1H NMR. Blue = L complex, green
= aqua adduct; orange = free L.
4.3.10 Photoirradiation of RuII Arene Complexes with UVA followed by UV-vis
Absorption Spectroscopy
In order to investigate the effect of the wavelength of light on the photolysis process
(in addition to visible light), selected RuII arene complexes (1, 8−10, and 13−16) were
also photoirradiated by UVA (irr = 300−400 nm) at 310 K. The photoirradiation was 
followed by UV-vis absorption spectroscopy and the spectra are shown in Figure 4.23
For the selected RuII arene complexes (1, 8−10, and 13−16), photoirradiation with
UVA in aqueous solution at 310 K during ca. 3−5 h (photoirradiation was terminated 
when no further changes were observed). Similar spectral changes as when
photoirradiated with visible light can be observed, but in half of the photoirradiation
time. The electronic absorption spectra exhibit the characteristic shift and change in
intensity, with higher and stronger changes being observed around the 200–300 nm
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region. The presence of an isosbestic point at ca. 310 nm indicates the formation of a
single photoproduct. HR-MS spectra were consistent with the formation of the
corresponding aqua complexes as the photoproducts.
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Figure 4.23. UV-vis absorption spectra of the photolysis reaction with UVA
photoirradiation (irr = 300–400 nm) during ca. 3–5 h, of RuII arene pyridine or
pyridine-derivative complexes 1, 8–10, and 13–16 in aqueous solution at 310 K. Inset:
UV-vis absorption spectra for the photolysis reaction with visible light (irr = 400–660
nm) during ca. 10–12 h.
4.3.11 Photoirradiation of RuII Arene Complexes with UVA followed by 1H
NMR Spectroscopy
In order to confirm the nature of the photoproduct produced by the photolysis of the
selected RuII arene complexes (1, 8−10, and 13−16) with UVA photoirradiation (irr =
300−400 nm), their 1H NMR spectra were recorded at different stages of
photoirradiation in D2O at 310 K for ca. 3−5 h. In an identical fashion as when using 
visible light, all the photoirradiated complexes selectively release their pyridine-
derivative ligand with the subsequent in situ formation of the corresponding aqua
complex as the only photoproduct. Spectra for complex 1 are shown in Figure 4.24.
When using UVA as the source of photoirradiation, a larger extent of
photoconversion of all the selected [(6-arene)Ru(N,N')(L)]2+ complexes to their
corresponding aqua species [(6-arene)Ru(N,N')(OH2)]2+ can be achieved with less
than half the photoirradiation time (i.e. from 425 min to 180 min in the case of 1).
Table 4.12 lists the percentage of species detected by 1H NMR after ca. 4−6 h of 
continuous UVA photoirradiation at 310 K for complexes 1, 8−10, and 13−16.
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Figure 4.24. 1H NMR spectra of complex 1 during its aqueous photolysis with: (top)
UVA photoirradiation (irr = 300−400 nm) or (bottom) visible light (irr = 400−660 
nm) at 310 K. Blue = Py complex, green = aqua adduct; ■ = bpm,▲ = Py, ● = p-
cym. Free Py is indicated with orange ▲.
Table 4.12. Percentage of species present after ca. 3−5 h of photoirradiation in 
aqueous solution with UVA photoirradiation (irr = 300−400 nm) at 310 K for 
complexes 1, 8−10, and 13−16 by 1H NMR.
Compound Time(min) Ru−L 
% Species
Ru−OH2 Free L
(1) [(6-p-cym)Ru(bpm)(Py)]2+ 180 0 100 100
(8) [(6-hmb)Ru(bpm)(Py)]2+ 138 5.5 94.5 94.5
(9) [(6-ind)Ru(bpm)(Py)]2+ 149 0 100 100
(10) [(6-p-cym)Ru(phen)(Py)]2+ 220 14.1 85.9 85.9
(13) [(6-ind)Ru(bpy)(Py)]2+ 226 46.0 54.0 54.0
(14) [(6- p-cym)Ru(bpm)(3-AcPy)]2+ 189 0 100 100
(15) [(6- p-cym)Ru(bpm)(3-NA)]2+ 204 12.4 87.6 87.6
(16) [(6- p-cym)Ru(bpm)(3-AcOPy)]2+ 210 12.8 87.2 87.2
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4.3.12 Photocontrolled Nucleobase Binding
In order to investigate the ability of the [(6-arene)Ru(N,N')(L)][PF6]2 complexes to
bind to DNA bases, a photoirradiation experiment with visible light (irr = 400−660 
nm) at 310 K in the presence of 9-ethylguanine (9-EtG) was performed for complexes
1−6, 8−10, and 12−16. As shown in Figure 4.25 (selected example for complex 1),
photoirradiation of the complexes with visible light at 310 K in D2O in the presence
of 1 mol equiv of 9-EtG resulted in the initial formation of the corresponding aqua
adduct [(6-arene)Ru(N,N')(OH2)]2+ followed by coordination of the nucleobase to
the Ru centre to form [(6-arene)Ru(N,N')(9-EtG-N7)]2+. The binding to 9-EtG is not
reversible upon the termination of photoirradiation. Figure 4.26 shows the 2D 1H-1H
NOESY spectra which was used to assign the proton resonances and to confirm the
structure of [(6-p-cym)Ru(bpm)(9-EtG-N7)]2+ (1-EtG). An NOE cross-peak between
H(8) of 9-EtG and the 2,2'-CH of bpm was observed, suggesting coordination of 9-
EtG through N7 as previously observed.16 The 1H NMR signals for the 9-EtG adduct
of complex 1 have the same chemical shift as the isolated 9-EtG complex 15
described in Chapter 3, as they are the same species. For the rest of the RuII arene
complexes which also selectively photorelease the pyridine or the pyridine-derivative
ligands, a similar behaviour was observed when the photoirradiation was carried out
in the presence of 9-EtG. The mass-to-charge ratios and isotopic models obtained
from HR-MS spectra are consistent with the formation of the corresponding guanine
adducts, Table 4.13. A similar photoirradiation experiment was performed in the
presence solely of 9-EtA (9-ethyladenine), resulting in that no coordination to the Ru
centre of this nucleobase was observed.
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Figure 4.25. 1H NMR spectra during the aqueous photolysis (λirr = 400−660 nm) of 1
in the presence of 9-EtG. Blue = [(6-p-cym)Ru(bpm)(Py)]2+, green = [(6-p-
cym)Ru(bpm)(OH2)]2+, magenta = [(6-p-cym)Ru(bpm)(9-EtG-N7)]2+; ■ = bpm, ▲ 
= Py, ● = p-cym. Free Py is indicated with orange ▲ and coordinated 9-EtG with
magenta ♦.
Figure 4.26. 1H-1H NOESY NMR spectrum of [(η6-p-cym)Ru(bpm)(9-EtG-N7)]2+
(15) in D2O (aromatic region only). Magenta = [(6-p-cym)Ru(bpm)(9-EtG-N7)]2+;
■ = bpm protons, ♦ = H8 of coordinated 9-EtG. 
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Table 4.13. Mass-to-charge ratios obtained from HR-MS spectra for the photolysis
products of RuII arene complexes 1−6, 8−10, and 12−16.in the presence of 9-EtG.
Observed peak
[M]2+
Chemical formula
Calc m/z
Found m/z
(1)−(7),
(14)−(17)
[(6-p-cym)Ru(bpm)(9-EtG-N7)]2+ C25H29N9ORu
286.5767
286.5755
(8) [(6-hmb)Ru(bpm)(9-EtG-N7)]2+ C27H33N9ORu
300.5924
300.5916
(9) [(6-ind)Ru(bpm)(9-EtG-N7)] C24H25N9ORu
278.5610
278.5601
(10) [(6-p-cym)Ru(phen)(9-EtG-N7)]2+ C29H31N7ORu
297.5815
297.5820
(13) [(6-p-cym)Ru(bathophen)(9-EtG-N7)]2+ C41H39N7ORu
373.6130
373.6127
4.3.13 Photocontrolled CT-DNA Interactions in Cell-Free Media
In order to explore the possibility and nature of the interactions of this new family of
photoactivatable compounds with DNA, three complexes (1, 4 and 11) were selected
for further studies with CT-DNA in cell-free media.
4.3.13.1 DNA Binding Kinetics
Reaction mixtures of DNA and complexes [(6-p-cym)Ru(bpm)(Py)]2+ (1), [(6-p-
cym)Ru(bpm)(4,4'-bpy)]2+ (4) and [(6-p-cym)Ru(phen)(Py)]2+ (10) were prepared
in three ways: (A) in the dark (henceforth referred to as non-irradiated), (B)
following the addition to DNA of (beforehand) irradiated 1, 4 and 10 (pre-
irradiated), or (C) by addition of 1, 4 and 10 to DNA followed by photoirradiation
of the resulting mixture (irradiated). The samples were photoirradiated with
visible light (λirr = 400−660 nm) at selected photoirradiation times. The binding 
kinetics experiments with CT-DNA where then performed as described in Chapter
2. The results, summarised in Table 4.14, indicate that the non-irradiated forms of
1, 4, and 10 are not bound to DNA significantly in 10 mM NaClO4 (less than 5%
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for 1 and 10 and ca. 20% of 4 after 48 h). Pre-irradiated forms of complexes 1, 4,
and 10 reacted with DNA in ca. 40%, 54%, and 58%, respectively after 24 h; and
irradiated forms of 1, 4 and 10 reacted in ca. 41%, 50%, and 54%, respectively
after 24 h. It can be seen that pre-irradiated RuII arene complexes bind faster but
to the same extent as the irradiated DNA mixtures, Figure 4.27.
Table 4.14. Percentage of binding of non-irradiated, pre-irradiated, or irradiated
forms of complexes 1, 4 and 10 to CT-DNA in 1.0 mM NaClO4 as determined by
FAAS.
a Incubations with DNA were at 310 K. The concentration of DNA was 50 g/mL. Data are the average
of two independent experiments.
b Photoirradiation was carried out in absence of DNA for 24 h, followed by a further incubation with
DNA in the dark.
c Photoirradiation of was carried out in presence of DNA for 24 h.
ND Not determined.
Figure 4.27. Percentage of binding to CT-DNA by pre-irradiated (red) and irradiated
(blue) forms of complexes [(6-p-cym)Ru(bpm)(Py)][PF6]2 (1), [(6-p-
cym)Ru(bpm)(4,4'-bpy)][PF6]2 (4) and [(6-p-cym)Ru(phen)(Py)][PF6]2 (10) as a
function of time.
Non-irradiateda Pre-irradiatedb Irradiatedc
Time (hours) 1 4 10 1 4 10 1 4 10
24 3.1 18.7 3.7 40.2 54.5 57.6 41.1 50.3 54.0
48 1.0 17.4 7.9 41.5 62.2 49.7 ND ND ND
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4.3.13.2 DNA Transcription by RNA Polymerase in Vitro
Cutting of pSP73KB DNA by NdeI and HpaI restriction endonucleases yielded a 212-
bp fragment. This fragment contained the T7 RNA polymerase promotor. The RuII
arene complexes were tested as their non-irradiated, pre-irradiated and irradiated
forms. All samples were precipitated and redissolved after incubation with DNA
(7.8×10–5 M, 0.5 μg/20 μL) to remove the unbound RuII arene complexes; rb of
complexes 1, 4 and 10 was determined using EAS and FAAS. The autoradiogram of
the inhibition of RNA synthesis by T7 RNA polymerase on pSP73KB DNA
containing adducts of the RuII arene complexes or cisplatin is shown in Figure 4.28.
The bands corresponding to the transcription of DNA modified by the non-irradiated
forms of complexes 1, 4, and 10 are rather faint in intensity indicating that RNA
synthesis on the modified fragment do not stop the polymerase, except for complex
[(6-p-cym)Ru(bpm)(4,4'-bpy)][PF6]2 (4), which was found to bind to DNA without
photoirradiation (ca. 20%). The pre-irradiated, and irradiated forms of 1, 4, and 10
yielded fragments of newly synthesized RNA of defined sizes, which indicates that
RNA synthesis on these templates was prematurely terminated. The major stop sites
produced occurred at similar positions in the gel and were exclusively at guanine
residues, Figure 4.29 and are identical for the three RuII arene complexes. The total
intensity of the bands on the autoradiogram corresponding to transcripts of single-
ruthenated DNA fragments (modified to the same level (rb)) differed. The intensities
of those corresponding to the transcription of DNA modified by the pre-irradiated
forms of complexes 1, 4 and 10 are slightly stronger than those of those
corresponding to the transcription of DNA modified by the irradiated forms.
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The profiles are similar to that obtained for DNA treated with the anticancer drug
cisplatin and also to those reported previously for the RuII arene compounds, such as
[(η6-arene)Ru(en)Cl]+.17
Figure 4.28. Autoradiogram of 6% polyacrylamide/8 M urea sequencing gel showing
inhibition of RNA synthesis by T7 RNA polymerase on pSP73KB DNA containing
adducts of RuII arene complexes or cisplatin. Lanes: chain terminated marker RNAs,
cisplatin, at rb = 0.02; A, U, G and C, the template modified by RuII arene
compounds.
Figure 4.29. Schematic diagram showing the portion of the sequence used to monitor
inhibition of RNA synthesis by RuII arene complexes. The arrows indicate the start of
the T7 RNA polymerase, which used as template the upper strand of pSP73KB DNA,
respectively. The numbers correspond to the nucleotide numbering in the sequence
map of pSP73KB plasmid. (●) Indicates major stop sites for DNA modified by 
ruthenation.
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4.3.13.3 Unwinding of Supercoiled pUC19 Plasmid DNA
The plasmid was incubated with the RuII arene complexes 1, 4 and 10 in 10 mM
NaClO4, at pH ≈ 6 for 24 h at 310 K in their pre-irradiated and irradiated forms. All
samples were precipitated and redissolved after incubation with DNA to remove free,
unbound RuII species. The rb(c) value was determined by EAS and FAAS. The native
agarose gel resulting from DNA modified by the RuII arene complexes 1, 4, and 10 in
their pre-irradiated forms are shown in Figure 4.30 and the corresponding irradiated
forms is shown in Figure 4.31. The DNA unwinding angle produced by the adducts
formed by pre-irradiated and irradiated forms of the RuII arene complexes 1 and 4,
and 10 was determined to be 6.6±1.7°, 5.2±2.2°, and 6.1±2.2°, respectively using this
approach. The commigration point of the modified supercoiled and nicked DNA
(rb(c)) was reached at rb = 0.16, 0.19 and 0.17 for complexes 1, 4, and 10 respectively,
Table 4.15. From the autoradiogram it can also be noticed that an increasing amount
of nicked (OC) form occurred during photoirradiation of the RuII arene complexes in
the presence of DNA (irradiated form), rb(c) for 1 and 10 is not changed whereas
DNA is almost completely nicked with increasing ruthenation in the case of 4.
Table 4.15. Unwinding of supercoiled pUC19 DNA by RuII arene complexes 1, 4 and
11.
Compound rb(c)
Unwinding
Angle (°)
(1) [(6-p-cym)Ru(bpm)(Py)][PF6]2 0.160.03 6.61.7
(4) [(6-p-cym)Ru(bpm)(4,4'-bpy)][PF6]2 0.190.04 5.22.2
(10) [(6-p-cym)Ru(phen)(Py)][PF6]2 0.170.04 6.12.0
Cisplatin 0.08 13
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Figure 4.30. The unwinding of supercoiled pUC19 plasmid DNA (1.0 × 10−4 M, 0.5
μg/15 μL) by complexes 1, 4, and 10 in their pre-irradiated forms. Left and right
lanes are controls (unmodified DNA); top bands correspond to the form of nicked
plasmid (OC) and the bottom bands to the closed, negatively supercoiled plasmid
(SC). ri values increase on going from left to right lanes (molar ratio of free Ru
complex to nucleotide phosphates at the onset of incubation with DNA).
Figure 4.31. The unwinding of supercoiled pUC19 plasmid DNA (1.0 ×10–4 M, 0.5
μg/15 μL) by complexes 1, 4, and 10 in their irradiated forms. Left and right lanes are
controls (unmodified DNA); ri values increase on going from left to right lanes; top
bands correspond to the form of nicked plasmid (OC) and the bottom bands to the
closed, negatively supercoiled plasmid (SC).
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4.3.13.4 DNA Melting Temperature
CT-DNA was modified by RuII arene complexes 1, 4 and 10 in their irradiated forms
at various rb values in 10 mM NaClO4 at 310 K for 24 h. The samples were then
dialysed and the rb was determined by EAS and FAAS. The salt concentration was
then further adjusted by the addition of NaClO4 to values in the range of 0.01−0.22 M. 
The DNA melting temperature (tm) is dependent both on the amount of bound Ru and
on the salt concentration. The observed trend for the three complexes 1, 4 and 10 is a
constant oscillation of the tm values, indicating that the DNA adducts formed are
unstable at higher ionic strengths and temperatures, Table A.4.48. The tm changes are
relatively small and a slight stabilisation effect is observed at low ionic strengths. At
the highest ionic strength, a tendency for a slight destabilisation was observed.
4.3.13.5 Circular Dichroism (CD)
CD spectra of DNA modified by complexes 1, 4 and 10 in their irradiated forms (at
298 K in 10 mM NaClO4) were also recorded at rb values in the range of 0.010−0.125. 
These complexes have no intrinsic CD signals as they are achiral and any CD signal
above 300 nm is therefore attributed to the interaction of the complexes with DNA.
Below 300 nm any change in the normally found spectrum for DNA in canonical B-
conformation (B-DNA) is due either to the DNA induced CD (ICD) of the metal
complex or the metal-complex-induced perturbation of the DNA spectrum. As can be
seen from Figure 4.32, the conservative CD spectrum transforms at wavelengths
below 300 nm upon interaction of the three complexes with CT-DNA. There is a
significant increase for complexes 1 and 4 and a decrease for complex 10 in the
intensity of the positive band around 280 nm. The signature of complex 4 coordinated
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to CT-DNA is a strong positive ICD centered at around 400 nm. The signature of
complexes 1 and 10 bound to CT-DNA includes no such ICD. The changes in CD
spectra of CT-DNA modified by RuII arene complexes 1 and 10 complexes (at
different rb values) were monitored at 246 and 278 nm; the changes exerted by
complex 4 were also monitored at 400 nm, Figure A.4.48.
Figure 4.32. Circular dichroism (CD) spectra of CT-DNA (1 × 10−4 M) modified by
RuII arene complexes 1, 4 and 10 in their irradiated forms; the medium was 10 mM
NaClO4, pH ≈ 6.  
4.3.13.6 Flow Linear Dichroism (LD)
Binding of all three RuII arene complexes to CT-DNA was also monitored by linear
dichroism spectroscopy, Figure 4.33. It is well established that the magnitude of the
LD signal measured within the DNA absorption band (i.e. at the 258 nm maximum) is
a function of its persistence length. It is known that changes in flexibilities, or the
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formation of rigid bends or kinks induced by strongly bound compounds, can
manifest themselves as decreases in the abilities of the modified DNA molecules to
align themselves in the hydrodynamic flow gradient of the LD cell. The magnitudes
of the LD signals at 258 nm decrease as a function of rb for the irradiated forms of
RuII arene complexes 1, 4 and 10. The changes in the LD spectrum of CT-DNA
modified by complexes 1, 4, and 10 (at different rb values) were monitored at 258.5
nm, Figure A.4.49. The largest changes are induced by complex 4. Complexes 1 and
10 behave similarly and within the same range.
Figure 4.33. Linear dichroism spectra of CT-DNA modified by RuII arene complexes
1, 4, and 10. LD spectra were recorded for DNA in 10 mM NaClO4. The
concentration of DNA was 2.3 × 10−4 M.
4.3.13.7 Ethidium Bromide (EtBr) Fluorescence
The ability of complexes to displace the DNA intercalator EtBr from CT-DNA, was
probed by monitoring the relative fluorescence of the EtBr-DNA adduct after treating
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the DNA with varying concentrations of the RuII arene complexes 1, 4 and 10 in their
irradiated forms. The 24-hour irradiated DNA mixtures were dialysed before the
fluorescence measurement and rb was determined by EAS and FAAS. Figure 4.34
shows a plot of relative fluorescence versus rb for the three RuII arene complexes
along with cisplatin, transplatin and monofunctional dienPt. All three adducts of the
RuII arene complexes decreased the EtBr fluorescence.
Figure 4.34. EtBr fluorescence versus rb for DNA modified by cisplatin (), dienPt
(), transPt (), and RuII arene complexes 1 (), complex 4 (), and complex 10
() in their irradiated forms in 10 mM NaClO4 at 310 K (24h photoirradiation
followed by 24 h incubation).
4.3.14 Cancer Cell Growth Inhibition (IC50 Values)
The IC50 values in ambient light conditions (i.e. no irradiation provided) for the RuII arene
complexes (1−6 and 8−16) against the A2780 human ovarian cancer cell line are
given in Table 4.16. In general, the complexes were moderately active against the
A2780 human ovarian cancer cell line in ambient light conditions and their potencies
vary in several orders of magnitude. The most potent complex [(6-p-
cym)Ru(bathophen)(Py)][PF6]2 (12) had an IC50 value under these conditions of 7.4
µM, comparable to that of cisplatin (2.2 µM) under the same conditions. As a general
trend, the most active complexes against the A2780 human ovarian cancer cell line in
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ambient light conditions contain p-cym as the arene and bpm as the N,N' chelating
ligand. A change in the arene and chelating ligand to ind or hmb and phen in
complexes 8, 9 and 10, respectively was found to decrease the activity. Within the
cytotoxic series of compounds, complexes that displayed activity have either Py or 3-
(substituted)Py as the L group, being the Py-bearing complexes the most active.
Table 4.16. IC50 values for RuII arene complexes against the A2780 human ovarian
cancer cell line in ambient light conditions.
Compound IC50 μM 
(1) [(6-p-cym)Ru(bpm)(Py)][PF6]2 9.0
(3) [(6-p-cym)Ru(bpm)(4-MeOPy)][PF6]2 70.0
(4) [(6-p-cym)Ru(bpm)(4,4'-bpy)][PF6]2 61.1
(8) [(6-hmb)Ru(bpm)(Py)][PF6]2 23.2
(9) [(6-ind)Ru(bpm)(Py)][PF6]2 92.0
(10) [(6-p-cym)Ru(phen)(Py)][PF6]2 25.9
(12) [(6-p-cym)Ru(bathophen)(Py)][PF6]2 7.4
(15) [(6-p-cym)Ru(bpm)(NA)][PF6]2 19.0
(16) [(6-p-cym)Ru(bpm)(3-AcOPy)][PF6]2 9.2
Cisplatin 1.5
a Complexes 2, 5, 6, 13 and 14 had IC50 values larger than 100 μM against the cell line tested (vide
supra).
4.3.15 Photocytotoxicity: Cancer Cell Growth Inhibition upon UVA
Photoirradiation
The cytotoxic effects of four RuII arene complexes, compounds 1, 2, 3, and 4, with
and without UVA photoirradiation were tested. Based on the primary screening
protocol selected for the assay, it was observed that they have reduced cytotoxic
potency under the tested concentrations and were not chosen for further IC50
determination. However, interesting observations can be made from the experiment.
Results of the primary screening with UV photoirradiation and in dark conditions are
shown in Figure 4.35. The T/Ccorr values determined highly depend on the cell line
used. A427 (human lung carcinoma) and 5637 (human urinary bladder carcinoma)
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appear to be more sensitive towards the complexes compared to DAN-g (human
pancreas carcinoma). Both in the dark and in light conditions the most cytotoxic
compound towards A427 and DAN-g human cancer cell lines is compound 3 whereas
complex 2 is towards 5637. Overall, there was no statistical significant difference
between the photoirradiated samples and those which were not photoirradiated due to
the insufficient activation of the compounds with UVA photoirradiation (as shown by
the photoirradiation experiments described previously in this Chapter) and/or to the
photodecomposition products having similar cytotoxic effects.
Figure 4.35. Results of the primary screening with (A) UVA photoirradiation and (B)
when the plates were kept in the dark. The concentrations used were 1 (61.74 mM), 2
(50.53 mM), 3 (79.25 mM), and 4 (65.53 mM).
4.4 Discussion
4.4.1 X-ray Crystal Structures
To the best of my knowledge, the X-ray crystal structures of 2, 6, 7, 10 and 13 are the
first reported examples of [(η6-arene)Ru(N,N')(L)]2+ where L is 4-MePy (2), 4-BzPy
(6), trz (7), or Py (10, 13). The overall structures of the solved [(η6-
arene)Ru(N,N')(L)]2+ complexes do not differ greatly from each other and are found
Chapter 4: Photoactivatable RuII Arene Complexes
186
to adopt the familiar pseudo-octahedral three-legged piano stool geometry common to
all other RuII arene structures5,6 with the Ru atom π-bonded to the arene ligand (p-cym
in 2, 6, 7, and 10; ind in 11), σ-bonded to a pyridine nitrogen (2, 6, 10, and 11), a
triazole (7), and to two nitrogen atoms of the chelating ligand (bpm for 2, 6, and 7;
phen for 10; bpy for 13) which constitute the three legs of the piano stool. The
corresponding bond lengths and angles are comparable to analogous RuII arene
complexes containing N,N' chelated ligands.21 Neither the nature of the corresponding
N,N'-chelating ligand nor the N-σ-donor, have an influence the corresponding RuII–
arene(centroid) distances (~ 1.70 Å). Interestingly, for all the complexes, one of the Ru–
N,N' bonds is found to be always longer than the other. A close inspection of the Ru–
NL bond lengths for complexes 2 and 6 reveals no significant difference between
them. A larger distortion from planarity on the bpm ligand is found for 2 compared to
6 (7.09°, and 6.80°, respectively). The nature of the arene does not influence
significantly the Ru–N,N'(bpm) bond lengths (comparing any of the p-cym complexes
to ind in compound 10 revealed no major variation). As described in the results
section, there are extended short range interactions in the X-ray crystal structures of
complexes 2, 6, 7, 10 and 11; i.e. intermolecular π-π interactions, hydrogen bonds and 
pseudo-trapping of small molecules that involve either the N,N' chelating ligands or
the pyridine-derivatives (which could allow intercalation into DNA and therefore
contribute to the cytotoxicity of this new class of compounds). The synthesis of
complex 7 produced a mixture of products that was difficult to separate. However,
through crystallisation complex 7 was obtained but in rather low yields. The synthesis
of complex 7 was performed aiming to investigate the photorelease of biological
active compounds such as triazoles.18
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4.4.2 Photochemistry
The photochemistry in aqueous solution at 310 K of the RuII arene complexes 1−6,
8−10, and 12−16 (Table 4.1 and Figure 4.1) of the general formula [(η6-
arene)Ru(N,N')(L)]2+ where N,N' is a bidentate chelating ligand and L is a pyridine or
pyridine-derivative was investigated under visible (λirr = 400−660 nm) or UVA 
photoirradiation (λirr = 300−400 nm), using both experimental (UV-vis and 
1H NMR
spectroscopies) as well as theoretical methods (DFT and TD-DFT calculations). The
experimental results showed that this family of RuII arene complexes can selectively
and exclusively photodissociate the monodentate ligand (L) when excited with visible
(λirr = 400−660 nm) or UVA photoirradiation (λirr = 300−400 nm), while the 
corresponding bound arenes and chelating ligands remain intact. It was observed that
with the use of UVA photoirradiation, the formation of the corresponding reactive
RuII arene aqua species can be achieved in a shorter period of time and the process is
much more efficient than when visible light is employed. This evidence is in good
agreement with the more intense absorption bands in the UV-region of the absorption
spectrum displayed by all the RuII arene complexes studied. The presence of
isosbestic points in their UV-vis absorption spectra is also in good agreement with the
formation of the single photoproduct in all cases, the reactive aqua adduct Ru−OH2
(and the corresponding free L ligand detected by 1H NMR). It is clear that since the
Ru−OH2 species do not form in the dark, the photoactivation of the complexes allows
strict control of the Ru−N(L) bond hydrolysis reaction. Their remarkable behaviour
contrasts to that observed for the analogous RuII arene complexes of the form [(η6-
arene)Ru(L)3]2+ where arene = benzene, toluene, or isopropyltoluene; and L = NH3 or
H2O, for which visible light photoirradiation in aqueous solution leads in each case to
the aquation of the arene as the only observable photoreaction (to produce
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[Ru(OH2)3L3]2+ plus the corresponding free arene).19 As shown by the TD-DFT
calculations, the selective photochemical dissociation of the L ligand is consistent
with the presence of Ru−N(L) σ*-antibonding orbitals (typically the LUMO+3) which 
participate in several singlet and triplet transitions. Furthermore, although in most
cases there is one dissociative Ru–N,N(chelating) σ*-antibonding orbital (LUMO+1, as 
shown by the calculations), such dissociative nature is only towards one aromatic ring
(i.e. one pyrazine ring in bpm in complexes 1–9 and 14–16). The second aromatic
ring in all the chelating ligands remains strongly bound thus preventing their
dissociation, providing further photochemical stability to this family of complexes
towards light-induced chelating ligand loss. On the basis of the computational work,
as well as photochemistry rates and examples reported in the literature, triplets states
are believed to play a key role in the ligand photodissociation mechanism of these
RuII arene complexes. In fact, despite the presence of some dissociative singlet
excited states, the slow formation of the Ru−OH2 species (more than 10 h of
photoirradiation with visible light in some cases) confirms this hypothesis. As in the
case of other RuII (poly)pyridyl complexes, such states can also undergo
photochemical reactions due to their distorted geometry20,21 which yield free ligand
molecules and a RuII (poly)pyridyl residue, generally an aqua or solvento complex.
From the computational point of view, it is believed that all the RuII pyridine
complexes studied in this Chapter follow a relatively similar photoinduced ligand
dissociation mechanism. It is likely that this dissociation occurs from a series of 3MC
triplet states with dissociative character (T4–T5). At lower energy 3MC with non-
dissociative character are present (T1–T3). The nature of these low-lying triplet states
is also consistent with the absence of fluorescence of the complexes in solution. There
is evidence that competitive-radiationless decay processes are much faster than these
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potential photochemical processes for some d6 metal complexes, particularly for RuII
(poly)pyridyl complexes.22 Figure 4.36, shows a summary of the photochemical
decomposition mechanisms for the RuII arene complexes based on the computational
data. After intersystem crossing promoted by the strong spin-orbital coupling, both
3MC non-dissociative and dissociative triplet states can be populated. The non-
dissociative 3MC states are responsible for the return of the excited molecules to the
ground state (consistent with the absence of fluorescence). The dissociative 3MCs
which can be populated by thermal activation and cause the selective dissociation of
the L ligand. An attempt to understand the relationship between the photoactivity and
structure of the RuII arene pyridine and pyridine-derivative complexes was also made
on the basis of the experimental data. The experimental observations can be
summarised as follows,
(a) Change of the basic Py ring for a 4-substituted Py ring. More electron-
donating substituents on the Py ring in the para-position moderately increase the
extent of the photo-induced hydrolysis, whereas no effect on the rate is observed.
(b) Change of the basic Py ring for a 3-substituted Py ring. Both the extent and the
rate of photo-induced hydrolysis decrease on changing the meta-substituent on the Py
ring following the order ketone > amide ≈ ester.  
(c) Change of the arene. More electron-donating substituents on the arene ring
increase both the extent and the rate of photo-induced hydrolysis.
(d) Change of the N,N'-chelating ligand. The more aromatic character, the lesser
the extent of photo-induced hydrolysis. However, no effect on the rate is observed.
This might be an indication that the corresponding rates and extents of the photolysis
reactions could also be related to the formation of the more thermodynamically
favoured aqua adducts. Such a hypothesis is further supported by the experimental
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observations that showed that the photoactivatable RuII arene complexes 8 and 9,
displayed the best rates and extent of the photo-induced hydrolysis (i.e. they generate
~100% of their corresponding aqua adduct in the less time of photoirradiation, either
with visible or UVA). The presence of a better electron-donating arene (such as hmb
in 8 or ind in 9) stabilises the aqua derivatives to a greater extent than those of the
other complexes.
Figure 4.36. Proposed photochemical decomposition mechanisms for the RuII arene
pyridine or pyridine-derivative complexes based on the TD-DFT computational data.
4.4.3 Photocontrolled DNA Interactions in Cell-Free Media
Three complexes of the form [(η6-p-cym)Ru(N,N')(L)]2+ where N,N' is bpm (1, 4) and
L is Py (1, 10) or 4,4'-bpy (4) were selected for further studies with CT-DNA in cell
free media. As it was shown in the results section (vide supra), upon photoactivation
the three complexes undergo a clean and selective photorelease of the corresponding
pyridine (1, 10) or the pyridine-derivative ligand 4,4'-bpy (4) to form a
monofunctional reactive aqua species [(η6-p-cym)Ru(N,N')(OH2)]2+. Although the
photoactivation of these three Ru–L complexes is very similar, their effects on DNA
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differ from each other (both in dark and light conditions) as revealed by their IC50
values (in ambient light) and DNA binding experiments, particularly in the case of
complex 4. This evidence suggest that the nature of the pyridine-derivative (both
when bound and when photoreleased from the metal centre) as well as the N,N'
chelating ligand play a key role on the mode of interaction of these complexes.
Incorporating an extended pyridine such as 4,4'-bpy (as in complex 4) provides
already a low ca. 20% of interaction of Ru compound with DNA after 48 h in the dark
(non-irradiated form) which might account for its mild cytotoxicity towards the
A2780 human ovarian cancer cell line in ambient light conditions. In comparison, less
than 5% of interaction with DNA was determined for 1 and 10 after 48 h, also in the
non-irradiated forms. Upon photoirradiation, the corresponding monofunctional
reactive aqua species [(η6-p-cym)Ru(N,N')(OH2)]2+ are formed accompanied by the
selective release of the corresponding L ligand. All the aqua adducts were found to
bind to DNA at varying rates. The pre-irradiated forms of Ru complexes bind faster
but to the same extent as the irradiated forms. These results are in good agreement
with the fact that irradiating [(η6-p-cym)Ru(N,N')(L)]2+ is a requirement for the
generation of the reactive aqua species. The relatively long photoirradiation times
needed to start generating the corresponding aqua adducts limits the initial binding of
the Ru complexes to DNA, but as soon as the full photoconversion is achieved, the
overall extent does not vary. The rate of binding to DNA, however, is slower than that
determined for the anticancer drug cisplatin (t1/2 ca. 2 h under similar conditions),23
for which DNA binding is thought to be responsible for its cytotoxic properties. In
contrast, another RuII analogue [(η6-bip)Ru(en)Cl]+, which has also been shown to be
cytotoxic to cancer cells,4 reacts much more rapidly with DNA under similar
conditions (t1/2 ca. 10 min).17 The relatively small extent of binding of the non-
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irradiated forms of the Ru complexes along with the slower kinetics of binding to
DNA only upon photoirradiation is an advantageous characteristic that may allow
more drug to reach its target in vivo without being deactivated by reacting with other
biological molecules. In vitro RNA synthesis by RNA polymerases on DNA
templates containing several types of bifunctional adducts of platinum or Ru
complexes can be prematurely terminated at the level or in the proximity of DNA
adducts. Importantly, monofunctional DNA adducts of several platinum complexes
are unable to terminate RNA synthesis.24 A similar approach was used for these
experiments. The results of the transcription mapping experiments suggest that the
non-irradiated forms of 1, 4 and 10 bind to DNA only upon photoirradiation,
inhibiting RNA synthesis in a similar fashion and with similar stopsites to cisplatin
and to the Ru complex [(η6-bip)Ru(en)Cl]+. For the pre-irradiated and irradiated
forms of complexes 1, 4, and 10 the stopsites were only guanine residues, which
agrees well with the photocontrolled nucleobase binding studies performed (followed
by multidimensional 1H NMR spectroscopy; see results section) which show that
these complexes bind importantly to 9-EtG but do not bind to 9-EtA. The strong
preference for guanine bases may allow these RuII arene complexes to target
selectively G-rich regions of DNA, such as telomeres which play key role in cell
divison.25 DNA binding upon photoirradiation of RuII complexes 1, 4 and 10, results
in a mild degree of unwinding (6–7°) which is very similar for the three complexes
but smaller than that observed for the RuII complexes [(η6-arene)Ru(en)Cl]+ (7 and
14°).30 The unwinding angles produced by the adducts of RuII arene compounds 1, 4
and 10 resemble more to those produced by monofunctional cisplatin adducts (6° and
13° for mono or bifunctional adducts, respectively).26 The aromatic ligands such as
the corresponding N,N' chelating (bpm or phen) in the DNA adducts of the RuII arene
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compounds, could be geometrically and favourably-positioned to interact with the
double helix. This hypothesis is supported by previous reports on the observation that
the single ring p-cym arene ligand (in contrast to extended aromatic rings) in
analogous monofunctional RuII arene complexes does not intercalate into the DNA
base-pair stack.30 In this respect, and in contrast to cisplatin, potential intercalating
ligands such as phen or bpm, might interact with DNA by aromatic π-stacking 
between base pairs. This type of interaction is known to result in the lengthening,
stiffening, and unwinding of the helix.26 The DNA cleaving ability of phen solely has
made it a frequently used reagent in DNA footprint studies27 whereas bpm has been
studied for its tendency to from aggregates via stacking between large planar
molecules both in the solid state and solution.28 The binding of the RuII arene
compounds 1, 4 and 10 to DNA upon photoirradiation may also affect its melting
behaviour. Previously,28 two important factors have been considered to account for
the thermal stability of DNA modified by monofunctional RuII complexes in media of
relatively low ionic strength (0.01 M Na+).
1. A destabilising effect of conformational distortions.
2. A stabilising effect of the positive charge on the Ru moieties and of
noncovalent binding, such as changes in solvent structure and the counterion
distribution around the phosphate groups of DNA which may help to overcome
unfavourable electrostatics for the hybridisation of the strands of the duplex.29
Under the conditions of the experiments, it is assumed that all the RuII arene
complexes have produced monofunctional adducts with DNA upon photoirradiation.
It is likely that some conformational distortions due to the formation of the adducts
will destabilise the helix, as has been consistently observed in earlier studies with
various other Ru and platinum compounds. The tm changes induced by the RuII arene
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compounds 1, 4 and 10 in the irradiated forms are small, however. It is possible that
the fluctuations in the tm values due to the modification by the RuII arene compounds
1, 4 and 10 is a consequence of the DNA adducts being unstable at higher ionic
strengths and temperatures which in turn might be associated with the stabilising
effect that arises from non-covalent interactions of the aromatic ligands (arene or N,N'
chelating) with the duplex inferred from both the DNA unwinding angles (7o is a
typical unwinding angle for monofunctional binders) and quenching of EtBr
fluorescence, as well as from the overall positive charge on these RuII arene
compounds. The magnitudes of the LD signals at 258 nm decrease as a function of rb
for all RuII arene complexes in the irradiated forms. These results suggest that the
formation of DNA adducts might be accompanied by the appearance of flexible hinge
joints at the site of the lesion. CD spectra showed that the binding of 1 and 4 to DNA
and concomitant release of pyridine or 4,4'-bpy upon photoirradiation results in
conformational alterations in double-helical DNA of a non-denaturational character,
similar to those induced in DNA by antitumor cisplatin. In contrast, upon
photoirradiation, the binding of 10 to DNA accompanied by the photorelease of
pyridine results in conformational alterations in DNA of a denaturational character,
similar to those induced in DNA by clinically ineffective transplatin. The signature of
complex 4 coordinated to CT-DNA is a strong positive ICD centered at around 400
nm. This could imply that the molecule become oriented as a consequence of their
noncovalent interactions with DNA. Hence, these results suggest the case for
combined coordinative, intercalative, and monofunctional coordination binding
modes of complexes 1, 4 and 10 upon photoirradiation.
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4.4.4 Cancer Cell Growth Inhibition (IC50 Values)
Complexes 2, 5, 6, 13 and 14 were non cytotoxic against the A2780 human ovarian
cancer cell line under ambient light conditions up to the maximum concentration
tested (100 μM). It has been previously observed a loss of cytotoxicity in ambient 
light conditions towards cancer cells for complexes of the type [(6-hmb)Ru(en)(X)]+
when X is replaced by Py.6 The loss of activity in this complex is assumed to arise
from its negligible aquation believed to be the first step towards anticancer activity.
The discovery of complexes that do not hydrolyse over a large period of time but
retain significant cytotoxicity implies a different mechanism of action for complexes
1, 3, 4, 8, 9, 10, 12, 15, and 16. The cytotoxicity of several isomers of
[Ru(azpy)2(bipy)]2+ incapable of hydrolysis has been reported.30 Wang et. al. reported
significant anticancer activity for the complex [(6-hmb)Ru(en)(SPh)]2+ which does
not undergo hydrolysis.6 Since no spontaneous hydrolysis is observed for complexes
1, 3, 4, 8−9, 10, 12, 15 and 16, the species responsible for the cytotoxicity could be
the intact cation or the corresponding aqua adducts generated by direct displacement
of the L ligands by strong nucleophiles within the media or the cell. The intact cations
might exert a cytotoxic effect by mechanisms which include modification of
mitochondrial membrane permeability (as observed, for example, with lipophilic
cations of Au(I) carbene complexes31) and/or DNA intercalation by the aromatic
ligands as observed in experiments of DNA interactions in cell-free media.
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4.5 Summary
This work provides the first example of a family of piano-stool RuII arene complexes
of the form [(η6-arene)Ru(N,N')(L)]2+ (where N,N' is a chelating ligand and L is a
pyridine or a pyridine-derivative) that can selectively photodissociate the
monodentate ligand (L) when excited with UVA or visible light. Such a unique
feature allows control of the hydrolysis reaction of the complexes and, therefore, the
formation of a reactive aqua species that otherwise would not form in the dark. Their
photochemical behaviour was thoroughly explored, not only experimentally but also
using TD-DFT calculations. From the computational point of view, it is believed that
all the RuII pyridine complexes follow a relatively similar photochemical-L-ligand-
dissociation mechanism. It is likely that photodecomposition occurs from a series of
3MC triplet states with dissociative character (T4–T5). At lower energy, 3MC states
with non-dissociative character are present (T1–T3). The nature of these low-lying
triplet states is also consistent with the absence of fluorescence of the complexes in
solution. The process proved to be much more efficient when UVA-range irradiation
was used and a preliminary structure-photoactivity relationship was established. The
presence of a better electron-donating arene (such as hmb in 8 or ind in 9) seems to
stabilise the aqua derivatives to a greater extent than those of the other complexes. On
the other hand, and as demonstrated from the experiments of interactions with 9-EtG
and 9-EtA, light activation can be used to phototrigger binding of these potential
anticancer agents with discriminating preference towards 9-EtG. Furthermore, in
order to investigate also the possibility of phototriggering the binding to DNA of the
RuII arene pyridine or pyridine-derivative complexes, studies on CT-DNA interactions
in cell-free media were carried out. The CT-DNA binding studies show that
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complexes 1, 4 and 10 in the pre-irradiated forms are bound faster but to the same
extent as the irradiated forms. The non-irradiated forms, as expected bind negligibly.
Further results on DNA interactions in cell-free media strengthen the case for
combined coordinative, intercalative, and monofunctional coordination binding
modes of complexes 1, 4 and 10 upon photoirradiation. These combined results
suggest that DNA might be an important target for these complexes. Under the
premise that hydrolysis is known to be one mechanism which provides a pathway for
cytotoxicity, we were not able to establish an obvious mechanism of action which
would account for the cytotoxicity of these RuII arene pyridine or pyridine-derivative
complexes in ambient light conditions. The protocol for photocytotoxicity proved to
be partially inadequate, since the time of photoirradiation used was not the optimal to
produce enough quantities of the corresponding RuII arene aqua adducts. Therefore,
there is the possibility that the intact cations might exert a cytotoxic effect by
mechanisms which include modification of mitochondrial membrane permeability (as
observed, for example, with lipophilic cations of Au(I) carbene complexes)31 and/or
DNA intercalation by the aromatic ligands (as it was observed from the experiments
of DNA interactions in cell-free media). These encouraging results indicate that the
photochemistry of these RuII arene complexes can be exploited to integrate them with
the promising biological properties inherent in half-sandwich RuII complexes, thus
increasing their potential as anticancer agents.
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Chapter 5
Hydride-Transfer of Ruthenium(II) Arene Complexes
5.1 Introduction
The observation that some RuII arene complexes can form stable hydride
complexes1,2,3 in aqueous solution using formate as the hydride donor,4,11,19 has
opened up a path towards water-soluble organometallic complexes for catalysis. This
area attracts continuously growing interest because of environmentally friendly
processing, simple product separation and pH dependent selectivity in aqueous
media.5,6 For example, the RuII complexes [(η6-C6Me6)Ru(bpy)(OH2)]2+ and [(η6-
C6Me6)Ru(phen)Cl]+ where bpy is 2,2'-bipyridine and phen is 1,10-phenanthroline
and other related complexes7 have been shown to catalyse the reduction of ketones
(such as cyclohexanone and acetophenone) to alcohols and imines;8,9,10 although the
conditions for optimum turnover are (usually) not biologically compatible.11,12 It has
been noticed that catalytic activity usually requires the presence of a labile
coordination site on the RuII centre and/or arene displacement;13,14 it is also believed
that the nature of all the coordinated ligands can have a pronounced effect on the
catalytic properties of these complexes. This observation has led to the development
of a wide range of synthetic routes to complexes as catalytic precursors containing
various substituted arenes together with other ligands such as halides, carboxylates,
amines, oxygen or nitrogen chelating groups, Schiff bases, carbenes, phosphines,
alkyl, and aryl groups.15,16,17 In the field of biocatalysis, RhIII
pentamethylcyclopentadienyl18,29 and RuII arene complexes19 have been shown to
catalyse the reduction of β-nicotinamide adenine dinucleotide (NAD+) in the presence
of formate as the hydride source. This reduction is regioselective, giving the
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biologically relevant 1,4-NADH isomer and in the case of the RhIII derivative, it was
further shown how it can drive enzymatic reactions relying on NADH as a cofactor.20
In the present work, hydride-transfer reactions of a series of RuII arene halido
complexes to regioslectively reduce NAD+ in the presence of formate under
biologically relevant conditions are described. It is also shown herein, that this
reaction can be specifically phototriggered if an initial RuII arene pyridine complex is
irradiated with UVA (λirr = 300−400 nm) or visible light (λirr = 400−660 nm). The 
reverse metabolic-like reaction (1,4-NADH → NAD+) was also investigated,
exploring the hydride-donor potential of 1,4-NADH to RuII arene complexes. A
preliminary elucidation of the mechanism(s) involved is attempted.
5.2 Experimental Section
5.2.1 Materials
β-Nicotinamide adenine dinucleotide hydrate (NAD+), β-nicotinamide adenine 
dinucleotide reduced dipotassium salt (1,4-NADH), sodium borohydride (NaBH4),
sodium formate (NaHCO2), silver nitrate (AgNO3), and potassium
hexafluorophosphate (KPF6) were obtained from Sigma-Aldrich. The RuII arene
halido precursors [(6-p-cym)Ru(bpm)Cl][PF6], [(6-bip)Ru(bpm)Cl][PF6], [(6-
hmb)Ru(bpm)Cl][PF6], [(6-ind)Ru(bpm)Cl][PF6], and [(6-p-
cym)Ru(phen)Cl)][PF6] were synthesised as described in Chapter 3 following a
method previously described.21 The RuII arene halido complexes [(6-
(hmb)Ru(en)Cl][PF6], [(6-ind)Ru(bpy)Cl][PF6], [(6-ind)Ru(4,4'-Me2-bpy)Cl][PF6],
and [(6-p-ind)Ru(phen)Cl][PF6] were kindly provided by Dr Abraha Habtemariam
from the Department of Chemistry at the University of Warwick and synthesised
according to a reported method.22 The RuII arene pyridine precursors [(6-p-
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cym)Ru(bpm)(Py)][PF6]2, [(6-hmb)Ru(bpm)(Py)][PF6]2, [(6-
ind)Ru(bpm)(Py)][PF6]2, [(6-p-cym)Ru(phen)(Py)][PF6]2, and [(6-
ind)Ru(bpy)(Py)][PF6]2 were synthesised as described in Chapter 4. The solvent used
for UV-vis absorption spectroscopy was deionised water. The solvents used for 1H
NMR spectroscopy were methanol-d4 and D2O from Aldrich unless otherwise stated.
5.2.2 Hydride-Transfer Reactions Using Sodium Borohydride (NaBH4)
The following experiment was carried out under normal ambient light conditions (i.e.
no photoirradiation provided). An excess of NaBH4 (2.5 mol equiv) was added to 300
mM solutions of the RuII arene halido complexes in 90% H2O/10% D2O at room
temperature. The 1H NMR spectra of the resulting solutions were recorded at 310 K at
various time intervals for 4−6 h. 
5.2.3 Interactions of RuII Arene Complexes with Sodium Formate (NaHCO2)
The following experiment was carried out under normal ambient light conditions (i.e.
no photoirradiation provided). An excess of NaHCO2 (25 mol equivalent) was added
to 300 mM solutions of the RuII arene halido complexes in 90% H2O/10% D2O at
room temperature. The 1H NMR spectra of the resulting solutions were recorded at
310 K at various time intervals for 24–48 h. The pH* of the solutions was recorded at
the beginning and at the end of the experiment.
5.2.4 Interactions of RuII Arene Complexes with Sodium Formate (NaHCO2)
upon Visible Light Photoirradiation
1H NMR spectra of 300 mM (90% H2O/10% D2O) solutions of the RuII arene pyridine
complexes in the presence of an excess of NaHCO2 (25 mol equiv) were acquired at
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different stages of photoirradiation with visible light (λirr = 400−660 nm) at 310 K for 
12 h. The pH* of the solutions was recorded at the beginning and at the end of the
experiment.
5.2.5 Preparation of a RuII Arene Formato Complex
The complex [(η6-p-cym)Ru(bpm)(O2CH)][PF6] where p-cym = para-cymene and
bpm = 2,2'-bipyrimidine, was synthesised using a similar procedure previously
reported.23 Using an aluminium-foil-covered flask at room temperature [(6-p-
cym)Ru(bpm)Cl][PF6] and AgNO3 in a 1:1 mixture of MeOH/H2O (10 mL) were
refluxed overnight (18 h). Precipitated AgCl was then removed by filtration. A 25 mol
equiv excess of sodium formate (NaHCO2) was added and the mixture was left
stirring for 30 min at room temperature. The volume was reduced by rotary
evaporation and a 2–5 mol equiv of KPF6 was added. The precipitate that formed was
collected by filtration and washed with portions of Et2O/MeOH and dried overnight in
vacuum resulting in a microcrystalline product. Details of the amounts of reactants,
volumes of solvents mixture, colour changes, and nature of the product are described
below.
[(6-p-cym)Ru(bpm)(O2CH)][PF6] (16). [(6-p-cym)Ru(bpm)Cl][PF6] (0.10 g, 0.17
mmol), AgNO3 (0.03 g, 0.17 mmol), NaHCO2 (0.10 g, 2.94 mmol) and KPF6 (0.16 g,
0.85 mmol); the solution turned from bright yellow to dark green; a dark yellow solid
was obtained; yield 64% (0.07 g, 0.11 mmol). Elemental analysis calc. for
C19H23F6N4O3PRu %C: 37.94, %H: 3.85, %N: 9.32; found %C: 37.59, %H: 3.59,
%N: 10.09. HR-MS: calc for C19H21N4O2Ru [M]+ m/z 439.0708, found m/z 439.011.
1H NMR (D2O, 500 MHz) δH: 1.02 (6H, d, J = 6.90), 2.08 (3H, s), 2.58 (1H, sep, J =
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6.90), 6.04 (2H, d, J = 6.49), 6.29 (2H, d, J = 6.49), 7.66 (1H, s), 7.92–7.94 (2H, m),
9.19 (2H, dd, J = 1.97, J = 4.88), 9.90 (2H, dd, J = 1.99, J = 5.80).
5.2.6 Aqueous Solution Chemistry of the RuII Arene Formato Complex
5.2.6.1 Determination of the Ru−O2CH Bond Hydrolysis
The following experiment was carried out under normal ambient light conditions (i.e.
no photoirradiation provided). Hydrolysis of the RuII arene formato complex was
monitored by UV-vis spectroscopy. The nature of the hydrolysis products as well as
the extent of the reaction were verified by 1H NMR spectroscopy or HR-MS. For UV-
vis spectroscopy, the RuII arene formato complex was dissolved in H2O to give a 100
μM solution. The absorbance was recorded at several time intervals at the selected 
wavelength (at which the maximum changes in absorbance were registered) at 310 K
over 8 h. A plot of the change in absorbance with time was computer-fitted to the
pseudo first-order rate equation: A = C0 + C1e-kt (where C0 and C1 are computer-fitted
constants and A is the absorbance corresponding to time) using Origin version 8.0
(Microcal Software Ltd.) to give the half-life (t1/2, min) and rate constant value (k,
min–1). For 1H NMR spectroscopy, the RuII arene formato complex was dissolved in
90% H2O/10% D2O to give a 100 μM solution. The 1H NMR spectra at 310 K were
recorded at various time intervals. The relative amounts of RuII arene formato species
or aqua adduct were quantified (determined by integration of peaks in 1H NMR
spectra).
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5.2.7 Regioselective Reduction of NAD+ by RuII Arene Complexes in the
Presence of Formate
The following experiment was carried out under normal ambient light conditions (i.e.
no photoirradiation provided). An equimolar amount of NAD+ was added to an NMR
tube containing a 300 mM solution of the RuII arene halido complexes and an excess
of NaHCO2 (25 mol equiv) in 90% H2O/10% D2O at room temperature. The 1H NMR
spectra of the resulting solutions were recorded at 310 K at various time intervals for
24–48 h.
5.2.8 Regioselective Reduction of NAD+ by RuII Arene Complexes in the
Presence of Formate upon UVA Photoirradiation
An equimolar amount of NAD+ was added to an NMR tube containing a 300 mM
solution of the RuII arene pyridine complexes and an excess of NaHCO2 (25 mol
equiv) in 90% H2O/10% D2O at room temperature. 1H NMR spectra of the resulting
solutions were acquired at different stages of photoirradiation with UVA (λirr =
300−400 nm) at 310 K for 12 h. 
5.2.9 Interactions of RuII Arene Complexes with 1,4-NADH
The following experiment was carried out under normal ambient light conditions (i.e.
no photoirradiation provided). An equimolar amount of 1,4-NADH was added to an
NMR tube containing a 300 mM solution of the RuII arene halido complexes in 90%
H2O/10% D2O at room temperature. The 1H NMR spectra of the resulting solutions
were recorded at 310 K at various time intervals for 24–48 h.
Chapter 5: Hydride-transfer of RuII arene complexes
209
5.2.10 Interactions of RuII Arene Complexes with 1,4-NADH upon UVA
Photoirradiation
An equimolar amount of 1,4-NADH was added to an NMR tube containing a 300 mM
solution of the RuII arene pyridine complex in 90% H2O/10% D2O at room
temperature. 1H NMR spectra of the resulting solutions were acquired at different
stages of irradiation with UVA (λirr = 300−400 nm) at 310 K for 12 h. 
5.2.11 Qualitative Studies of 1,4-NADH upon UVA Photoirradiation
A 100 μM solution of 1,4-NADH in water was irradiated with UVA (λirr = 300−400 
nm) at 310 K. The photoreaction was followed by UV-vis spectroscopy at different
stages of photoirradiation for 12 h.
5.3 Results
5.3.1 Hydride-Transfer Reactions Using Sodium Borohydride (NaBH4)
The possibility that some of the RuII arene halido complexes studied in Chapter 3 and
other related RuII arene analogues could react directly with NaBH4 to generate
hydride species (Ru–H) was investigated. The [(6-arene)Ru(N,N')Cl]+ complexes
studied in this section are listed in Table 5.1 and their general structures are shown in
Figure 5.1. The attempts to generate Ru–H species upon interaction with NaBH4 were
studied by means of 1H NMR spectroscopy. Addition of 2.5 mol equiv of NaBH4 to
300 mM solutions containing complexes 1–10 in 90% H2O/10% D2O at 298 K caused
a colour change from bright yellow to dark-brown. The 1H NMR spectrum at 310 K
of the RuII arene complexes 1–4 acquired after ca. 45 min suggested the formation of
several Ru–H species in each case, as indicated by the presence of multiple low-
intensity singlets in the higher-field region of the spectrum between –6 and –10 ppm.
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Table 5.1. [(6-arene)Ru(N,N')Cl]+ complexes studied in this section.
Compound Arene N,N'
(1) p-cym bpm
(2) p-cym phen
(3) hmb bpm
(4) ind bpm
(5) hmb en
(6) ind bpy
(7) ind 4,4'-Me2-bpy
(8) ind phen
(9) thn bpm
(10) bip bpm
Figure 5.1. Structures of the monocationic complexes studied in this section
synthesised as PF6 salts.
The 1H NMR spectrum of the RuII arene complexes 5–9 acquired after ca. 30 min
suggested the formation of single Ru–H species in each case, as indicated by the
presence of medium-to-high-intensity sharp singlets in the higher field region of the
spectrum, Figure 5.2. For complexes 5–9 the sharp singlets appear at –8.35, –6.20, –
6.30, –6.14, and –8.03 ppm, respectively. In the case of complex 10 no reaction was
observed after 60 min.
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Figure 5.2. High-field region 1H NMR spectra of solutions (300 mM) containing the
RuII arene complexes 5–9 and NaBH4 (2.5 mol equiv) in 90% H2O/10% D2O at 310 K
after 45 min suggesting the presence of Ru–H species.
5.3.2 Interactions of RuII Arene Complexes with Sodium Formate (NaHCO2)
Given the evidence that the RuII arene chlorido complexes 1–9 could directly react
with NaBH4 to generate Ru–H species in solution, their reaction with sodium formate
(as a source of hydride) was investigated. The selected [(6-arene)Ru(N,N')Cl]+
complexes are listed in Table 5.2 and their general structures are shown in Figure 5.3.
Table 5.2. [(6-arene)Ru(N,N')Cl]+ complexes studied in this section.
Compound Arene N,N'
(1) p-cym bpm
(2) p-cym phen
(3) hmb bpm
(4) ind bpm
(9) thn bpm
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All the reactions were carried out in NMR tubes as 300 mM (90% H2O/10% D2O)
solutions and changes in the spectra were followed during 24 h at 310 K. The initial
pH* of the RuII arene complexes solutions in the presence of formate (25 mol equiv)
was 6.9–7.2. The 1H NMR spectra of complexes 1−4 and 9 initially contained one
major set of peaks assigned to the corresponding chlorido species and then a second
set of peaks increased in intensity with time. The new set of peaks has the same
chemical shifts as those of the aqua adducts under the same conditions (300 mM
solutions in 90% H2O/10% D2O at 310 K; the aqua adducts were separately prepared
by treatment of the chlorido complexes with AgNO3 in water at room temperature
overnight and removal of AgCl by filtration). A third set of peaks in the 1H NMR
spectra was also observed over time and was attributed to the formation of a RuII
formate adduct (Ru–O2CH) in each case. Peaks assigned to the bound formate in all
compounds are high-field shifted in comparison to those of free formate (8.40 ppm
under the same conditions; 310 K and pH* ≈ 7.0). The O2C–H peak in the formate
adduct of complex 1 has a chemical shift of 7.29 ppm whereas in the formate adducts
of complexes 2, 3, 4, and 9, the corresponding singlet is observed at 7.65, 7.68, 7.68,
and 7.66 ppm, respectively. The mass-to-charge ratios and isotopic models obtained
from HR-MS spectra were consistent with the formation of the formato complexes as
the corresponding products in each case, Table 5.3. In most of the cases the reactions
reach equilibrium within the first hour after mixing. No further changes in the amount
of species present in solution after 24 h were observed, as quantified by integration of
the peaks in the 1H NMR spectra. No significant changes in the initial pH* values of
solutions of RuII arene complexes in the presence of formate (25 mol equiv) at the end
of the reaction were observed. Figure 5.4 shows the progress of the reaction of [(6-
hmb)Ru(bpm)Cl]+ (3) followed by 1H NMR spectroscopy as a generic example.
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Figure 5.3. Structures of the monocationic complexes studied in this section
synthesised as PF6 salts.
Table 5.3. Mass-to-charge ratios obtained from HR-MS spectra for the products of
reaction of a 300 mM solution (90% H2O/10% D2O) of RuII arene complexes 1–4 and
9 with sodium formate (molar ratios 1:25, respectively) at 310 K and pH* ≈ 6.9–7.2. 
Observed peak [M]+ Chemical formula
Calc m/z
Found m/z
(1) [(6-p-cym)Ru(bpm)(O2CH)]+ C19H21N4O2Ru
439.0708
439.0709
(2) [(6-p-cym)Ru(phen)(O2CH)]+ C21H25N4O2Ru
467.1021
467.1015
(3) [(6-hmb)Ru(bpm)(O2CH)]+ C17H18N4O2Ru
423.0259
423.0254
(4) [(6-ind)Ru(bpm)(O2CH)]+ C17H18N4O2Ru
204.7250
204.9615
(9) [(6-thn)Ru(bpm)(O2CH)]+ C23H23N2O2Ru 461.0824
461.0804
The reactions of the RuII arene complexes 1–4 and 9 with sodium formate were found
to display a wide range of rates. It can be seen that for complexes where p-cym
(arene) is kept constant but the N,N'-chelating ligand is varied, the time needed to
reach equilibrium is longer in the case of complex 1 than that for complex 2, Table
5.4. When the chelating ligand is kept as bpm, changing the arene modifies the rate in
the decreasing order ind (4) > p-cym (1) > hmb (3) ≈ thn (9).
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Figure 5.4. 1H NMR spectrum showing the aromatic region just after mixing (top)
and after ca. 21 min (bottom) of the reaction of a 300 mM solution (90% H2O/10%
D2O) of RuII arene complex [(6-hmb)Ru(bpm)(O2CH)]+ (3) with sodium formate
(molar ratios 1:25, respectively) at 310 K and pH* ≈ 6.9. Inset: 1H NMR spectra
(aliphatic region) after ca. 21 min of reaction. Blue = [(6-hmb)Ru(bpm)Cl]+; Green
= [(6-hmb)Ru(bpm)(OH2)]2+; Pink = [(6-hmb)Ru(bpm)(O2CH)]+; ■ = bpm, ● = 
hmb; ♦ = bound HCO2.
Table 5.4. Percentage of species present at equilibrium for the reaction of a 300 mM
solution (90% H2O/10% D2O) of RuII arene complexes 1–4 and 9 with sodium
formate (molar ratios 1:25, respectively) at 310 K and pH* ≈ 6.9–7.2 followed by 1H
NMR.
Compound Time
(min)a Ru−Cl
% Speciesb
Ru−OH2 Ru−O2CH
(1) [(6-p-cym)Ru(bpm)Cl]+ 59 24.1 11.0 64.9
(2) [(6-p-cym)Ru(phen)Cl]+ 17 46.5 3.7 49.7
(3) [(6-hmb)Ru(bpm)Cl]+ 21 16.5 12.5 71.0
(4) [(6-ind)Ru(bpm)Cl]+ 81 1.94 13.3 84.7
(9) [(6-thn)Ru(bpm)Cl]+ 20 19.8 22.4 57.7
a Time needed to reach equilibrium.
b No changes in the percentage of species were observed after 24 h of reaction.
The reaction of complex 2 was found to give the lowest yield compared to those of
the other complexes. The percentage of species present in solution was further
monitored after 24 h of incubation at 310 K. In each case, no changes were observed
and no evidence of Ru–H species in the high-field region of the spectrum was
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detected by 1H NMR. A plausible reduction reaction upon hydride-transfer from the
RuII arene formate adducts to acetone (to generate iso-propanol) was assessed by
adding 10 mol equiv to the equilibrated solutions. No reaction was observed.
5.3.3 Interactions of RuII Arene Complexes with Sodium Formate (NaHCO2)
upon Visible Light Photoirradiation
The possibility that some of the photoactivatable RuII arene pyridine complexes
studied in Chapter 4 could react directly with formate in solution upon
photoirradiation with visible light (λirr = 400−660 nm) and further generate hydride 
species (Ru–H) was investigated. The selected [(6-arene)Ru(N,N')(Py)]2+ complexes
are listed in Table 5.5 and their general structures are shown in Figure 5.5.
Table 5.5. [(6-arene)Ru(N,N')(Py)]2+ complexes studied in this section.
Compound Arene N,N'
(11) p-cym bpm
(12) p-cym phen
(13) hmb bpm
(14) ind bpm
(15) ind bpy
All the reactions were carried out in NMR tubes as 300 mM (90% H2O/10% D2O)
solutions and followed by 1H NMR spectroscopy at different stages of
photoirradiation with visible light (λirr = 400−660 nm) for 12 h at 310 K. The initial 
pH* of solutions of RuII arene pyridine complexes in the presence of sodium formate
(25 mol equiv) was in the range of 7.0–7.4. The spectra of each of the complexes
initially contained a set of peaks assigned to the original Ru−Py complex.  
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Further photoirradiation with visible light (λirr = 400−660 nm) at 310 K produced a 
second set of peaks which increased in intensity over time and are assigned to the
corresponding aqua species (along with the peaks assigned to the released Py ligand
as it has been described in Chapter 4).
Figure 5.5. Structures of the dicationic complexes studied in this section synthesised as PF6
salts.
An additional set of peaks began to increase in intensity just after the first indication
of aqua adducts being formed; this new set of peaks is related to the formation of the
corresponding formato complexes (Ru−O2CH) in each case. The pH* of the irradiated
solutions at the end of the photoirradiation experiment was ca. 7.0 in all cases.
Typical spectra recorded during the course of the photoirradiation are shown for [(6-
p-cym)Ru(bpm)(Py)]2+ (11) in Figure 5.6.
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Figure 5.6. 1H NMR spectra during the aqueous photolysis with visible light (λirr =
400–660 nm) of a 300 mM solution (90% H2O/10% D2O) of [(6-p-
cym)Ru(bpm)(Py)]2+ (11) in the presence of sodium formate (molar ratios 1:25,
respectively) at 310 K and pH* ≈ 7.0. Blue = [(6-p-cym)Ru(bpm)(Py)]2+; Green =
[(6-p-cym)Ru(bpm)(OH2)]2+; Pink = [(6-p-cym)Ru(bpm)(O2CH)]+; ■ = bpm, ● = 
p-cym; ♦ = bound HCO2. Free Py is indicated with Orange ▲.
Peaks assigned to the formate adducts for all compounds have the same chemical
shifts as those of the formate adducts obtained by direct reaction of the chlorido
complexes 1–4 and 9 with formate in aqueous solution under the same conditions
since they are the same species (vide supra). The mass-to-charge ratios and isotopic
models obtained from HR-MS spectra of the resulting irradiated samples of the Py
complexes 11–14 are also identical to those of the formate adducts of complexes 1–4
(vide supra). The HR-MS spectra of the irradiated solution of complex [(6-
ind)Ru(bpy)(Py)]2+ (15) (for which no chlorido analogue was investigated) gave the
observed peaks: [(6-ind)Ru(bpy)(O2CH)]+ calc. for C20H19N2O2Ru [M]+ m/z
421.0490, found m/z 421.0490. Table 5.6 lists the percentage of species detected by
1H NMR after 12 h of continuous visible light photoirradiation (λirr = 400−660 nm) of 
complexes 11−15.
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Table 5.6. Percentage of species present after 4−18 h of photoirradiation with visible 
light (λirr = 400−660 nm) for 300 mM solutions (90% H2O/10% D2O) of RuII arene
complexes complexes 11−15 in the presence of sodium formate (molar ratios 1:25,
respectively) at 310 K and pH* ≈ 7.0−7.4 followed by 1H NMR.
Compound Irr Time(min) Ru−Py
% Species
Ru−OH2 Ru−O2CH
(11) [(6-p-cym)Ru(bpm)(Py)]2+ 690 46.7 18.0 35.3
(12) [(6-p-cym)Ru(phen)(Py)]2+ 568 61.6 32.0 6.4
(13) [(6-hmb)Ru(bpm)(Py)]2+ 245 14.6 14.4 71.0
(14) [(6-ind)Ru(bpm)(Py)]2+ 336 8.4 4.4 87.2
(15) [(6-ind)Ru(bpy)(Py)]2+ 583 59.3 39.6 1.1
For complexes 11, 12 and 15 less than ca. 50% of the original RuII arene pyridine
complex had been photoconverted to the corresponding aqua adduct after ca. 10 h of
continuous visible light photoirradiation. A change of arene (i.e. from p-cym to hmb)
modifies the extent of the photoreaction as well as the time needed to achieve the
photoconversion (as described in Chapter 4). In the present experiment, the fastest
reactions are those of complexes [(6-hmb)Ru(bpm)(Py)]2+ (13) and [(6-
ind)Ru(bpm)(Py)]2+ (14). The aqua adducts generated upon photoirradiation where
found to react further with the excess of formate present in the solution, to generate
the corresponding formato complexes. A plausible reduction reaction upon hydride-
transfer from the RuII arene formate adducts to acetone (to generate iso-propanol) was
assessed by adding 10 mol equiv to the equilibrated solutions. No reaction was
observed. No binding of formate was observed either for any of the RuII arene
pyridine complexes in the absence of photoirradiation even after 30 days of
incubation at 310 K and pH* ≈ 7.0−7.4. 
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5.3.4 Synthesis and Characterisation of a RuII Arene Formato Complex
The formato complex [(6-p-cym)Ru(bpm)(O2CH)][PF6] (16), Figure 5.7 was isolated
and characterised in order to study the possibility of generating hydride species (Ru–
H) in solution that could further be used as catalysts for hydride-transfer reactions.
Figure 5.7. Structure of the formato complex [(6-p-cym)Ru(bpm)(O2CH)][PF6] (16)
synthesised as PF6 salt.
Complex 16 was synthesised as PF6 salt in good yields (64%) and was fully
characterised by 1D and 2D 1H NMR methods as well as HR-MS. Compared to its
chlorido analogue (complex 1), the 1H NMR resonances of complex 16 are high-field-
shifted by ca. 0.3 ppm. The binding of the formate ligand to the RuII centre was
confirmed by the appearance of a sharp singlet at 7.66 ppm (compared to free formate
at 8.40 ppm under the same conditions, 310 K and pH* ≈ 7.2), Figure 5.8. 
Figure 5.8. 1H NMR spectrum of a 300 mM solution of [(6-p-
cym)Ru(bpm)(O2CH)][PF6] (16) in 90% H2O/10% D2O at 310 K and pH* ≈ 7.2.  =
bpm, ● = p-cym; ♦ = bound O2CH.
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5.3.5 Aqueous Solution Chemistry of the RuII Arene Formato Complex
The aqueous solution chemistry (with respect to hydrolysis and/or hydride formation)
of the RuII arene complex 16 was studied at 310 K over 8−14 h. 
5.3.5.1 Hydrolysis Equilibria
In order to characterise the products of hydrolysis, to monitor formation of Ru–H
species, and to determine the extent of the reaction of complex 16, the changes in the
1H NMR spectrum of a freshly-made 100 μM solution (90% H2O/10% D2O) were
followed for 24 h at 310 K. The 1H NMR spectrum of complex 16 initially contained
one major set of peaks (formato species) and then a second set of peaks increased in
intensity over time. The new set of peaks had the same chemical shifts as those of the
aqua adduct under the same conditions (100 μM solution in 90% H2O/10% D2O at
310 K and pH* ≈ 7.2). Figure 5.9 shows the changes of the 1H NMR spectrum during
the hydrolysis reaction of complex 16.
Figure 5.9. 1H NMR spectra recorded during the hydrolysis reaction of a 100 μM 
solution (90% H2O/10% D2O) of [(6-p-cym)Ru(bpm)(O2CH)][PF6] (16) at 310 K
and pH* ≈ 7.2. Pink = [(6-p-cym)Ru(bpm)(O2CH)]+; Green = [(6-p-
cym)Ru(bpm)(OH2)]2+; ■ = bpm, ● = p-cym; ♦ = bound HCO2.
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The mass-to-charge ratio and isotopic model obtained from HR-MS spectra were
consistent with the formation of the aqua complex as the corresponding product;
observed peak: [(6-p-cym)Ru(bpm)(OH2)]+ calc. for C18H22N4ORu [M]2+ m/z
206.0418, found m/z 206.0408. The hydrolysis reaction for complex 16 reached
68.2% of completion after 24 h. No arene loss (p-cym) and no formation of Ru–H
species were detected over this period, even after the addition of freshly distilled
acetone (10 mol equiv) to promote a possible hydride-transfer reaction (vide supra).
5.3.5.2 Kinetics of Hydrolysis
Dissolution of compound 16 in H2O at 310 K gave rise to ligand substitution reactions
as indicated by the concomitant changes in the UV-Vis absorption bands. The time
evolution spectrum for complex 16 is shown in Figure 5.10.
Figure 5.10. Time evolution of the hydrolysis reaction of a 100 μM H2O solution of
complex 16 at 310 K followed by UV-vis spectroscopy for ca. 8 h.
The time dependence of the absorbance for complex 16 at the selected wavelength
followed pseudo first-order kinetics. Figure 5.11 shows the dependence of the
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absorbance at λ = 288 nm over ca. 8 h during aquation of [(6-p-
cym)Ru(bpm)(O2CH)][PF6] (16) at 310 K. The corresponding rate constant (k × 10−3,
min−1) and half-life (t1/2, min) are 15.3 ± 0.58 and 45.3, respectively (the errors quoted
are fitting errors).
Figure 5.11. Dependence of the absorbance at λ = 288 nm over ca. 8 h during
aquation of [(6-p-cym)Ru(bpm)(O2CH)][PF6] (16) at 310 K. The red solid line is the
best fit to pseudo-first order kinetics.
5.3.6 Regioselective Reduction of NAD+ by RuII Arene Complexes in the
Presence of Formate
The possibility of using selected RuII arene chlorido complexes as catalytic agents on
the regioselective reduction of β-nicotinamide adenine dinucleotide (NAD+) to
reduced β-nicotinamide adenine dinucleotide (1,4-NADH) in the presence of sodium 
formate (as a source of hydride) was investigated. The selected [(6-
arene)Ru(N,N')Cl]+ complexes are listed in Table 5.7 and their general structures are
shown in Figure 5.12. The interactions were studied by means of multidimensional 1H
NMR spectroscopy over 24–48 h at 310 K.
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Table 5.7. [(6-arene)Ru(N,N')Cl]+ complexes studied in this section.
Compound Arene N,N'
(1) p-cym bpm
(3) hmb bpm
(4) ind bpm
(9) thn bpm
Figure 5.12. Structures of the monocationic complexes studied in this section
synthesised as PF6 salts.
The pH* of the RuII arene chlorido solutions prior to the addition of NAD+ was 6.9–
7.2. A decrease of the pH* value to 5.2–5.8 after addition of NAD+ was recorded.
Figure 5.13 shows the 1H NMR spectra of [(6-hmb)Ru(bpm)Cl]+ (3) in 90%
H2O/10% D2O (300 mM) at 310 K in the presence of an excess of sodium formate
and NAD+ (molar ratios 1:25:1, respectively) after 300 min of reaction as a generic
example. The spectrum initially contained three major sets of peaks assigned to the
chlorido complex [(6-hmb)Ru(bpm)Cl] (3), the aqua adduct [(6-
hmb)Ru(bpm)(OH2)]2+, and the formate adduct [(6-hmb)Ru(bpm)(O2CH)]+ at
equilibrium. Upon addition of NAD+ (1 mol equiv), some changes in the 1H NMR
spectrum were noticed within the first 30 min of reaction. The structures and
numbering scheme for NAD+, 1,4-NADH and 1,6-NADH are shown in Figure 5.14.
The changes suggest the fast regioselective reduction of NAD+ to 1,4-NADH as
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indicated by a decrease on the intensity of the signals of free NAD+ (H2 at 9.38 ppm)
and the new peaks assignable to 1,4-NADH (H2 at 6.92 ppm and H4a/H4b at 2.70
ppm). The 1H NMR spectra within the first 30 min of reaction, also reveal the
emergence of a second singlet around 7.20 ppm that could be tentatively assigned to
H2 in 1,6-NADH (as a minor product). It was noticed that after a total of ca. 300 min,
the initial amount of NAD+ had been fully consumed.
Figure 5.13. 1H NMR spectra during the reaction of a 300 mM solution (90%
H2O/10% D2O) of [(6-hmb)Ru(bpm)Cl]+ (3) in the presence of NaHCO2 and NAD+
(molar ratios 1:25:1, respectively) at 310 K and pH* ≈ 5.2. ♦ Pink = [(6-
hmb)Ru(bpm)(O2CH)]+; = 1,6-NADH. NAD+ is indicated in dark green and 1,4-
NADH in red.
The progress of the reaction was further monitored for the next 24 h (once the initial
amount of NAD+ had been consumed), Figure 5.15. The appearance of a sharp singlet
around –7.49 ppm, which increased in intensity over time, occurred simultaneously
with an accumulation of 1,4-NADH (t ≈ 400 min) and the appearance of a second 
signal around –9.92 ppm after ca. 480 min. The nature of these high-field sharp
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singlets may be related to the formation of Ru–H species. No significant changes in
the amount of formate adduct (Ru–O2CH) present in solution during the first 560 min
of reaction were observed.
Figure 5.14. Structures and numbering scheme for NAD+, 1,4-NADH and 1,6-
NADH.
Figure 5.15. 1H NMR spectra in the high-field region during the reaction of a 300
mM solution (90% H2O/10% D2O) of [(6-hmb)Ru(bpm)Cl]+ (3) in the presence of
NaHCO2 and NAD+ (molar ratios 1:25:1, respectively) at 310 K and pH* ≈ 5.2.
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A slight decrease in the amount of 1,4-NADH (that had been generated during the
first 5 h of reaction) was detected just as the maximum intensity of the high-field
signals was reached. Since the accumulation of 1,4-NADH seemed to be linked with
the formation of Ru–H species, an extra mol equiv of NAD+ was added to the solution
at this stage (t ≈ 560 min). The 1H NMR spectra after ca. 5 min after the addition of a
second mol equiv of NAD+ (t' = 0 min), resulted in the immediate disappearance of
the Ru–H peaks, Figure 5.16.
Figure 5.16. 1H NMR spectra recorded during the reaction of a 300 mM solution
(90% H2O/10% D2O) of [(6-hmb)Ru(bpm)Cl]+ (3) in the presence of NaHCO2 and
NAD+ (molar ratios 1:25:1, respectively) at 310 K and pH* ≈ 5.2. A second mol equiv
was added after 560 min of reaction. ♦ Pink = [(6-hmb)Ru(bpm)(O2CH)]+; = 1,6-
NADH. NAD+ is indicated in dark green and 1,4-NADH in red.
As the reaction progressed, an increase on the 1,4-NADH signals and a subsequent
decrease in the intensity of those for NAD+ was observed; simultaneously, the signals
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of Ru–H species were restored. A decrease in the intensity of the formate adduct
signals [(6-hmb)Ru(bpm)(O2CH)]+ following the addition of extra amounts of NAD+
was also detected. No changes on the amount of 1,6-NADH were observed.
Around t' = 504 min (after the addition of extra NAD+), the second mol equiv of
NAD+ was again fully consumed. The Ru−H signal at –7.49 ppm was restored and 
reached again a maximum intensity, whereupon it began to decrease and ultimately
disappeared (t' = 924 min).The decay in the intensity of this Ru−H signal seems to be 
accompanied by a simultaneous and fast decrease in intensity of all the signals
initially assigned to the RuII arene species present in solution and of those of 1,4- and
1,6-NADH, Figure 5.17.
Figure 5.17. 1H NMR spectra recorded ca. 924 min after a second mol equiv of
NAD+ was added to the reaction of a 300 mM solution (90% H2O/10% D2O) of [(6-
hmb)Ru(bpm)Cl]+ (3) in the presence of NaHCO2 and NAD+ (initial molar ratios
1:25:1, respectively) at 310 K and pH* ≈ 5.2. ♦ Pink = [(6-hmb)Ru(bpm)(O2CH)]+;
= 1,6-NADH. NAD+ is indicated in dark green and 1,4-NADH in red.
Complex [(6-ind)Ru(bpm)Cl]+ (4) was also found to catalyse the reduction reaction
of NAD+ to 1,4-NADH (as observed by 1H NMR spectroscopy) in a similar fashion to
complex 3 under the same conditions (310 K and pH* ≈ 5.2). Complexes [(6-p-
cym)Ru(bpm)Cl]+ (2) and [(6-thn)Ru(bpm)Cl]+ (9) did not catalyse the hydride-
transfer reaction under these conditions.
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5.3.7 Regioselective Reduction of NAD+ by RuII Arene Complexes in the
Presence of Formate upon UVA Photoirradiation
Complex [(6-hmb)Ru(bpm)(Py)]2+ (13), Figure 5.18 was selected to explore the
possibility of phototriggering the regioselective reduction of NAD+ to 1,4-NADH in
the presence of sodium formate. By fast-activating the RuII arene pyridine complex 13
in aqueous solution with UVA photoirradiation (λirr = 300−400 nm), the formation of 
a reactive aqua species can be achieved in a relatively short period of time (see
Chapter 4). If the reaction is performed in the presence of sodium formate (25 mol
equiv), a stable formate adduct is formed (vide supra). UVA photoirradiation was
selected over visible light because the photolysis process of this family of complexes
has been shown to be much more efficient than when visible light is employed (see
Chapter 4). The interactions were studied by means of multidimensional 1H NMR
spectroscopy.
Ru
N
N
N
N
2+
13
N
Figure 5.18. Structure of the dicationic complex studied in this section synthesised as
PF6 salt.
All the reactions were carried out in an NMR tube in a 90% H2O/10% D2O solution
and followed at different stages of photoirradiation with UVA (λirr = 300−400 nm) at 
310 K. The initial pH* of the solution (prior to the addition of NAD+) was 7.6; once
NAD+ was added a decrease to 5.8 was registered. Figure 5.19 shows the progress of
the reaction for complex 13 within the first 330 min of photoirradiation. As it has
been herein described (vide supra and also in Chapter 4), the spectra initially
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contained a set of peaks assigned to the original Ru−Py complex, [(6-
hmb)Ru(bpm)(Py)]2+ (13). Further photoirradiation with UVA at 310 K produces a
second set of peaks which increased in intensity as photoirradiation was continued
and are assigned to the corresponding aqua species [(6-hmb)Ru(bpm)(OH2)]2+ (along
with the peaks assigned to the released Py ligand). An additional set of peaks
increased in intensity just after the first indication of aqua adduct being formed was
detected; this new set of peaks corresponds to the formation of the formate adduct
[(6-hmb)Ru(bpm)(O2CH)]+. The 1H NMR signals of this formate adduct have the
same chemical shift as those observed when the RuII arene chlorido complex 3 was
used as the starting material (since it is the same species).
Figure 5.19. 1H NMR spectra recorded during the aqueous photolysis (λirr = 300–400
nm) of a 300 mM solution (90% H2O/10% D2O) of [(6-hmb)Ru(bpm)(Py)]2+ (13) in
the presence of NaHCO2 and NAD+ (molar ratios 1:25:1, respectively) at 310 K and
pH* ≈ 5.8. ♦ Pink = [(6-hmb)Ru(bpm)(O2CH)]+. Free Py is indicated with Orange
▲. NAD+ is indicated in dark green and 1,4-NADH in red.
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An overall of ca. 300 min of photoirradiation with UVA (λirr = 300–400 nm) were
needed to achieve full conversion of the original Py compound to the corresponding
aqua adduct. During the first ca. 130 min of photoirradiation with UVA (λirr =
300−400 nm) some additional (simultaneous) changes in the 1H NMR spectrum were
noticed. These changes resemble to those observed for the reaction of the chlorido
complex [(6-hmb)Ru(bpm)Cl]+ (3) with NAD+ after ca. 300 min. The changes point
again to the relatively fast reduction of NAD+ to 1,4-NADH, as indicated by a
decrease in the intensity of the signals corresponding to free NAD+ and the new peaks
assignable to 1,4-NADH. The overall changes in the 1H NMR spectra indicate that
although the initial amount of NAD+ is not fully consumed in this case (as opposed to
the chlorido analogue), the reaction to generate 1,4-NADH is relatively faster.
Furthermore, when a control solution of the pyridine RuII arene complex, NAD+ and
formate under the same conditions was kept in the dark (as a control), no reaction was
observed. After ca. 300 min, the photoirradiation was suspended and the mixture was
allowed to further react in the dark at 310 K. The resulting spectrum is shown in
Figure 5.20. Within the next 300 min (and overall reaction time of ca. 660 min) the
appearance of multiple low-intensity signals in the aromatic region was detected. The
1H NMR spectra suggest again 1,6-NADH formation (as was also observed for the
chlorido complexes 3 and 4) but no evidence of Ru–H species (i.e. signals in the high
field region of the spectrum) was detected over this period.
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Figure 5.20. 1H NMR spectra recorded ca. 660 min after aqueous photolysis (λirr =
300–400 nm and 330 min of photoirradiation) of a 300 mM solution (90% H2O/10%
D2O) of [(6-hmb)Ru(bpm)(Py)]2+ (13) in the presence of NaHCO2 and NAD+ (molar
ratios 1:25:1, respectively) at 310 K and pH* ≈ 5.8. ♦ Pink = [(6-
hmb)Ru(bpm)(O2CH)]+;= 1,6-NADH. Free Py is indicated with Orange ▲. NAD+
is indicated in dark green and 1,4-NADH in red.
5.3.8 Interactions of RuII Arene Complexes with 1,4-NADH
In order to explore the possibility of a hydride-transfer reaction from 1,4-NADH to
selected RuII arene chlorido complexes, an equimolar amount of 1,4-NADH was
added to an NMR tube containing a 300 mM solution of the halido RuII arene
complexes 1, 2, 3, and 9 in 90% H2O/10% D2O at room temperature. The pH* of the
solutions prior to the addition of 1,4-NADH was 6.8–7.1; once added, the pH* of the
solutions increased to 8.5–9.1. The 1H NMR spectra of the resulting solutions were
recorded at 310 K at various time intervals during 12 h. Figure 5.21 shows the
progress of the reaction for complex 3 after 270 min. The appearance of a high-
intensity sharp singlet in the high-field region of the spectrum (–7.44 ppm) within the
first 15 min of reaction was noticed. It suggests that a fast hydride-transfer reaction
from 1,4-NADH to the RuII arene complex 3 to generate a Ru–H species could be
taking place. In the low-field region of the spectrum of [(6-hmb)Ru(bpm)Cl]+ (3),
the appearance of a new set of signals was also detected during the first 15 min of
reaction. The new set of peaks is attributable to the formation of NAD+ whose
increasing concentration seems to be related to the decrease in intensity of the signals
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of 1,4-NADH and the complete disappearance of the Ru–H signal after 270 min.
During the course of the reaction, a slight decrease in the intensity of the signals for
the corresponding aqua adducts of complexes 1, 2, 3, and 9 was recorded. No further
changes were observed after 12 h. Table 5.8 lists the time when the maximum
intensity for the corresponding Ru–H species of the RuII arene complexes 1, 2, 3, and
9 were detected as well as the chemical shift of the corresponding hydride peaks.
Figure 5.21. 1H NMR spectra of a 300 mM solution (90% H2O/10% D2O) of [(6-
hmb)Ru(bpm)Cl]+ (3) with 1,4-NADH (molar ratios 1:1) at 310 K and pH* ≈ 8.7. 
Blue = [(6-hmb)Ru(bpm)(OH2)]2+; ■ = bpm. NAD+ is indicated in dark green and
1,4-NADH in red.
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Table 5.8. Time of detection (min) and chemical shift (ppm) of the signal associated
with Ru–H species generated from the reaction of a 300 mM solution (90% H2O/10%
D2O) of the [(6-arene)Ru(N,N')Cl]+ complexes 1, 2, 3, and 9 with 1,4-NADH (molar
ratios 1:1) at 310 K and pH* ≈ 8.5–9.1.  
Compound Time (min) Chemical shift (ppm)
(1) [(6-p-cym)Ru(bpm)Cl]+ 31 –6.13
(2) [(6-p-cym)Ru(phen)Cl]+ 34 –6.21
(3) [(6-hmb)Ru(bpm)Cl]+ 15 –7.44
(9) [(6-thn)Ru(bpm)Cl]+ 22 –6.61
5.3.9 Interactions of RuII Arene Complexes with 1,4-NADH upon UVA
Photoirradiation
In order to explore the possibility of phototriggering the hydride-transfer from 1,4-
NADH to a photoactivatable RuII arene pyridine complex with UVA photoirradiation
(λirr = 300–400 nm) in aqueous solution, an equimolar amount of 1,4-NADH was
added to an NMR tube containing a 300 mM solution of the RuII arene pyridine
complex 13 in 90% H2O/10% D2O at room temperature. It was noticed that if the
initial solution was placed under an UVA lamp, it emitted an intense blue colour
which disappeared upon photoirradiation, Figure 5.22.
Figure 5.22. Blue-coloured emission of a 300 mM solution (90% H2O/10% D2O) of
[(6-hmb)Ru(bpm)(Py)]2+ (13) in the presence of 1,4-NADH (molar ratios 1:1) at 310
K and pH* ≈ 8.5 upon UVA photoirradiation (λirr = 300−400 nm). 
The 1H NMR spectra of the resulting solution were recorded at 310 K at various time
intervals for 24 h. Figure 5.23 shows the progress of the reaction during the first 330
min. The spectra initially contained a set of peaks assigned to the original Ru−Py 
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complex, [(6-hmb)Ru(bpm)(Py)]2+ (13). Further photoirradiation with UVA (λirr =
300−400 nm) at 310 K produces a second set of peaks which increase in intensity as 
photoirradiation is maintained and are assigned to the correspondent aqua species
[(6-hmb)Ru(bpm)(OH2)]2+ (along with the peaks assigned to the released Py ligand)
as it had been previously observed for this system (vide supra and within Chapter 4).
During the first 120 min of photoirradiation with UVA some additional changes in the
1H NMR spectrum were noticed. These changes point to the fast oxidation of 1,4-
NADH to NAD+, as indicated by a decrease in the intensity of the signals of free 1,4-
NADH and the new peaks assignable to NAD+.
Figure 5.23. 1H NMR spectra during the aqueous photolysis (λirr = 300–400 nm) of a
300 mM solution (90% H2O/10% D2O) of [(6-hmb)Ru(bpm)(Py)]2+ (13) in the
presence of 1,4-NADH (molar ratios 1:1) at 310 K and pH* ≈ 8.5. Blue = [(6-
hmb)Ru(bpm)Cl]+; Bright Green = [(6-hmb)Ru(bpm)(OH2)]2+; ■ = bpm. Free Py is 
indicated with Orange ▲. NAD+ is indicated in dark green and 1,4-NADH in red.
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The overall changes in the 1H NMR spectra indicate that the initial amount of 1,4-
NADH is fully consumed to generate NAD+ after ca. 330 min of photoirradiation. No
changes in the amount of [(6-hmb)Ru(bpm)(OH2)]2+ initially generated by
photoirradiation with UVA (λirr = 300−400 nm) were observed, nor the formation of 
Ru–H peaks in the high-field region of the spectrum. When a control mixture of the
RuII arene pyridine complex 13 and 1,4-NADH under the same conditions was kept in
the dark, no reaction was observed.
5.3.10 Qualitative Studies of 1,4-NADH with UVA Photoirradiation
In order to explore the qualitative photochemistry of 1,4-NADH, a 100 μM aqueous 
solution of 1,4-NADH was irradiated with UVA (λirr = 300−400 nm) during ca. 330
min at 310 K. The photoreaction was followed by UV-vis spectroscopy at different
stages of photoirradiation. The resulting absorption spectrum is shown in Figure 5.24.
Figure 5.24. UV-vis absorption spectrum of the aqueous photolysis (λirr = 300–400
nm) of 1,4-NADH in aqueous solution (100 μM) at 310 K. 
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Photoirradiation of 1,4-NADH with UVA (λirr = 300–400 nm) produces noticeable
changes in the shape of its UV-vis absorption spectrum. An important decrease on the
340 nm absorption band occurs simultaneously with an increase on the 260 nm high-
energy band.
5.4 Discussion
5.4.1 Interactions of RuII Arene Complexes with Sodium Formate (NaHCO2),
NAD+ and 1,4-NADH
The interaction of RuII arene chlorido complexes with an excess of sodium formate in
aqueous solution at 310 K, showed that a very stable formate adduct can be formed.
This adduct (Ru–O2CH) is generated by the direct binding of formate to the RuII
centre in the reactive aqua species (Ru–OH2) formed in situ via the Ru–Cl bond
hydrolysis (in complexes 1, 2, 3, 4, and 9). This reactive aqua species presumably
binds to the negatively charged oxygen in the carboxylate moiety (as has been
previously suggested for similar formate and other carboxylate metal complexes).11,24
The binding of formate to the RuII centre in these complexes was confirmed by the
appearance of a sharp singlet at 7.66 ppm in the 1H NMR spectrum (high-field shifted
compared to free formate at 8.40 ppm under the same conditions; 310 K and pH* ≈ 
6.9–7.2). This shifting has been previously observed for analogous RuII arene formato
and acetato complexes24,25,26 and could be attributed to the shielding effect exerted on
the proton in the formato ligand upon coordination (of the carboxylate oxygen) to the
metal centre. The formato complex [(6-p-cym)Ru(bpm)(O2CH)]+ (16) was
synthesised, isolated and characterised; it was found to display a half-life of
hydrolysis of 45 min to a relatively high extent (68.2%). As could be expected, no
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hydrolysis reaction for complex 16 was observed in aqueous solution when an excess
of formate (25 mol equiv) is also present in the solution. The Ru–O2CH adducts of all
of the complexes studied here, did not catalyse the reduction of the organic substrate
acetone (10 mol equiv) at 310 K and pH* ≈ 6.9–7.2, suggesting that they display a 
high stability and inertness towards hydride-transfer to acetone under the
experimental conditions tested. Previous studies have also demonstrated the
occurrence of stable RuII arene formato complexes in solution and in the solid state7,27
as well as non-arene octahedral RuII formato complexes.28 Furthermore, the pH
dependence of the catalytic activity towards reduction of aromatic ketones of
analogous RuII arene complexes has been studied.22 The optimum pH conditions were
found to be ca. 4, which is close to the pKa of formic acid (3.77; at this pH value,
formic acid and formate are in 1:1 equilibrium). Surprisingly, the conversion of NAD+
into 1,4-NADH catalysed by the RuII arene complexes in the presence of sodium
formate (25 mol equiv) in aqueous solution at 310 K was observed. The evidence
suggests that a hydride-transfer reaction by the RuII arene formato complexes of 3 and
4, occurs via the proposed mechanism (based in previously published work)29,31,21
shown in Figure 5.25. The first step of the reaction shown in Figure 5.25(A), proceeds
via the hydrolysis of the corresponding Ru–Cl bonds in complexes 3 and 4, followed
by a rapid binding of formate to the RuII centre in the Ru–OH2 species. The binding
generates remarkably stable Ru–O2CH adducts (at pH* values ca. 7), Figure 5.25(B).
When NAD+ is added and the pH* value of the solution drops (to more acidic
conditions), the following step in the reaction is believed to involve a β-hydrogen 
elimination.
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This process is thought to proceed via ring-slippage of the arene (hmb in complex 3
and ind in complex 4) characterised by a change from 6- to 4- coordination, as has
been previously proposed for analogous complexes,29 Figure 5.25(C).
Figure 5.25. Proposed mechanism for the hydride-transfer reaction from HCO2 to the
RuII arene complexes [(6-hmb)Ru(bpm)Cl]+ (3) and [(6-ind)Ru(bpm)Cl]+ (4) via a
ring slippage process. R represents hmb (3) or ind (4).
The final products in this step are the corresponding Ru–H species and CO2, Figure
5.25(D). The formation of the Ru−H species is characterised by the appearance of 
sharp singlets in the high-field region of the 1H NMR spectrum (between –7 and –8
ppm) as it has been observed in similar RuII arene hydride species.19,30 The release of
CO2 could also be contributing to the observed decrease in pH*. The fact that the
formation of the corresponding Ru–H species occurs after more than 11 h of reaction
at 310 K for complexes 3 and 4 but not at all for the other RuII arene complexes [(6-
p-cym)Ru(bpm)Cl]+ (2) and [(6-thn)Ru(bpm)Cl]+ (9), suggests that the hydride-
transfer from formate to the RuII centre might be the slow rate-determining step. It is
also believed that the hydride-transfer is highly dependent on the nature of the arene,
being most facile with the relatively strongest electron-donor arenes (such as hmb and
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ind). However, it is not clear at present whether this effect is mainly steric or
electronic in nature, or both. The hypothesis on the rate-determining step has been
tested previously19 and the results of the experiments showed in the first place, that
when NaHCO2 was replaced by NaDCO2 in the reaction of NAD+ and the analogous
RuII arene complex [(6-hmb)Ru(en)Cl]+, a pronounced kinetic isotope effect was
observed. Secondly, the turnover frequency of the reaction decreased in the order hmb
> ind ≈ p-cym. Furthermore, in the RuII arene system herein studied, it was observed
that once the corresponding Ru–H species are formed (after more than 11 h) then a
fast hydride-transfer to NAD+ takes place, until it is fully consumed. A plausible
mechanism for the regioselective reduction of NAD+ to 1,4-NADH has been
previously suggested29,31 for NAD+-models. Based on those results, a proposed
mechanism for the RuII arene complexes described herein is shown in Figure 5.26. It
is believed that the amide functionality in NAD+ could coordinate to the RuII arene
complex,18,31 Figure 5.26(E) through an open coordination site made available by the
well documented ring-slippage mechanism29,34 (also proposed for the hydride-transfer
from formate to the RuII centre, Figure 5.25(C) or 5.26(C) vide supra). This
mechanism includes the formation of a kinetically-favoured six-membered ring
transition state. It is suggested that this intermediate further provides the driving force
for the regioselective hydride-transfer at C4 of NAD+, Figure 5.26(F); by an induced
electronic effect of the bound carbonyl group, the C4 position might become a more
electrophilic site towards hydride-transfer. This step also includes the reversion of the
4- to 6- coordination of the arene (hmb in 3 or ind in 4), along with binding and
hydride-transfer31 or concerted binding with hydride-transfer.
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Figure 5.26. Proposed mechanism for the regioselective reduction of NAD+ to 1,4-
NADH by the RuII arene complexes [(6-hmb)Ru(bpm)Cl]+ (3) and [(6-
ind)Ru(bpm)Cl]+ (4). R represents hmb (3) or ind (4).
It should also be noted that hydride-transfer (step E to F in Figure 5.26), could be a
reversible process (vide infra). Finally, displacement of the 1,4-dihydro product by a
H2O molecule recycles the RuII arene aqua species completing the catalytic cycle,
Figure 5.26(G). In the reduction process herein studied, 1,4-NADH is the major
product of the reaction (especially at early stages), though the presence of 1,6-NADH
was also detected by 1H NMR (mainly towards the end of the reaction). This
observation is in good agreement with a recent report that the kinetic product from the
reduction of the NAD+-model (1-benzylnicotinamide triflate) is the 1,4- rather than
the 1,6-dihydro isomer.18,29,31 This reduction is believed to occur via the
rearrangement of the 1,4-dihydro isomer formed from the catalysed reduction of
NAD+ by the RhIII complex [(Cp*)Rh(bpy)(OH2)]2+ where Cp* is
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pentamethylcyclopentadienyl and bpy is 2,2'-bipyridine.29,31 This rational could also
be applied to explain the formation of 1,6-NADH in the case of the catalytic reduction
of NAD+ by the RuII arene systems herein discussed. On the other hand, if more
NAD+ is introduced into the RuII arene catalytic system, the cycle is restarted and then
accumulation of 1,4-NADH is again observed (along with the regeneration of the
signal for the Ru–H species of complexes 3 and 4 in the negative region of the 1H
NMR spectrum). In order to prove the feasibility of the occurrence of the reverse
reaction in Figure 5.26 steps E to F, a separate experiment was performed. The
interaction of the RuII arene complexes [(6-p-cym)Ru(bpm)Cl]+ (1), [(6-p-
cym)Ru(phen)Cl]+ (2), [(6-hmb)Ru(bpm)Cl]+ (3) or [(6-thn)Ru(bpm)Cl]+ (9) with
1,4-NADH at 310 K and initial pH* ≈ 6.9–7.2 was followed by 1H NMR
spectroscopy. The 1H NMR spectra of the reaction suggest that 1,4-NADH could be
transferring a hydride anion to the corresponding Ru–OH2 adducts (formed in situ by
hydrolysis of the corresponding Ru–Cl bonds) to generate a detectable Ru–H species
(sharp singlet between –6.10 and –7.50 ppm) and the observed accumulation of
NAD+. Reported examples of hydride-transfer from 1,4-NADH (as the hydride
source) to metal complexes are (to the best of my knowledge) not known. The
hydride-transfer from porphyrin NADH-analogues to a manganeseIV-oxo complex,
[(TMP)MnIV(O)] where TMP = 5,10,15,20-tetrakis(2,4,6-trimethylphenyl) porphyrin,
has been reported32 and it was found to occur via disproportionation of
[(TMP)MnIV(O)] to [(TMP)MnIII]+ and [(TMP)MnV(O)]+ that acts as the hydride
acceptor. Others have investigated the non-enzymatic oxidation of NADH by a large
number of different quinones both theoretically and experimentally.33 It was
concluded that the smaller benzo- and naphtha-quinones are capable of oxidising
NADH in aqueous solution, whereas the larger anthraquinone is not. The plausible
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mechanisms for the oxidative conversion of 1,4-NADH to NAD+ observed in the case
of the RuII hydride complexes studied herein might proceed according to the proposed
hydride-transfer scheme shown in Figure 5.27. The first step of the reaction shown in
Figure 5.27(A), proceeds via the hydrolysis of the corresponding Ru–Cl bonds,
followed by the plausible coordination of the amide functionality in 1,4-NADH to the
RuII arene complexes, most probably through direct displacement of the bound water
molecule, Figure 5.27(B).
Figure 5.27. Proposed mechanism for the hydride-transfer reaction of 1,4-NADH to
[(6-hmb)Ru(bpm)Cl]+ (3).
The next step would involve the direct hydride-transfer from 1,4-NADH to the RuII
arene complex via the formation of the kinetically-favoured six-membered ring
transition state, Figure 5.27(C) (analogous to the one shown in Figure 5.26(E))
through a vacant coordination site which becomes available by the same ring-slippage
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mechanism29,34 (previously suggested vide supra). This step includes the reversion of
the 4- to 6- coordination of the arene (p-cym in 1 and 2, hmb in 3, or thn in 9), and
finally the release of the NAD+ product and generation of the RuII hydride species,
Figure 5.27(D). The results of these experiments confirm that 1,4-NADH can indeed
transfer a hydride anion to RuII arene complexes.
5.4.2 Interactions of RuII Arene Complexes with Sodium Formate (NaHCO2),
NAD+ and 1,4-NADH upon UVA and Visible Light Photoirradiation
The reaction of the half-sandwich RuII arene pyridine complexes (11–15) with an
excess of sodium formate (25 mol equiv) in aqueous solution at 310 K and pH* ≈ 
6.8–7.1, showed that very stable RuII arene formate adducts (Ru–O2CH) can be
achieved exclusively upon photoirradiation with UVA (λirr = 300–400 nm) or visible
(λirr = 400–660 nm) light. The corresponding adducts (Ru–O2CH) are more
quantitatively generated if UVA photoirradiation is used and they are not susceptible
to photodecomposition. The binding of formate to the RuII centre thus generates
identical species as those formed from the reaction of the RuII arene chlorido
analogues. The corresponding Ru–O2CH adducts formed in solution upon
photoirradiation with UVA or visible light, display the same reactivity as those
achieved by the direct reaction of the analogue chlorido species (vide supra), i.e. they
did not catalyse the reduction of the organic substrate acetone (10 mol equiv) under
the experimental conditions. The pH* value seems to be a determinant factor for the
hydride-transfer to proceed (being optimal under acidic conditions, vide supra). As
observed for the RuII chlorido analogues, the pyridine RuII arene complex [(6-
hmb)Ru(bpm)(Py)]2+ (13) was found to catalyse the conversion of NAD+ into 1,4-
NADH in aqueous solution at 310 K in the presence of an excess of sodium formate
(molar ratios 1:1:25, respectively) exclusively upon photoirradiation with UVA (λirr =
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300–400 nm) or visible light (λirr = 400–660 nm). When a control solution of the RuII
arene pyridine complex 13, along with NAD+ and formate was kept in the dark, no
reaction was observed. Figure 5.28 shows the proposed mechanism (based on
published work11,18,29,31 and on the results discussed above for the chlorido
complexes; vide supra) for the phototriggered reduction of NAD+ into 1,4-NADH
catalysed by the RuII arene pyridine complex 13. The first step in the regioselective
reduction, involves the photolysis of the corresponding Ru–N(Py) bond in complex 13
(and the selective release of the Py ligand), Figure 5.28 (A) followed by an almost
simultaneous binding of formate to the RuII centre in the Ru–OH2 species formed in
situ upon photoirradiation, Figure 5.28(B). The reduction reaction is assumed to
proceed via the slow-rate hydride-transfer mechanism also proposed for the chlorido
complexes 3 and 4 (vide supra, Figure 5.26). Two main differences between the RuII
arene halido complexes (3 and 4) and the RuII arene pyridine complexes are observed.
The first one is that the aqua adduct of these latter complexes is clearly achieved
exclusively upon UVA or visible light photoirradiation. The second difference is that
no Ru–H signal is detected despite the fact that the reduction to 1,4-NADH is indeed
observed (by 1H NMR spectroscopy). This could be due not only to the reduced
generation of 1,4-NADH (which was proved to also contribute to the generation of
Ru–H species, vide supra) but also due to the probable simultaneous
photodegradation of 1,4-NADH to NAD+ upon photoirradiation by UVA (λirr = 300–
400 nm) as it has been recently suggested.35 It is believed that NAD+, adenosine 5'-
diphosphoribose (ADPR) and a second compound, which may be nicotinamide (NA)
are the photoproducts resulting from long-time exposures (2 days) of 1,4-NADH to
UVA photoirradiation (λirr = 300–400 nm) in water and normal-atmosphere-oxygen
conditions. In that report it was also observed that ADPR and NA emerge exclusively
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in oxygen-poor conditions. Therefore, at higher oxygen concentrations and shorter
photoirradiation periods (as the ones used for the RuII arene pyridine system), NAD+
must be the only photoproduct although still as a minor species. Further evidence to
support this hypothesis was obtained from the reaction of the RuII arene pyridine
complex 13 with 1,4-NADH under UVA light photoirradiation, where the only
photoproducts present in solution at the end of the reaction (after 330 min of
photoirradiation) were found to be the Ru–OH2 species, free Py, and NAD+ (and no
evidence of generation of Ru–H species). The observed loss of the intrinsic
photoemission of 1,4-NADH whilst converted to NAD+ upon photoirradiation is in
good agreement with the reaction mechanism.
Figure 5.28. Proposed mechanism for the reaction of [(6-hmb)Ru(bpm)(Py)]2+ (13),
NaHCO2 and NAD+ upon photoirradiation by UVA (λirr = 300–400 nm). R represents
hmb (13).
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5.5 Summary
The interaction of RuII arene chlorido complexes with an excess of sodium formate
(25 mol equiv) in aqueous solution at 310 K, showed that a formate adduct can be
formed upon hydrolysis of the corresponding Ru−Cl bonds. The formate adduct thus 
produced is very stable in aqueous solution (pH* ≈ 7.0) and does not undergo 
hydrolysis provided that an excess of formate (25 mol equiv) is also present. It was
observed that the isolated formato complex [(η6-p-cym)Ru(bpm)(O2CH)] (16)
underwent hydrolysis in aqueous solution at 310 K with a half-life of 45 min and up
to more than 65% extent. The same class of formate adducts can also be produced if a
RuII arene pyridine complex is irradiated with UVA (λirr = 300−400 nm) or visible 
light (λirr = 400−660 nm) under the same conditions (310 K and pH* ≈ 7.0). This 
observation provides further evidence that such RuII arene formate complexes are also
stable towards photoirradiation. None of the RuII arene formato adducts catalysed the
reduction of acetone, suggesting a decreased reactivity for these complexes at
biologically relevant pH* values. Four selected RuII arene complexes of the form [(η6-
arene)Ru(N,N')Cl][PF6] where arene is para-cymene (p-cym, 1), hexamethylbenzene
(hmb, 3), indane (ind, 4) or thn (tehtrahydronaphtalene, 9); and N,N' is 2,2'-
bipyrimidine (bmp) were tested for hydride-transfer reactions. It was found that
complexes 3 and 4 (but not 1 and 9) can catalyse the regioselective reduction of
NAD+ in the presence of formate in water (25 mol excess) to form 1,4-NADH. The
reaction occurs via the formation of a 1H NMR detectable Ru−H (hydride) species. A 
second reduction product was also detected in latter stages of the reaction as a minor
side-product, 1,6-NADH. The catalytic activity seems to be dependent on the arene
with the hexamethylbenzene (hmb) complex 3, showing the better activity by
providing electronic stability during the formation of the Ru−H species and be 
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favoured at lower pH* values. It was also shown that the regioselective reduction of
NAD+ to NADH can be phototriggered by photoactivating a RuII arene pyridine
complex, [(η6-hmb)Ru(bpm)(Py)]2+ (13). In this case, no detectable 1H NMR signals
for Ru−H species were observed due to the reduced accumulation of 1,4-NADH 
(from NAD+), which seems to be related to the formation of such hydride species. In
this context, 1,4-NADH was proved for the first time (to the best of my knowledge) to
participate in hydride-transfer reactions to RuII arene chlorido complexes to form a
Ru−H species and NAD+. When the reaction was repeated using a photoactivatable
RuII arene pyridine complex using UVA photoirradiation, instead of the readily
hydrolysable halido complex, the only photoproducts present in solution at the end of
the reaction were the Ru–OH2 species, free Py, and NAD+ with no evidence for the
generation of Ru–H species. This observation accounts for the simultaneous
photodecomposition of 1,4-NADH upon photoirradiation which might explain its
reduced accumulation (as a product).
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Chapter 6
Bifunctional Ru(II) Arene Complexes
6.1 Introduction
Soon after the discovery of cisplatin in the 1960s,1,2,3 extensive studies of platinum
ammine halide analogues led to a series of empirical rules governing the
chemotherapeutic potential of this class of derivatives.4 Specifically, it was then
concluded that active compounds should: (1) be neutral, presumably to facilitate
passive diffusion into cells; (2) have two leaving groups in a cis- configuration; (3)
contain non-leaving groups with poor trans- labilising ability, similar to that of NH3
or organic amines; and (4) have leaving groups with a window of lability centred on
the chlorido ligand. Several recent studies have focused on applying analogous
structure-activity relationships (SARs) to other metal complexes for anticancer drug
design.5 Half-sandwich RuII arene complexes of the general formula [(η6-
arene)Ru(X)(Y)(Z)]n+ where X and Y are two monodentate ligands or if linked, XY is
a bidentate chelating ligand; and Z is a leaving group have recently been shown to be
potential anticancer drugs.6 Their primary geometry has been extensively used as a
template to build cisplatin constitutional analogues which would ideally retain the
biological activity. The first reported synthesis and structural characterisation of an
organometallic RuII complex with similarity to cisplatin, bearing two ammonia ligands
and one chloride [(η6-benzene)Ru(NH3)2Cl][PF6],7,8 appeared thirty years ago but
involved mainly studies of its photochemical properties. More recently, the synthesis
and properties of a novel RuII arene complex namely [(η6-p-cym)Ru(NH3)2Cl]+ have
been described,9 finding that despite its constitutional similarity to cisplatin, the
complex displays an IC50 value 500 times larger than that for the platinum drug under
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the same conditions. It is probable that the lack of activity arises from its instability in
aqueous (and organic) solutions. The synthesis of numerous RuII arene dichlorido
complexes bearing N-donor ligands10 (mainly but not restricted to N-pyridine based)
and mixed donor ligands (such as phosphines)11 have also been tried. They have been
shown not only to display interesting biological activities12 but also have found use in
other areas of research, such as catalysts in organic synthesis.13,14 Various approaches
towards bifunctional RuII arene complexes have included the use of bulkier N-
monodentate ligands or non N-based monodentate ligands such as paullone
derivatives,15 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane (pta),16 pyr(id)ones,17 as
well as biologically active groups such as staurosporine18 or tyrphostin19 derivatives.
Drawn from several studies with platinum anticancer compounds,20,27a it seems that
the presence of an H-bond donor atom may be a desirable feature in the design of
bifunctional RuII arene complexes in order to, for example, aim for intrastrand cross-
linking on DNA in a similar fashion to cisplatin.21 In this respect, monodentate NH2R
ligands have been used.22,23 However, the evidence suggests that the coordinated N-
donor group can undergo ligand substitution reactions in solution and complexes such
as [(η6-mesitylene)Ru(NH2R2)Cl2] where R = ethyl or butyl, decompose in solution.24
In this work, the synthesis and structural characterisation of the first known examples
(to the best of my knowledge) of neutral water soluble organometallic RuII complexes
which possess constitutional similarity to cisplatin in the solid state and display
similar behaviour in aqueous solution is described. It is also discussed how these
complexes can readily bind to nucleobases in a similar fashion to that observed for
cisplatin. The potential as cytotoxic agents for the neutral RuII arene complexes was
also explored by means of cancer cell growth inhibition assays (IC50 values).
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6.2 Experimental Section
6.2.1 Materials
RuCl3·3H2O was acquired from Precious Metals Online (PMO Pty Ltd) and used as
received. N,N'-dimethylbenzylamine (dmba) and NH4PF6 were obtained from
Aldrich. The RuII arene precursor dimers [(η6-p-cym)RuCl2]2 and [(η6-bip)RuCl2]2
where arene is para-cymene (p-cym) or biphenyl (bip), were prepared following
literature methods25 as described in Chapter 2. The solvents used for UV-vis
absorption spectroscopy were dry methanol (reagent grade) and deionised water. For
NMR spectroscopy the solvents used were acetone-d6, chloroform-d3, methanol-d4 and
D2O purchased from Aldrich unless otherwise stated. All chemicals were used without
further puriﬁcation. 
6.2.2 Preparation of Dichlorido RuII Arene Complexes
Neutral complexes of the form [(η6-arene)Ru(NH3)Cl2] where arene is p-cym or bip
were synthesised using a similar procedure. A suspension of the appropriate RuII arene
dimer [(η6-arene)RuCl2]2, N,N'-dimethylbenzylamine (dmba) and NH4PF6 in 10 mL
of dry MeOH (reagent grade) was stirred at room temperature under N2 atmosphere
for 18 h. The clear orange solution that formed was evaporated and the resulting solid
was redissolved in the minimal amount of MeOH and left standing at 277 K for 5 h.
The precipitate that formed was filtered off and washed with portions of Et2O/MeOH
and dried overnight in vacuum resulting in a microcrystalline product. Details of the
amounts of reactants, colour changes, and nature of the products for the individual
reactions are described below, as well as any variations in the synthetic procedure.
[(η6-p-cym)Ru(NH3)Cl2] (1). [(η6-p-cym)RuCl2]2 (0.10 g, 0.16 mmol), N,N'-
dimethylbenzylamine (dmba) (0.05 mL, 0.32 mmol) and NH4PF6 (0.05 g, 0.32 mmol)
Chapter 6: Bifunctional RuII arene complexes
255
in dry MeOH; the solution turned from brick red to orange; bright orange crystals
obtained; yield 68% (0.04 g, 0.11 mmol). Suitable crystals for X-ray diffraction were
grown from a saturated dichloromethane solution at room temperature. Elemental
Analysis calc. for C19H31Cl2N2PRu %C: 37.76, %H: 5.17, %N: 4.63; found %C:
37.72, % H: 5.04, %N: 4.21. ESI-MS: calc for C10H19Cl2NRu {[M]–[H+]}+ m/z 324.2,
found m/z 324.0. 1H NMR ((CD3)2CO, 500 MHz) δH: 1.30 (6H, d; J = 7.50), 2. 20
(3H, s), 5.36 (2H, d, J = 6.25), 5.58 (2H, d, J = 6.25).
[(η6-bip)Ru(NH3)Cl2] (2). [(η6-bip)RuCl2]2 (0.10 g, 0.16 mmol), N,N'-
dimethylbenzylamine (dmba) (0.049 mL, 0.32 mmol) and NH4PF6 (0.05 g, 0.32
mmol) in dry MeOH; the solution turned from brick red to orange; bright orange
crystals obtained; yield 66% (0.04 g, 0.11 mmol). Suitable crystals for X-ray
diffraction were grown from a saturated acetonitrile solution at room temperature.
Elemental Analysis calc. for C12H15Cl2NORu %C: 39.90, %H: 4.19, %N: 3.88; found
%C: 39.83, %H: 4.32, %N: 4.43. ESI-MS: calc for C12H14Cl2NRu {[M]–[H+]}+ m/z
344.2, found m/z 343.9. 1H NMR ((CD3)2CO, 500 MHz) δH: 5.77 (1H, t, J = 5.63),
5.93 (2H, t, J = 5.63), 6.03 (2H, t, J = 5.63), 6.12 (2H, d, J = 6.25), 6.24 (1H, d, J =
6.25).
6.3 Results
6.3.1 Synthesis and Characterisation
The reaction of [(η6-arene)RuCl2]2 where the arene is p-cym or bip, with two mol
equiv of N,N'-dimethylbenzylamine (dmba) and 2 mol equivalents of NH4PF6 in dry
MeOH under N2 atmosphere at room temperature, afforded the neutral compounds
[(η6-p-cym)Ru(NH3)Cl2] (1) and [(η6-bip)Ru(NH3)Cl2] (2) in good yields (68% and
66%, respectively), Figure 6.1. Both complexes were fully characterised by 1D and
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2D 1H NMR methods as well as elemental analysis, ESI-MS, and X-ray
crystallography.
Figure 6.1. Structures of the neutral complexes studied in this work.
Compared to the corresponding parent dimers, the 1H NMR resonances for both
arenes in the RuII complexes are high-field-shifted by ca. 1 ppm. Figure 6.2 shows the
1H NMR spectrum of complex [(6-p-cym)Ru(NH3)Cl2] (1) in acetone-d6 solution as
a generic example.
Figure 6.2. 1H NMR spectrum of [(6-p-cym)Ru(NH3)Cl2] (1) in acetone-d6 solution.
6.3.2 X-ray Crystal Structures
Suitable crystals for X-ray diffraction of complexes 1 and 2 were grown from a
saturated dichloromethane or acetonitrile solution at room temperature, respectively.
Selected bond lengths and angles are given in Table 6.1, the structures with
numbering schemes are shown in Figure 6.3 and the crystallographic data are listed in
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Table A.6.1. The neutral RuII arene complexes adopt the familiar pseudo-octahedral
three-legged piano stool geometry common to all other RuII arene structures6,26 with
the Ru centre π-bonded to the arene ligand (p-cym in 1 and bip in 2), coordinated to
one ammonia nitrogen, and to two chlorine atoms which constitute the three legs of
the piano stool. The unit cell of the RuII arene complex 1 was found to contain the
N,N'-dimethylbenzylammonium hexafluorophosphate ionic pair, (dmba–H)(PF6).
Table 6.1. Selected bond lengths (Å) and angles (o) for [(η6-p-cym)Ru(NH3)Cl2]
(dmba–H)(PF6) (1) and [(η6-bip)Ru(NH3)Cl2] (2).
Bond length/angle (1) (2)
Ru(1)–arene(centroid) 1.657 1.670
Ru(1)–Cl(1) 2.427(2) 2.4284(8)
Ru(1)–Cl(2) 2.421(2) 2.4246(9)
Ru(1)–N(1) 2.116(8) 2.135(3)
N(1)–Ru(1)–Cl(1) 83.80(2) 84.29(8)
N(1)–Ru(1)–Cl(2) 84.30(2) 84.73(8)
Cl(2)–Ru(1)–Cl(1) 85.11(8) 85.26(3)
Figure 6.3. X-ray structure of the neutral RuII arene complexes [(η6-p-
cym)Ru(NH3)Cl2] (1) and [(η6-bip)Ru(NH3)Cl2] (2). Thermal ellipsoids show 50%
probability. The hydrogen atoms have been omitted for clarity.
The Ru–Cl and the Ru–N bond lengths in the two new neutral RuII arene complexes
are almost the same (~2.42 and ~2.13 Å). The Ru–p-cym(centroid) distance (as measured
from Mercury version 2.2.) in complex 1 is slightly shorter than the one found for the
bip analogue 2. The RuII arene molecules in the unit cell of complex 1 are closely
related through an extended intermolecular H-bond network to the ionic pair (dmba–
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H)(PF6), Figure 6.4. The values for the hydrogen bonds range from 2.396 Å for the
(NH)Ru···F bond up to 2.780 Å for the NH···Cl. Selected H-bond lengths and angles
not described herein are shown in Table A.6.2.
Figure 6.4. H-bond interactions for one RuII arene complex in the X-ray crystal
structure of [(η6-p-cym)Ru(NH3)Cl2] (1). Atoms not involved in the specified
interactions were omitted for clarity.
For the N,N'-dimethylbenzylammonium cation, (dmba–H)+ in the unit cell of complex
1, a weak - interaction between two adjacent benzyl rings (bz) was found with a
bz(centroid)−bz(centroid) distance of 3.920 Å, Figure 6.5 (main feature). The mean planes
distance between the two bz rings involved in the interaction is 3.440 Å. The space-
filling model of (dmba–H)+ (inset in Figure 6.5), shows the presence of the aromatic
stacking where the shortest atomic contact C(204)···C(205) is 3.495 Å and the angle
between the mean planes defined by the bz rings is 0°.
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Figure 6.5. Intermolecular π-π stacking interaction between two molecules of N,N'-
dimethylbenzylammonium cation through the bz rings in the crystal packing of [(η6-p-
cym)Ru(NH3)Cl2] (1). Inset: Spacefilling model showing the π-π stacking interaction. 
Complex [(η6-bip)Ru(NH3)Cl2] (2) was found to pair in the unit cell via H-bonding
interactions between two of the ammonia protons and the chlorido ligands, Figure 6.6.
The bond lengths for each N−H∙∙∙Cl bond are 2.606 and 2.668 Å and the angles are 
144.38 and 139.44°, respectively. Selected H-bond lengths and angles not described
herein are shown in Table A.6.3. Complex [(η6-bip)Ru(NH3)Cl2] (2) lays back-to-back
with an adjacent complex, pairing in an intermolecular π-π stacking interaction. The 
mean planes involving the uncoordinated phenyl (ph) rings in the bip arene are
parallel, Figure 6.7. The spacefilling model of complex 2 (inset in Figure 6.7) shows
the presence of the aromatic stacking with the shortest atomic contact C(8)∙∙∙C(10) 
being 3.587 Å and a ph(centroid)−ph(centroid) distance of 3.687 Å. The uncoordinated ph
ring is tilted 41.06º relative to the main plane defined by the Ru−ph(bound).
Chapter 6: Bifunctional RuII arene complexes
260
Figure 6.6. X-ray crystal structure of [(η6-bip)Ru(NH3)Cl2] (2) showing N−H∙∙∙Cl 
contacts.
Figure 6.7. X-ray crystal structure of [(η6-bip)Ru(NH3)Cl2] (2) showing a π-π 
stacking interaction between two uncoordinated bip rings in neighbouring molecules.
Inset: Space-filling model showing the π-π stacking interaction. 
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6.3.3 Aqueous Solution Chemistry
The hydrolysis of the neutral RuII arene complexes 1 and 2 was studied at 310 K over
8−14 h. The nature of the hydrolysis products and equilibria of the individual 
reactions were verified by either 1H NMR spectroscopy or ESI-MS. The time
dependence of the increase in concentration of aqua adducts or decrease in
concentration of halido species was followed using UV-vis spectroscopy.
6.3.3.1 Hydrolysis Equilibria
In order to characterise the products of hydrolysis and determine the extent of the
reactions, freshly-made 100 μM (5% MeOD-d4/95% D2O) solutions of complexes 1
and 2 were allowed to equilibrate for 24 h at 310 K and then were studied at the same
temperature using 1H NMR spectroscopy. Figure 6.8 shows the 1H NMR spectrum of
complex 1 at 310 K followed over time in the aliphatic region for the CH3(iso-propyl)
protons on the p-cym ring (seen as a doublet). The 1H NMR spectra of complexes 1
and 2 initially contained one major set of peaks (dichlorido species) and then a second
and third set of peaks increased in intensity over time. The new sets of peaks are
believed to correspond to the mono- and di-aqua adducts, [(η6-
arene)Ru(NH3)(OH2)Cl]+ and [(η6-arene)Ru(NH3)(OH2)2]2+. The mass-to-charge
ratios obtained from ESI-MS spectra of the solutions after 24 h were consistent with
the formation of the di-aqua complexes; Table 6.2 (observed as the base peaks of the
spectra). For the complex [(η6-bip)Ru(NH3)Cl2] (2) an additional set of peaks was
also observed in its 1H NMR spectrum, for the product which had undergone arene
loss during the aquation. Table 6.3 summarises the percentage of species detected at
equilibrium by 1H NMR after 24 h of reaction.
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Figure 6.8. 1H NMR spectrum in the aliphatic region of complex [(η6-p-
cym)Ru(NH3)Cl2] (1) in 5% MeOD-d4/95% D2O at 310 K recorded at different stages
of aquation. ■ = [(η6-p-cym)Ru(NH3)(Cl)2], ▲ = [(η6-p-cym)Ru(NH3)(OH2)Cl]+, ● =
[(η6-p-cym)Ru(NH3)(OH2)2]2+.
Table 6.2. Mass-to-charge ratios obtained from ESI-MS spectra for the products of
hydrolysis of RuII arene complexes 1 and 2.
Observed peak
[M]+
Chemical formula
Calc m/z
Found
m/z
(1) {[(η6-p-cym)Ru(NH3)(H2O)2]−[(H+)]}+ C10H20NO2Ru
288.35
288.90
(2) [{[(η6-bip)Ru(NH3)(H2O)2]−[(H+)]}+ C12H17NO2Ru
308.34
308.90
Table 6.3. Percentage of species present at equilibrium after 24 h of the reaction in a
100 μM (5% MeOD-d4/95% D2O) solution at 310 K of complexes 1 and 2 followed
by 1H NMR.
% Species
Compound Ru−X Ru−OH2 Ru−(OH2)2 Arene loss
(1) [(η6-p-cym)Ru(NH3)Cl2] 3.1 20.8 76.1 0.0
(2) [(η6-bip)Ru(NH3)Cl2] ~ 24.1a ~ 2.2a ~ 18.0a ~ 55.7a
a Approximate value due to peak overlap
From Table 6.3, it can be seen that the p-cym complex 1, undergoes mono- and
dihydrolysis to a larger extent than complex 2. Changing the arene from p-cym (1) to
bip (2) greatly modifies the stability of the complex in aqueous solution at 310 K.
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6.3.3.2 Kinetics of Hydrolysis
Dissolution of compounds 1 and 2 in 5% MeOH/95% H2O at 310 K gave rise to
ligand substitution reactions at the RuII centre as indicated by the concomitant
changes in UV-Vis absorption bands. The time evolution spectra for the two RuII
arene complexes at 310 K are shown in Figure 6.9. The initial electronic absorption
spectrum of aqueous [(η6-p-cym)Ru(NH3)Cl2] (1) at 310 K exhibits peaks with
maxima at ca. 255 nm, 320 nm and 410 nm. The highest energy absorption band
increases in intensity while the lower energy band decreases. The band centred at ca.
320 nm disappears upon hydrolysis. In the case of [(η6-bip)Ru(NH3)Cl2] (2) in
aqueous solution, the initial electronic absorption spectrum at 310 K exhibits peaks
with maxima at ca. 255 nm and 274 nm which increase only slightly in intensity over
a period of ca. 6 h. There is no indication of an isosbestic point in the corresponding
UV-vis spectra in either case.
Figure 6.9. Time evolution of the hydrolysis reaction for 100 μM (5% MeOH/95% 
H2O) solutions of complexes 1 and 2 at 310 K followed by UV-vis spectroscopy.
The decrease in absorbance at 255 nm followed over time for complexes 1 and 2 in
100 μM (5% MeOH/95% H2O) at 310 K is shown in Figure 6.10. Both complexes
display biexponential dependence as shown by the fit to the data. The rate constants
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for complex 2 were determined over the period of time before the onset of arene loss
(at ~160 min detected by 1H NMR). The corresponding rate constants and half-life
values are listed in Table 6.4. It can be seen that the bip complex 2 hydrolyses slower
than the p-cym analogue complex 1. The first hydrolysis rate is ca. 1 time slower for
the bip complex (2). The second aquation rates are within the same range for both
complexes.
Figure 6.10. Dependence of the absorbance at 255 nm over ca. 7 h during aquation of
100 μM (5% MeOH/95% H2O) solutions of [(6-p-cym)Ru(NH3)Cl2] (1) and over ca.
160 min of [(6-bip)Ru(NH3)Cl2] (2) at 310 K.
Table 6.4. Hydrolysis data for complexes 1 and 2 determined by UV-vis spectroscopy
as 100 μM (5% MeOH/95% H2O) solutions.
(1) (2)
First Aquation
k1 × 10−3 (min−1)a,b 720.0 ± 21.8 555.0 ± 27.2
(t1/2)1 (min) 1.0 1.2
Second Aquation
k2 × 10−3 (min−1)a,c 15.2 ± 0.7 15.9 ± 5.8
(t1/2)2 (min) 45.7 43.6
a The errors quoted are fitting errors
b,c The rate constants for complex 2 were determined over the period of time before the onset of arene
loss (at ca. 160 min detected by 1H NMR)
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6.3.4 Interactions with Nucleobases
Attempts were made to prepare 9-EtG adducts of complexes 1 and 2. The interactions
were studied by means of multidimensional 1H NMR spectroscopy and the nature of
the products verified by ESI-MS. An equimolar amount of 9-EtG was added to an
NMR tube containing a 100 μM solution of 1 or 2 in 5% MeOD-d4/95% D2O at 31O
K, the reaction was then followed for ca. 6 h. The reactions occur via the in situ
formation of the corresponding reactive aqua adducts (mono- and di-) for each
complex upon hydrolysis. The binding is assumed to be through the N7 position as
has been previously observed for similar RuII arene guanine adducts.27,28 Peaks
assigned to the bound 9-EtG-N7 in all complexes are shifted to low field in
comparison to those of free 9-EtG under the same conditions (H8 peak of free 9-EtG
appears at 8.1 ppm). For both complexes, it was observed that after ca. 10 min of
reaction a second and third set of singlets low-field-shifted and with increased
intensity appeared. These peaks are presumably related to the mono- and dinucleobase
adducts. The H8 peak in the mono-guanine adduct of complex 1, [(η6-p-
cym)Ru(NH3)(9-EtG-N7)Cl]+ (1-EtG), has a chemical shift of 8.20 ppm (versus 8.08
ppm for free 9-EtG under the same conditions). The second singlet, tentatively
assigned to the di-guanine adduct [(η6-p-cym)Ru(NH3)(9-EtG-N7)2]2+ (1-EtG2) has a
chemical shift of 8.40 ppm, Figure 6.11(A). During this same time period another
signal was detected around 8.15 ppm which might correspond either to a tris-9-EtG-
N7 adduct (formed upon hydrolysis of the NH3 bond) or to the formation of 9-EtG-
N3-bound adducts; no further attempts to characterise it were made. An analogous
behaviour was observed for complex 2, for which the H8 peak in the mono-guanine
adduct [(η6-bip)Ru(NH3)(9-EtG-N7)Cl]+ (2-EtG) has a chemical shift of 8.20 ppm
(versus 8.08 ppm for free 9-EtG under the same conditions). The second singlet
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tentatively assigned to the di-guanine adduct [(η6-bip)Ru(NH3)(9-EtG-N7)2]2+ (2-
EtG2) has a chemical shift of 8.34 ppm, Figure 6.11(B). Several other peaks in the
same region were also observed for the reaction of complex 2 with 9-EtG. These
signals may correspond to the species that underwent arene loss over time and no
further attempts were made to characterise them.
Figure 6.11. Time dependence 1H NMR spectra of (A) complex [(η6-p-
cym)Ru(NH3)Cl2] (1) and (B) [(η6-bip)Ru(NH3)Cl2] (2) in 5% MeOD-d4/95% D2O at
310 K in the presence of 9-EtG. ♦ Magenta = [(6-p-cym)Ru(NH3)(9-EtG-N7)Cl]+
(1-EtG)/[(6-bip)Ru(NH3)(9-EtG-N7)Cl]+ (2-EtG); ♦ Yellow = [(6-p-
cym)Ru(NH3)(9-EtG-N7)2]2+ (1-EtG2)/[(6-bip)Ru(NH3)(9-EtG-N7)2]2+ (2-EtG2).
Table 6.5 lists the percentage of species detected after 24 h for the reaction of
complexes 1 and 2 (before the onset of arene loss for the bip complex) with 9-EtG. As
it can be seen, after 106 min, complex 1 had reacted with 9-EtG to form 20.4% of the
corresponding mono-guanine adduct [(6-p-cym)Ru(NH3)(9-EtG-N7)Cl]+ (1-EtG)
and 53.0% of the di-guanine adduct [(6-p-cym)Ru(NH3)(9-EtG-N7)2]2+ (1-EtG2). In
the case of complex 2, after 56 min it had reacted with 9-EtG to form 4.8% of the
corresponding mono-guanine adduct [(6-bip)Ru(NH3)(9-EtG-N7)Cl]+ (2-EtG) and
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32.0% of the di-guanine adduct [(6-bip)Ru(NH3)(9-EtG-N7)2]2+ (2-EtG2). The
mass-to-charge ratios obtained from ESI-MS data were used to characterise some of
the guanine adducts, Table 6.6.
Table 6.5. Time dependence of nucleobase adduct formation for RuII arene
complexes 1 and 2 determined by 1H NMR spectroscopy.
Compound Time(min)
% Mono-
(9-EtG-N7)
adduct
% Di-
(9-EtG-N7)
adduct
(1) [(η6-p-cym)Ru(NH3)Cl2] 106a 20.4 53.0
1440 20.4 53.0
(2) [(η6-bip)Ru(NH3)Cl2] ~ 160b,c ~ 4.8b,c ~ 32.3b,c
1440 ND ND
a Time needed to reach equilibrium
b Time before the onset of arene loss
c Approximate value due to peak overlap
ND Not determined
Table 6.6. Mass-to-charge ratios obtained from ESI-MS spectra for the products of 9-
EtG interactions of RuII arene complexes 1 and 2.
Observed peak
[M]n+
Chemical formula
Calc m/z
Found
m/z
(1) {[(6-p-cym)Ru(9-EtG-N7)(H2O)2]2+–[H+]}+ C17H27N5O3Ru
450.50
450.06
{[(6-p-cym)Ru(9-EtG-N7)]2+ C17H23N5ORu
207.23
207.54
(2) {[(6-bip)Ru(9-EtG-N7)(H2O)2]2+–[H+]}+ C19H22N5O3Ru
469.50
469.03
[(6-bip)Ru(9-EtG-N7)Cl]+ C16H19ClN5ORu
469.91
470.03
[(6-bip)Ru(9-EtG-N7)]2+ C19H18N5ORu 217.53
217.23
(1)
(2)
{[Ru(9-EtG-N7)2]2+–[H+]}+ C14H17N10O2Ru
458.43
458.09
6.3.5 Cancer Cell Growth Inhibition (IC50 values)
The IC50 values for the neutral RuII arene complexes 1 and 2 against the A2780 human
ovarian cancer cell line were determined and are listed in Table 6.7.
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Table 6.7. IC50 values for RuII arene complexes 1 and 2 against the A2780 human
ovarian cancer cell line.
Compound IC50 μM 
(1) [(6-p-cym)Ru(NH3)Cl2] > 100
(2) [(6-bip)Ru(NH3)Cl2] > 100
Cisplatin 0.5
The neutral complexes 1 and 2 were found to be inactive against the A2780 human
ovarian cancer cell line up to the maximum concentration tested (100 μM).  
6.4 Discussion
Two new RuII arene complexes of the type [(6-arene)Ru(NH3)Cl2] where arene is p-
cym (1) or bip (2), showing structural similarity to cisplatin were synthesised and
fully characterised, including analysis of their X-ray crystal structures. In order to
explore their potential as cytotoxic agents, the aquation process, the model nucleobase
binding, and the IC50 values were investigated.
6.4.1 Synthesis and Characterisation
In this work, the synthesis of the first known examples (to the best of my knowledge)
of neutral RuII arene complexes of the type [(6-arene)Ru(NH3)Cl2] with structural
similarity to cisplatin, was achieved by reacting the appropriate [(η6-arene)RuCl2]2
dimer with two mol equiv of N,N-dimethylbenzylamine (dmba) and two mol equiv of
NH4PF6 in dry MeOH under N2 atmosphere at room temperature. The two neutral
compounds [(η6-p-cym)Ru(NH3)Cl2] (1) and [(η6-bip)Ru(NH3)Cl2] (2) were afforded
in good yields (68% and 66%, respectively). The first known examples of transition
metal complexes of the form [(6-benzene)M(NH3)2Cl][PF6] (where M = Ru or Os)
were reported over thirty years ago8 and their synthetic approach was rather
complicated and in most of the cases gave mixtures of products. It involved reacting
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the [(η6-benzene)M(Cl)2]2 dimer in concentrated aqueous ammonia in methanol,
followed by the addition of a saturated aqueous NH4PF6 solution used to precipitate
the complexes as the corresponding PF6 salts. In the alternative synthetic approach
used in this work, the first step in the synthesis is believed to involve the fast acid-
base reaction between N,N'-dimethylbenzylamine (dmba) which acts as the Brönsted-
Lowry base and the ammonium cation (NH4+) which is the Brönsted-Lowry proton
donor, to form equimolar amounts of ammonia (NH3) in situ which then react with the
RuII arene dimer to afford complexes 1 and 2. A similar reaction mechanism has also
been suggested for the synthesis of the cationic complex [(η6-p-cym)Ru(NH3)2Cl]+.9
In organic chemistry, ammonia is known to act as a nucleophile in substitution
reactions.29 NH3 can act as a ligand in transition metal complexes since it is a pure σ-
donor and shows intermediate hard-soft behaviour.30 The presence of the N,N'-
dimethylammonium ion (dma-H)+ in solution was detected by 1H NMR spectroscopy
((CD3)2CO, 500 MHz δH ppm: 3.01 (6H, s), 4.50 (2H, s), 7.50 (3H, m), 7.66 (2H, m))
thus providing further evidence to support the proposed mechanism. Furthermore, the
nature of the solvent appears to play an important role in the quality of the products,
since the syntheses carried out in CH3CN and CH2Cl2 also afforded complexes 1 and
2 but in lower yields (less than 40% in both cases). This observation suggests that the
reaction might proceed by a nucleophilic substitution pathway. The intermediate
species generated upon the nucleophilic attack of NH3 on the RuII centre might be
considerably better stabilised by the interactions with a medium polarity-index solvent
such as methanol (5.1) compared to either a more polar solvent as CH3CN (5.8) or
less polar such as CH2Cl2 (3.1).29,31
Chapter 6: Bifunctional RuII arene complexes
270
6.4.2 X-ray Crystal Structures
The molecular structures of complexes 1 and 2 were determined by single crystal X-
ray diffraction. Suitable crystals were grown from a saturated dichloromethane
solution at room temperature for complex 1 and from a saturated solution of
acetonitrile at room temperature for complex 2. In both cases the complexes adopt the
familiar pseudo-octahedral three-legged piano stool geometry. The (dma-H)(PF6)
ionic pair was found in the crystal packing of the RuII arene complex 1. The
corresponding Ru–arene(centroid) distances in 1 and 2 (1.657 and 1.670 Å, respectively)
are considerably shorter (~0.02−0.05 Å) than those found in related complexes where 
the RuII centre is bound to an aromatic XY-chelating ligand (XY are N, O, or S).32
This could be a consequence of the lack of π-orbitals on the NH3 group (as opposed to
aromatic N,N'-chelating ligands) making the aromatic arenes the only π-acceptor 
ligands coordinated to the RuII centre, thus strengthening the π-bond. The Ru−Cl 
distances are not affected by a change of arene but are slightly longer than those
found in related structures where N belongs to a pyridine ring.33 The corresponding
Ru−NH3 bond lengths in complexes 1 and 2 (2.116(8) and 2.135(3) Å, respectively)
are within the range found in similar complexes such as [(η6-p-cym)Ru(NH3)2Cl]+,9
where the distances are 2.1504(15) and 2.1425(15) Å, but are slightly larger than the
ones found in analogous complexes where the nitrogen donor atom belongs to a
pyridine derivative.9,33 A significant number of H-bond interactions were found
throughout the corresponding unit cells of the RuII arene complexes 1 and 2, where
mainly the NH3 groups (as H-bond donor groups) are involved. This feature is
particularly interesting since it is known that the activity of platinum am(m)ine
anticancer compounds depends on the presence of hydrogen-bond donor NH groups.28
Similarly, the critical role of having N–H donor atoms within bidentate chelating
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ligands in RuII arene complexes for controlling and promoting interactions with model
DNA nucleobases, has been also demonstrated for {(η6-arene)Ru(en)}2+ derivatives
(en is ethylenediamine), for which a strong preference towards guanine derivatives
has been established.27 This site-selectivity appears to be controlled by the NH2
groups of the en ligand, which can form strong hydrogen bonds with the C6O
carbonyl group of guanine bases. Thus, the presence of a H-bond donor (such as NH3
groups) may be an important feature in the future design of bifunctional RuII arene
complexes such as 1 and 2. Furthermore, the X-ray crystal structures of compounds 1
and 2 also show an increased number of intra and/or intermolecular π-π stacking 
interactions, a common feature observed in similar RuII complexes containing
extended aromatic rings.34 The (dmab–H)(PF6) ionic pair in the crystal packing of 1
actively participates to H-bond and stacking interactions in the solid state. Amongst
the latter interactions, an interesting π-π stacking was observed between molecules of 
the cation (dmab–H)+. The phenomenon of stacking among positively charged π-rich 
systems despite strong electrostatic repulsion, has been theoretically and
experimentally studied.35 This type of non-bonding interaction, symbolised by (+)–
(π)/(+) –(π) accounts for pairing of basic amino acid side chains such as arginines and 
histidines in proteins. In the case of complex 2, an intermolecular π-π stacking 
interaction was observed through both of the phenyl rings in the bip arene with a
ph(centroid)–ph(centroid) distance of 3.687 Å, indicative of an effective stacking.36
6.4.3 Aqueous Solution Chemistry
The hydrolysis of complexes 1 and 2 at 310 K was studied using UV-vis
spectroscopy. The extent of the reaction and the nature of the products were verified
by 1H NMR spectroscopy or ESI-MS. The decrease in absorbance at 225 nm with
time for 1 and 2 in 5% MeOH/95% H2O displayed a bi-exponential dependence, as
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shown by the fit to the data. Related mononuclear RuII arene complexes undergo a
monoexponential decrease in absorbance because of loss of a chloride and
substitution by water.37 In complexes 1 and 2, there are two chlorido ligands that can
be substituted by water. The absence of a clear isosbestic point in their UV-vis
absorption spectra correlates to biexponential kinetics. The loss of the first chlorido
ligand would be expected to be faster than the substitution of the second because of
the formation of increased positive charge on the molecules whilst going from [M] → 
[M]+ → [M]2+. This is true for both complexes 1 and 2, where the first hydrolysis rate
(k1) of complex 1 is not only ca. 48 times faster than the second (k2) but ca. 1.5 times
faster than k1 for the bip complex 2 (k1 = 555.0 × 10–3 min–1). The donation of
electron density to the RuII centre by the p-cym ring in 1 (and to a lesser extent by the
bip arene in 2) decreases the positive charge on the metal centre making it more
favourable for the first chlorido ligand to leave thus speeding up the hydrolysis
reaction. This could also account for the faster first-hydrolysis rate for complex 1
compared to that of complex 2. On the other hand, the already increased
destabilisation of complex 2 brought about by the hydrolysis of the first chlorido
ligand along with the poor electron-donating properties of the bip arene (compared to
p-cym in complex 1) might account for the observed arene loss, a phenomenon which
has been previously reported for other RuII bip complexes containing
phenylazopyridines as π-acceptor ligands.32b
6.4.4 Interactions with Nucleobases
DNA is a potential target for transition metal anticancer complexes.38 For this reason,
reactions of complexes 1 and 2 with 9-EtG as a model nucleobase were investigated
in aqueous solution at 310 K. Both complexes react relatively rapidly with N7 of 9-
EtG (less than 2 h to reach equilibrium in both cases) and to a moderate extent, to
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form what is believed to be mono- and di-guanine adducts upon hydrolysis. A similar
profile of reactivity has been found for cisplatin, which by having two available
reactive sites can bind to its target site DNA in a bifunctional manner, forming intra-
and inter-strand crosslinks.39,40,41 Furthermore, coordination to two guanine bases has
also been demonstrated for the fragment {η6-benzene)Ru}2+.42 Overall, the reactions
of complex 1 with 9-EtG take longer to reach equilibrium compared to those of
complex 2, but are more quantitative. Around 20% and 50% of the mono- and di-
guanine adducts of complex 1, respectively were formed after 106 min of reaction
whereas complex 2 forms only little amounts of the mono-guanine adduct (less than
5%) and around 30% of the di-guanine adduct before the onset of arene loss (ca. 160
min). It is possible that a larger extent of guanine-substitution could occur in the case
of complex 2 after ca. 160 min (as detected by 1H NMR) given that three vacant
positions are generated. On the other hand, in all the 9-EtG (both the mono- and the
di-guanine) adducts of complexes 1 and 2, the 1H NMR peaks corresponding to H8
are shifted to lower field relative to free 9-EtG under the same conditions from a
minimum of ca. 0.02 ppm for the mono-guanine adduct of complex 2 [(η6-
bip)Ru(NH3)(9-EtG-N7)Cl]+ (2-EtG), up to a maximum of ca. 0.4 ppm for the di-
guanine adduct of complex 1 [(η6-p-cym)Ru(NH3)(9-EtG-N7)2]2+ (1-EtG2).
Metallation at the N7 site of purine bases usually produces a low field shift of the H8
resonance by about 0.3–1 ppm.43 This same behaviour has been previously observed
for en RuII and OsII arene complexes.44
6.4.5 Cancer Cell Growth Inhibition (IC50)
None of the neutral complexes of the type [(η6-arene)Ru(NH3)Cl2] containing either
p-cym (1) or bip (2) were cytotoxic against the A2780 human ovarian cancer cell line
up to the maximum concentration tested (100 μM). It is known that metal 
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coordination complexes can undergo ligand substitution reactions with components of
the media in which they are dissolved.45 In the case of complexes 1 and 2, the
diminished anticancer activity could be due to their tendency to hydrolyse in aqueous
solution and therefore become inactivated by the components in the media even
before reaching the cell or by other biomolecules once within the cell. This same
hypothesis of inactivation has been previously suggested for complexes of the type
[(η6-p-cym)Ru(X)(Y)Z] where X, Y or Z are monodentate ligands such as halides,
acetonitrile or isonicotinamide.6 Further studies are needed to account for the reduced
anticancer potency of complexes 1 and 2.
6.5 Summary
In this Chapter it has been shown that neutral half-sandwich RuII constitutional
analogues of cisplatin can be synthesised by the reaction of N,N'-
dimethylbenzylamine, NH4PF6 and the corresponding RuII arene dimer. These
analogues display extensive H-bond interactions in the solid state (as cisplatin does)
through the NH3 and Cl ligands. The biexponential hydrolysis rates of complexes
[(η6-arene)Ru(NH3)Cl2] 1 (p-cym) and 2 (bip), vary over many orders of magnitude;
from half-lives of minutes (ca. 1 min for the first aquation of complex [(η6-p-
cym)Ru(NH3)Cl2] (1)) to hours (ca. 1 h for the second aquation of complex [(η6-
bip)Ru(NH3)Cl2] (2)) at 310 K. The possibility of using these complexes as anticancer
agents was investigated by exploring their interactions with the model nucleobase 9-
EtG in aqueous solution. Both complexes were found to readily form mono- and di-
guanine adducts upon hydrolysis, which equilibrate in solution after 106 min
(complex 1) and 56 min (complex 2). The reaction of complex 1 is slower but more
quantitative. Hydrolysis is known to be a mechanism to provide a pathway for
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cytotoxicity.6 However, none of the neutral complexes were cytotoxic against the
A2780 human ovarian cancer cell line up to the maximum concentration tested (100
μM). It is assumed that the reduced potency could arise from the inactivation of their 
aqua adducts by the components in the media even before reaching the cell or by
other biomolecules within the cell. Further studies are needed to account for their
reduced cytotoxicity.
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Future Work and Perspectives
This Chapter deals with potential new areas of investigation that could be opened up
based on the results in the previous chapters. Furthermore, it also discusses the
experiments, discoveries, and observations made along the lines of the major work
presented in this thesis which were not further developed but are together an
important body of information worth of further study.
7.1 Hydrophobicity, Cancer Cell Growth Inhibition, Cell Uptake,
and Cell Distribution
In Chapter 3 it was shown how the systematic variation of the different ligands
surrounding the RuII centre in complexes of the type [(η6-arene)Ru(N,N')X]+ can lead
not only to significant changes in the chemical reactivity in relation to hydrolysis but
also in the interaction with biologically relevant molecules such as nucleobases and
DNA. The cytotoxic activity seems to be also highly dependent on the nature of the
N,N' chelating ligand as demonstrated by the half-sandwich RuII arene complexes
containing 1,10-phenanthroline (phen) and 4,7-diphenyl-1,10-phenanthroline
(bathophen) which were found to be highly potent towards A2780 human ovarian
cancer cells. Remarkably potent is the bathophen derivative (IC50 value of 0.5 μM). 
Preliminary DNA binding studies also showed that in addition to phen, complexes
with 2,2'-bipyrimidine (bpm) can also bind to DNA. It is then concluded that further
studies are needed to identify the mechanism that inactivates some of the complexes
suppressing the cytotoxic activity up to the maximum concentration tested (100 μM). 
Partition coefficient (Log P) values could be thus determined; they give a measure of
Chapter 7: Future Work and Perspectives
282
how hydrophilic or hydrophobic a compound is and this information has been used to
establish a relationship between hydrophobicity, cell uptake, and anticancer activity
for some PtII and PtIV complexes1,2 as well as for other metallo-anticancer drugs.3,4,5
An extended set of experiments with CT-DNA in cell-free media (such as DNA
transcription by RNA polymerase in vitro, DNA melting temperature, circular and
linear dichroism, or quenching of EtBr fluorescence) could also be carried out in order
to establish in more detail the mode in which these complexes interact with DNA. On
the other hand, low IC50 values (in the range of ca. 9.0–25.0 μM) were determined for 
some of the photoactivatable RuII arene complexes with pyridine or pyridine-
derivative ligands introduced in Chapter 4. Since these complexes do not hydrolyse
spontaneously, there is the possibility that the intact cations might exert a cytotoxic
effect by mechanisms which could include, for example, modification of
mitochondrial membrane permeability. Cell-uptake studies and Log P value
determination could be useful tools in an attempt to elucidate their mechanism of
cytotoxicity.
7.2 Studies of RuII Arene Halido Complexes with Antileukaemic
Thiopurine Drugs
An interesting approach to the design of metal-based drugs is the preparation of
complexes with active chemotherapeutic agents as ligands to obtain a synergistic
effect.6 The drug 6-mercaptopurine (MP) is a well-known clinical agent for therapy of
human leukemias and its 6-thioguanine (TG) analogue(s) are active against some
types of human cancers.7 They belong to the family of drugs known as
antimetabolites8 which inhibit the use of a metabolite.9 Such antimetabolites are often
similar in structure to the metabolite that they interfere with, Figure 7.1, such as the
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antifolates that interfere with the action of folic acid. These compounds are used in
chemotherapy for cancer given that their presence can have toxic effects on cells, such
as halting cell growth and cell division.10 MP is also used as an immunosuppressive
drug in transplant surgery11 and most recently has been shown to impair HIV
replication. The incorporation of MP into DNA is known to be an essential step for its
cytotoxic activity. However, the structural effects of the MP substitution on duplex
DNA have not been fully characterised.12
Figure 7.1. Structures of the DNA nucelobase guanine (G) and the antimetabolites 6-
mercaptopurine (MP) and 6-thioguanine (TG). R represents the phosphate
deoxyribose backbone.
The RuII arene complex [(6-p-cym)Ru(MP)(Cl)][PF6] (14) introduced in Chapter 3,
might be one of the few examples of piano-stool complexes which incorporate MP as
the chelating ligand. A new family of complexes derived from [(6-p-
cym)Ru(MP)(Cl)][PF6] (14) could be studied, paying special attention to the
investigation of their interactions with DNA as well as the overall chemical reactivity.
7.3 Synthesis of Photoactivatable Dinuclear RuII Arene Pyridine
Complexes
Given that the photochemical studies on the mononuclear RuII arene complexes
bearing pyridine or pyridine-derivatives studied in Chapter 4, showed that light
activation can be used to phototrigger binding of these potential anticancer agents to
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nucleobases and to DNA, the incorporation of a second RuII centre into the basic
scaffold of the molecule (using the unbound N,N' atoms in the bpm chelating ligand)
would in principle generate a new family of dinuclear RuII arene complexes such as
the prototype shown in Figure 7.2(A).
Figure 7.2. Structures of potential photoactivatable dinuclear RuII arene complexes
where L is a pyridine or a pyridine-derivative ligand.
It has been previously reported that the dinuclear RuII indane complex [{(η6-
ind)Ru(Cl)}2(μ-2,3-dpp)2][PF6]2,13 undergoes photoinduced arene loss in aqueous
media and in the presence of CT-DNA, producing novel types of DNA cross-links
that can not be readily achieved by chemical reactions alone. What is more, having
two metal centers (Mn+, where M1n+ = M2n+ or M1n+ ≠ M2n+) in the same molecule
linked by an electron-rich (poly)pyridyl chelating ligand dramatically changes the
photochemical reactivity of complexes and therefore their potential applications.14,15,16
It is thus possible that by photoreleasing two L ligands from the dinuclear RuII arene
complex (depicted in Figure 7.2(A)), cell-lethal bifunctional lesions on DNA could be
generated. The formation of dinuclear RuII arene complexes could also be achieved by
carefully selecting the bridging ligand to incorporate it into the basic scaffold. The
two metal centres could be linked not only through the N,N'-chelating but also
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through the monodentate ligand so as to generate structures as that shown in Figure
7.2(B). Those RuII arene dinuclear complexes would display high positive charges
which could in turn improve and enhance their interactions with DNA, both with or
without irradiation.
7.4 Photorelease of Biologically Active Molecules
From the structure-photoactivity relationship done for the RuII arene pyridine and
pyridine-derivative complexes studied in Chapter 4, it is clear that the synthesis and
photochemical behaviour of this family of complexes is exceptionally rich. A more
detailed study could therefore be directed towards the potential role that the released
ligand might have in the media where the photoactivation is actually happening.
Coordination of a bioactive molecule to the RuII centre in these systems and its
eventual photorelease could be coupled to biological assays where the activity of the
bioactive molecule (once free) could be tested. This strategy could also be used to
photorelease the biologically relevant molecule from the RuII centre into a specific
compartment of the cell or be used as a probe through specific
quenching/enhancement of fluorescence if the ligand is bound/free. Along this line,
preliminary results from a collaboration with Miss Flavia Barragán from the
Universitat de Barcelona in Spain, show that we were able to couple a biologically
active polypeptide to the {(η6-p-cym)Ru(bpm)}2+ fragment and proved its further
specific photorelease using UVA irradiation in a similar fashion as the pyridine or
pyridine-derivative ligands do.
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7.5 Bio-inspired Hydride-Transfer Reactions of RuII Arene
Complexes
In Chapter 5, it was proved for the first time (to the best of my knowledge) that 1,4-
NADH can participate in hydride-transfer reactions to RuII arene chlorido complexes
forming Ru−H species plus NAD+. This reaction is of importance since it mimics the
function of NADH in cells. The bio-inspired hydride-transfer is currently being
explored towards the reduction of biologically relevant substrates. We are using
sodium pyruvate as the substrate, aiming to mimic the function of the enzyme lactate
dehydrogenase which catalyses the interconversion of pyruvate and lactate with
concomitant interconversion of 1,4-NADH and NAD+,17 Figure 7.3.
Figure 7.3. Catalytic reaction of the enzyme lactate dehydrogenase (LDH).
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Appendix
A.3.1. Computational details: Mechanism of Hydrolysis
The Slater Type Orbital (STO) basis set comprised a triple-ζ plus 5p orbital set (TZP) on Ru 
with double-ζ plus polarisation (DZP) on all other atoms (ADF BASIS key: type DZP). 
Default convergence criteria were applied for SCF and cartesian geometry optimisations. For
optimisations in internal coordinates, in particular TS searches, the angle threshold was set to
1.5° (default = 0.5 º). This criterion was relaxed due to the long bond lengths at the transition
states, which make it harder to define torsional terms accurately. The same problem occurs
for reactant and product species because the respective entering and leaving groups are
included in the calculation, and their relatively weak interaction with the rest of the complex
again leads to less well defined torsional terms. However, the energetic consequences of
relaxing the angle constraints are negligible. The Amsterdam Density Functional (ADF)
program reported a single negative eigenvalue in the Hessian matrix for all transition state
optimisations. A representative TS was confirmed as a first order saddle point with frequency
calculations as described earlier. The conductor-like screening model (COSMO) as
implemented in ADF was used to simulate the aqueous environment with ε = 78.4, probe 
radius = 1.9 Å, and the ND parameter which controls integration accuracy set to 4 (default 3).
The atomic radii (Å) used were Ru = 1.950, O = 1.517, C = 1.700, N = 1.608, H = 1.350, Cl =
1.725, Br = 1.850, and I = 1.967.
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Table A.3.1. Crystallographic data for [(6-p-cym)Ru(bpm)I][PF6] (3), [(6-bip)Ru(bpm)Cl][PF6] (4), [(6-bip)Ru(bpm)I][PF6] (6), [(6-
etbz)Ru(bpm)Cl][PF6] (7), and [(6-p-cym)Ru(bpm)(9-EtG-N7)][PF6]2 (15)
3 4 6 7 15
Formula C18H20F6IN4PRu C20H16F6ClN4PRu C20H16F6IN4PRu C17H16ClF6N4O2PRu C25H31F12N9O2P2Ru
Molar Mass 665.32 593.86 685.31 589.83 880.60
Crystal system monoclinic monoclinic monoclinic monoclinic Orthorhombic
Crystal Size/mm3 0.20 x 0.20 x 0.08 0.50 x 0.10 x 0.02 0.20 x 0.20 x 0.20 0.30 x 0.10 x 0.01 0.60 x 0.16 x 0.16
Space group P2(1) P2(1)/n P2(1)/n P2(1)/c Pbca
Crystal Orange/block Orange/block Orange/block Brown/block Red block
a/ Å 8.4028(5) 12.4224(10) 12.3617(2) 11.4826(5) 19.4807(2)
b/ Å 11.4784(4) 12.361(3) 12.1203(2) b = 24.1735(7) 16.83500(10)
c/ Å 11.7850(11) 15.0821(6) 15.4384(3) c = 7.1171(3) 19.85560(10)
α/deg 104.362(8) 90 90 90 90 
β/deg 90 106.376(5) 107.858(2) 93.836(4) 90 
γ/deg 90 90 90 90 90 
Z 2 4 4 8
R [F>4σ (F)] 0.0194 0.0326 0.0205 0.0382 0.0290 
Rwb 0.0428 0.0934 0.0505 0.0526 0.0746
GOFc 1.032 1.079 1.080 0.756 1.057
Δρ max and min/eÅ-3 +0.389, –0.470 +0.821, –0.572 +1.637, –0.695 +0.697, –0.649 +0.796, –0.742
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Table A.3.2. H-Bonding in the X-Ray crystal structures of [(6-p-cym)Ru(bpm)I][PF6] (3), [(6-bip)Ru(bpm)Cl][PF6] (4), [(6-bip)Ru(bpm)I][PF6] (6), and
[(6-etbz)Ru(bpm)Cl][PF6](7)
Compound
D H A
D-H
(Å)
H...A
(Å)
D...A
(Å)
D-H-A
(°)
3 C(13)
C(13)
C(4)
C(11)
C(16)
H(13A)
H(13A)
H(4A)
H(11A)
H(16A)
F(12)
F(14)
F(16)
F(12)
F(11)
0.98
0.98
0.93
0.93
0.98
2.68
2.65
2.49
2.64
2.37
3.268(3)
3.395(3)
3.339(4)
3.553(3)
3.337(3)
118.7
133.1
151.3a
168.2b
167.1c
4 C(3)
C(3)
C(4)
C(14)
C(20)
C(15)
C(17)
C(24)
C(20)
H(3A)
H(3A)
H(4A)
H(14A)
H(20A)
H(15A)
H(17A)
H(24A)
H(20A)
F(6)
F(3)
F(3)
N(5)
F(5)
N(12)
F(2)
F(4)
F(4)
0.93
0.93
0.93
0.98
0.93
0.98
0.98
0.93
0.93
2.31
2.84
2.96
2.46
2.65
2.56
2.34
2.66
2.88
3.213(6)
3.353(8)
3.440(8)
3.355(4)
3.327(6)
3.512(4)
3.157(5)
3.508(8)
3.509(9)
164.7d
116.3d
113.3d
151.1e
129.7f
162.9g
140.0h
151.6h
125.6i
6 C(2)
C(13)
C(4)
C(11)
H(2A)
H(9A)
H(9A)
H(10A)
F(15)
F(13)
I(1)
F(15)
0.95
0.95
0.95
0.95
2.43
2.49
2.98
2.57
3.2907(19)
3.0685(19)
3.8021(16)
3.477(2)
150.8
119.3j
145.1k
168.2l
7 C(17)
C(9)
C(15)
C(3)
H(17A)
H(9A)
H(15A)
H(3A)
Cl(1)
F(6)
F(3)
F(2)
1.00
0.95
1.00
0.95
2.52
2.47
2.42
2.44
3.411(4)
3.088(5)
3.115(5)
3.213(4)
147.6m
122.2n
125.8o
138.1p
Symmetry operators used to generate equivalent atoms involved in these contacts:
a [x+1, y+1, z]; b [x+1, y, z]; c [x, y+1, z]; d [2–x, –y, –z]; e [x–1/2, 1/2–y, 1/2+z]; f [x–1/2, 1/2–y, z–1/2]; g [3/2–x, y–1/2, 1/2–z]; h [5/2–x, y–1/2, 1/2–z]; i [2–x, 1–y, –z]; j [x–
1/2, 1/2–y, 1/2+z]; k [x–1/2, 1/2–y, z–1/2]; l [3/2–x, y–1/2, 1/2–z]; m [5/2–x, y–1/2, 1/2–z]; n [2–x, 1–y, –z]; o [–x, –y, 1–z]; p [x, 1/2–y, 1/2+z]; q [x–1, y, z]; r [x–1, y, 1+z].
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Table A.4.1. Crystallographic data of [(6-p-cym)Ru(bpm)(4-MePy)][PF6]2 (2), [(6-p-cym)Ru(bpm)(4-BzPy)][PF6]2 (6), [(6-p-cym)Ru(bpm)(trz)][PF6]2
(7), [(6-p-cym)Ru(phen)(Py)][PF6]2 (10), [(6-ind)Ru(biPy)(Py)][PF6]2 (13).
2 6 7 10 13
Formula C24H27F12N5P2Ru C30H27F12N5P2Ru C21H27F12N7OP2Ru C33H39F12N3O2P2Ru C24H23F12N3P2Ru
Molar Mass 776.52 848.58 784.51 900.68 744.46
Crystal system Monoclinic Monoclinic Monoclinic Monoclinic Monoclinic
Crystal size/mm3 0.40 x 0.20 x 0.10 0.40 x 0.20 x 0.08 0.40 x 0.40 x 0.10 0.30 x 0.20 x 0.15 0.30 x 0.20 x 0.20
Space group P2(1)/n C2/c P2(1)/c P2(1)/c P2(1)/c
Crystal Green block Yellow block Yellow block Yellow block
a/ Å 10.7691(14) 37.0577(9) 15.5359(2) 11.90151(12) 11.3406(2)
b/ Å 23.718(3) 8.6964(2) 11.15838(17) 18.89949(16) 19.5778(3)
c/ Å 12.0221(14) 20.0783(5) 16.4506(2) 16.67645(19) 12.3483(3)
α/deg 90 90 90 90 90 
β/deg 106.688(12)° 95.974(2) 96.4121(13) 103.1051(10) 107.0675(19) 
γ/deg 90 90 90 90 90 
Z 4 8 4 4 4
R [F>4σ (F)]a 0.0446 0.0349 0.0307 0.0309 0.0283
Rwb 0.1101 0.0877 0.0829 0.0792 0.0732
GOFc 1.051 0.984 1.062 1.075 1.065
Δρ max and min/eÅ-3 +0.637, -0.982 +1.046, -0.546 +1.840, -0.774 +0.996, -0.663 +1.168, -0.707
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Table A.4.2. H-Bonding in the X-Ray crystal structures of [(6-p-cym)Ru(bpm)(4-BzPy)][PF6]2 (6), [(6-p-cym)Ru(bpm)(trz)][PF6]2 (7), and
[(6-p-cym)Ru(phen)(Py)][PF6]2 (10).
Symmetry operators used to generate equivalent atoms involved in these contacts:
a [x, y+1, z]; b [1-x, 1-y, 1-z]; c,d [x, 1/2-y, 1/2+z]
D H A D-H (Å) H...A (Å) D...A (Å) D-H-A (°)
6 C(11)
C(2)
C(14)
H(11A)
H(2A)
H(14A)
F(12)
F(24)
F(21)
0.95
0.95
0.95
2.39
2.43
2.42
3.281(3)
3.352(3)
3.287(3)
155.9
162.9a
151.8b
7 N(16)
N(16)
C(2)
C(4)
C(17)
H(16)
H(16)
H(2A)
H(4A)
H(17A)
O(100a)[c]
O(200b)[d]
F(16)
F(21)
F(16)
0.898(18)
0.898(18)
0.95
0.95
0.95
1.91(2)
1.89(2)
2.43
2.42
2.46
2.728(5)
2.737(7)
3.208(3)
3.200(3)
3.233(3)
151(3)
156(3)
138.4
139.2
138.4
10 C(2)
C(2)
C(2)
C(3)
C(4)
C(4)
C(16)
C(22)
H(2A)
H(2A)
H(2A)
H(3A)
H(4A)
H(4A)
H(16A)
H(22A)
F(23A)
F(23)
F(26A)
F(21A)
F(25)
F(25A)
F(26A)
O(102)
0.95
0.95
0.95
0.95
0.95
0.95
0.95
1.00
2.31
2.44
2.40
2.51
2.38
2.24
2.47
2.28
3.200(8)
3.130(2)
3.076(7)
3.179(13)
3.317(2)
3.163(11)
3.329(7)
3.199(2)
156.7
128.9
128.2
127.2
169.3c
164.8d
151.1
152.8
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Figure A.4.1. Selected orbitals (isovalue 0.02) for complexes 1–6 and 8–16 in the
ground state optimised geometry.
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16
Figure A.4.2. Selected orbitals (isovalue 0.02) and spin density surface (isovalue
0.0004) for complexes 1–6 and 8–16 in the lowest-lying triplet optimised geometry.
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Table A.4.3. Selected TD-DFT singlet transitions for complex 1.
Energy
(eV) Wavelength (nm) Oscillator Strength Major contributions
1 2.8012 443 0.0024 HOMO→L+1 (46%) 
HOMO→L+3 (20%) 
2 3.011 412 0.0059 H-2→L+3 (15%) 
H-1→L+3 (34%) 
3 3.0392 408 0.001 H-1→L+1 (21%) 
H-1→L+3 (13%) 
HOMO→L+1 (12%) 
HOMO→L+2 (10%) 
HOMO→L+3 (14%) 
HOMO→L+4 (12%) 
4 3.1191 398 0.001 H-2→L+1 (32%) 
H-2→L+2 (10%) 
H-2→L+4 (13%) 
H-1→L+1 (14%) 
5 3.1993 387 0.0027 HOMO→LUMO (75%) 
6 3.3581 369 0.0365 H-1→LUMO (79%) 
8 3.6553 339 0.0148 H-2→LUMO (41%) 
H-2→L+3 (16%) 
9 3.7767 328 0.0108 H-2→LUMO (48%) 
H-2→L+3 (-25%) 
13 4.1763 297 0.0804 H-1→L+2 (13%) 
HOMO→L+4 (54%) 
14 4.2527 291 0.0081 H-3→LUMO (16%) 
H-1→L+4 (59%) 
16 4.4026 281 0.0051 H-7→LUMO (29%) 
H-6→LUMO (61%) 
17 4.5092 275 0.0076 H-2→L+2 (19%) 
HOMO→L+5 (68%) 
18 4.5221 274 0.0085 H-2→L+1 (10%) 
H-2→L+2 (43%) 
H-2→L+3 (10%) 
HOMO→L+5 (23%) 
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24 4.782 259 0.0807 H-5→LUMO (12%) 
H-3→L+1 (13%) 
H-1→L+6 (12%) 
H-1→L+7 (18%) 
26 4.8081 258 0.1692 H-5→LUMO (18%) 
H-1→L+6 (11%) 
H-1→L+7 (18%) 
Figure A.4.3. Selected Electron Difference Density Maps (EDDMs) of singlet excited
state transitions of 1 in H2O (light violet indicates a decrease in electron density,
while purple indicates an increase).
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Table A.4.4. Selected TD-DFT singlet transitions for complex 2.
Energy
(eV) Wavelength (nm) Oscillator Strength Major contributions
1 2.805 442 0.0026 HOMO→L+1 (47%) 
HOMO→L+3 (20%) 
2 3.011 412 0.0065 H-2→L+3 (10%) 
H-1→LUMO (10%) 
H-1→L+3 (46%) 
3 3.046 407 0.0004 H-1→L+1 (18%) 
HOMO→L+1 (10%) 
HOMO→L+2 (11%) 
HOMO→L+3 (17%) 
HOMO→L+4 (15%) 
4 3.125 397 0.0011 H-2→L+1 (28%) 
H-2→L+2 (11%) 
H-2→L+4 (14%) 
H-1→L+1 (12%) 
HOMO→LUMO (11%) 
5 3.190 389 0.0036 HOMO→LUMO (68%) 
6 3.340 371 0.0377 H-1→LUMO (77%) 
8 3.636 341 0.0144 H-2→LUMO (57%) 
H-2→L+3 (10%) 
13 4.161 298 0.0718 HOMO→L+2 (10%) 
HOMO→L+4 (56%) 
21 4.683 264 0.0696 H-6→LUMO (36%) 
H-5→LUMO (29%) 
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24 4.738 262 0.0603 H-1→L+5 (64%) 
25 4.780 259 0.0618 H-3→L+1 (35%) 
H-1→L+7 (15%) 
27 4.803 258 0.2022 H-5→LUMO (19%) 
H-1→L+7 (13%) 
31 5.054 245 0.0409 H-6→L+1 (12%) 
H-4→L+1 (12%) 
H-1→L+7 (12%) 
35 5.160 240 0.0507 H-4→L+3 (15%) 
H-2→L+5 (49%) 
41 5.279 235 0.0395 H-5→L+2 (28%) 
H-4→L+2 (16%) 
45 5.387 230 0.0236 H-1→L+8 (38%) 
HOMO→L+8 (24%) 
Figure A.4.4. Selected Electron Difference Density Maps (EDDMS) of singlet
excited state transitions of 2 in H2O (light violet indicates a decrease in electron
density, while purple indicates an increase).
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Table A.4.5. Selected TD-DFT singlet transitions for complex 3.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.795 444 0.0034 H-1→L+3 (12%) 
HOMO→L+1 (38%) 
HOMO→L+3 (14%) 
2 2.992 414 0.0069 H-1→L+3 (40%) 
HOMO→L+3 (14%) 
3 3.036 408 0.0004 H-1→L+1 (21%) 
H-1→L+2 (11%) 
H-1→L+4 (11%) 
HOMO→LUMO (12%) 
HOMO→L+3 (11%) 
4 3.124 397 0.0013 H-2→L+1 (27%) 
H-2→L+2 (13%) 
H-2→L+4 (12%) 
Appendix: Chapter 4
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5 3.159 393 0.007 H-1→LUMO (22%) 
HOMO→LUMO (44%) 
6 3.297 376 0.0349 H-1→LUMO (52%) 
HOMO→LUMO (23%) 
12 4.046 306 0.0126 H-1→L+1 (18%) 
H-1→L+2 (50%) 
13 4.085 304 0.0126 H-3→LUMO (24%) 
HOMO→L+4 (42%) 
14 4.144 299 0.0298 H-3→LUMO (47%) 
HOMO→L+4 (22%) 
15 4.206 295 0.0569 H-3→LUMO (13%) 
H-1→L+3 (11%) 
H-1→L+4 (53%) 
26 4.784 259 0.2235 H-6→LUMO (38%) 
31 4.964 250 0.0457 H-1→L+5 (36%) 
H-1→L+6 (10%) 
HOMO→L+5 (11%) 
HOMO→L+7 (14%) 
34 5.059 245 0.0423 H-3→L+4 (11%) 
H-2→L+6 (16%) 
H-1→L+5 (13%) 
35 5.079 244 0.0469 H-4→L+2 (15%) 
H-3→L+4 (26%) 
47 5.407 229 0.1952 H-2→L+5 (45%) 
H-1→L+8 (21%) 
Figure A.4.5. Selected Electron Difference Density Maps (EDDMS) of singlet
excited state transitions of 3 in H2O (light violet indicates a decrease in electron
density, while purple indicates an increase).
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Table A.4.6. Selected TD-DFT singlet transitions for complex 4.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.808 442 0.0029 HOMO→L+1 (54%) 
2 3.016 411 0.0071 H-1→LUMO (10%) 
H-1→L+4 (38%) 
3 3.050 407 0.0005 H-1→L+1 (21%) 
HOMO→L+2 (12%) 
HOMO→L+4 (21%) 
HOMO→L+5 (10%) 
4 3.133 396 0.0011 H-5→L+1 (10%) 
H-4→L+1 (23%) 
5 3.210 386 0.0042 HOMO→LUMO (68%) 
6 3.359 369 0.0362 H-1→LUMO (68%) 
8 3.625 342 0.0105 H-5→LUMO (11%) 
H-4→LUMO (46%) 
13 4.008 309 0.0064 H-8→LUMO (15%) 
H-7→LUMO (43%) 
HOMO→L+2 (13%) 
HOMO→L+3 (10%) 
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21 4.355 285 0.0009 H-6→LUMO (91%) 
24 4.466 278 0.0405 H-4→L+1 (14%) 
H-4→L+2 (24%) 
H-4→L+3 (32%) 
25 4.541 273 0.1679 H-4→L+2 (35%) 
H-4→L+3 (19%) 
H-4→L+5 (15%) 
27 4.564 272 0.003 HOMO→L+6 (49%) 
HOMO→L+7 (32%) 
31 4.674 265 0.0019 H-2→L+3 (24%) 
H-2→L+4 (69%) 
35 4.744 261 0.065 H-5→L+1 (20%) 
H-4→L+1 (16%) 
41 4.873 254 0.0385 H-6→L+1 (17%) 
H-5→L+2 (35%) 
45 4.966 250 0.1434 H-5→L+2 (22%) 
H-5→L+4 (44%) 
H-4→L+4 (10%) 
Figure A.4.6. Selected Electron Difference Density Maps (EDDMS) of singlet
excited state transitions of 4 in H2O (light violet indicates a decrease in electron
density, while purple indicates an increase).
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Table A.4.7. Selected TD-DFT singlet transitions for complex 5.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.812 441 0.0036 H-3→L+1 (10%) 
H-2→L+1 (26%) 
H-2→L+3 (20%) 
HOMO→L+1 (12%) 
Appendix: Chapter 4
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2 3.006 413 0.0097 H-4→L+3 (10%) 
H-3→L+3 (25%) 
HOMO→LUMO (10%) 
HOMO→L+3 (11%) 
3 3.049 407 0.0003 H-2→L+1 (18%) 
H-2→L+2 (12%) 
H-2→L+4 (16%) 
4 3.134 396 0.0018 H-4→L+1 (21%) 
H-3→L+1 (21%) 
H-2→LUMO (13%) 
5 3.160 392 0.0105 H-4→L+1 (10%) 
H-2→LUMO (22%) 
HOMO→LUMO (35%) 
6 3.253 381 0.0111 H-2→LUMO (40%) 
HOMO→LUMO (-30%) 
7 3.410 364 0.0121 H-4→LUMO (11%) 
H-3→LUMO (71%) 
HOMO→LUMO (10%) 
10 3.717 334 0.0152 H-4→L+3 (25%) 
H-3→L+3 (17%) 
11 3.830 324 0.0257 H-4→LUMO (73%) 
12 3.903 318 0.0130 H-2→L+2 (11%) 
HOMO→L+1 (18%) 
HOMO→L+2 (46%) 
16 4.103 302 0.2253 H-3→L+1 (-13%) 
HOMO→L+1 (12%) 
HOMO→L+3 (33%) 
HOMO→L+4 (16%) 
17 4.144 299 0.2741 H-2→L+4 (16%) 
HOMO→L+5 (37%) 
18 4.184 296 0.1807 H-3→L+2 (10%) 
H-2→L+3 (10%) 
H-2→L+4 (22%) 
HOMO→L+5 (27%) 
22 4.303 288 0.0496 H-2→L+5 (64%) 
H-1→L+5 (13%) 
23 4.324 287 0.0186 H-2→L+5 (11%) 
H-1→L+2 (18%) 
H-1→L+3 (13%) 
H-1→L+4 (14%) 
H-1→L+5 (28%) 
35 4.712 263 0.1104 H-7→LUMO (27%) 
H-6→L+2 (23%) 
39 4.839 256 0.0814 H-6→L+2 (10%) 
H-4→L+4 (12%) 
40 4.869 255 0.0334 H-5→L+5 (15%) 
HOMO→L+8 (42%) 
47 5.128 242 0.0341 H-7→L+1 (26%) 
H-6→L+1 (38%) 
Appendix: Chapter 4
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48 5.184 239 0.0121 H-7→L+1 (30%) 
H-7→L+2 (12%) 
H-6→L+3 (33%) 
Figure A.4.7. Selected Electron Difference Density Maps (EDDMS) of singlet
excited state transitions of 5 in H2O (light violet indicates a decrease in electron
density, while purple indicates an increase).
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Table A.4.8. Selected TD-DFT singlet transitions for complex 6.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.816 440 0.0026 H-2→L+1 (40%) 
H-2→L+3 (24%) 
2 3.018 411 0.0052 H-4→L+3 (14%) 
H-3→L+3 (31%) 
3 3.051 406 0.0021 H-3→L+1 (19%) 
H-3→L+3 (22%) 
H-2→L+1 (11%) 
H-2→L+3 (10%) 
H-2→L+4 (11%) 
4 3.131 396 0.001 H-4→L+1 (31%) 
H-4→L+2 (11%) 
H-4→L+4 (13%) 
H-3→L+1 (11%) 
H-2→LUMO (12%) 
5 3.188 389 0.0028 H-2→LUMO (69%) 
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6 3.314 374 0.0081 H-3→LUMO (14%) 
HOMO→LUMO (80%) 
10 3.648 340 0.014 H-4→LUMO (60%) 
H-4→L+3 (10%) 
19 4.158 298 0.0512 H-2→L+4 (42%) 
H-1→L+2 (23%) 
20 4.184 296 0.0191 H-1→L+2 (66%) 
30 4.572 271 0.0196 H-2→L+5 (46%) 
H-1→L+5 (20%) 
33 4.680 265 0.0574 H-8→LUMO (41%) 
H-7→LUMO (28%) 
36 4.748 261 0.0645 H-3→L+5 (77%) 
37 4.781 259 0.0913 H-7→LUMO (12%) 
H-5→L+1 (18%) 
H-3→L+7 (18%) 
39 4.809 258 0.1779 H-7→LUMO (16%) 
H-5→L+1 (14%) 
H-3→L+7 (15%) 
Figure A.4.8. Selected Electron Difference Density Maps (EDDMS) of singlet
excited state transitions of 6 in H2O (light violet indicates a decrease in electron
density, while purple indicates an increase).
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Table A.4.9. Selected TD-DFT singlet transitions for complex 8.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.7755 447 0.0001 H-1→L+1 (31%) 
HOMO→L+3 (39%) 
2 2.921 424 0.0047 H-2→L+3 (13%) 
HOMO→L+1 (53%) 
HOMO→L+4 (15%) 
3 2.9731 417 0.0084 H-1→LUMO (17%) 
H-1→L+3 (63%) 
4 2.9943 414 0.0014 H-2→L+1 (33%) 
H-2→L+4 (10%) 
H-1→L+1 (10%) 
HOMO→LUMO (20%) 
5 3.1016 400 0.0007 H-2→L+1 (11%) 
HOMO→LUMO (69%) 
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6 3.1883 389 0.0336 H-1→LUMO (76%) 
H-1→L+3 (11%) 
8 3.5911 345 0.0145 H-2→LUMO (60%) 
H-2→L+3 (15%) 
11 3.9289 316 0.0219 H-1→L+2 (80%) 
13 4.0588 305 0.0608 HOMO→L+1 (15%) 
HOMO→L+4 (70%) 
19 4.515 275 0.041 H-1→L+5 (92%) 
22 4.6621 266 0.0478 H-5→LUMO (16%) 
H-4→L+2 (37%) 
25 4.7523 261 0.1927 H-5→LUMO (34%) 
H-4→LUMO (11%) 
29 4.9126 252 0.0675 H-8→LUMO (80%) 
33 5.0238 247  H-2→L+5 (78%) 
Figure A.4.9. Selected Electron Difference Density Maps (EDDMS) of singlet
excited state transitions of 8 in H2O (light violet indicates a decrease in electron
density, while purple indicates an increase).
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Table A.4.10. Selected TD-DFT singlet transitions for complex 9.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.8495 435 0.0001 H-1→L+1 (27%) 
HOMO→L+3 (49%) 
2 2.9861 415 0.0035 H-2→L+3 (20%) 
HOMO→L+1 (52%), 
HOMO→L+4 (11%) 
3 3.0497 407 0.007 H-1→LUMO (12%) 
H-1→L+3 (61%) 
4 3.0855 402 0.0007 H-2→L+1 (45%) 
H-2→L+4 (11%) 
H-1→L+1 (16%) 
HOMO→LUMO (10%) 
5 3.1763 390 0.0003 HOMO→LUMO (79%) 
6 3.2844 377 0.0354 H-1→LUMO (79%) 
8 3.6332 341 0.0155 H-2→LUMO (58%) 
H-2→L+3 (14%) 
9 3.7455 331 0.0091 H-2→LUMO (33%) 
H-2→L+3 (42%) 
12 4.0577 306 0.0171 H-1→L+2 (86%) 
13 4.1827 296 0.0593 HOMO→L+1 (16%) 
HOMO→L+4 (71%) 
21 4.6442 267 0.0609 H-1→L+5 (87%) 
22 4.7063 263 0.0824 H-5→LUMO (21%) 
H-4→L+2 (41%) 
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24 4.7992 258 0.2569 H-5→LUMO (37%) 
H-4→L+2 (12%) 
H-2→L+4 (11%) 
26 4.8184 257 0.023 H-7→L+2 (19%) 
H-4→L+1 (18%) 
H-4→L+4 (24%) 
H-3→L+1 (18%) 
32 5.1137 242 0.0577 H-5→L+1 (11%) 
H-4→L+1 (17%) 
H-2→L+5 (53%) 
33 5.1331 241 0.0401 H-5→L+1 (45%) 
H-4→L+1 (14%) 
H-2→L+5 (22%) 
Figure A.4.10. Selected Electron Difference Density Maps (EDDMS) of singlet
excited state transitions of 9 in H2O (light violet indicates a decrease in electron
density, while purple indicates an increase).
S1 S2 S3
S4 S5 S6
S8 S9 S12
Appendix: Chapter 4
A27
S13
S21
S22
S24 S26 S32
S33
Table A.4.11. Selected TD-DFT singlet transitions for the complex 10.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.8322 438 0.0022 H-1→L+2 (27%) 
HOMO→L+2 (36%) 
2 3.0001 413 0.0056 H-3→L+2 (15%) 
H-1→L+3 (24%) 
HOMO→L+2 (19%) 
3 3.0682 404 0.0006 H-1→L+2 (15%) 
H-1→L+3 (32%) 
HOMO→L+3 (17%) 
4 3.1602 392 0.0006 H-3→L+2 (14%) 
H-3→L+3 (24%) 
H-2→L+2 (14%) 
H-2→L+3 (21%) 
5 3.4519 359 0.005 H-1→LUMO (45%) 
HOMO→LUMO (21%) 
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6 3.5525 349 0.039 HOMO→LUMO (48%) 
HOMO→L+3 (15%) 
10 3.8892 319 0.0246 H-4→LUMO (10%) 
H-1→L+1 (12%) 
HOMO→L+1 (52%) 
11 3.9674 312 0.0516 H-2→LUMO (40%) 
H-1→L+1 (28%) 
17 4.4767 277 0.0335 H-3→L+3 (24%) 
H-2→L+3 (32%) 
HOMO→L+3 (11%) 
20 4.5894 270 0.1062 H-4→L+1 (58%) 
31 5.0741 244 0.1122 H-1→L+5 (27%) 
H-1→L+7 (10%) 
HOMO→L+5 (18%) 
36 5.1776 239 0.0433 H-3→L+4 (41%) 
HOMO→L+8 (24%) 
38 5.2235 237 0.018 H-6→LUMO (38%) 
H-3→L+4 (10%) 
H-1→L+8 (27%) 
Figure A.4.11. Selected Electron Difference Density Maps (EDDMS) of singlet
excited state transitions of 10 in H2O (light violet indicates a decrease in electron
density, while purple indicates an increase).
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Table A.4.12. Selected TD-DFT singlet transitions for complex 11.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.3311 532 0.0003 H-3→LUMO (53%) 
H-2→LUMO (34%) 
2 2.5061 495 0.0047 HOMO→LUMO (91%) 
3 2.5935 478 0.0111 H-1→LUMO (88%) 
4 2.794 444 0.0023 HOMO→L+2 (24%) 
HOMO→L+3 (48%) 
5 2.9878 415 0.0056 H-2→L+3 (14%) 
H-1→L+3 (34%) 
H-1→L+4 (23%) 
6 3.0142 411 0.0011 H-1→L+2 (15%) 
H-1→L+3 (-18%) 
HOMO→L+2 (12%) 
HOMO→L+4 (37%) 
7 3.0709 403 0.0022 H-3→LUMO (36%) 
H-2→LUMO (57%) 
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8 3.088 401 0.0011 H-3→L+4 (10%) 
H-2→L+2 (20%) 
H-2→L+4 (26%) 
9 3.2634 380 0.0283 H-4→LUMO (96%) 
11 3.4415 360 0.0489 H-1→L+1 (75%) 
15 3.6711 338 0.0134 H-3→L+3 (11%) 
H-2→L+3 (31%) 
H-1→L+3 (11%) 
16 3.8365 323 0.0144 H-2→L+1 (81%) 
18 4.0291 308 0.0237 H-3→L+1 (15%) 
HOMO→L+2 (28%) 
HOMO→L+4 (24%) 
19 4.08 304 0.0383 H-1→L+2 (33%) 
H-1→L+3 (14%) 
H-1→L+4 (28%) 
21 4.2723 290 0.1035 H-9→LUMO (16%) 
H-4→L+1 (55%) 
24 4.448 279 0.0249 H-7→LUMO (77%) 
29 4.6692 265 0.1369 H-9→LUMO (34%) 
H-4→L+1 (18%) 
H-4→L+2 (14%) 
33 4.7978 258 0.0715 H-10→LUMO (46%) 
H-4→L+2 (13%) 
H-4→L+3 (18%) 
H-4→L+4 (14%) 
42 5.0545 245 0.067 H-3→L+5 (13%) 
H-2→L+5 (72%) 
47 5.1855 239 0.2698 H-13→LUMO (21%) 
H-4→L+4 (16%) 
Figure A.4.12. Selected Electron Difference Density Maps (EDDMS) of singlet
excited state transitions of 11 in H2O (light violet indicates a decrease in electron
density, while purple indicates an increase).
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Table A.4.13. Selected TD-DFT singlet transitions for complex 12.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.804 437 0.0036 H-2→L+2 (17%) 
H-1→L+2 (33%) 
HOMO→L+2 (12%) 
2 2.975 417 0.0188 H-5→L+2 (-10%) 
HOMO→LUMO (10%) 
HOMO→L+2 (19%) 
HOMO→L+3 (12%) 
3 3.091 401 0.0005 H-5→L+2 (10%) 
H-2→L+3 (17%) 
H-1→L+3 (39%) 
4 3.204 387 0.0027 H-7→L+2 (10%) 
H-7→L+3 (19%) 
H-6→L+3 (15%) 
H-5→L+2 (10%) 
H-5→L+3 (18%) 
5 3.297 376 0.1807 HOMO→LUMO (72%) 
6 3.371 368 0.0557 H-1→LUMO (58%) 
7 3.470 357 0.2038 H-1→LUMO (10%) 
HOMO→L+1 (60%) 
8 3.555 349 0.134 H-1→L+2 (10%) 
HOMO→L+1 (20%) 
HOMO→L+3 (26%) 
10 3.680 337 0.2484 H-1→L+1 (75%) 
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12 3.845 322 0.0536 H-2→LUMO (71%) 
H-1→LUMO (10%) 
15 3.981 311 0.0438 H-5→L+1 (67%) 
H-2→L+1 (18%) 
16 4.021 308 0.0933 H-7→LUMO (13%) 
H-5→L+1 (19%) 
H-2→L+1 (57%) 
23 4.272 290 0.1456 H-8→LUMO (43%) 
H-6→L+1 (44%) 
30 4.506 275 0.0876 H-8→LUMO (10%) 
H-6→L+1 (13%) 
H-2→L+3 (30%) 
H-1→L+3 (17%) 
31 4.523 274 0.1308 H-8→LUMO (19%) 
H-6→L+1 (17%) 
H-2→L+3 (17%) 
H-1→L+3 (11%) 
44 4.895 253 0.0922 H-1→L+5 (31%) 
HOMO→L+7 (14%) 
46 4.930 251 0.105 H-8→L+2 (10%) 
H-1→L+5 (17%) 
HOMO→L+7 (12%) 
Figure A.4.13. Selected Electron Difference Density Maps (EDDMS) of singlet
excited state transitions of 12 in H2O (light violet indicates a decrease in electron
density, while purple indicates an increase).
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Table A.4.14. Selected TD-DFT singlet transitions for complex 13.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.8627 433 0.0002 H-1→L+1 (29%) 
HOMO→L+2 (56%) 
2 3.0012 413 0.0055 H-2→L+2 (24%) 
H-1→L+2 (29%) 
HOMO→L+1 (31%) 
3 3.059 403 0.0005 H-1→L+2 (45%) 
HOMO→L+1 (40%) 
4 3.1387 395. 0.0005 H-2→L+1 (67%) 
H-1→L+1 (15%) 
5 3.3872 366. 0.0001 HOMO→LUMO (84%) 
6 3.5106 353 0.052 H-1→LUMO (79%) 
7 3.5528 349 0.0005 H-2→L+1 (16%) 
H-1→L+1 (35%) 
HOMO→L+2 (25%) 
8 3.6943 336 0.0151 H-2→L+2 (45%) 
H-1→L+2 (-12%) 
10 4.2028 295 0.1902 H-3→LUMO (70%) 
HOMO→L+3 (12%)  
13 4.4738 277 0.0486 H-1→L+3 (87%) 
14 4.5377 273 0.0189 H-3→L+1 (88%) 
15 4.542 273 0.0439 H-1→L+5 (13%) 
HOMO→L+3 (11%) 
HOMO→L+4 (67%) 
17 4.5811 270 0.0691 HOMO→L+5 (62%) 
19 4.6267 267 0.0314 H-3→L+2 (45%) 
H-1→L+5 (36%) 
21 4.6733 265 0.0942 H-3→L+2 (49%) 
H-1→L+5 (18%) 
22 4.8071 257 0.0783 H-1→L+5 (20%) 
H-1→L+7 (37%) 
H-1→L+8 (32%) 
23 4.928 251 0.0369 H-2→L+3 (84%) 
Figure A.4.14. Selected Electron Difference Density Maps (EDDMS) of singlet
excited state transitions of 13 in H2O (light violet indicates a decrease in electron
density, while purple indicates an increase).
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Table A.4.15. Selected TD-DFT singlet transitions for complex 14.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.8085 441 0.0027 HOMO→L+1 (24%) 
HOMO→L+2 (18%) 
HOMO→L+4 (16%) 
2 3.0189 410 0.0047 H-3→L+4 (11%) 
H-1→L+4 (13%) 
3 3.0515 406 0.0026 H-1→L+1 (11%) 
H-1→L+4 (21%) 
4 3.134 395 0.001 H-3→L+1 (17%) 
H-3→L+2 (25%) 
H-3→L+5 (10%) 
H-1→L+2 (10%) 
5 3.2201 385 0.0022 HOMO→LUMO (79%) 
6 3.3888 366 0.0322 H-1→LUMO (78%) 
8 3.6698 338 0.0141 H-3→LUMO (29%) 
H-3→L+4 (14%) 
10 3.8035 326 0.014 H-3→LUMO (47%) 
H-3→L+4 (16%) 
14 4.0852 303 303.5 HOMO→L+1 (10%) 
HOMO→L+2 (13%) 
HOMO→L+3 (54%) 
HOMO→L+4 (17%) 
16 4.1931 296 0.0755 HOMO→L+5 (55%) 
17 4.2395 292 0.011 H-1→L+1 (12%) 
H-1→L+2 (10%) 
H-1→L+3 (51%) 
H-1→L+4 (11%) 
27 4.6589 266 0.0233 H-3→L+2 (20%) 
H-3→L+3 (10%) 
H-2→L+1 (11%) 
28 4.7063 263 0.0909 H-6→LUMO (16%) 
H-2→L+4 (19%) 
29 4.7211 262 0.0298 H-2→L+4 (40%) 
32 4.8006 258 0.1406 H-6→LUMO (21%) 
H-2→L+6 (12%) 
33 4.8199 257 0.0706 H-2→L+6 (51%) 
34 4.8357 256 0.0321 H-7→L+3 (10%) 
H-5→L+5 (22%) 
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Figure A.4.15. Selected Electron Difference Density Maps (EDDMS) of singlet
excited state transitions of 14 in H2O (light violet indicates a decrease in electron
density, while purple indicates an increase).
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Table A.4.16. Selected TD-DFT singlet transitions for complex 15.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.8057 442 0.003 HOMO→L+1 (46%) 
HOMO→L+3 (17%) 
2 3.016 411 0.0064 H-3→L+3 (11%) 
H-1→L+3 (33%) 
3 3.0451 407 0.0011 H-1→L+1 (-14%) 
H-1→L+3 (10%) 
HOMO→L+2 (11%) 
HOMO→L+3 (19%) 
HOMO→L+4 (14%) 
4 3.129 396 0.0011 H-3→L+1 (28%) 
H-3→L+2 (11%) 
H-3→L+4 (12%) 
H-1→L+1 (15%) 
5 3.2064 387 0.0033 HOMO→LUMO (77%) 
6 3.3661 368 0.0322 H-1→LUMO (78%) 
8 3.6559 33 0.0158 H-3→LUMO (33%) 
H-3→L+3 (15%) 
9 3.7803 328 0.0121 H-3→LUMO (35%) 
H-3→L+3 (22%) 
H-2→LUMO (12%) 
14 4.1678 297 0.0271 H-4→LUMO (56%) 
HOMO→L+4 (19%) 
15 4.1811 296 0.0553 H-4→LUMO (40%) 
HOMO→L+4 (30%) 
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21 4.4963 275 0.0251 H-2→L+5 (29%) 
H-1→L+5 (46%) 
22 4.5159 274 0.0145 H-3→L+1 (11%) 
H-3→L+2 (43%) 
H-2→L+2 (13%) 
29 4.7111 263 0.0761 H-7→LUMO (18%) 
H-6→L+2 (22%) 
31 4.7919 258 0.1191 H-7→LUMO (15%) 
HOMO→L+6 (15%) 
HOMO→L+8 (15%) 
32 4.8056 258 0.1008 H-7→LUMO (16%) 
HOMO→L+6 (15%) 
Figure A.4.16. Selected Electron Difference Density Maps (EDDMS) of singlet
excited state transitions of 15 in H2O (light violet indicates a decrease in electron
density, while purple indicates an increase).
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Table A.4.17. Selected TD-DFT singlet transitions for complex 16.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.811 441 0.0026 HOMO→L+1 (44%) 
HOMO→L+3 (20%) 
2 3.0236 410 0.0056 H-2→L+3 (16%) 
H-1→L+3 (28%) 
3 3.0522 406 0.0014 H-1→L+1 (19%) 
H-1→L+3 (17%) 
HOMO→L+2 (12%) 
HOMO→L+3 (14%) 
HOMO→L+5 (11%) 
4 3.1366 395 0.0011 H-2→L+1 (28%) 
H-2→L+2 (15%) 
H-2→L+5 (12%) 
H-1→L+1 (14%) 
5 3.2249 384 0.0026 HOMO→LUMO (78%) 
6 3.3919 365 0.0325 H-1→LUMO (78%) 
8 3.6686 337 0.0142 H-2→LUMO (31%) 
H-2→L+3 (19%) 
9 3.8035 325 0.0138 H-2→LUMO (57%) 
H-2→L+3 (21%) 
13 4.1977 295 0.0675 HOMO→L+4 (24%) 
HOMO→L+5 (41%) 
14 4.2014 295 0.0277 HOMO→L+4 (68%) 
HOMO→L+5 (10%) 
16 4.3552 284 0.0189 H-1→L+4 (93%) 
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24 4.6829 264 0.0196 H-1→L+6 (61%) 
25 4.7108 263 0.0811 H-6→LUMO (20%) 
H-5→L+2 (12%) 
28 4.8029 258 0.1504 H-6→LUMO (20%) 
H-2→L+4 (17%) 
H-2→L+5 (11%) 
29 4.8098 258 0.0953 H-4→L+4 (12%) 
H-2→L+4 (27%) 
30 4.8364 256 0.0468 H-7→L+2 (12%) 
H-5→L+2 (10%) 
H-5→L+5 (19%) 
Figure A.4.17. Selected Electron Difference Density Maps (EDDMS) of singlet
excited state transitions of 16 in H2O (light violet indicates a decrease in electron
density, while purple indicates an increase).
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Table A.4.18. Selected TD-DFT triplet transitions for the complex 1 in the ground
state optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.252 550 0.0 HOMO→L+1 (74%) 
HOMO→L+3 (21%) 
2 2.4005 516 0.0 HOMO→L+2 (17%) 
HOMO→L+3 (45%) 
HOMO→L+4 (23%) 
3 2.4861 498 0.0 H-1→L+1 (69%) 
H-1→L+3 (19%) 
4 2.5342 489 0.0 H-2→L+1 (13%) 
H-1→L+2 (12%) 
H-1→L+3 (48%) 
H-1→L+4 (16%) 
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5 2.7133 456 0.0 H-2→L+1 (58%) 
H-2→L+2 (10%) 
H-2→L+4 (14%) 
6 2.8504 434 0.0 H-2→L+3 (69%) 
7 2.9257 423 0.0 H-5→LUMO (18%) 
HOMO→LUMO (71%) 
8 3.1334 395 0.0 H-1→LUMO (86%) 
Figure A.4.18. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 1 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the ground state
optimised geometry.
T1 T2 T3
T4 T5 T6
T7 T8
Appendix: Chapter 4
A45
Table A.4.19. Selected TD-DFT triplet transitions for the complex 2 in the ground
state optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.260 549 0.0 HOMO→L+1 (72%) 
HOMO→L+3 (22%) 
2 2.414 513 0.0 HOMO→L+2 (14%) 
HOMO→L+3 (41%) 
HOMO→L+4 (24%) 
3 2.492 498 0.0 H-1→L+1 (64%) 
H-1→L+3 (26%) 
4 2.537 489 0.0 H-2→L+1 (13%) 
H-1→L+2 (10%) 
H-1→L+3 (39%) 
H-1→L+4 (18%) 
HOMO→L+3 (10%) 
5 2.712 457 0.0 H-2→L+1 (50%) 
H-2→L+2 (-11%) 
H-2→L+4 (-15%) 
6 2.856 434 0.0 H-2→L+3 (67%) 
7 2.920 425 0.0 H-5→LUMO (16%) 
HOMO→LUMO (67%) 
8 3.108 399 0.0 H-1→LUMO (80%) 
HOMO→LUMO (-10%) 
Figure A.4.19. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 2 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the ground state
optimised geometry.
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Table A.4.20. Selected TD-DFT triplet transitions for complex 3 in the ground state
optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.252 551 0.0 H-1→L+1 (13%) 
H-1→L+3 (11%) 
HOMO→L+1 (45%) 
HOMO→L+2 (11%) 
HOMO→L+3 (13%) 
2 2.407 515 0.0 H-1→L+2 (12%) 
H-1→L+3 (30%) 
H-1→L+4 (23%) 
HOMO→L+3 (17%) 
3 2.499 496 0.0 H-1→L+1 (33%) 
H-1→L+3 (32%) 
4 2.531 490 0.0 H-2→L+1 (12%) 
H-2→L+4 (11%) 
HOMO→L+3 (27%) 
5 2.678 463 0.0 H-3→L+1 (20%) 
H-3→L+2 (10%) 
H-2→L+1 (17%) 
6 2.859 434 0.0 H-3→L+3 (25%) 
H-2→L+3 (48%) 
7 2.905 427 0.0 H-6→LUMO (16%) 
H-1→LUMO (37%) 
HOMO→LUMO (36%) 
8 3.056 406 0.0 H-1→LUMO (38%) 
HOMO→LUMO (46%) 
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Figure A.4.20. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 3 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the ground state
optimised geometry.
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Table A.4.21. Selected TD-DFT triplet transitions for complex 4 in the ground state
optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.608 475 0.0 H-1→L+2 (10%) 
H-1→L+4 (12%) 
HOMO→L+1 (12%) 
HOMO→L+2 (14%) 
HOMO→L+4 (15%) 
HOMO→L+5 (11%) 
2 2.770 448 0.0 H-1→L+1 (16%) 
HOMO→LUMO (17%) 
HOMO→L+1 (28%) 
HOMO→L+4 (11%) 
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3 2.955 420 0.0 H-8→LUMO (21%) 
H-1→LUMO (24%) 
HOMO→LUMO (46%) 
4 3.171 391 0.0 H-1→LUMO (43%) 
HOMO→LUMO (12%) 
HOMO→L+1 (10%) 
5 3.253 381 0.0 H-4→L+4 (11%) 
H-1→L+2 (20%) 
HOMO→L+2 (17%) 
6 3.319 374 0.0 H-4→L+2 (17%) 
H-1→LUMO (11%) 
H-1→L+4 (14%) 
HOMO→L+4 (12%) 
7 3.450 359 0.0 H-8→LUMO (29%) 
H-7→LUMO (41%) 
HOMO→LUMO (12%) 
8 3.574 347 0.0 H-5→LUMO (16%) 
H-4→LUMO (52%) 
Figure A.4.21. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 4 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the ground state
optimised geometry.
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Table A.4.22. Selected TD-DFT triplet transitions for complex 5 in the ground state
optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.584 480 0.0 H-2→L+1 (25%) 
H-2→L+2 (17%) 
H-2→L+3 (14%) 
H-2→L+4 (22%) 
2 2.756 450 0.0 H-3→L+1 (18%) 
H-3→L+3 (12%) 
HOMO→LUMO (11%) 
HOMO→L+1 (12%) 
HOMO→L+3 (11%) 
3 2.940 422 0.0 H-7→LUMO (19%) 
H-2→LUMO (64%) 
4 3.023 410 0.0 HOMO→LUMO (10%) 
HOMO→L+4 (23%) 
HOMO→L+5 (52%) 
5 3.102 400 0.0 H-3→LUMO (26%) 
H-3→L+1 (10%) 
HOMO→LUMO (30%) 
6 3.260 380 0.0 H-4→L+1 (11%) 
H-3→L+1 (13%) 
H-3→L+2 (12%) 
H-3→L+3 (12%) 
HOMO→LUMO (13%) 
7 3.363 369 0.0 H-3→LUMO (56%) 
HOMO→LUMO (28%) 
8 3.446 360 0.0 H-7→LUMO (29%) 
H-6→LUMO (38%) 
H-2→LUMO (17%) 
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Figure A.4.22. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 5 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the ground state
optimised geometry.
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Table A.4.23. Selected TD-DFT triplet transitions for complex 6 in the ground state
optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.526 491 0.0 H-4→L+1 (12%) 
H-3→L+1 (18%) 
H-3→L+3 (13%) 
H-2→L+3 (29%) 
H-2→L+4 (13%) 
2 2.908 426 0.0 H-7→LUMO (15%) 
H-3→LUMO (10%) 
H-2→LUMO (66%) 
3 3.110 399 0.0 H-3→LUMO (65%) 
H-2→LUMO (12%) 
4 3.158 393 0.0 H-2→L+1 (43%) 
H-2→L+2 (11%) 
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5 3.269 379 0.0 H-3→L+1 (12%) 
H-3→L+2 (10%) 
6 3.322 373 0.0 HOMO→LUMO (85%) 
7 3.332 372 0.0 H-3→L+3 (22%) 
H-2→L+3 (10%) 
HOMO→LUMO (13%) 
8 3.447 360 0.0 H-1→LUMO (92%) 
Figure A.4.23. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 6 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the ground state
optimised geometry.
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Table A.4.24. Selected TD-DFT triplet transitions for complex 8 in the ground state
optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.3186 534 0.0 HOMO→L+1 (71%) 
HOMO→L+4 (22%) 
2 2.458 504 0.0 H-2→L+1 (28%) 
H-2→L+4 (10%) 
H-1→L+1 (44%) 
H-1→L+4 (14%) 
3 2.8788 430 0.0 H-5→LUMO (15%) 
HOMO→LUMO (82%) 
4 2.9615 418 0.0 H-1→LUMO (92%) 
5 3.3209 373 0.0 H-1→L+3 (70%) 
6 3.3873 366 0.0 H-5→LUMO (33%) 
H-4→LUMO (34%) 
HOMO→LUMO (12%) 
HOMO→L+3 (12%) 
7 3.5108 353 0.0 H-2→LUMO (13%) 
HOMO→L+3 (50%) 
8 3.5178 352 0.0 H-2→LUMO (69%) 
Figure A.4.24. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 8 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the ground state
optimised geometry.
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Table A.4.25. Selected TD-DFT triplet transitions for complex 9 in the ground state
optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.3213 534 0.0 H-1→L+1 (21%) 
HOMO→L+3 (77%) 
2 2.3465 528 0.0 HOMO→L+1 (75%), 
HOMO→L+4 (19%) 
3 2.4829 499 0.0 H-2→L+1 (14%) 
H-1→L+1 (53%) 
H-1→L+4 (13%) 
HOMO→L+3 (18%) 
4 2.5264 490 0.0 H-1→L+3 (89%) 
5 2.7131 456 0.0 H-2→L+1 (67%) 
H-2→L+4 (18%) 
H-1→L+1 (12%) 
6 2.8455 435 0.0 H-2→L+3 (82%) 
7 2.9069 426 0.0 H-5→LUMO (18%) 
HOMO→LUMO (76%) 
8 3.0666 404 0.0 H-1→LUMO (93%) 
Figure A.4.25. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 9 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the ground state
optimised geometry.
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Table A.4.26. Selected TD-DFT triplet transitions for complex 10 in the ground state
optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.2809 543 0.0 H-1→L+2 (51%) 
HOMO→L+2 (40%) 
2 2.4267 511 0.0 H-1→L+3 (80%) 
HOMO→L+3 (11%) 
3 2.5013 496 0.0 H-2→L+2 (18%) 
H-1→L+2 (30%) 
HOMO→L+2 (32%) 
HOMO→L+3 (10%) 
4 2.5628 484 0.0 H-2→L+3 (32%) 
HOMO→L+3 (34%) 
5 2.7302 454 0.0 H-3→L+2 (37%) 
H-3→L+3 (20%) 
HOMO→L+1 (12%) 
HOMO→L+3 (10%) 
6 2.7846 445 0.0 H-4→LUMO (11%) 
H-2→L+1 (20%) 
H-1→LUMO (13%) 
HOMO→L+1 (33%) 
7 2.8337 438 0.0 H-3→L+2 (16%) 
H-3→L+3 (46%) 
H-2→L+2 (10%) 
H-2→L+3 (16%) 
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8 3.0311 409 0.0 H-2→LUMO (11%) 
H-1→LUMO (10%), 
HOMO→LUMO (74%) 
Figure A.4.26. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 10 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the ground state
optimised geometry.
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Table A.4.27. Selected TD-DFT triplet transitions for complex 11 in the ground state
optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 1.8474 671 0.0 H-3→LUMO (60%) 
H-2→LUMO (32%) 
2 2.2446 552 0.0 HOMO->L+2 (-26%)
HOMO->L+3 (54%)
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3 2.3575 526 0.0 H-4→LUMO (20%) 
HOMO→LUMO (18%) 
HOMO→L+2 (14%) 
HOMO→L+4 (27%) 
4 2.3832 520 0.0 H-4→LUMO (30%) 
HOMO→LUMO (12%) 
HOMO→L+4 (22%) 
5 2.4432 507 0.0 H-1→LUMO (19%) 
H-1→L+2 (11%) 
H-1→L+3 (50%) 
6 2.4697 502 0.0 H-1→L+2 (18%) 
H-1→L+4 (29%) 
7 2.5169 493 0.0 H-4→LUMO (14%) 
H-1→L+3 (12%) 
HOMO→LUMO (41%) 
8 2.5582 485 0.0 H-4→LUMO (14%) 
H-1→LUMO (57%) 
HOMO→LUMO (11%) 
Figure A.4.27. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 11 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the ground state
optimised geometry.
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Table A.4.28. Selected TD-DFT triplet transitions for complex 12 in the ground state
optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.420 512 0.0 H-2→L+2 (22%) 
H-1→L+2 (39%) 
H-1→L+3 (16%) 
2 2.572 482 0.0 H-1→LUMO (21%) 
HOMO→L+1 (71%) 
3 2.678 463 0.0 HOMO→LUMO (93%) 
4 2.752 451 0.0 H-7→L+3 (12%) 
H-6→L+3 (12%) 
H-5→L+2 (14%) 
H-5→L+3 (28%) 
5 3.068 404 0.0 H-7→L+2 (10%) 
H-5→LUMO (10%) 
HOMO→L+2 (30%) 
6 3.148 394 0.0 H-1→LUMO (62%) 
HOMO→L+1 (18%) 
7 3.374 367 0.0 H-6→LUMO (11%) 
H-1→L+1 (50%) 
8 3.414 363 0.0 H-6→L+1 (13%) 
H-2→LUMO (46%) 
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Figure A.4.28. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 12 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the ground state
optimised geometry.
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Table A.4.29. Selected TD-DFT triplet transitions for complex 13 in the ground state
optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.3241 533 0.0 H-1→L+1 (14%) 
HOMO→L+2 (75%) 
2 2.3936 518 0.0 HOMO→L+1 (96%) 
3 2.5138 493 0.0 H-1→L+2 (95%) 
4 2.5283 490 0.0 H-2→L+1 (19%) 
H-1→L+1 (68%) 
HOMO→L+2 (10%) 
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5 2.7465 451 0.0 H-2→L+1 (79%) 
H-1→L+1 (17%) 
6 2.8335 437 0.0 H-2→L+2 (96%) 
7 2.9429 421 0.0 H-3→LUMO (47%) 
HOMO→LUMO (43%) 
8 3.2487 381 0.0 H-1→LUMO (89%) 
Figure A.4.29. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 13 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the ground state
optimised geometry.
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Table A.4.30. Selected TD-DFT triplet transitions for complex 14 in the ground state
optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.2499 551 0.0 HOMO→L+1 (40%) 
HOMO→L+2 (37%) 
HOMO→L+4 (16%) 
2 2.4019 516 0.0 HOMO→L+2 (13%) 
HOMO→L+3 (22%) 
HOMO→L+4 (39%) 
HOMO→L+5 (22%) 
3 2.5073 494 0.0 H-1→L+1 (37%) 
H-1→L+2 (33%) 
H-1→L+4 (15%) 
4 2.5521 485 0.0 H-3→L+2 (10%) 
H-1→L+3 (18%) 
H-1→L+4 (34%) 
H-1→L+5 (16%) 
5 2.7267 454 0.0 H-3→L+1 (28%) 
H-3→L+2 (35%) 
6 2.856 434 0.0 H-3→L+3 (23%) 
H-3→L+4 (50%) 
7 2.9384 422 0.0 H-6→LUMO (20%) 
HOMO→LUMO (71%) 
8 3.1766 390 0.0 H-1→LUMO (85%) 
Figure A.4.30. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 14 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the ground state
optimised geometry.
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Table A.4.31. Selected TD-DFT triplet transitions for the complex 15 in the ground
state optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.2514 550 0.0 HOMO→L+1 (73%) 
HOMO→L+3 (17%) 
2 2.4071 515 0.0 HOMO→L+2 (16%) 
HOMO→L+3 (52%) 
HOMO→L+4 (25%) 
3 2.5023 495 0.0 H-1→L+1 (65%) 
H-1→L+3 (21%) 
4 2.5446 487 0.0 H-3→L+1 (14%) 
H-1→L+2 (12%) 
H-1→L+3 (42%) 
H-1→L+4 (19%) 
5 2.7166 456 0.0 H-3→L+1 (47%) 
H-3→L+2 (11%) 
H-3→L+4 (11%) 
6 2.8511 434 0.0 H-3→L+3 (61%) 
7 2.9292 423 0.0 H-7→LUMO (19%) 
HOMO→LUMO (71%) 
8 3.1479 393 0.0 H-1→LUMO (84%) 
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Figure A.4.31. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 15 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the ground state
optimised geometry.
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Table A.4.32. Selected TD-DFT triplet transitions for complex 16 in the ground state
optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.4952 497 0.0 HOMO→L+1 (18%) 
HOMO→L+2 (23%) 
HOMO→L+3 (23%) 
HOMO→L+5 (21%) 
2 2.8055 442 0.0 HOMO→L+1 (35%) 
HOMO→L+3 (32%) 
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3 2.9418 421 0.0 H-6→LUMO (20%) 
HOMO→LUMO (67%) 
4 3.0719 403 0.0 H-1→LUMO (24%) 
H-1→L+1 (28%) 
5 3.2275 384 0.0 H-1→LUMO (64%) 
6 3.4668 357 0.0 H-6→LUMO (27%) 
H-5→LUMO (32%) 
H-3→LUMO (11%) 
HOMO→LUMO (17%) 
7 3.552 349 0.0 H-1→L+1 (21%) 
H-1→L+3 (41%) 
8 3.6313 341 0.0 H-2→LUMO (78%) 
Figure A.4.32. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 16 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the ground state
optimised geometry.
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Table A.4.33. Selected TD-DFT triplet transitions for complex 1 in the lowest-lying
triplet state optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 0.6484 1912 0.0 H-1→LUMO (67%) 
HOMO→LUMO (32%) 
2 0.8057 1538 0.0 H-1→LUMO (35%) 
HOMO→LUMO (64%) 
3 1.0691 1159 0.0 H-2→LUMO (98%) 
4 1.8923 655 0.0 HOMO→L+2 (97%) 
5 2.1397 579 0.0 H-1→L+2 (99%) 
6 2.4765 500 0.0 H-2→L+2 (96%) 
7 2.9304 423 0.0 H-5→L+1 (16%) 
HOMO→L+1 (83%) 
8 3.2859 377 0.0 H-1→L+1 (86%) 
The energy values of the triplet transitions in the Table are calculated relatively to the
energy of the lowest-lying geometry computed with multiplicity equal to 1 (singlet).
To calculate the relative energy of these triplet states with respect to the ground state,
0.97 eV must be added.
Figure A.4.33. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 1 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the lowest-lying
triplet state optimised geometry.
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Table A.4.34. Selected TD-DFT triplet transitions for complex 2 in the lowest-lying
triplet state optimised geometry
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 0.2814 4406 0.0 HOMO→LUMO (100%) 
2 0.8864 1399 0.0 H-1→LUMO (100%) 
3 1.055 1175 0.0 H-2→LUMO (100%) 
4 1.664 745 0.0 HOMO→L+2 (39%) 
HOMO→L+3 (61%) 
5 2.288 542 0.0 H-1→L+2 (39%) 
H-1→L+3 (61%) 
6 2.421 512 0.0 H-2→L+2 (38%) 
H-2→L+3 (62%) 
7 2.592 478 0.0 HOMO→L+1 (95%) 
8 3.147 394 0.0 H-5→L+1 (24%) 
H-2→L+1 (13%) 
H-1→L+1 (53%) 
The energy values of the triplet transitions in the Table are calculated relatively to the
energy of the lowest-lying geometry computed with multiplicity equal to 1 (singlet).
To calculate the relative energy of these triplet states with respect to the ground state,
1.09 eV must be added.
Figure A.4.34. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 2 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the lowest-lying
triplet state optimised geometry.
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Table A.4.35. Selected TD-DFT triplet transitions for complex 3 in the lowest-lying
triplet state optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 -0.301 -4119 0.0 HOMO→LUMO (100%) 
2 0.901 1376 0.0 H-3→LUMO (15%) 
H-1→LUMO (85%) 
3 1.087 1140 0.0 H-2→LUMO (100%) 
4 1.594 778 0.0 HOMO→L+2 (9%) 
HOMO→L+3 (91%) 
5 2.358 526 0.0 H-2→L+3 (28%) 
H-1→L+3 (68%) 
6 2.397 517 0.0 H-3→L+3 (10%) 
H-2→L+3 (72%) 
H-1→L+3 (18%) 
7 2.451 506 0.0 HOMO→L+1 (97%) 
8 3.114 398 0.0 H-3→LUMO (71%) 
H-1→LUMO (15%) 
The energy values of the triplet transitions in the Table are calculated relatively to the
energy of the lowest-lying geometry computed with multiplicity equal to 1 (singlet).
To calculate the relative energy of these triplet states with respect to the ground state,
1.12 eV must be added.
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Figure A.4.35. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 3 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the lowest-lying
triplet state optimised geometry.
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Table A.4.36. Selected TD-DFT triplet transitions for complex 4 in the lowest-lying
triplet state optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 0.861 1440 0.0 HOMO→LUMO (70%) 
2 1.334 929 0.0 H-4→LUMO (85%) 
HOMO→L+2 (13%) 
HOMO→L+4 (10%) 
3 2.003 619 0.0 H-2→LUMO (56%) 
4 2.486 499 0.0 H-4→LUMO (11%) 
HOMO→L+1 (14%) 
HOMO→L+2 (33%) 
HOMO→L+4 (13%) 
5 2.592 478 0.0 HOMO→L+1 (81%) 
6 2.792 444 0.0 H-4→L+2 (44%) 
H-4→L+4 (28%) 
7 3.033 409 0.0 HOMO→L+2 (18%) 
HOMO→L+4 (47%) 
8 3.161 392 0.0 H-1→LUMO (98%) 
The energy values of the triplet transitions in the Table are calculated relatively to the
energy of the lowest-lying geometry computed with multiplicity equal to 1 (singlet).
To calculate the relative energy of these triplet states with respect to the ground state,
1.13 eV must be added.
Figure A.4.36. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 4 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the lowest-lying
triplet state optimised geometry.
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Table A.4.37. Selected TD-DFT triplet transitions for complex 5 in the lowest-lying
triplet state optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 0.945 1311 0.0 HOMO→LUMO (71%) 
2 1.391 892 0.0 H-4→LUMO (69%) 
H-3→LUMO (15%) 
HOMO→L+3 (18%) 
3 2.077 597 0.0 H-3→LUMO (49%) 
H-1→LUMO (13%) 
4 2.485 499 0.0 H-1→LUMO (12%) 
HOMO→L+1 (51%) 
HOMO→L+3 (11%) 
5 2.550 486 0.0 H-1→LUMO (20%) 
HOMO→L+1 (42%) 
HOMO→L+3 (15%) 
6 2.717 456 0.0 H-4→LUMO (14%) 
H-1→LUMO (33%) 
HOMO→L+3 (13%) 
7 2.915 425 0.0 H-1→L+4 (10%) 
H-1→L+5 (14%) 
HOMO→L+4 (34%) 
HOMO→L+5 (39%) 
8 2.948 421 0.0 H-4→L+2 (10%) 
H-4→L+3 (42%) 
H-3→L+3 (10%) 
The energy values of the triplet transitions in the Table are calculated relatively to the
energy of the lowest-lying geometry computed with multiplicity equal to 1 (singlet).
To calculate the relative energy of these triplet states with respect to the ground state,
1.14 eV must be added.
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Figure A.4.37. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 5 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the lowest-lying
triplet state optimised geometry.
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Table A.4.38. Selected TD-DFT triplet transitions for complex 6 in the lowest-lying
triplet state optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 1.036 1197 0.0 HOMO→LUMO (63%) 
2 1.574 788 0.0 H-3→LUMO (76%) 
3 2.049 605 0.0 H-4→LUMO (63%) 
4 2.553 486 0.0 HOMO→L+1 (48%) 
HOMO→L+2 (13%) 
HOMO→L+3 (22%) 
5 2.638 470 0.0 H-1→LUMO (97%) 
6 2.680 463 0.0 HOMO→L+1 (46%) 
HOMO→L+3 (29%) 
7 2.786 445 0.0 H-2→LUMO (99%) 
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8 3.198 388 0.0 H-7→L+1 (37%) 
H-4→L+1 (13%) 
H-3→L+1 (38%) 
The energy values of the triplet transitions in the Table are calculated relatively to the
energy of the lowest-lying geometry computed with multiplicity equal to 1 (singlet).
To calculate the relative energy of these triplet states with respect to the ground state,
1.15 eV must be added.
Figure A.4.38. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 6 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the lowest-lying
triplet state optimised geometry.
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Table A.4.39. Selected TD-DFT triplet transitions for complex 8 in the lowest-lying
triplet state optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 0.3423 3622 0.0 HOMO→LUMO (97%) 
2 1.3997 886 0.0 H-2→LUMO (77%) 
H-1→LUMO (22%) 
3 2.1007 590 0.0 H-2→LUMO (15%) 
H-1→LUMO (51%) 
Appendix: Chapter 4
A72
4 2.489 498 0.0 HOMO→L+1 (44%) 
HOMO→L+3 (22%) 
HOMO→L+4 (16%) 
5 2.664 465 0.0 HOMO→L+1 (53%) 
HOMO→L+3 (17%) 
HOMO→L+4 (16%) 
6 3.193 388 0.0 H-5→L+1 (33%) 
H-2→L+1 (14%) 
H-1→L+1 (38%) 
7 3.2822 378 0.0 H-8→LUMO (11%) 
H-7→LUMO (24%) 
H-4→LUMO (18%) 
HOMO→L+2 (14%) 
HOMO→L+6 (12%) 
8 3.3501 370 0.0 H-1→L+1 (41%) 
HOMO→L+2 (33%) 
The energy values of the triplet transitions in the Table are calculated relatively to the
energy of the lowest-lying geometry computed with multiplicity equal to 1 (singlet).
To calculate the relative energy of these triplet states with respect to the ground state,
1.00 eV must be added.
Figure A.4.39. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 8 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the lowest-lying
triplet state optimised geometry.
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Table A.4.40. Selected TD-DFT triplet transitions for complex 9 in the lowest-lying
triplet state optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 -0.3525 -3517 0.0 HOMO→LUMO (97%) 
2 0.7912 1567 0.0 H-2→LUMO (18%) 
H-1→LUMO (77%) 
3 0.9384 1321 0.0 H-2→LUMO (80%) 
H-1→LUMO (17%) 
4 1.4875 833 0.0 HOMO→L+2 (75%) 
HOMO→L+3 (13%) 
5 2.0916 592 0.0 H-1→L+2 (82%) 
H-1→L+3 (14%) 
6 2.2193 558 0.0 H-2→L+2 (84%) 
H-2→L+3 (14%) 
7 2.5782 480 0.0 HOMO→L+1 (91%) 
8 3.0924 400 0.0 H-5→L+1 (15%) 
H-2→L+1 (11%) 
H-1→L+1 (64%) 
The energy values of the triplet transitions in the Table are calculated relatively to the
energy of the lowest-lying geometry computed with multiplicity equal to 1 (singlet).
To calculate the relative energy of these triplet states with respect to the ground state,
1.21 eV must be added.
Figure A.4.40. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 9 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the lowest-lying
triplet state optimised geometry.
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Table A.4.41. Selected TD-DFT triplet transitions for complex 10 in the lowest-lying
triplet state optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 0.1799 6890 0.0 HOMO→LUMO (98%) 
2 0.874 1419 0.0 H-4→LUMO (6%) 
H-1→LUMO (93%) 
3 1.1812 1050 0.0 H-3→LUMO (92%) 
H-2→LUMO (7%) 
4 1.9618 632 0.0 HOMO→L+3 (99%) 
5 2.4429 507 0.0 H-1→L+3 (98%) 
6 2.5616 484 0.0 H-3→L+3 (99%) 
7 2.7037 459 0.0 H-2→LUMO (33%) 
HOMO→L+1 (57%) 
8 2.7351 453 0.0 H-2→L+2 (38%) 
H-1→L+1 (12%) 
HOMO→L+2 (34%) 
The energy values of the triplet transitions in the Table are calculated relatively to the
energy of the lowest-lying geometry computed with multiplicity equal to 1 (singlet).
To calculate the relative energy of these triplet states with respect to the ground state,
1.00 eV must be added.
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Figure A.4.41. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 10 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the lowest-lying
triplet state optimised geometry.
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Table A.4.42. Selected TD-DFT triplet transitions for complex 11 in the lowest-lying
triplet state optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 1.689 733 0.0 H-3→LUMO (58%) 
H-2→LUMO (34%) 
2 2.126 583 0.0 H-4→LUMO (64%) 
HOMO→LUMO (22%) 
3 2.252 551 0.0 HOMO→LUMO (12%) 
HOMO→L+2 (11%) 
HOMO→L+3 (56%) 
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4 2.3187 535 0.0 H-1→LUMO (42%) 
HOMO→LUMO (34%) 
5 2.357 526 0.0 H-4→LUMO (11%) 
H-1→LUMO (34%) 
HOMO→LUMO (18%) 
HOMO→L+4 (16%) 
6 2.3949 518 0.0 H-1→L+4 (12%) 
HOMO→LUMO (10%) 
HOMO→L+4 (42%) 
7 2.4764 500 0.0 H-1→L+2 (17%) 
H-1→L+3 (47%) 
8 2.5051 495 0.0 H-1→L+3 (23%) 
H-1→L+4 (42%) 
The energy values of the triplet transitions in the Table are calculated relatively to the
energy of the lowest-lying geometry computed with multiplicity equal to 1 (singlet).
To calculate the relative energy of these triplet states with respect to the ground state,
1.41 eV must be added.
Figure A.4.42. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 11 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the lowest-lying
triplet state optimised geometry.
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Table A.4.43. Selected TD-DFT triplet transitions for complex 12 in the lowest-lying
triplet state optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 0.859 1444 0.0 H-5→LUMO (66%) 
H-1→LUMO (24%) 
2 1.363 909 0.0 HOMO→LUMO (59%) 
3 2.377 522 0.0 H-6→LUMO (41%) 
H-2→LUMO (22%) 
4 2.412 514 0.0 H-6→L+3 (63%) 
H-2→L+3 (17%) 
HOMO→L+3 (27%) 
5 2.490 498 0.0 H-2→L+2 (13%) 
H-1→L+1 (20%) 
HOMO→L+2 (63%) 
6 2.509 494 0.0 H-6→LUMO (26%) 
H-2→LUMO (25%) 
HOMO→L+1 (29%) 
7 2.699 459 0.0 H-2→LUMO (32%) 
HOMO→L+1 (58%) 
8 2.874 431 0.0 H-5→LUMO (34%) 
H-1→LUMO (41%) 
HOMO→L+2 (10%) 
The energy values of the triplet transitions in the Table are calculated relatively to the
energy of the lowest-lying geometry computed with multiplicity equal to 1 (singlet).
To calculate the relative energy of these triplet states with respect to the ground state,
1.01 eV must be added.
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Figure A.4.43. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 12 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the lowest-lying
triplet state optimised geometry.
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Table A.4.44. Selected TD-DFT triplet transitions for complex 13 in the lowest-lying
triplet state optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 -0.2468 -5024 0.0 HOMO→LUMO (99%) 
2 0.9022 1374 0.0 H-2→LUMO (20%) 
H-1→LUMO (75%) 
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3 1.0014 1238 0.0 H-2→LUMO (73%) 
H-1→LUMO (18%) 
4 1.5429 804 0.0 HOMO→L+1 (10%) 
HOMO→L+2 (83%) 
5 2.1136 587 0.0 H-1→L+1 (11%) 
H-1→L+2 (86%) 
6 2.2382 554 0.0 H-2→L+1 (10%) 
H-2→L+2 (81%), 
7 2.8118 441 0.0 H-3→L+1 (12%) 
HOMO→L+1 (73%) 
8 3.055 406 0.0 H-3→LUMO (80%) 
H-3→L+1 (11%) 
The energy values of the triplet transitions in the Table are calculated relatively to the
energy of the lowest-lying geometry computed with multiplicity equal to 1 (singlet).
To calculate the relative energy of these triplet states with respect to the ground state,
1.12 eV must be added.
Figure A.4.44. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 13 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the lowest-lying
triplet state optimised geometry.
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Table A.4.45. Selected TD-DFT triplet transitions for complex 14 in the lowest-lying
triplet state optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 2.2586 549 0.0 H-1→L+2 (13%) 
HOMO→L+2 (64%) 
HOMO→L+4 (15%) 
2 2.4021 516 0.0 H-2→L+1 (34%) 
H-1→L+1 (59%) 
3 2.4188 512 0.0 HOMO→L+3 (42%) 
HOMO→L+4 (23%) 
HOMO→L+5 (22%) 
4 2.4932 498 0.0 H-2→L+2 (45%) 
H-2→L+4 (11%) 
H-1→L+2 (25%) 
5 2.5525 486 0.0 H-3→L+2 (15%) 
H-2→L+3 (20%) 
H-2→L+4 (12%) 
H-2→L+5 (10%) 
H-1→L+3 (16%) 
H-1→L+4 (10%) 
6 2.7481 451 0.0 H-3→L+2 (68%) 
H-3→L+5 (10%) 
7 2.8323 438 0.0 H-4→L+1 (84%) 
8 2.851 434 0.0 H-3→L+3 (35%) 
H-3→L+4 (40%) 
H-3→L+5 (11%) 
The energy values of the triplet transitions in the Table are calculated relatively to the
energy of the lowest-lying geometry computed with multiplicity equal to 1 (singlet).
To calculate the relative energy of these triplet states with respect to the ground state,
0.52 eV must be added.
Figure A.4.45. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 14 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the lowest-lying
triplet state optimised geometry.
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Table A.4.46. Selected TD-DFT triplet transitions for complex 15 in the lowest-lying
triplet state optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 1.4987 827 0.0 HOMO→L+1 (96%) 
2 2.2646 547 0.0 H-1→L+2 (78%) 
H-1→L+4 (18%) 
3 2.4261 511 0.0 H-1→L+3 (43%) 
H-1→L+4 (22%) 
H-1→L+5 (23%) 
4 2.4351 509 0.0 HOMO→LUMO (92%) 
5 2.4998 496 0.0 H-2→L+2 (73%) 
H-2→L+4 (20%) 
6 2.5575 485 0.0 H-3→L+2 (14%) 
H-2→L+3 (36%) 
H-2→L+4 (19%) 
H-2→L+5 (18%) 
7 2.755 450 0.0 H-3→L+2 (68%) 
H-3→L+5 (10%) 
8 2.8224 439 0.0 H-4→L+1 (92%) 
The energy values of the triplet transitions in the Table are calculated relatively to the
energy of the lowest-lying geometry computed with multiplicity equal to 1 (singlet).
To calculate the relative energy of these triplet states with respect to the ground state,
1.74 eV must be added.
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Figure A.4.46. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 15 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the lowest-lying
triplet state optimised geometry.
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Table A.4.47. Selected TD-DFT triplet transitions for complex 16 in the lowest-lying
triplet state optimised geometry.
Energy
(eV)
Wavelength
(nm)
Oscillator
Strength Major contributions
1 -0.2687 -4615 0.0 HOMO→LUMO (91%) 
2 2.0344 609 0.0 H-2→LUMO (48%) 
H-1→LUMO (20%) 
3 2.3014 539 0.0 H-2→LUMO (18%) 
H-1→LUMO (42%) 
4 2.3969 517 0.0 HOMO→L+2 (62%) 
5 2.6641 465 0.0 HOMO→L+1 (91%) 
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6 2.7443 452 0.0 H-2→L+2 (11%) 
H-1→L+2 (57%) 
7 3.2159 386 0.0 H-6→L+1 (52%) 
H-2→L+1 (11%) 
H-1→L+1 (27%) 
8 3.3275 373 0.0 H-7→LUMO (19%) 
H-3→LUMO (43%) 
H-2→L+2 (10%) 
The energy values of the triplet transitions in the Table are calculated relatively to the
energy of the lowest-lying geometry computed with multiplicity equal to 1 (singlet).
To calculate the relative energy of these triplet states with respect to the ground state,
1.25 eV must be added.
Figure A.4.47. Selected Electron Difference Density Maps (EDDMS) of triplet
excited state transitions of 16 in H2O (pink indicates a decrease in electron density,
while red indicates an increase). Calculations were performed using the lowest-lying
triplet state optimised geometry.
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Table A.4.48. Changes in DNA Melting Temperature (Δtm) by irradiated forms of
complexes 1, 4, and 10 at different rb values and ionic strengths [ClO4]– (M).
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Figure A.4.48. The changes induced in CD spectra of CT-DNA modified by RuII
arene complexes 1, 4, and 10 in their irradiated forms at different rb values.
Figure A.4.49. The changes induced in LD spectra of CT-DNA modified by RuII
arene complexes 1, 4, and 10 in their irradiated forms at different rb values.
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Table A.6.1 Crystallographic data for [η6-p-cym)Ru(NH3)Cl2] (1) and [η6-
bip)Ru(NH3)Cl2] (2)
1 2
Formula C19H31Cl2F6N2PRu C12H13Cl2NRu
Molar Mass 604.40 343.20
Crystal system Yellow needle Orange block.
Crystal size/mm3 0.16 x 0.02 x 0.02 0.10 x 0.06 x 0.02
Space group P-1 P-1
Crystal system Triclinic Triclinic
a/ Å 8.8456(7) 5.7821(3)
b/ Å 10.9737(9) 8.9621(4)
c/ Å 13.4054(12) 11.9292(6)
α/deg 110.456(4) 93.831(3) 
β/deg 91.907(5) 101.256(2) 
γ/deg 90.991(6) 105.661(3) 
Z 2 2
R [F>4σ (F)] 0.0884  
Rwb 0.1866 0.0664
GOFc 1.123 1.060
Δρ max and min/eÅ-3 1.102, –0.886
Table A.6.2.Hydrogen bond lengths (Å) and angles (°) in [η6-p-cym)Ru(NH3)Cl2] (1)
Symmetry operators used to generate equivalent atoms involved in these contacts:
a [–x+1, –y+1, –z+1]
b [–x, –y+1, –z+1]
c [1–x, –y, 1–z].
D H A
D–H
(Å)
H···A
(Å)
D···A
(Å)
D–H–A
(°)
N(208)
N(208)
N(1)
N(1)
N(1)
C(110)
C(110)
C(110)
H(28A)
H(28A)
H(1A)
H(1C)
H(1B)
H(11B)
H(11A)
H(11A)
Cl(1)
Cl(2)
Cl(1)
F(14)
Cl(2)
Cl(2)
F(11)
F(15)
0.85(2)
0.85(2)
0.85(2)
0.85(2)
0.85(2)
0.98
0.98
0.98
2.78(8)
2.54(7)
2.56(3)
2.40(6)
2.63(3)
2.67
2.43
2.67
3.407(9)
3.279(9)
3.392(9)
3.142(9)
3.460(9)
3.626 (10)
3.351(11)
3.430(11)
132(9)
145(10)
167(9)a
147(9)a
165(9)b
165.6b
157.0c
137.2c
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Table A.6.3. Hydrogen bond lengths (Å) and angles (°) in [η6-bip)Ru(NH3)Cl2] (2)
D H A
D–H
(Å)
H···A
(Å)
D···A
(Å)
D–H–A
(°)
N(1)
N(1)
N(1)
H(1B)
H(1C)
H(1D)
Cl(1)
Cl(1)
Cl(2)
0.910
0.910
0.910
2.667
2.742
2.606
3.410
3.587
3.388
139.42a
155.02b
144.41c
Symmetry operators used to generate equivalent atoms involved in these contacts:
a [–x+1, –y, –z+1]
b [x–1, y, z]
c [–x+1, –y, –z+1]
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